AO 120 (Rev. 08/10)

TO:

## Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

# REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK

DOCKET NO. DATE FILED 1/25/2017 U.S. DISTRICT COURT for the District of Delaware  PLAINTIFF SHIONOGI INC. and ANDRX LABS, L.L.C.  PATENT OR TRADEMARK DOTE TRADEMARK 1 6,790,459 99/14/2004 Andrx Labs, L.L.C.  3 Andrx Labs, L.L.C.  In the above—entitled case, the following patent(s)/ trademark(s) have been included:  DATE INCLUDED INCLUDED BY Amendment Answer Cross Bill Other Pleading PATENT OR TRADEMARK 1 Control of PATENT OR TRADEMARK 1 In the above—entitled case, the following patent of PATENT OR TRADEMARK 1 In the above—entitled case, the following patent of PATENT OR TRADEMARK 1 In the above—entitled case, the following patent of PATENT OR TRADEMARK 1 In the above—entitled case, the following patent of PATENT OR TRADEMARK 1 In the above—entitled case, the following patent or patent or trademark or patent or trademark or patent or patent or trademark or patent o	In Compliand filed in the U.S. Dist			1116 you are hereby advised the District of Delaware	nat a court action has been on the following
PATENT OR DATE OF PATENT OR TRADEMARK NO. DATE OF PATENT OR TR	☐ Trademarks or	Patents. (  the patent :	action involve	s 35 U.S.C. § 292.):	
SHIONOGI INC. and ANDRX LABS, L.L.C.  AUROBINDO PHARMA LTD. and AUROBINDO PHARMA USA, INC.  PATENT OR DATE OF PATENT OR TRADEMARK  1 6,790,459  9/14/2004  Andrx Labs, L.L.C.  2 6,866,866  3/15/2005  Andrx Labs, L.L.C.  3  4  5  In the above—entitled case, the following patent(s)/ trademark(s) have been included:  PATENT OR DATE OF PATENT OR TRADEMARK  1  PATENT OR TRADEMARK  OR TRADEMARK  1  2  3  4  5  In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT	DOCKET NO.	DATE FILED 1/25/2017	U.S. Di		ct of Delaware
TRADEMARK NO. OR TRADEMARK  1 6,790,459  9/14/2004  Andrx Labs, L.L.C.  2 6,866,866  3/15/2005  Andrx Labs, L.L.C.  3  4  5  In the above—entitled case, the following patent(s)/ trademark(s) have been included:  DATE INCLUDED  INCLUDED BY Amendment Answer Cross Bill Other Pleading  PATENT OR TRADEMARK  OR TRADEMARK  1  2  3  4  5  In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT	PLAINTIFF SHIONOGI INC. and AN	DRX LABS, L.L.C.		AUROBINDO PHARMA	LTD. and AUROBINDO
2 6,866,866  3/15/2005  Andrx Labs, L.L.C.  3  4  5  In the above—entitled case, the following patent(s)/ trademark(s) have been included:  DATE INCLUDED  INCLUDED BY Amendment   Answer   Cross Bill   Other Pleading PATENT OR DATE OF PATENT OR TRADEMARK  1  2  3  4  5  In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT				HOLDER OF PATE	ENT OR TRADEMARK
3	1 6,790,459	9/14/2004	Andr	x Labs, L.L.C.	
In the above—entitled case, the following patent(s)/ trademark(s) have been included:  DATE INCLUDED  INCLUDED BY Amendment Answer Cross Bill Other Pleading  PATENT OR DATE OF PATENT OR TRADEMARK  1  2  3  4  5  In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT	2 6,866,866	3/15/2005	Andr	x Labs, L.L.C.	
In the above—entitled case, the following patent(s)/ trademark(s) have been included:  DATE INCLUDED   INCLUDED BY	3				
In the above—entitled case, the following patent(s)/ trademark(s) have been included:  DATE INCLUDED    Amendment	4				
DATE INCLUDED  INCLUDED BY Amendment	5				
PATENT OR TRADEMARK NO.  DATE OF PATENT OR TRADEMARK  1  2  3  4  In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT    Answer   Cross Bill   Other Pleading     HOLDER OF PATENT OR TRADEMARK    HOLDER OF PATENT OR TRADEMARK   HOLDER OF P			the following	patent(s)/ trademark(s) have be	en included:
TRADEMARK NO. OR TRADEMARK  1 2 3 4 5 In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT  HOLDER OF PATENT OR TRADEMARK  1 2 2 3 4 5 Expression of the patents of the	DATE INCLUDED		mendment	☐ Answer ☐ Cross	s Bill
2 3 4 5 In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT  DECISION/JUDGEMENT				HOLDER OF PATE	ENT OR TRADEMARK
3 4 5 5 In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT	1				
4 5  In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT	2				
In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT	3				
In the above—entitled case, the following decision has been rendered or judgement issued:  DECISION/JUDGEMENT	4				
DECISION/JUDGEMENT	5				
	In the abov	e—entitled case, the followi	ng decision h	as been rendered or judgement is	ssued:
CLERK (BY) DEPUTY CLERK DATE	DECISION/JUDGEMENT				
	CLERK	(1	BY) DEPUTY	CLERK	DATE



#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMI United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov UNITED STATES DEPARTMENT OF COMMERCE

APPLICATION NUMBER FILING OR 371(C) DATE FIRST NAMED APPLICANT ATTY. DOCKET NO./TITLE 09/705,625 11/03/2000

Xiu Xiu Cheng

96056 Florek & Endres PLLC 1156 Avenue of the Americas Suite 600 New York, NY 10036

**CONFIRMATION NO. 6705 POA ACCEPTANCE LETTER** 



Date Mailed: 10/29/2010

141-603

#### NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 10/22/2010.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

/vvan/				
		<del></del>		

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101



#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEPARTMENT OF COMME United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vriginia 22313-1450 www.usplo.gov

Xiu Xiu Cheng

APPLICATION NUMBER FILING OR 371(C) DATE FIRST NAMED APPLICANT

11/03/2000

ATTY. DOCKET NO./TITLE 141-603

**CONFIRMATION NO. 6705** 

47888 HEDMAN & COSTIGAN, P.C. 1230 AVENUE OF THE AMERICAS 7th floor NEW YORK, NY 10020

09/705.625

**POWER OF ATTORNEY NOTICE** 

Date Mailed: 10/29/2010

#### NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 10/22/2010.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

/	'vvan/			

Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101

#### POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby 37 CFR	revoke all previous powers of attorney g 3.73(b).	given in the appl	ication identified	in the at	tached state	ment under
I hereby						
✓ Prac	ctitioners associated with the Customer Number:		96056			
OR						
Prac	ctitioner(s) named below (if more than ten patent p	ractitioners are to b	e named, then a cus	tomer num	ber must be use	ed):
	Name	Registration Number		Vame		Registration Number
<u> </u>						
any and all	r(s) or agent(s) to represent the undersigned befor patent applications assigned only to the undersign this form in accordance with 37 CFR 3.73(b).	e the United States ned according to the	Patent and Tradema e USPTO assignmer	ark Office (l nt records o	JSPTO) in conn r assignment do	ection with ocuments
Please cha	inge the correspondence address for the application	on identified in the a	ttached statement u	nder 37 CF	R 3.73(b) to:	
OR	he address associated with Customer Number:	9	06056			
Fim	n or vidual Name				****	
Address	violati i i i i i i i i i i i i i i i i i i					
City		State			Zip	
Country						
Telephon	e	· · · · · · · · · · · · · · · · · · ·	Email	_		
Assignee N	lame and Address:					
Andrx La						
	inge Drive orida 33314					
·						
the practi	this form, together with a statement und tch application in which this form is used tioners appointed in this form if the appo identify the application in which this Pow	. The statement inted practitione	under 37 CFR 3.7 r is authorized to	73(b) mav	he complete	d by one of
		URE of Assignee of				
	The individual whose signature and title is	s supplied below is	authorized to act on	behalf of t	he assignee	
Signature				Date Se	otember o	20,2010
Name	David A. Buch	nen		Telephone		<i>*</i>
Title	Senior VP/ General Counsel					

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Electronic Acknowledgement Receipt				
EFS ID:	8684580			
Application Number:	09705625			
International Application Number:				
Confirmation Number:	6705			
Title of Invention:	METHODS FOR TREATING DIABETES VIA ADMINISTRATRION OF CONTROLLED RELEASE METFORMIN			
First Named Inventor/Applicant Name:	Xiu Xiu Cheng			
Customer Number:	47888			
Filer:	Matthew J Solow/jonathan goodman			
Filer Authorized By:	Matthew J Solow			
Attorney Docket Number:	141-603			
Receipt Date:	22-OCT-2010			
Filing Date:	03-NOV-2000			
Time Stamp:	15:38:55			
Application Type:	Utility under 35 USC 111(a)			

## **Payment information:**

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /₊zip	Pages (if appl.)
1	Assignee showing of ownership per 37	6790459statement.pdf	73842		1
'	CFR 3.73(b).	o, you systate menapar	4f7cf085fe48c54331fb95ebf3da307c8c460 ef6		<u>'</u>

#### **Warnings:**

Information: AUROBINDO EX. 1006, 5

2 Power of Attorney		AndrxLabsPOA.pdf -	171203	no	1
	Tower of Attorney	·	a2c5c2c827e09c383c1e79893ffb0cc5247af 0d9		
Warnings:	Warnings:				
Information:					
	Total Files Size (in bytes): 245045				

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

#### New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

#### National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

#### New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

	STATEMENT UNDER	37 CFR 3.73(b)
Applicant/	nt/Patent Owner: Xiu Xiu Cheng, Chih-Ming Chen, Steve Ja	n, Joseph Chou
Application	ion No./Patent No.: 6,790,459	Filed/Issue Date: September 14, 2004
Titled:	METHODS FOR TREATING DIABETES VIA ADMINIST	RATION OF CONTROLLED RELEASE METFORMIN
Andrx Lat	abs, LLC , a corporation	on
(Name of Ass		signee, e.g., corporation, partnership, university, government agency, etc.
states that	at it is:	
1. 🗙	the assignee of the entire right, title, and interest in;	
2.	an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is	%); or
3.	the assignee of an undivided interest in the entirety of (a com	plete assignment from one of the joint inventors was made)
the patent	nt application/patent identified above, by virtue of either:	
A.	An assignment from the inventor(s) of the patent application/  the United States Patent and Trademark Office at Reel copy therefore is attached.	patent identified above. The assignment was recorded in, Frame, or for which a
OR	copy increiore to attached.	
в. 🗶	A chain of title from the inventor(s), of the patent application/p	patent identified above, to the current assignee as follows:
	1. From: X. Cheng, C.Chen, S. Jan, J.Chou	To: ANDRX CORPORATION
	The document was recorded in the United States F Reel 011687 , Frame 0690	Patent and Trademark Office at, or for which a copy thereof is attached.
	2. From: Andrx Corporation, A Florida Corporation	To: Andrx Corporation, A Delaware Corporation
	The document was recorded in the United States F	Patent and Trademark Office at
	Reel <u>013792</u> , Frame <u>0227</u>	, or for which a copy thereof is attached.
	3. From: ANDRX CORPORATION	To: ANDRX LABS, LLC
	The document was recorded in the United States F	atent and Trademark Office at
	Reel <u>013788</u> , Frame <u>0187</u>	, or for which a copy thereof is attached.
	Additional documents in the chain of title are listed on a supp	plemental sheet(s).
	s required by 37 CFR 3.73(b)(1)(i), the documentary evidence or concurrently is being, submitted for recordation pursuant to 37	
	NOTE: A separate copy (i.e., a true copy of the original assignm ccordance with 37 CFR Part 3, to record the assignment in the re	
The under	ersigned (whose title is supplied below) is authorized to act on b	ehalf of the assignee.
		Uctober 15,2010
Si	Signature	Date
David A. I	. Buchen	Senior VP/ General Counsel
Pr	Printed or Typed Name	Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



#### UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Addrew COMMISSIONER FOR PATENTS PO. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NUMBER FILING OR 371 (c) DATE FIRST NAMED APPLICANT ATTY. DOCKET NO./TITLE

09/705,625

11/03/2000

Xiu Xiu Cheng

141-603

**CONFIRMATION NO. 6705** 

\*OC000000025208359\*

47888 HEDMAN & COSTIGAN P.C. 1185 AVENUE OF THE AMERICAS NEW YORK, NY 10036

Date Mailed: 08/06/2007

#### NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 07/23/2007.

The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the above address as provided by 37 CFR 1.33.

the



#### UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO./TITLE
			000 1010

09/705,625

11/03/2000

Xiu Xiu Cheng

300.1012

CONFIRMATION NO. 6705

23280 DAVIDSON, DAVIDSON & KAPPEL, LLC 485 SEVENTH AVENUE, 14TH FLOOR NEW YORK, NY 10018

Date Mailed: 08/06/2007

#### NOTICE REGARDING CHANGE OF POWER OF ATTORNEY

This is in response to the Power of Attorney filed 07/23/2007.

• The Power of Attorney to you in this application has been revoked by the assignee who has intervened as provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).

ill

Office of Initial Patent Examination (571) 272-4000, or 1-800-PTO-9199
OFFICE COPY

NO TO	BEIWOIK NEGOCIOTI ACTOL 1995	. no bersor	Application Number	09/705,62	formation unless it displays a valid OMB control number
10 2 2007 E TE	RANSMITTAL		Filing Date	November	3, 2000
اپير ٢٠٥١ ک	FORM		First Named Inventor	Cheng et a	al.
			Art Unit	1615	
(to be used for	all correspondence after initial	filim m)	Examiner Name	T. Ware	
(10 DC USCU 101	<u> </u>	3	Attorney Docket Number	141-603	
		ENC	LOSURES (Check al	ll that apply	()
Amendm A A	smittal Form ee Attached ent/Reply fter Final ffidavits/declaration(s) n of Time Request		Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a  Provisional Application  Power of Attorney, Revocation  Change of Correspondence  Terminal Disclaimer		After Allowance Communication to TC  Appeal Communication to Board of Appeals and Interferences  Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below):  Statement Under 37 CFR 3.73 (b)
Information	Abandonment Request on Disclosure Statement		Request for Refund  CD, Number of CD(s)  Landscape Table on C	:D	Return Receipt Postcard
Reply to Incomple	Missing Parts/ te Application eply to Missing Parts nder 37 CFR 1.52 or 1.53	Rema			
Firm Name	SIGNA	TURE (	OF APPLICANT, ATTO	DRNEY, C	DR AGENT
Firm Name	HEDMAN & COSTIGAN,	P.C.			
Signature	160	11			
Printed name	Matthew J. Solow				
Date	July 19, 2007			Reg. No.	56,878

Signature Date July 19, 2007 Matthew J. Solow Typed or printed name This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

the date shown below:

gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/81 (01-06) Approved for use through 12/31/2008. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	09/705,625
Filing Date	November 3, 2000
First Named Inventor	Cheng et al.
Title	Methods for Treating Diabetes Via
Art Unit	1615
Examiner Name	T. Ware
Attorney Docket Number	141-603

I hereby revoke a	II previo	us powers of attorney gi	ven in the	above-ide	ntified applic	ation.			
I hereby appoint:									
✓ Practitioners a	ssociated	with the Customer Number:		478	88				
OR									
Practitioner(s)	named be	low:							
		Name			Registrat	tion Number	•		
<u> </u>									
	<del></del>								
	<del></del>		<del>  </del> -						
						· · · · · · · · · · · · · · · · · · ·			
as my/our attorney(s) Trademark Office cor		s) to prosecute the application erewith.	identified ab	ove, and to t	ransact all busin	ess in the U	Inited Stat	es Patent and	
Please recognize or o	hange the	correspondence address for t	he above-ide	entified applic	cation to:				
	Please recognize or change the correspondence address for the above-identified application to:								
OR	The address associated with the above-mentioned Customer Number:  OR								
OR	s associat	ed with Customer Number:							
Firm or Individua	l Name								
Address				i		· · · · · · · · · · · · · · · · · · ·			
City				State			Zip		
Country				[ <del>**</del> :11					
Telephone I am the:				Email					
Applicant/In	entor.								
<del>     </del>		the entire interest. See 37 CFR	2 7 7 1						
		FR 3.73(b) is enclosed. (Form							
	•	SIGNATURE of	Applicant o	r Assignee	of Record				
Signature	1	obesta hoom	21			Date	Tuy	fossis!	
Name	Roberta					Telephone	954-762-	6211	
Title and Company	Vice Pre	sident, Chief Compliance Offic	er and Assis	tant General	Counsel; Andrx	Corporation	n		
NOTE: Signatures of all signature is required, se		rs or assignees of record of the ent	ire interest or t	their representa	ative(s) are require	ed. Submit mu	ittiple forms	if more than one	;
✓ *Total of 1		forms are submitted.							

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/96 (04-07) Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

he Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER STOCK 3.10	<u>101</u>
Applicant/Patent Owner: Xiu Xiu Cheng et al.	
Application No./Patent No.: 6,790,459 Filed/Issue Date: September	er 14, 2004
Entitled: METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROL	LED RELEASE METFORMIN
Andrx Labs, LLC , a <u>Limited Liability Company</u> (Name of Assignee) (Type of Assignee, e.g., corpor	vation, partnership, university, government agency, etc.)
states that it is:  1.  the assignee of the entire right, title, and interest; or	
2. an assignee of less than the entire right, title and interest (The extent (by percentage) of its ownership interest is %)	
in the patent application/patent identified above by virtue of either:	
A An assignment from the inventor(s) of the patent application/patent identified in the United States Patent and Trademark Office at Reel, Fithereof is attached.  OR	
B. A chain of title from the inventor(s), of the patent application/patent identified	d above, to the current assignee as follows:
To: Andrx Corporation The document was recorded in the United States Patent and Tradem Reel 011687, Frame 0690, or for which a coperation.  Andrx Corporation, A Florida Corporation The document was recorded in the United States Patent and Tradem.	nark Office at py thereof is attached. A Delaware Corporation nark Office at
Reel <u>013792</u> , Frame <u>0227</u> , or for which a c	opy thereof is attached.
3. From: Andrx Corporation To: Andrx Labs, LLC	
The document was recorded in the United States Patent and Tradem Reel 013788 , Frame 0187 , or for which a	
Additional documents in the chain of title are listed on a supplemental sh	eet.
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain cassignee was, or concurrently is being, submitted for recordation pursuant to 37 C	of title from the original owner to the FR 3.11.
[NOTE: A separate copy (i.e., a true copy of the original assignment documen Division in accordance with 37 CFR Part 3, to record the assignment in the 302.08]	
The undersigned (whose title is supplied below) is authorized to act on behalf of th	ie assignee.
Ebertahooman	July 12,2007
Signature	Date
Roberta Loomar	954-762-6211
Printed or Typed Name	Telephone Number
Vice President, Chief Compliance Officer and Assistant General Counsel	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





#### IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicants:

Xiu Xiu CHENG, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

METHODS FOR TREATING DIABETES VIA

ADMINISTRATION OF CONTROLLED

**RELEASE METFORMIN** 

Art Unit:

1615

#### RESPONSE TO NOTICE REGARDING DRAWINGS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 August 2, 2004

Sir:

In response to the Notice Regarding Drawings, dated June 21, 2004, Applicants submit replacement drawings, Figures 1-8.

If any additional fees are deemed to be due at this time, the Commissioner is authorized to charge payment of the same to Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:

Robert J. Paradiso

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14<sup>th</sup> Floor New York, NY 10018 (212)736-1940

**FORM PTO-1083** 

COMMISSIONER FOR PA

P.O. BOX 1450

Alexandria, VA 22313-1450

In re application of: Xiu Xiu CHENG, et al.

Serial No.: 09/705,625 November 3, 2000 Filed:

For:

METHODS FOR TREATING DIABETES VIA ADMINISTRATION

OF CONTROLLED RELEASE METFORMIN

Sir:

Transmitted herewith is a Response to Notice Regarding Drawings in the above-identified application.

- [] Small entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.
- A verified statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.
- [X] No fee for additional claims is required.
  - [] A filing fee for additional claims calculated as shown below, is required:

FOR:	(Col. 1) REMAINING	(Col. 2) HIGHEST	<u>-</u>	SMALL ENTITY   RATE   FEE	OR	LARGE ENTITY RATE FEE
	AFTER	PREVIOUSLY	PRESENT			
	AMENDMENT	PAID FOR	EXTRA			
TOTAL CLAIMS	* Minu	s 20** =		x \$ 9   \$		x \$ 18  \$
INDEP. CLAIMS	* Minu	s 3*** =	0	x \$ 42  \$		x \$ 84  \$
[ ] FIRST PRES	SENTATION OF	MULTIPLE DE	EP. CLAIM	+ \$140 \$		+ \$280 \$
-						

TOTAL: \$ OR TOTAL:

Docket No.: 300.1012 Date: August 2, 2004

- If the entry in Co. 1 is less than the entry in Col. 2, write "0" in Col. 3.

  If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

  If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.
- [X] Also transmitted herewith are:
  - [ ] Petition for one-month extension under 37 C.F.R. 1.136 (in duplicate)
  - [X] Other: Eight sheets of drawings
- [] Check(s) in the amounts of \$.00 is/are attached to cover:
  - ∏ Filing fee for additional claims under 37 C.F.R. 1.16
  - Petition fee for one month extension under 37 C.F.R. 1.136
  - [X] Other:
- The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this [X] communication or credit any overpayment to Deposit Account No. 50-0552. A duplicate copy of this sheet is enclosed.
  - Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by [X] check submitted herewith.
  - [X] Any patent application processing fees under 37 C.F.R. 1.17.
  - Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, [X] and it is hereby requested that this be a petition for an automatic axtension of time under 37 CFR

1.136.

Robert J. Paradiso, Reg. No. 41,240 DAVIDSON, DAVIDSON & KAPPEL, LLC 485 Seventh Avenue, 14th Floor


New York, New York 10018


(212) 736-1940


I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" on August 2, 2004


DAVIDSON, DAVIDSON & KAPPEL, LLC


Juerdolino Decoste Guendoline Decosta












20

Inventor: Xiu Xiu Cheng, et al. Application Serial No.: 09/705,625

6/8



9

AMOUNT RELEASED (%)

8


120





RELEASE METFORMIN Inventor: Xiu Xiu Cheng, et al. Application Serial No.: 09/705,625

7/8






METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE METFORMIN

Inventor: Xiu Xiu Cheng, et al. Application Serial No.: 09/705,625

8/8





\*RETURN TO FMF - LOCATION 7540 Pat

			1011 1040 K (1.//
QUERY CONTROL FOR			RTIS USE ONLY
Application No. <u>0970</u>	95625 Prepared	d by Da	Tracking Number
Examiner-GAU	n - 16 15 Date	6-2-AU	Week Date
	No. of qu	ueries (A)	
	Affni Chic	PDrafts Jerser	)
	J	ACKET /	
a. Serial No.	f. Foreign Priority	k. Print Claim(s)	p. PTO-1449
b. Applicant(s)	g. Disclaimer	I. Print Fig.	q. PTOL-85b
c. Continuing Data	h. Microfiche Appendix	m. Searched Colum	•
d. PCT	i. Title	n. PTO-270/328	(s.)Sheets/Figs
e. Domestic Priority	j. Claims Allowed	o. PTO-892	t. Other

SPECIFICATION	MESSAGE Sheats/fias: Copy mark. Fias
a. Page Missing	1-8.
b. Text Continuity	MESSAGE Sheats/figs: Copy mark. Figs 1-8. Plaase Pasolva.
c. Holes through Data	· ·
d. Other Missing Text	
e. Illegible Text	
f. Duplicate Text	
g. Brief Description	
h. Sequence Listing	
i. Appendix	·
j. Amendments	
k. Other	
CLAIMS	
a. Claim(s) Missing	
b. Improper Dependency	
c. Duplicate Numbers	Thank You
d. Incorrect Numbering	initials $DG$
e. Index Disagrees	RESPONSE SEE ATTACHMENT
f. Punctuation	948
g. Amendments	T C
h. Bracketing	
i. Missing Text	
j. Duplicate Text	
k. Other	
	initials (1/1)



#### UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NUMBER
FILING/RECEIPT DATE
FIRST NAMES APPLICANT
ATTORNEY DOCKET NUMBER
CHENG, XIU XIU
300.1012

DAVIDSON, DAVIDSON & KAPPEL, LLC 485 SEVENTH AVENUE, 14TH FLOOR NEW YORK NY 10018 Examiner TRAN, SUSAN

<u>Art Unit</u> 1615

Paper Number

Date Mailed: 06-21-04

## **Notice Regarding Drawings**

Corrected drawings for the above-identified application, received in the USPTO on 11-3-00 are still not acceptable for the reason(s) identified on the attached PTO-948. Applicant is given one opportunity to correct the informalities within a two-month time period from the mailing date of this Notice. THIS TIME PERIOD IS NOT EXTENDABLEUNDER EITHER 37 CFR 1.136(a) OR 1.136(b). Failure to take corrective action within the set period will result in abandonment of the application.

ATTACHMENT: PTO-948 Notice of Draftsperson's Patent Review

RETURN CORRECTED DRAWINGS TO:

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Joshua D. Chase

Office of Patent Publication,

**Publishing Division** 

703-305-8430

# Best Available Copy

#### NOTICE OF DRAFTSPERSON'S PATENT DRAWING REVIEW

categories of drawings: Black ink or Color (3 sets required).  Color drawings are not acceptable until petition is granted. Fig(s)  Pencil and non black ink not permitted. Fig(s)  2. PHOTOGRAPHS. 37 CFR 1.84(b)  One (1) full-tone set is required. Fig(s)  Photographs may not be mounted. 37 CFR 1.84(e)  Photographs must meet paper size requirements of 37 CFR 1.84(f). Fig(s)  Poor quality (half-tone). Fig(s)  3. TYPE OF PAPER. 37 CFR 1.84(e)  Paper not flexible, strong, white, and durable. Fig(s)  Erasures, alterations, overwritings. interlineations, folds, copy machine marks not accepted. Fig(s)  4. SIZE OF PAPER. 37 CFR 1.84(f): Acceptable sizes:  21.0 cm by 29.7 cm (DIN size A4) or  21.6 cm by 27.9 cm (8 1/2x 11 inches)  All drawing sheets not the same size. Sheet(s)  Drawings sheets not an acceptable size. Fig(s)  5. MARGINS. 37 CFR 1.84(g): Acceptable margins:  Top 2.5 cm Left 2.5 cm Right 1.5 cm Bottom 1.0 cm  Margins not acceptable. Fig(s)  Top (T)  Left (L)  Right (R)  Bottom (B)  6. VIEWS. 37 CFR 1.84(h)  REMINDER: Specification may require revision to correspond to drawing changes, e.g., if Fig. 1 is changed to Fig. 1A, Fig 1B and Fig. 1C, etc., the specification, at the Brief Description of the Drawings, must likewise be changed.  Views not labeled separately or properly.  Fig(s)  7. SECTIONAL VIEWS. 37 CFR 1.84(h)(3)  Sectional designation should be noted with Arabic or Roman numbers. Fig(s)	8. ARRANGEMENT OF VIEWS. 37 CFR 1.84(i)  Words do not appear on a horizontal, left-to-righ fashion when page is either upright or turned so that the top becomes the right side, except for graphs. Fig(s)  9. SCALE. 37 CFR 1.84(k)  Scale not large enough to show mechanism without crowding when drawing is reduced in size to two-thirds in reproduction.  Fig(s)  10. CHARACTER OF LINES, NUMBERS, & LETTERS. 37 CFR 1.84(l)  Ines, numbers & letters not uniformly thick and well defined, clean, durable, and black (poor line quality). Fig(s)  Solid black areas pale. Fig(s)  Solid black shading not permitted. Fig(s)  12. NUMBERS, LETTERS, & REFERENCE  CHARACTERS. 37 CFR 1.84(p)  Numbers and reference characters not plain and legible. Fig(s)  Figure legends are poor. Fig(s)  Figure legends are poor. Fig(s)  Fig(s)  English alphabet not used. 37 CFR 1.84(p)(2)  Fig(s)  Numbers, letters and reference characters must be at least 32 cm (1/8 inch) in height. 37 CFR 1.84(p)(2)  Fig(s)  13. LEAD LINES. 37 CFR 1.84(q)  Lead lines missing. Fig(s)  14. NUMBERING OF SHEETS OF DRAWINGS. 37 CFR 1.84(t)  Sheets not numbered consecutively, and in Arabin numbers beginning with number 1. Sheet(s)  15. NUMBERING OF VIEWS. 37 CFR 1.84(u)  Views not numbered consecutively, and in Arabin numbers beginning with number 1. Fig(s)  16. DESIGN DRAWINGS. 37 CFR 1.152  Surface shading shown not appropriate.  Fig(s)  Solid black surface shading is not permitted excewhen used to represent the color black as well as
---	--





#### PART B - FEE(S) TRANSMITTAL



Ad send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE **Commissioner for Patents** P.O. Box 1450 Alexandria, Virginia 22313-1450

(703) 746-4000 or <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications. CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1) Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission. 02/11/2004 23280 7590 DAVIDSON, DAVIDSON & KAPPEL, LLC Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below. 485 SEVENTH AVENUE, 14TH FLOOR NEW YORK, NY 10018 (Depositor's name) Ashby (Signature April 29, 2004 (Date) FIRST NAMED INVENTOR FILING DATE ATTORNEY DOCKET NO. CONFIRMATION NO. APPLICATION NO. 11/03/2000 300.1012 09/705.625 Xiu Xiu Cheng 6705 TITLE OF INVENTION: METHODS FOR TREATING DIABETES VIA ADMINISTRATRION OF CONTROLLED RELEASE METFORMIN ADMINISTRATION SMALL ENTITY ISSUE FEE **PUBLICATION FEE** TOTAL FEE(S) DUE DATE DUE APPLN, TYPE NO \$1330 \$0 \$1330\_\_ 05/11/2004 nonprovisional \$1360 **EXAMINER** ART UNIT CLASS-SUBCLASS TRAN, SUSAN T 1615 424-468000 1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). 2. For printing on the patent front page, list (1) the names of up to 3 registered patent attorneys or Davidson, Davidson & agents OR, alternatively, (2) the name of a single  $\hfill \Box$  Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. Kappel, LLC firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent "Fee Address" indication (or "Fee Address" Indication form attorneys or agents. If no name is listed, no name PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer Number is required. will be printed. 3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type) PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (B) RESIDENCE: (CITY and STATE OR COUNTRY) (A) NAME OF ASSIGNEE Andrx Labs, LLC Davie, Florida Pleas check the appropriate assignee category or categories (will not be printed on the patent); ☐ individual ☐ Carporation or other private group entity 4a. The following fee(s) are enclosed: 4b. Payment of Fee(s): State Fee A check in the amount of the fee(s) is enclosed. □ Publication Fee ☐ Payment by credit card. Form PTO-2038 is attached. 2 The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number 50-0552 (enclose an extra copy of this form). Advance Order - # of Copies 10 Director for Patents is requested to apply the Issue fee and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above. (Authorized Signature) <sup>(Date)</sup>April 29, 2004 Robert Paradi Rea No NOTE; The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office. 05/04/2004 WABRHAM2 00000058 09705625 1330.00 OP This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. Alexandria, Virginia 22313-1450. 02 FC:8001 30.00 OP

TRANSMIT THIS FORM WITH FEE(S)

SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

#### NOTICE OF ALLOWANCE AND FEE(S) DUE

7590

02/11/2004

DAVIDSON, DAVIDSON & KAPPEL, LLC 485 SEVENTH AVENUE, 14TH FLOOR NEW YORK, NY 10018

EXAMINER TRAN, SUSAN T ART UNIT PAPER NUMBER 1615

DATE MAILED: 02/11/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/705,625	11/03/2000	Xiu Xiu Cheng	300.1012	6705

TITLE OF INVENTION: METHODS FOR TREATING DIABETES VIA ADMINISTRATRION OF CONTROLLED RELEASE METFORMIN

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$0	\$1330	05/11/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

☐ Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Page 1 of 3

#### PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

(703) 746-4000 or Fax

INSTRUCTIONS: This for appropriate. All further corr indicated unless corrected b maintenance fee notification	elow or directed otherwise	ratent, advance orders and not in Block 1, by (a) specifying	tification of a new co	of maintenance fees werrespondence address;	vill be mailed to the current and/or (b) indicating a sepa	correspondence address as trate "FEE ADDRESS" for
CURRENT CORRESPONDENCE	E ADDRESS (Note: Legibly mark-up	with any corrections or use Block 1)	]	Fee(s) Transmittal. Thi papers. Each additiona	mailing can only be used for its certificate cannot be used for a paper, such as an assignment of mailing or transmission.	for any other accompanying
	VIDSON & KAPPE ENUE, 14TH FLOOR		 	Cer I hereby certify that th States Postal Service v addressed to the Mail	rtificate of Mailing or Trans is Fee(s) Transmittal is being with sufficient postage for fir I Stop ISSUE FEE address TO, on the date indicated bel	g deposited with the United st class mail in an envelope above, or being facsimile
			[			(Depositor's name)
						(Signature)
						(Date)
APPLICATION NO.	FILING DATE	FIRST NAME	ED INVENT	TOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/705,625	11/03/2000	Xiu X	iu Cheng		300.1012	6705
TITLE OF INVENTION: M	ETHODS FOR TREATING	DIABETES VIA ADMINIST	RATRIO	N OF CONTROLLED	RELEASE METFORMIN	
APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PU	BLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330		\$0	\$1330	05/11/2004
EXAM	INER	ART UNIT	CL	ASS-SUBCLASS	]	
TRAN, S	USAN T	1615		424-468000		
CFR 1.363).  Change of corresponde Address form PTO/SB/12  "Fee Address" indicative PTO/SB/47; Rev 03-02 (Number is required.  3. ASSIGNEE NAME AND DIFFASE NOTE: Upless	on (or "Fee Address" Indicator more recent) attached. Use RESIDENCE DATA TO B an assignee is identified beld to the USPTO or is being s	correspondence agents C firm (har agent) as attorneys will be p  E PRINTED ON THE PATEN tow, no assignee data will apparent the firm of the cover agent.	of up to COR, alternativing as a and the nais or agent wrinted.  NT (print one ar on the COMPLET.	natent Inclusion of a	ttorneys or 1	ate when an assignment has ignment.
Please check the appropriate	assignee category or catego	ries (will not be printed on the	patent);	□ individual □ o	corporation or other private g	roup entity
4a. The following fee(s) are	enclosed:	4b. Payment of	` '			
☐ Issue Fee				ount of the fee(s) is end card. Form PTO-2038		
☐ Publication Fee ☐ Advance Order - # of	Copies	The Dir	rector is he	ereby authorized by cl	harge the required fee(s), or	credit any overpayment, to
		Deposit Ac		any previously paid i		
(Authorized Signature)		(Date)				
NOTE: The Issue Fee an	d Publication Fee (if requir a registered attorney or ag cords of the United States P.	ed) will not be accepted from ent; or the assignce or other atent and Trademark Office.	n anyone party in			
This collection of information obtain or retain a benefit application. Confidentialitiestimated to take 12 minu completed application for case. Any comments on suggestions for reducing Patent and Trademark 22313-1450. DO NOT SEND TO: Commissioner	ation is required by 37 CFR by the public which is to fy is governed by 35 U.S.C. tes to complete, including gm to the USPTO. Time with amount of time you this burden, should be sent Office, U.S. Department SEND FEES OR COMPLE for Patents, Alexandria, Vir	1.311. The information is reile (and by the USPTO to pro 122 and 37 CFR 1.14. This col athering, preparing, and subm II vary depending upon the in require to complete this form to the Chief Information Offi of Commerce, Alexandria, TTED FORMS TO THIS AD 1313 1450.	quired to ocess) an lection is itting the ndividual m and/or cer, U.S. Virginia DDRESS.			



#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/705,625	11/03/2000	Xiu Xiu Cheng	300.1012	6705
23280 75	90 02/11/2004		EXAMI	NER
DAVIDSON, DA	VIDSON & KAPPEL, LI	LC .	TRAN, SU	JSAN T
485 SEVENTH AV NEW YORK, NY 1	ENUE, 14TH FLOOR		ART UNIT	PAPER NUMBER
NEW TORK, NT	10010		1615	
	•		DATE MAILED: 02/11/2004	ī

#### Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

	Application No.	Applicant(s)	-			
	09/705,625	CHENG ET AL.				
Notice of Allowability	Examin r	Art Unit				
	Susan T. Tran	1615				
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED or other appropriate comn IGHTS. This application is and MPEP 1308.	in this application. If not included nunication will be mailed in due cou subject to withdrawal from issue a	ırse. <b>THIS</b>			
1. This communication is responsive to <u>Amendment filed 07/</u>		<u>2/01/03</u> .				
2. X The allowed claim(s) is/are 1,4,5,7-11,14,15,18,22,26-31 a						
3. The drawings filed on <u>11/03/00</u> are accepted by the Exami		(6)				
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) ☐ All b) ☐ Some* c) ☐ None of the:</li> </ul>						
<ol> <li>Certified copies of the priority documents have</li> </ol>						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this national stage application from the						
International Bureau (PCT Rule 17.2(a)).						
* Certified copies not received:						
<ul> <li>5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.</li> <li>(a) The translation of the foreign language provisional application has been received.</li> <li>6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.</li> </ul>						
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of	f this communication to file this application. THIS TH	a reply complying with the requirent REE-MONTH PERIOD IS NOT EX	ments noted			
7. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			TICE OF			
<ol> <li>CORRECTED DRAWINGS (as "replacement sheets") must</li> <li>(a)  including changes required by the Notice of Draftspers</li> <li>1)  hereto or 2)  to Paper No</li> </ol>	son's Patent Drawing Revie	•				
(b) $\square$ including changes required by the proposed drawing c		ch has been approved by the Exar				
(c) $\square$ including changes required by the attached Examiner'	s Amendment / Comment o	or in the Office action of Paper No.	·			
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t	.84(c)) should be written on he margin according to 37 (	the drawings in the front (not the ba FR 1.121(d).	ck) of			
<ol> <li>DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT FOR T</li> </ol>	sit of BIOLOGICAL MATHE DEPOSIT OF BIOLOG	FERIAL must be submitted. Note SICAL MATERIAL.	e the			
Attachment(s)						
1 ☐ Notice of References Cited (PTO-892)	5☐ Notice of In	formal Patent Application (PTO-15	2)			
2 Notice of Draftperson's Patent Drawing Review (PTO-948)	6☐ Interview S	ummary (PTO-413), Paper No	·			
3⊠ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No	3), 7□ Examiner's	Amendment/Comment				
4 Examiner's Comment Regarding Requirement for Deposit of Biological Material	8⊡ Examiner's 9⊡ Other	Statement of Reasons for Allowan  James M.,  JAMES M. SPE  PRIMARY EXAMI  A U 16 15	Spear IAR INER			

Sheet 1 of 4

Sheet 2 of 4

								<u>V</u>	RAU	315					
FORM PTO-1 (REV. 7-80)				MENT TRAD							ATTY, DOCKET 300,1012	NO.	SERIAL N 09/705,625		
1	REFEREN			BY A	PPLIC	ANT				·	APPLICANTS Chih-Ming CHEN	, et al.			
·											FILING DATE November 3, 2000	00	GROUP	1615	
								11	C DAT	ENT DOCUME			,	· • • · ·	
EXAMINER INITIAL									J. 1741	DATE	NAME	CLASS	SUB- CLASS		
5.7	ВА	5	5	6	ı	4	5	7	8.	3/25/97	Dong et al.	524	377		
	ВВ	5	5	5	9	_	4	5	-4	1/7/97	Kuczynski et al.	424	486		
	ВС	1-	, ·	5	4	5	4	,	3	8/13/96	Kuczynski et al.	424	473		
	BD	5		5	4	3	1	5	6	8/6/96	Roorda et al.	424	484		
	BE	5		5	1	2	2	9	3	4/30/96	Landrau et al.	424	449		
	BF	5		4	_	3	5	7	2	5/9/95	Wong et al.	604	892.1		
								4	8	5/3/94	Balaban et al.	604	892.1		
	BG	-5		3	0	8	3						473		
	ВН	- 5		1	8	5	1	5	8	2/9/93	Ayer et al	424			
<del> </del>	BI	- 5		_1	7	8 -	8	6	7	1/12/93	Guittard et al.	424	473	700,625  ROUP 14-   (e   S    JB-ASS   FILING DATE IF APPROPRIATE  7  6  3  4  9  2.1  2.1  3  3  3  4  5.06  2.1  JB-ASS   TRANSLATION YES	· · · · · ·
	BJ	1_5	5	1	4	1	7	5	2	8/25/92	Ayer et al.	424	473		
-	BK	5	5	1	2	0	5	4	8	6/9/92	McClelland et al.	424	473 ·		
<del> </del>	BL	1-5	5	1	1	0	5	9	7	5/5/92	Wong et al.	424	438		
<del>  </del>	BM		5	0	9	1	i	9	0	2/25/92	Kuczynski et al.	424	473		
-	BN	1.5	5	0	7	1	6	0	7	12/10/91	Ayer et al.	264	112		
	во	1.5	5	0	2	4	8	4	3	6/18/91	Kuczynski et al.	514	255.06		
	ВР	14	-	9	6	3	1	4_	1	10/16/90	Eckenhoff	604	892.1		
	BQ	14		8	9	2	7	3	9	1/9/90	Shah et al.	424	473		
3,7	BR	4	1	8	6	5	5	9	8	9/12/89	Eckenhoff	604	892.1		
· 								FORE	EIGN P	ATENT DOCU	MENTS				
										DATE	COUNTRY	CLASS	SUB-	TRANSLATIO	ON .
													CLASS	YES	NO
	BS	T													
					OTI	ER RE	FERE	VCES (	Includi	ng Author, Title,	Date, Pertinent Pages	, Etc.)			
	ВТ									·					
EXAMINER		•		S	$\overline{\tau}$						DATE CONSIDE	RED I	18/04		
				dered, w	hether	or not		is in c	onform	ance with MPEF				ince and not cons	idered

Sheet 3 of 4

<del></del>					X	<b>_</b>	أعدت								
FORM F (REV. 7	PTO-1449 -80)		. DEPAR TENT AN		OF C	OMME	RCE				ATTY. DOCKE: 300.1012	ΓNO.	SERIAL 1 09/705,62		
		EFERENC al sheets if			PPLIC	CANT				•	APPLICANTS: Chih-Ming CHEI	N, et al.			
				•							FILING DATE November 3, 200	0	GROUP 1614-	1615	
					•			u	.S. PAT	TENT DOCUME	ENTS	W	· · · · · · · · · · · · · · · · · · ·		
EXAMI INITIAL										DATE	NAME	CLASS	SUB- CLASS	FILING DA	
2	77.	CA	4	8	5	1	. 2	2	9	7/25/89	Magruder et al.	424	457	ATRONG	MIL .
		СВ	4	. 7.	8	3	3	3	7	1 1/8/88	Wong et al.	424	468		
	ļ	СС	4	7	7	7	0	4	9	10/11/88	Magruder et al.	424	457		
		CD	4	7	0	4	1	1	8	11/3/87	Eckenhoff	424	438		
		CE	4	6	9	.2	3	3	6	9/8/87	Eckenhoff et al.	424	468		
		CF	4	6	2	7	8	5	0	12/9/86	Deters et al.	604	892.1		
		CG	4	6	2	4	8	4	7	11/25/86	Ayer et al.	424	467		
	· <del></del>	СН	4	6	1	5	6	9	8	. 10/7/86	Guittard et al.	604	892.1	ļ <u>.</u>	
		CI	. 4	6.	1	2	0	0	8	9/16/86	Wong et al.	604	892.1		· · ·
		CJ	4	6	0	9	3	7	4 .	9/2/86	Ayer	424	473	· · ·	. <u></u>
		СК	4	5	8	7	1	1	7	5/6/86	Edgren et al.	424	473	ļ	·
	<b> </b> -	CL	4	5	2	2	6	2	5	6/11/85	Edgren	424	473		
•	<b>-</b>	СМ	4	1	1	1	2	0	1	9/5/78	Thecuwes	424	473		
	<u> </u>	CN	4	0	8	8	8	6	4	5/9/78	Theeuwes et al.	219	121.71		
	-	со	4	0	8		4	7	2	3/21/78	Bohuon	\$14	555		
		СР	4	0	7	7	4	0	7	3 <i>/7/</i> 78	Thecuwes et al.	424	427		
	. ``	CQ	4	0	6	3	0	6	4	12/13/77	Saunders et al.	219	121.7		
		·						FORE	IGN P	ATENT DOCUM	MENTS		· .		
				•				ė		DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLAT	ION
	· .			i i	<del></del>	<del></del> [	— т						CLASS	YES	NO
	:_	CR													1
	<del></del>	<u>i</u>			отн	ER RE	FEREN	CES (I	ncludin	g Author, Title,	Date, Pertinent Pages	, Etc.)	<del></del>		
	i	CS	•			•				· · ·			<del></del>	<del></del>	
•EXAMIN	ÆR: Initi	al if refere	nce consid	dered, wi	nether	or not c	itation	is in co	nforma	nce with MPEP	DATE CONSIDER			nce and not con	sidered
Include co	py of this	form with	next com	municati	on to	pplica	nt.					,			



FORM F (REV. 7	PTO-1449 (-80)		S. DEPAR' TENT AN								ATTY, DOCKET 300,1012	ſ NO.	SERIAL N 09/705,62		
LIS	T OF RE	FERENC	ES CITE	D BY A	PPLIC	CANT					ADDI ICANITO		L		
(U	Jse severa	l sheets if	necessary)	1							APPLICANTS: Chih-Ming CHEI	N, et al.			
		:									FILING DATE November 3, 200	0	GROUP 1614	1615	:
						•		U	.S. PAT	ENT DOCUME	ENTS				
EXAMII INITIAL										DATE	NAME	CLASS	SUB- CLASS	FILING DATE	É IF TE
δ	<u>T.</u>	DA	4	0	3	6	2	2	8	7/19/77	Thecuwes	424	473		
		DB	4	0	3	4	7	5	8	7/12/77	Thecuwes	424	427		
		DC	4	0	0	8	7 -	1	9	2/22/11	Theeuwes et al.	424	427		
		DD	3	9	5	7	8	5	3	5/18/76	Bohuan	560	143		
-		DE	3	9	5	2	7	4	1	4/27/76	Baker	424	405		
		DF	3	9	1	6	8	9	9	11/4/75	Thecuwes et al.	424	424		
2	1	DG	3	8	4	5	7	7	0	11/5/74	Theeuwes et al.	424	427		
		DH										·			
		DI													
		DJ							,						
-		DK													
		DL													
		DM								· · · · · · · · · · · · · · · · · · ·					
•		DN					•								
		DO													
		DP													
	,	DQ													
								FORE	IGN PA	ATENT DOCUM	ÆNTS				
										DATE	COUNTRY	CLASS	SUB-	TRANSLATIO	N
			·									0.2.100	CLASS	YES	NO
		DR													
					отн	ER RE	FEREN	CES (I	ncludin	g Author, Title.	Date, Pertinent Pages	, Etc.)			
		DS								<del>-</del>					
EXAMIN	ER		s . c	5							DATE CONSIDER	RED 1/2	8/04	<del></del>	
*EXAMIN	VER: Initi	al if refere	nce consid	iered, w	hether	or not c	itation	is in co	nforma	nce with MPEP	609, Draw line throug		ot in conforma	nce and not consid	lered.
Include co	py of this	torm with	next com	municat	ion to	applica	nt,					·			· · ·

ORM PTO-144	E .			:	U P	.S. DEF ATENT	PARTMI AND T	ENT OF RADE	COMMERCE MARK OFFICE	ATTY, DOCKET NO.: 300.1012		SERIAL NO.: 09/705,625		
	WHAT	BE MA	RIOR	ART C	ITED	BY A	PPLIC	ANT	•	APPLICANT(S): Xiu Xiu	CHENG, et al			
	(Use s	everal :	sheets i	neces:	sary)					FILING DATE: November 3, 2000		GROUP: 1615	:	
		•••						u.s	S. PATENT DOC					
XAMINER		DOC	UMEN	T NUME	BER				DATE	NAME	CLASS	SUBCLASS	FILING DAT	
T. 2	AA	6	4	7	5	5	2	1	11/05/2002	Timmins et al.	424	469	Sep. 16, 19	99
	АВ													
-	AC													
	AD				_									
	AE												<i>'</i>	
	AF													
	AG					·							1	
	•					•		FORE	IGN PATENT D	OCUMENTS				
		DOC	UMEN	r nume	BER				DATE	COUNTRY	CLASS	SUBCLASS	TRANSLAT	ION
													YES	NC
	АН													
	Al													
	AJ													
	AK													
	AL													
					01	HER P	RIOR A	vRT (Inc	luding Author, T	ille, Date, Pertinent Pages	, Etc.)			
	AM	. And	x Pilot (	Biostod	Data (	<del>20 pag</del>	<del>08)</del>		No de	ati				
	AN													
	AO													
	AP													
	AQ													
	AR													
	AS													
AMINER	S	7							•	DATE CONSIDERED	1/28/	r of		. —



Application No.	Applicant(s)	
09/705,625	CHENG ET AL.	
Examiner	Art Unit	
Susan T. Tran	1615	

	1816. A		ORIGI	NAL			_, , , , , , , , , , , , , , , , , , ,	ICATIC CRO	SS REFERENC	E(S)	Majorot, ferriliferi West 1, Majorot,	
С	LAS	SS		SUBCLASS	CLASS				NE SUBCLASS	· · · · · · · · · · · · · · · · · · ·	K) ************************************	
7/1/2	424	4		468	424	464	465	469	470	472	474	489
INT	rER	NATI	ONAL (	CLASSIFICATION	424	490		73.00				
A	6	1	к	9/14						TROUGH AND A		100000000000000000000000000000000000000
A	6	1	к	9/16				abani sa da sa				
A	6	1	к	9/20	7-11-12-12-13	AVELVE VAV	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					The state of the s
A	6	1	к	9/22			N. I				e i kantosu, ingwesio	74.640
A	6	1.	κ	9/27		7 (000000000000000000000000000000000000	Officers and see Consider S.				TOTAL CONTRACTOR	47 5 11 27 11 27
		100000000	Tran sistant	01/28/04 Examiner) (Date	e)	1 Canada (100 Cana	AMES M. IMARY EX	ANNINER		Total (	Claims Allo	owed: 21
,5005 ( 			600 (100 (110) 23 (110) 24 (110)			Jame	W M	Spe 2-00	av	the first of the contract of the property of t	.G. Claim(s)	O.G. Print Fig
	(Le	gal li	nstrum	ents Examiner) (	Date)	0 (Prir	nary Examiner	2-0	6-04		1	1

(		renur	nbere	Ι	ne sam	e ord		oresen	ted b		cant			1.0.44.00.0		1		L∐R	.1.47
Final	Original		Final	Original		Final	Original		Final	Original	in the second	Final	Original	in Chang	Final	Original		Final	Original
1	1		18	31			61			91			121			151			181
	2			32			62			92	1 1 W. H		122			152			182
	3			33			63			93			123			153			183
2	4			34			64			94			124			154			184
3	5		19	35			65			95			125			155	urmar cara		185
	6		20	36			66			96			126			156			186
4	7		21	37			67			97			127			157			187
5	8			38			68			98			128			158			188
6	9			39			69			99			129			159			189
7	10			40			70			100			130			160			190
8	11			41	1		71			101	e ei eefi.		131			161	4		191
	12		_	42			72			102			132			162			192
	13	Kabi		43			73			103			133			163			193
9	14			44			74			104			134			164			194
10	15			45			75			105			135			165			195
	16			46			76			106			136			166			196
	17			47			77			107			137			167			197
11	18			48			78			108			138			168			198
	19			49			79			109			139			169	- 200		199
	20			50			80	i Ald		110			140	Jeneral.		170			200
	.21			51			81			111			141	ing in the		171			201
12	22			52			82			112			142			172			202
	23			53			83			113			143			173			203
	24			54			84			114			144			174			204
	25			55			85			115			145			175			205
13	26			56			86			116			146			176			206
14	27			57			87			117			147			177			207
15	28			58		_	88	Maria Period		118			148	1	*****	178			208
16	29			59			89			119			149	1 - 1		179			209
17	30			60			90			120			150			180	NDO aper No		

Index	of Claims	

Application N	ĺО
---------------	----

Susan T. Tran

09/705,625

Examiner

Applicant(s)

CHENG ET AL.

Art Unit

1615

Rejected Allowed ÷

(Through num ral) Cancelled Restricted

Non-El ct d Interference

App al Α 0 Objected

Final	Original	1/28/04							F-1-1									1.00				1				1 1	- 1	
Final	Origin	8/0						1 1	2 1		<u>m</u>							F-12		<u>m</u>	- 1							
Ē	o jë									Final	Original								Final	Original								
	~	1/2								证	Orię							115	ш	Örij								
								$\perp$				_		<b>_</b>		4	_				$\dashv$		_	╄				
	1	=									51		_	4		$\perp$	_	4		101	_	-		-				_
	2					1	$\sqcup \bot$	_			52	_	$\perp$	<del> </del>		_		-		102		_	╁	╀	↓_	$\vdash$		
	3	_		-	-						53	_	┿.	<b></b>	$\vdash \vdash$	$\perp$				103			+	+	-		-	
	4	=				-	$\vdash$				54	$\dashv$	-	-			_	- 1		104	$\dashv$	-	ļ	╁			$\dashv$	$\dashv$
	5	=			+	+					55 56	-	+	+	$\vdash$			-		105 106	$\dashv$		+	+-	-	-	$\dashv$	$\dashv$
+	7	=		+			$\vdash$				57	$\perp$			<del>├</del> ─┼	+				107	-+	-	-	╁			-	$\dashv$
		=	-+	+		-	$\vdash$	-			58	-	+	+	$\vdash$	+				107	-+	+	+	+-	$\vdash$		$\dashv$	$\dashv$
	8	=		+				+			59		+	+	$\vdash$	+		- 1		109				+	$\vdash$		$\dashv$	$\dashv$
	10	_		$\dashv$	+		$\vdash$	-			60	+	+	+	H	-		-		110	$\dashv$	+	+	+	$\vdash$			$\dashv$
	11	=		+	+	+		+			61		+	+	$\vdash$	+		-		111	$\dashv$		+-	+			$\neg$	$\dashv$
	12	-	$\vdash$	-	-	$\vdash$	$\vdash$	+			62		+	+	$\vdash$	+		-		112	+	+	+	$\vdash$		H	-	$\dashv$
	13		$\dashv$	+-	+	+-	$\vdash$	+			63		+	+	+	+				113	$\dashv$	+-	+	+	-			$\dashv$
	14	=	$\vdash +$	+	+	+	-	+			64	$\dashv$	+-	+	+	+	-			114	-	+	$\dagger$	+		$\vdash$	$\dashv$	$\dashv$
	15	=	$\dashv$	+	+	H	$\vdash$	+			65	$\dashv$	+	+	<del>   </del>		+			115	$\dashv$	_	+	t		H		$\dashv$
	16	-	$\dashv$	+	+	$\vdash$	$\vdash$	+			66		+	+	$\vdash$			1:00		116	$\dashv$	十	+-	T		$\Box$		$\dashv$
	17		$\forall$	+	+		- -				67		十	+	$\vdash$	$\top$		1		117	$\neg \uparrow$	$\top$	1	T		П		$\dashv$
	18	=									68			1						118								
	19			T	+		H		100		69	$\neg$	+	1				1 -		119	1		1	Т				
	20				1	1					70		T	1						120				1			$\neg$	
	21										71		$\top$					1		121			T		Г			
	22	=							bi		72			1						122	$\neg \vdash$							
	23										73								-	123								
	24										74									124								
	25					L.,					75									125					L			
	26	=									76			1_						126			1					
	27	=				<u> </u>	Ш				77							4		127			_	_			_	$\dashv$
	28	=							Ė.		78		4_	↓_						128			1					$\dashv$
	29	=				ļ.,					79		$\perp$		$\sqcup$	_				129	_		1	┺			_	_
	30	=			4_	<u> </u>	$\sqcup \bot$				80		_	1	$\sqcup$	_				130			-	_			_	$\dashv$
	31	=			_		Ш		file.		81			4	$\sqcup$			1000		131	$\perp$		4	ـــ				_
	32	_			_		$\sqcup$				82	_			$\vdash \vdash$	_		1985		132	$\dashv$	_		<u> </u>	$\vdash$		_	_
	33			4	_	<b>-</b>		$\perp$			83	_	+	+	$\vdash$					133	-+	-	+	╀	ļ		_	_
	34			+	+	$\vdash$	$\vdash \vdash$	+			84		+	$\perp$	$\vdash$	+		-		134	+		+	+	$\vdash$			$\dashv$
	35	=			+	$\vdash$	$\vdash \vdash$	+			85	+	+-	+		+		-135		135 136	+	-+-	+-	+-		$\vdash$	-	$\dashv$
	36 37	=	$\dashv$	+	+	$\vdash$	$\vdash$	+			86 87	+	+	+	$\vdash$	+-	-			136	$\dashv$		+-	+-	$\vdash$		$\dashv$	$\dashv$
	38	-	-+	+	+	$\vdash$	$\vdash$	+			88	+	+	+		+	-			138	$\dashv$	+	+	+	-	$\vdash$	$\dashv$	$\dashv$
	39	_	$\dashv$	+	+	$\vdash$	$\vdash$	+			89	-	+-	+-	+	+-				139	$\dashv$	-+-	+	╁╌	$\vdash$	$\vdash$	$\dashv$	$\dashv$
	40	_	$\vdash$	$\dashv$		+-					90	+	+	+	$\vdash$	+			····	140	$\dashv$	+	+	+			$\dashv$	$\dashv$
	41	_	$\dashv$	+	+	+-	++	+-			91	+	+	+	$\vdash$	+				141	$\dashv$		+	+		$\vdash$		$\dashv$
	42		$\dashv$	+	+	+	$\vdash$	+			92	+	+	+	$\vdash$	+	-+-			142	$\dashv$	+	$\dagger$	+-		H	$\neg$	$\exists$
	43		-		+-	+	+ +				93	-+-	+-	+-	$\vdash$	+	$\dashv$			143	$\dashv$	$\dashv$	†	+				$\neg$
	44	_	-	+	+	<b>†</b>	-	$\dashv \dashv$			94		+	$\top$	-	$\dashv \dashv$				144	_	$\dashv$	1	T				
	45		$\dashv$	+	+-	+		+			95	_	$^{+}$	$\top$		$\top$				145	$\dashv$		1	†				$\neg$
	46		$\dashv$	$^{+}$	+	+-	<del>                                     </del>	$\top$			96	一十	$\top$		1	$\neg$		1 1		146	十	$\top$		1		П	$\neg$	$\Box$
	47		$\dashv$	+		$\vdash$	$\vdash$	$\dashv \dashv$	77.7		97		$\top$			$\top$				147		$\neg \vdash$	1	†				
	48	$\exists$	$\dashv$	$\top$	$\top$	<del>                                     </del>	t	$\top$	ii.		98	_	$\top$			$\top$		1.0		148				1				
	49		$\neg$	$\top$	$\top$	T					99	$\neg \vdash$	T	Т						149								
	50			$\top$					No.		100									150			L					



#### UNITED STATES PATENT AND TRADEMARK OFFICE

Re

Application of:

Xiu Xiu Cheng, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods for Treating Diabetes Via Administration Of Controlled Release

Metformin

Examiner: T. Ware

Art Unit: 1615

#### INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

February 28, 2003

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R.§1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application.

Applicants note that reference AM is being submitted in an envelope labeled "PROPRIETARY MATERIAL NOT OPEN TO PUBLIC. TO BE OPENED ONLY BY EXAMINER OR OTHER AUTHORIZED U.S. PATENT AND TRADEMARK OFFICE EMPLOYEE." as this material in the envelope is considered proprietary and is being submitted for consideration under MPEP §724 (8th Edition).

The biostudy (which resulted in the data submitted as reference AM) was performed using formulations prepared in accordance with U.S. Patent No. 6,099,859. It is noted that the exemplified formulations did <u>not</u> provide a T<sub>max</sub> between 8-12 hours except when the formulation prepared in accordance with Example 3 was administered at dinner. As set forth in the accompanying biostudy data, the mean T<sub>max</sub> values for the Examples of the '859 were as follows: Example 1 (fasting) 4.67 hours (*See*, *e.g.*, pages 1 and 3 of the biostudy); Example 2 (fasting) 4.33 hours (*See*, *e.g.*, pages 10 and 12 of the biostudy); Example 2 (fed a.m.) 6.80 hours (*See*, *e.g.*, pages 13, 14 and 16 of the biostudy); Example 3 (fed a.m.) 6.67 hours (*See*, *e.g.*, pages 4 and 6 the biostudy); Example 3 (Fed p.m.) 9.67 hours (*See*, *e.g.*, pages 17 and 20 of the biostudy). Therefore, the only instance that the T<sub>max</sub> was between 8-12 hours was Example 3 fed in the P.M. (at dinner).

In addition, pages 2, 5, 11, 15, 19 of the biostudy data includes plasma concentration v. time graphs and data for formulations prepared in accordance with Examples 1(fasting), 3 (fed), 2 (fasting), 2 (fed), and 3 (fed), respectively, of U.S. Patent No. 6,099,859; pages 8 and 9 of the biostudy data include plasma concentration v. time graphs and data for formulations prepared in accordance with Example 2 (fasting and fed) and Example 3 (fed a.m. and p.m.) of U.S. Patent No. 6,099,859; and pages 7 and 18 include plasma concentration v. time graphs and data for formulations prepared in accordance with Example 3 (fed a.m. and p.m.) of U.S. Patent No. 6,099,859.



This Information Disclosure Statement is being filed after a First Office Action but before a Final Office Action or Notice of Allowance. Pursuant to 37 C.F.R. § 1.98(c), a check for \$180.00 is enclosed to cover the required fee. However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Respectfully submitted,
DAVIDSON, DAVIDSON & KAPPEL, LLC

By:

Clifford M. Davidson Reg. No. 32,728

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940

		<del></del>	نذ										
FORM PTO-1440 (REV. 7-80)	EE 0 1	Alles .	300	U	J.S. DE	PARTM T AND 1	ENT OF	F COMMERCE MARK OFFICE	ATTY. DOCKET NO.: 300.1012		SERIAL NO.: 09/705,625		
VI	WHAT	DEPARTE !	IOR ART	CITED	BYA	\PPLIC	CANT	•	APPLICANT(S): Xiu Xiu	u CHENG, et al			
	(Use s	several she	eets if nece	essary)		•		-	FILING DATE: November 3, 2000		GROUP: 1615	:	
							U.	S. PATENT DOC			<u> </u>		
*EXAMINER INITIAL	CAMINER DOCUMENT NUMBER DATE						NAME	CLASS	SUBCLASS	FILING DATE			
	AA	6	4 7	5	5	2	1	11/05/2002	Timmins et al.	424	469	Sep. 16, 1999	9
	АВ												
	AC						<u> </u>			Ī			
	AD												
	AE			T					·				
	AF												
	AG												
							FOR	EIGN PATENT D	OCUMENTS				
		DOCU	JMENT NU	MBER			-	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATIO	ON
			DOCOMENT NOMBER									YES	NO
<del></del>	<del> </del>	<del>                                     </del>	<u> </u>	<del>-j</del>	1	Τ_	·	<del> </del>		<u> </u>	<u> </u>	<b> </b>	<del> </del>
	AH	++			┼─	+	┼	<del> </del>		<del> </del>	<u> </u>	<del> </del>	
	Al	++	-	+-	$\vdash$	<del> </del>	<del> </del>	<u> </u>		<del>                                     </del>			
<del> </del>	AJ			+	<del> </del> -	<del>                                     </del>	<del>                                     </del>	-		ļ			ļ ·
	AK	┼┼		<del></del>	—	<del> </del>	<del> </del>	<del> </del>		<u> </u>		<del> </del>	<u> </u>
ļ	AL		L_		<u> </u>		<u> </u>	<u> </u>	·	<u> </u>	<u> </u>	<u> </u>	<u> </u>
ļ	<del></del>	·		0	THER F	PRIOR F	ART (In	cluding Author, T	itle, Date, Pertinent Pages	s, Etc.)	· · · · · · · · · · · · · · · · · · ·	<del></del>	
	AM	. Andrx I	Pilot Biostu	udy Data	(20 pag	jes)				<del></del>	<del></del>	<del></del>	· · · · · · · · · · · · · · · · · · ·
	AN	ļ	·		· :-								
	AO	<del> </del>				•		· · · · · · · · · · · · · · · · · · ·	·				<del></del>
	AP	<u> </u>						<u> </u>	· ,				
	AQ	<u> </u>				<del></del>		· .					
	AR	<u> </u>		·	-							<u> </u>	
	AS	<u> </u>	:					• 1	·				•
EXAMINER			,						DATE CONSIDERED				•
										·			
*EXAMINER: Initia copy of this form v	al if refere with next o	nce consid	dered, whe	ether or no	ot citatio	on is in (	conform	nance with MPEP	609; Draw line through ci	tation if not in c	onformance and no	t considered. In	clude

#### / NITED STATES PATENT AND TRADEMARK OFFICE

Examiner: To Be Assigned

Art Unit: 1614

Re: A

Application of: Chih-Ming CHEN, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

METHODS FOR TREATING

DIABETES VIA ADMINISTRATION

OF CONTROLLED RELEASE

**METFORMIN** 

#### INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

September 17, 2001

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R.§1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying PTO-1449 Form for consideration by the Examiner in connection with the examination of the above-identified patent application.

This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of a first Office Action on the merits. Accordingly, it is believed that no fee is due.

I hereby certify that the documents referred to as attached therein and/or fee are being deposited with the United States Postal Service with sufficient postage as "first class mail" in an envelope addressed to "Assistant Commissioner for Patents, Washington, D.C. 20231" on September 17,

DAVIDSON, DAVIDSON & KAPPEL, LLC

However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

It is respectfully requested that the references cited on the accompanying PTO Form-1449 be considered and made of record. If any of the publications listed thereon are missing, the Examiner is requested to contact the undersigned so that a copy can be promptly forwarded.

It is respectfully submitted that the pending claims are patentable over all the references made of record at this time.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:

Robert J. Paradiso Reg. No. 41,240

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940

FORM PTO-1449 U.S. DEPARTMENT OF CO ATTY. DOCKET NO. SERIAL NO. (REV. 7-80) PATENT AND TRADEMARK OFFICE 300.1012 09/705,625 LIST OF REFERENCES CITED BY APPLICANT APPLICANTS (Use several sheets if necessary) Chih-Ming CHEN, et al. FILING DATE GROUP November 3, 2000 1614 U.S. PATENT DOCUMENTS EXAMINER DATE NAME **CLASS** SUB-FILING DATE IF INITIAL CLASS APPROPRIATE 1/4/00 AA 6 n 0 Al-Razzak et al. 424 464 AΒ 8 1/12/99 Cho 424 450 9 11/25/97 Inman et al. 691 514 ΑD 5 6 8 8 1 11/18/97 Ayer et al. 424 422 ΑE 7 6 n 10/7/97 Ubillas et al 514 557 ΑF 6 6 7 9/16/97 Shapiro 514 55 ΑG 7 0 9/16/97 Wong et al. 424 472 AΗ 5 6 5 0 7/22/97 Wright et al. 424 473 ΑI 5 6 3 2 2 4 5/20/97 Efendic et al. 514 12 5/13/97 Luo et al. 514 284 FOREIGN PATENT DOCUMENTS DATE COUNTRY CLASS SUB-TRANSLATION CLASS YES NO AK • 9/23/99 wo A61K 9/24 ΑL 9 9 9/23/99 wo A61K 9/20 9 9 2 9 AM 3 6/17/99 wo A61K 31/155 6 3 3/21/96 wo A61K 31/155 OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) ΑO Physicians' Desk Reference (54th Ed. 2000), pp. 831-835. Sheen, Andre J., Clinical Pharmacokinetics of Metformin, Clinical Pharmacokinetics, May 30, 1996, 5:359-371. ΑP ΑQ Bailey, Clifford J., et al., Metformin, The New England Journal of Medicine, Feb. 29, 1996, 334:574-579. AR Dunn, Christopher J., et al., Metformin: A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs (1995), 49:721-747. AS Karttunen, P., et al., The Pharmacokinetics of Metformin: A Comparison of the Properties of a Rapid-Release and a Sustained-Release Preparation, pp. 31-36. DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (REV. 7-80) PATENT AND TRADEMARK OFFICE 300.1012 09/705,625 LIST OF REFERENCES CITED BY APPLICANT **APPLICANTS** (Use several sheets if necessary) Chih-Ming CHEN, et al. FILING DATE GROUP November 3, 20000 1614 U.S. PATENT DOCUMENTS EXAMINER DATE NAME CLASS SUB-FILING DATE IF INITIAL CLASS APPROPRIATE BA 3/25/97 Dong et al. 524 377 BB 1/7/97 Kuczynski et al. 424 486 BC 8/13/96 Kuczynski et al. 424 473 8/6/96 Roorda et al. 424 484 5 BE 9 4/30/96 Landrau et al. 424 449 BF 3 7 5/9/95 Wong et al. 604 892.1 BG 0 5/3/94 Balaban et al. 604 892.1 BH 8 2/9/93 473 Ayer et al. 424 ВΙ 5 1/12/93 Guittard et al. 424 473 BJ 5 8/25/92 Ayer et al. 424 473 BK 2 6/9/92 5 1 0 McClelland et al. 8 424 473 BL 0 9 7 5/5/92 Wong et al. 424 438 BM 0 2/25/92 Kuczynski et al. 473 424 7 BN 5 0 6 0 12/10/91 Ayer et al. 264 112 во 0 2 8 3 6/18/91 Kuczynski et al. 514 255.06 BP 4 9 10/16/90 Eckenhoff 892.1 604 BQ 4 9 7 9 8 2 1/9/90 Shah et al. 424 473 BR 6 9 5 8 9/12/89 Eckenhoff 604 892.1 FOREIGN PATENT DOCUMENTS DATE COUNTRY CLASS SUB-TRANSLATION CLASS YES NO BS OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) BT **EXAMINER** DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE FORM PTO-1449 ATTY. DOCKET NO. SERIAL NO. (REV. 7-80) PATENT AND TRADEMARK OFFICE 300.1012 09/705,625 LIST OF REFERENCES CITED BY APPLICANT APPLICANTS: (Use several sheets if necessary) Chih-Ming CHEN, et al. FILING DATE GROUP November 3, 2000 1614 U.S. PATENT DOCUMENTS **EXAMINER** DATE NAME CLASS SUB-FILING DATE IF INITIAL CLASS APPROPRIATE Q CA 7/25/89 Magruder et al. 424 457 CB 7. 11/8/88 Wong et al. 424 468 CC 0 9 10/11/88 Magruder et al. 424 457 CD 7 0 11/3/87 Eckenhoff 424 438 CE 6 3 9/8/87 Eckenhoff et al. 424 468 CF 6 7 8 0 12/9/86 Deters et al. 604 892.1 CG 8 11/25/86 424 467 Ayer et al. CH 10/7/86 Guittard et al. 604 892.1 6. CI 2 0 0 9/16/86 Wong et al. 604 892.1 CJ 4 0 6 9/2/86 Ayer 424 473 CK 7 5/6/86 473 Edgren et al. 424 CL 6/11/85 Edgren 424 473 CM 4 2 0 9/5/78 Theeuwes 424 473 CN 0 5/9/78 6 Theeuwes et al. 219 121.71 CO 0 0 3/21/78 Bohuon 514 555 CP 0 4 3/7/78 Theeuwes et al. 424 427 12/13/77 Saunders et al. 219 121.7 FOREIGN PATENT DOCUMENTS DATE COUNTRY **CLASS** SUB-TRANSLATION CLASS YES NO CR OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) CS **EXAMINER** DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. (REV. 7-80) PATENT AND TRADEMARK OFFICE 300.1012 09/705,625 LIST OF REFERENCES CITED BY APPLICANT APPLICANTS: (Use several sheets if necessary) Chih-Ming CHEN, et al. FILING DATE GROUP November 3, 2000 1614 U.S. PATENT DOCUMENTS **EXAMINER** DATE NAME CLASS SUB-FILING DATE IF INITIAL APPROPRIATE CLASS DA 0 7/19/77 Theeuwes 424 473 7/12/77 Theeuwes 424 427 DC 4 0 0 9 2/22/77 Theeuwes et al. 424 427 DD 9 3 5 7 8 5/18/76 3 Bohuon 560 143 DE 3 4/27/76 Baker 424 405 DF 3 9 8 9 11/4/75 Theeuwes et al. 424 424 3 DĠ 8 11/5/74 Theeuwes et al. 424 427 DH DI DJ DK DL DM DN DO DP FOREIGN PATENT DOCUMENTS DATE COUNTRY **CLASS** SUB-TRANSLATION **CLASS** YES NO DR OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.) DS **EXAMINER** DATE CONSIDERED \*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





#### UNITED STATES PATENT & TRADEMARK OFFICE

Re: Application of:

Xiu Xiu Cheng, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods for Treating Diabetes Via Administration Of Controlled Release

Metformin

Examiner: T. Page

Art Unit: 1615

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 November 25, 2003

# Communication accompanying the Statement of Substance of Interview Under 37 CFR §1.133

Sir:

Upon review of the prosecution history of the present application during the preparation of this response, it was noted that complete copies of the PTO-1449 forms submitted with the Information Disclosure Statements of September 17, 2001 and February 28, 2003 were not initialed and returned to the undersigned. As certain references were disassociated from the file, Applicants again include herewith the Information Disclosure Statements of September 17, 2001 and February 28, 2003, along with the PTO-1449 forms and the references cited therein. The Examiner is requested to consider all of the references herein and return the initialed PTO-1449 forms to the undersigned.

According to currently recommended Patent Office policy the Examiner is specifically authorized to contact the undersigned in the event that a telephonic interview will advance the prosecution of this application.



An early and favorable action is earnestly solicited.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: \_

Clifford M. Davidsor

Reg. No. 32,728

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940

300.1012

#### UNITED STATES PATENT & TRADEMARK OFFICE

Re: Application of:

Xiu Xiu Cheng, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods for Treating Diabetes Via Administration Of Controlled Release

Metformin

Examiner: T. Page

Art Unit: 1615

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 November 25, 2003

#### Statement of Substance of Interview Under 37 CFR §1.133

Sir:

Reconsideration of the present application in view of the following remarks is respectfully requested.

#### I. <u>INTRODUCTORY COMMENTS</u>

The undersigned gratefully acknowledges the courtesies extended by Examiner Page to the undersigned and Ted Whitlock, Esq. during the Interview conducted at the USPTO on November 20, 2003.

The Interview conducted on November 20, 2003 also included a separate discussion of applicant's copending Application Serial No. 09/705,630. A separate Amendment Under 37 CFR§1.111 and Statement of Substance of Interview Under 37 CFR §1.133 have been submitted for Serial No. 09/705,630.

#### II. REMARKS

During the Interview, the undersigned discussed the Office Action dated July 14, 2003 and applicants' response dated October 14, 2003.

In that Office Action, the Examiner had indicated that claim 25 would be allowable if rewritten in independent form. By virtue of the amendment the subject matter of claim 25 was rewritten in independent form, without prejudice to applicants pursuing remaining subject matter in continuation applications.

It was agreed that the claims were allowable over the prior art previously relied upon by the Examiner.

Nevertheless, during the course of the interview, the rejection of claims 1, 4-5, 7-15, 18-24, and 26-31 under 35 U.S.C. 103(a) over Lewis et al. in combination with Chiao and Drug Facts and Comparisons or Moeckel et al. in combination with Chiao and Drug Facts and Comparisons; and claims 1, 4-5, 7-15, 18-24, and 26-31 under 35 U.S.C. 103(a) over Cheng et al. in view of Drug Facts and Comparisons, was discussed.

During the interview, it was pointed out to Supervisory Examiner Page that Lewis et al. is directed to a combination product (insulin sensitizer plus another antidiabetes agent, which could be metformin), wherein it is stated that one or both of the active agents could be in modified release form. It was noted that Lewis et al. provide no in-vivo data whatsoever, and in fact do not mention any possible pharmacokinetic parameters which their formulations should meet. As stated in the last Office Action, Lewis et al. "do not teach the exact release profile(s) of the instant claims." It was further argued that Chaio and Drug Facts and Comparisons do not overcome the deficiencies of Lewis et al. with respect to the particular T<sub>max</sub> range set forth in the

claims. Supervisory Examiner Page agreed that the claimed  $T_{max}$  range was patentable over the combination of Lewis, Chiao and Drug Facts and Comparisons.

During the interview, it was pointed out to Supervisory Examiner Page that the Moeckel et al. reference, while directed to retarded tablets containing metformin, does not suggest that the formulations described therein are useful for once-a-day administration. Instead, Moeckel et al. state that the retarded tablets of their invention "release metformin in a controlled manner over a time period of 0.5-10 hours preferably over 4 hours (FIG. 1)." (Column 5, lines 30-32). It was noted that Moeckel et al. provide no in-vivo data whatsoever, and in fact do not mention any possible pharmacokinetic parameters which their formulations should meet. As stated in the last Office Action, Moeckel et al. "do not teach the exact release profile(s) of the instant claims." It was further argued that Chaio and Drug Facts and Comparisons do not overcome the deficiencies of Lewis et al. with respect to the particular  $T_{max}$  range set forth in the claims. In response, Supervisory Examiner Page agreed that the claimed  $T_{max}$  range was patentable over the combination of Moeckel, Chiao and Drug Facts and Comparisons.

During the Interview, with respect to the rejection based on the combination of Cheng, et al. and Drug Facts and Comparisons, the  $T_{max}$  data presented in the Cheng, et al. reference was discussed in detail, and the Examiner's attention was directed to the discussion provided in applicants' responsive papers of February 2003 with respect to the  $T_{max}$  information presented in the '859 patent. It was pointed out to Supervisory Examiner Page that the '859 patent was the U.S. priority application to the Cheng, et al. reference. The relationship of the claimed  $T_{max}$  range of claim 1 (5.5 – 7.5 hours) when the dosage forms of the invention are administered after dinner was discussed with respect to providing the highest level of the drug in the blood at night (e.g., when gluconeogenesis is greatest; see the specification at pages 13-14). Supervisory Examiner Page considered the closest prior art to teach a  $T_{max}$  of 8 hours (the Cheng, et al. reference).

300.1012

Supervisory Examiner Page agreed that the "applicants' arguments regarding the Tmax

are persuasive that the method claims distinguish over the prior art" and indicated that the claims

of record are allowable. (See the Examiner Interview Summary Record of November 20, 2003).

During the Interview, the rejection of claims 1, 4-5, 7-15, and 18-31 for obviousness-type

double patenting as being unpatentable over claims 1-29 of U.S. Patent No. 6,099,859; claims 1-

39 of U.S. Patent No. 6,284,275; and claims 1-4 of U.S. Patent No. of U.S. Patent No. 6,099,862

were discussed. In addition the provisional rejection of claims 1, 4-5, 7-15, and 18-31 over

claims 1-29 of copending Application No. 09/726,193 was discussed.

During the interview, the Examiner indicated that the above-mentioned obviousness-type

double patenting rejections would not be maintained as per the policy of the USPTO and In re

Schneller, 158 USPQ 210 (CCPA 1968).

According to currently recommended Patent Office policy the Examiner is specifically

authorized to contact the undersigned in the event that a telephonic interview will advance the

prosecution of this application.

An early and favorable action is earnestly solicited.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By:

lifford M. Davidson

leg. No. 32,728

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018

(212) 736-1940

4

FORM®TO-1083

COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, VA 22313-1450

In re application: Xiu Xiu Cheng, et a

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods For Treating Diabetes Via Administration Of Controlled Release Metformin

Sir:

[]

[]

Transmitted herewith is an Statement of Substance of Interview in the above-identified application.

Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established. 

Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.

No fee for additional claims is required. 

A filing fee for additional claims calculated as shown below, is required:

	(Col. 1)_	(Col. 2)	_	SMALL	ENTITY		LARGE ENTITY
FOR:	REMAINING	HIGHEST	_	RATE	FEE	<u>or</u>	RATE FEE
	AFTER	PREVIOUSLY	PRESENT	-			
	AMENDMENT	PAID FOR	EXTRA	_			
TOTAL CLAIMS	* Minus	** =	0	x \$ 9	\$		x \$ 18 \$
INDEP. CLAIMS	* Minus	*** =	0	x \$ 42	\$		x \$ 84  \$
[ ] FIRST PRES	SENTATION OF	MULTIPLE DE	EP. CLAIM	+ \$140	\$ <u> </u>		+ \$280 \$

TOTAL: TOTAL: OR

Docket No.: 300.101

Date: November 25, 2003

- If the entry in Co. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

[X]	Also	transmitted	herewith are:
-----	------	-------------	---------------

[ ] Petition for extension under 37 C.F.R. 1.136

[X] Other: Communication and Copies of previously submitted Information Disclosure Statements of September 17, 2001 and February 28, 2003 including PTO-1449 forms, and References Cited therein.

- Check(s) in the amount of \$0.00 is/are attached to cover: [ ]
  - [ ] Filing fee for additional claims under 37 C.F.R. 1.16
  - Petition fee for extension under 37 C.F.R. 1.136
  - [ ] Other:
- The Commissioner is hereby authorized to charge payment of the following fees associated with this [X] communication or credit any overpayment to Deposit Account No. 50-0552.
  - Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by [X] check submitted herewith.
  - Any patent application processing fees under 37 C.F.R. 1.17.
  - Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, [X] and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR

1.136.

Clifford M. Davieson, Reg. No. 32,728 DAVIDSON & KAPPEL, LLC

485 Seventh Avenue, 14th Floor New York, New York 10018

Tel: (212) 736-1940 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with sufficient postage to the United States Postal Service as "first class mail" in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" on

November 25, 2003 DSON, DAVIDSON & KAPPEL, LLC

AUROBINDO EX. 1006, 54

#### **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



AK

#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 9/24	A1	(11) International Publication Number: WO 99/47128 (43) International Publication Date: 23 September 1999 (23.09.99)
(21) International Application Number: Po	CT/US99/052	33 (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
(22) International Filing Date: 10 March	1999 (10.03.9	
(30) Priority Data: 09/044,446 19 March 1998 (19.03	3.98) Ü	TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

(71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US).

(72) Inventors: TIMMINS, Peter, 5 Heathbank Avenue, Irby, Merseyside L61 4XD (GB). DENNIS, Andrew, B.; 7 Pear Tree Close, Barnston, Merseyside L60 1YD (GB). VYAS, Kiren, A.; 34 Adisham Green, Sittingbourne, Kent ME10 2SR (GB).

(74) Agents: RODNEY, Burton et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).

Published

With international search report.

patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(54) Title: BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD

#### (57) Abstract

A biphasic controlled release delivery system for pharmaceuticals which have high water solubility, such as the antidiabetic metformin HCl salt, is provided which provides a dosage form that has prolonged gastric residence and includes (1) an inner solid particulate phase formed of substantially uniform granules containing a pharmaceutical having a high water solubility, and one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, and (2) an outer solid continuous phase in which the above granules of inner solid particulate phase are embedded and dispersed throughout, the outer solid continuous phase including one or more hydrophobic polymers, one or more hydrophobic polymers and/or one or more hydrophobic materials such as one or more waxes, fatty alcohols and/or fatty acid esters, which may be compressed into tablets or filled into capsules. Methods for forming the so-described biphasic controlled release delivery system for treating diabetes are also provided.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR `	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	. GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom ·	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinca	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN -	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	. MR	Mauritania	·· UG	Uganda
BY	Belarus	IS	Iceland	· MW	Malawi	US	United States of America
· CA	Canada	IT	Italy	MX	Mexico	· UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		_
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		•
EE	Estonia	LR	Liberia	SG	Singapore		

## BIPHASIC CONTROLLED RELEASE DELIVERY SYSTEM FOR HIGH SOLUBILITY PHARMACEUTICALS AND METHOD

#### Field of the Invention

5 The present invention relates to a new dosage form for highly water soluble medicaments, such as the antidiabetic metformin, which provides for extended release of the drug and also for prolonged gastric residence which enables efficient delivery of drugs normally absorbed in the upper gastrointestinal tract, and to a method for preparing such dosage form.

#### Background of the Invention

Metformin is an antihyperglycemic agent of the biguanide class used in the treatment of non-insulin dependent diabetes mellitus (NIDDM). It is usually marketed in the form of its hydrochloride salt as Glucophage® (TM-BMS).

Metformin hydrochloride has intrinsically poor permeability in the lower portion of the gastrointestinal tract leading to absorption almost exclusively in the upper part of the gastrointestinal tract. Its oral bioavailability is in the range of 40 to 60% decreasing with increasing dosage which suggests some kind of 25 saturable absorption process, or permeability/transit time limited absorption. It also has a very high water solubility (>300 mg/ml at 25°C). This can lead to difficulty in providing a slow release rate from a formulation and problems in controlling the initial burst of drug from such a formulation. These two difficulties are further compounded by the high unit dose, 500 mg per tablet, usually required for metformin hydrochloride (1997-PDR).

Drugs that have absorption limited to the upper
35 gastrointestinal tract coupled with poor absorption in the
distal small intestine, large intestine and colon are
usually regarded as inappropriate candidates for

formulation into oral controlled delivery systems. This limitation on absorption (for example, in the upper gastrointestinal tract) is referred to as the "absorption window".

ingested material from the stomach (where digestion takes place) into the small intestine (where absorption principally occurs) and on to the large intestine (where water is absorbed/secreted as part of body fluid regulation processes). Residence time for non-digestible materials in the stomach depends on whether one is dealing with a fed or a fasted subject. Typical gastric emptying times for particulate material (greater than a few millimeters in diameter) varies from a few tens of minutes in the fasted state to a few hours in the fed state. Transit times through the small intestine are consistently of the order of 3 to 4 hours.

Oral controlled release delivery systems function by releasing their payload of drug over an extended period of time following administration. Thus, controlled release dosage forms may only spend a relatively short period in the regions of the gastrointestinal tract where good absorption of certain drugs can occur. The dosage form will pass on to regions of the intestine where absorption of certain drugs is poor or non-existent, still releasing its contained drug albeit with a significant percentage of its payload still to be delivered. Drug when released from the dosage form in the circumstances described will not be absorbed. Thus, administration of a drug subject to a window of absorption in a conventional controlled release delivery system can lead to subtherapeutic blood levels and ineffective treatment of the disease state for which the drug was intended.

20

25

35

Drugs with very high solubility in water (for example, greater than 100 mg/ml) can be difficult to formulate into a controlled release oral dosage form. Solubility is a driving force for a drug substance to

dissolve in water; the greater the solubility the greater the rate of dissolution when all other factors are maintained constant.

In a controlled release dosage form, the formulator tries to reduce the rate of dissolution by, for example, embedding the drug in a polymeric matrix or surrounding it with a polymeric barrier membrane through which drug must diffuse to be released for absorption. To reduce the rate of release of drug from the dosage form to an appropriate level consistent with the blood level profile desired for a 10 drug possessing very high water solubility, very large amounts of polymer would be required for the matrix or barrier membrane. If the total daily dose of drug to be delivered is of the order of only a few milligrams this may 15 be feasible, but many drugs having the solubility properties described require total daily doses of the order of many hundreds of milligrams. Whilst it is possible to create oral controlled release dosage forms for such products by use of large amounts of polymer, an 20 unacceptably large dosage form may result.

A further problem with highly water soluble drugs formulated into a controlled release dosage form is that a significant and variable "burst" of drug can occur from these systems. The burst of highly water soluble drug is 25 the initial rapid release of drug that occurs from oral controlled release dosage forms when first contacting fluid, such as gastric fluids, prior to release controlling mechanisms of the dosage form establishing themselves and a stable release rate being provided. Hydration of any polymer matrix used to formulate the dosage form is a prerequirement of establishing a stable release rate. Thus, a readily hydrating polymer is required to establish the desired stable release rate. However, if the polymer used is slow to hydrate, then an undesireable variable burst can occur.

30

35

Studies by Vidon et al (1) strongly suggest that there is permeability limited absorption of metformin.

Perfusing drug into the jejunum via an intubation technique showed a 2.5 fold greater area under the plasma concentration-time profile (a measure of the quantity of drug absorbed) compared with similar introduction of drug into the ileum. Drug was not detectable in plasma when drug was perfused into the colon. Drug will transit down the small intestine following dissolution from an ingested dosage form and, if absorption rate is slow, it is possible that drug can reach regions of poor permeability before absorption of a given dose is complete. In such a case, increasing the given dose may be predicted to result in a reduction in the percentage of administered dose absorbed.

Improvements in the therapeutic regimes employing metformin might be achieved by a dosage form that allows a reduction in dosing frequency, providing patient convenience that would probably improve compliance. Conventional extended release formulations have been demonstrated to invariably compromise the availability of metformin (2). This is probably because the dosage form carries a significant proportion of the drug content remaining to be released, as the dosage form is carried to regions of the gastrointestinal tract with very poor permeability to the drug. To reduce dosing frequency, the rate of release from the dosage form must be such as to extend effective plasma levels, but the potential for effective delivery at this rate is compromised by the combined influences of the significant reduction in permeability to the drug in passing from the proximal small intestine down to the colon and the limited residence time in the regions of the gastrointestinal tract where the drug is well absorbed. That transit time down the "useful" region of the gastrointestinal tract is only likely to be of the order of a few hours.

15

20

25

30

35

Maintained or even improved bioavailability from an extended release dosage form that releases metformin at a rate likely to provide the desired plasma levels of drug for an extended time period might, however, be possible

from a dosage form that has extended residence time in the upper gastrointestinal tract, resisting mechanisms that promote normal transit time for solid materials. That this principle might work in practice was demonstrated in an inhouse study where metformin was co-administered with propantheline, an agent that reduces gastrointestinal motility. Compared with giving metformin alone, the combination provided an increased AUC, a delayed tmax and an extended time period over which therapeutically beneficial plasma levels of drug were maintained.

Giving a drug such as metformin for the treatment of diabetes with a further drug, such as propantheline, not used for the treatment of diabetes and where the sole intent of using the second agent is to achieve extended residence time in the upper GI tract, has many disadvantages although it is likely to allow effective extended delivery of metformin to an optimal absorption site. The co-administered drug may have other undesirable pharmacological effects or side effects deleterious to the patients well being and detract from the improved quality of life offered by the treatment for their diabetes. Furthermore, it may be difficult or impossible to appropriately co-formulate the two agents due to chemical compatibility issues or solubility differences, the latter preventing the required release rate of agent influencing residence time in the upper GI tract. Thus, the patient could be required to take separate, multiple medications to achieve the desired effect. The timing of taking the two medications would be critical to effective delivery of the drug with the limited window of absorption and many patients may thus fail to take their medication correctly resulting in ineffective treatment of their diabetes.

#### Prior Art Gastro-Retentive Systems

10

20

25

30

It would be desirable to provide a dosage form that inherently has the property of extended gastric residence, possessing some resistance to the pattern of waves of

motility present in the gastrointestinal tract that serve to propel material through it. There have been many attempts to provide for this, with varying degrees of success.

5

Possible approaches described in prior art include:

- (1) Floating or buoyant systems:

  These are designed to have a low density and thus

  should float on gastric contents after

  administration until the system either disintegrates

  (and presumably the resultant particles empty from

  the stomach) or the device absorbs fluid to the

  point where its density is such that it loses

  buoyancy and can pass more easily from the stomach

  with a wave of motility responsible for gastric

  emptying.
- These are designed to imbibe fluid following administration such that the outer layer becomes a viscous, tacky material that adheres to the gastric mucosa/mucus layer. This should encourage gastric retention until the adhesive forces are weakened for example by continuing hydration of the outer layer of the device or by the persistent application of shear.
- These are designed to be sufficiently small on administration so as not to make ingestion of the dosage form difficult (for example, less than approximately 23 mm long and less than 11 mm wide for an oval or capsule-shaped tablet). On ingestion they rapidly swell or unfold to a size that precludes passage through the pylorus until after drug release has progressed to a required degree.

Gradual erosion of the system or its breakdown into smaller particles enables it to leave the stomach.

#### Re: (1) Buoyant/floating systems

5

10

20

25

30

35

Buoyant systems designed to float on the gastric contents have been designed where buoyancy is created by low density of the formulation components. For example, Watanabe et al (3) used low density shells such as spherical polystyrene foam particles in which polymer and drug layers were loaded. Such a system has the required low density and will not need to disintegrate into small pieces to empty from the stomach, but may not have a controlled loss of density alternatively required for it to eventually exit from the stomach. It also has limited capacity for loading with drug in the thin layers that can be applied around the polystyrene shells. It would be difficult to also layer large amounts of polymer on such a system to retard the release of very water soluble drugs.

Sheth described hydrodynamically balanced systems including both capsules and tablets (4,5,6) which had low density to enable floating on the stomach contents and which slowly eroded after administration, losing buoyancy and being expelled from the stomach.

Buoyancy can also be combined with control of drug release at different pH values to make for a device with better control in case of drugs with very marked dependency of solubility on pH (7); hence dissolution of contained drug depending on environment pH.

These approaches may be applicable to many drugs dosed in doses of up to a maximum of a few hundred milligrams per day but may not be applicable to similar or higher dose levels of highly water soluble drugs. Where large amounts of polymer are needed to retard drug release as in the case of use of high water soluble drugs a capsule dosage form may not be possible on grounds of size. Furthermore, the relatively homogenous distribution of drug in the tablet versions of this technology would not readily

control the burst effect seen with a very water soluble drug.

A bilayer tablet approach (8) where the buoyancy generation comes from a separate layer to the drug containing layer having a release rate controlling property might overcome some of the problems seen with the hydrodynamically balanced systems, but this type of system would probably only be able to carry low drug payloads due to size constraints.

Approaches involving in situ gas generation within the system, where the gas is trapped within the dosage form on generation, encouraging buoyancy, might offer improved control over degree, onset time and persistence of buoyancy. Ichikawa (9) described such a device with a drug loaded core surrounded by the gas generating layer, which in turn was surrounded by a polymeric layer responsible for controlling drug release from the system.

10

15

20

25

35

Such floating or buoyant dosage forms seem to have met with limited clinical success due to the requirement that such dosage forms be taken with a suitable amount of fluid (normal gastric contents could be as little as a few tens of milliliters so that the total amount of fluid thus available would not be conducive to performance of such systems even when taken with a draught of water). Davis et al (10) found no benefit of floating formulations over nonfloating formulations when studied in vivo. Their performance may also be posture dependent. A patient sitting upright may ensure prolonged gastric residence of a buoyant dosage form, whereas a supine patient might allow ready presentation of the floating dosage form to the pylorus and thus allow rapid exit of the dosage form from the stomach (11). The physical size of such dosage forms seems to be as important if not more important as ability to float in encouraging prolonged gastric residence. Hence, floating/buoyant dosage forms might be expected to

only have limited applications.

#### Re: (2) Bioadhesive systems

Polycarbophil has been identified as a suitable polymer for encouraging adhesion of orally administered dosage forms to the gastric mucosa, thereby prolonging residence time for a system designed to slowly deliver drug to absorptive sites in the proximal small intestine (Longer et al, J. Pharm. Sci., 74, 406-411 (1985)). The success seen in animal models with such systems has been found not to translate to human subjects due to differences in mucous amounts, consistency and turnover between animals and humans. Bioadhesive systems allow dosage forms to adhere to mucous, not mucosa. The mucous layer in humans would appear to slough off readily, carrying any dosage form with Therefore, bioadhesive dosage forms would not appear to offer a solution for extended delivery of drug over a period of more than a few hours to the upper small intestine in humans.

#### Re: (3) Swelling/expanding systems

15

20 Other solutions to encouraging prolonged gastric residence have included dosage forms that unfold rapidly within the stomach to a size that resists gastric emptying. Such systems retain their integrity for an extended period and will not empty from the stomach at all until breakdown into small pieces occurs. Caldwell (12) describes a cross shaped device made of erodible polymer and loaded with drug which is folded and inserted into a hard gelatin capsule. Following oral administration the gelatin shell disintegrates and the folded device opens out. With a minimum size of 1.6cm and a maximum size of 5cm it will not pass from the stomach through the pylorus until the polymer erodes to the point where the system is sufficiently small that it can be passed from the stomach. Such a system may in fact obstruct the pylorus or even open earlier or later 35 than intended possibly causing obstruction in the esophagus or small intestine. As such, it may represent a potential hazard to the patient.

An alternate approach to using size to modulate gastric residence of a dosage form is to use a hydrophilic erodible polymer system that is of a convenient size for administration to humans. On imbibing fluid the system swells over a short period of time to a size that will encourage prolonged gastric retention, allowing sustained delivery of contained drug to absorption sites in the upper gastrointestinal tract. Because these systems are made of an erodible and hydrophilic polymer or polymer mixture, 10 they readily erode over a reasonable time period to pass from the stomach. The time period of expansion is such that this will not occur in the esophagus and if the system passes into the intestine in a partially swollen state, the erodibility and elastic nature of the hydrated polymer will eliminate the chance of intestinal obstruction by the 15 device.

Mamajek et al, U.S. Patent No. 4,207,890, describes a system wherein a drug release rate controlling (metering) component and a swelling component are mixed with drug enclosed within a membrane. The swelling component draws in fluid through the membrane, which maintains system integrity during its functioning, and the drug metering component controls the rate of drug release through the membrane.

20

35

Urquart (13) describes a different approach which consists of a matrix of hydrogel that imbibes fluid to swell the system so that it reaches a size encouraging prolonged gastric retention. This matrix surrounds a plurality of tiny pills consisting of drug with a release rate controlling wall of fatty acid and wax surrounding each of the pills.

Shell (14,15,16) has described systems for delivering drugs for the treatment of diseases of the upper gastrointestinal tract or for delivering drugs that might be irritating or injurious to the gastrointestinal mucosa. A swelling hydrogel polymer has embedded within it drug particles that dissolve once the hydrogel matrix is

hydrated. The swollen matrix is of a size to encourage gastric retention but only dissolved drug reaches the mucosa and this can be delivered in a sustained manner. Such a system thus does not insult the mucosa with solid particles of irritant drug and is suitable for delivering drug to upper gastrointestinal tract. These systems only apply in case of drugs of limited water solubility.

In the case of metformin, it is desirable to provide a dosage form that allows extended delivery of the drug and has a prolonged gastric residence via swelling of the system rather than unfolding or expanding of a folded device, and that may be manufactured on a commercial scale. The prolonged gastric residence time is required due to the window of absorption seen with metformin.

10

15

20

25

30

Another problem for extended delivery of metformin is its very high water solubility. High levels of polymer would be needed if many prior art approaches to provide the required release rate are employed. This could result in a rapid and variable initial release (burst) of drug from an extended release dosage form. The latter will thus give rise to difficulty in providing a true control of drug release and minimal inter-patient variability in drug plasma levels (arising from the possibility of variable burst of drug from tablets given to different patients).

Prior Art Controlled Release Systems for Very Soluble Drugs

Typical prior art techniques for creating a controlled release oral dosage form would involve either matrix systems or multi particulate systems. Matrix systems may be formulated by homogeneously mixing drug with hydrophilic polymers, such as hydroxypropylmethylcellulose, hydroxypropylcellulose, polyethylene oxide, carbomer, certain methacrylic acid derived polymers, sodium alginate, or mixtures of components selected from these, and compressing the resultant mixture into tablets (employing some other excipients where needed). Hydrophobic polymers,

such as ethyl cellulose, certain polymeric methacrylic acid esters, cellulose acetate butyrate, poly(ethylene-co-vinyl-acetate) may be uniformly incorporated with the above materials to give additional control of release. A further alternative involves embedding drug within a wax based tablet, by granulation or simply mixing of drug with a wax, such as carnauba wax, microcrystalline wax or commercially available purified fatty acid esters. As noted above, it may not be possible to use these approaches with very highly water soluble drugs.

Multi particulate systems consist of a dosage form based on a plurality of drug loaded spheres, prepared by layering drug onto a core, usually a sugar-starch mixture sphere of around 0.8mm diameter, until a sufficient level is reached, and then providing a drug release barrier around the drug-loaded sphere. Drug-loaded spheres can also be made by wet massing a mixture of drug and excipients, forcing the wet mass through a perforated screen to form short strands which are rounded in a spheronisation apparatus before drying and having the drug release barrier applied. The drug release barrier can be a wax, such as carnauba wax or glyceryl fatty acid esters, or a polymeric barrier, such as a mixture of ethyl cellulose and hydroxypropylmethylcellulose. These work well for moderately soluble drugs with doses in the units of milligrams to less than a few hundred milligrams per day.

15

20

25

30

35

In several examples, prior art systems seem to provide a controlled release formulation of a very water soluble drug by improving the multi particulate system approach. Fisher discloses a multi particulate system for highly soluble drugs especially opiate agonists (17) based on drug containing cores surrounded by a drug release controlling barrier which has the property of being partially soluble at a highly acidic pH.

Hansraj (18) coats drug loaded cores with methacrylic or acrylic acid derived polymers whose properties are modified by inclusion of at least one

anionic surfactant. In such a system, drug release of highly water soluble drugs is controlled without having to resort to the use of thick coatings on the release rate controlling layer.

Rollet (19) achieves prolonged release of a drug from a multi particulate formulation based on fine particles of hydrophilic and hydrophobic silicas or silicates. Presumably, this system would function for drugs of high water solubility.

5

20

25

30

35

Multi particulate systems are usually filled into capsules to provide unit dose forms because of the damage caused to such particles in trying to compress them into tablets. Total dose contained in a single unit is constrained by the loading possible in a hard gelatin capsule of easily swallowable size and is usually not more than a few hundred milligrams.

Single unit controlled release systems applicable to highly water soluble drugs include the application of multiple layers around a dose form as described by Howard (20). Where coating is not employed, special mixtures of polymers or formation of a complex with the drug have been used. Macrae (21) uses mixtures of polyethylene oxide and hydroxypropylmethylcellulose with optional enteric polymers to produce a constant release rate for highly water soluble drugs. Belenduik (22) combines the highly water soluble drug with a hydrophilic polymer based on acrylic acid and disperses this in a hydrophobic matrix.

Variations of Alza osmotic systems have been described suitable for highly water soluble drugs such as venlafaxine hydrochloride (23). These systems need two layers, a drug layer and an osmotically driven displacement layer all surrounded by a water permeable/drug impermeable membrane with an exit passage in this membrane for the drug.

Granules of highly water soluble clavulanate were prepared (24) having to employ a barrier layer of a hydrophobic waxy material in order to provide for

controlled release of this material when co-formulated with controlled release amoxycillin trihydrate granules in capsule or compressed tablet.

#### 5 <u>Description of the Invention</u>

10

15

20

25

35

In accordance with the present invention, a novel way has been found of formulating drug with high water solubility and a limited window of absorption such as metformin or a salt thereof which has a window of absorption in the upper gastrointestinal tract, to provide a dosage form that inherently has prolonged gastric residence. This is accomplished (a) without need for coadministration of a drug such as propantheline, and (b) without need for low density formulation or gas generation within the formulation, The formulation of the invention (a) achieves extended gastric residence by virtue of size but will degrade in vivo so as not to have potential for causing gastric or intestinal obstruction, and (b) controls drug release adequately where the initial burst of drug is under control. The formulations of the invention will provide for an extended release formulation of drug with minimal interpatient variability in pharmacokinetic parameters.

The invention is applicable to all drugs having high water solubility and a limited window of absorption.

The biphasic controlled release delivery system of the invention is a heterogeneous two phase system which includes (1) an inner solid particulate phase in the form of individual granules or particles containing (a) drug which has a high water solubility and a limited window of absorption (such as in the upper gastrointestinal tract), and (b) an extended release material formed of one or more hydrophilic polymers, and/or one or more hydrophobic polymers, and/or one or more other type hydrophobic compounds (such as one or more waxes, fatty alcohols and/or fatty acid esters), and (2) an outer solid continuous phase in which granules or particles of inner solid particulate

phase are dispersed and embedded, the outer solid continuous phase including an extended release material formed of one or more hydrophilic polymers, and/or one or more hydrophobic polymers, and/or one or more other type hydrophobic compounds (such as one or more waxes, fatty alcohols and/or fatty acid esters).

The biphasic controlled release formulation of the invention is particularly adapted for delivery of high water soluble drugs, such as metformin and pharmaceutically acceptable salts thereof, in controlled and extended manner without significant initial burst of drug, and wherein release of drug (liberated from the individual dispersed particles forming the inner solid particulate phase) is effectively controlled. Drug upon being released from the particles of the inner phase, in effect, migrates through the outer solid continuous phase and then is released from the formulation into the upper gastrointestinal tract to be available for absorption.

As indicated, the inner solid particulate phase will be formed of individual discrete particles or granules each of which contains drug and one or more polymeric materials and/or other hydrophobic-type materials. In effect, the components of the inner solid particulate phase are in particulate association without having a barrier layer around the individual particles or granules.

20

25

30

The outer solid continuous phase is preferably a continuous phase or matrix having the particles or granules including drug (forming the inner solid phase) dispersed throughout and embedded in the continuous outer solid phase.

In addition, in accordance with the present invention, a method for treating diabetes is provided wherein the biphasic controlled release formulation of the invention containing an antidiabetic pharmaceutical is administered to a patient in need of treatment. The antidiabetic pharmaceutical employed is a biguanide,

preferably metformin or a pharmaceutically acceptable salt thereof such as the hydrochloride, fumarate of succinate.

The term "extended release material" as present in the inner solid particulate phase and the outer solid continuous phase refers to one or more hydrophilic polymers and/or one or more hydrophobic polymers and/or one or more other type hydrophobic materials, such as, for example, one or more waxes, fatty alcohols and/or fatty acid esters. The "extended release material" present in the inner solid particulate phase may be the same as or different from the "extended release material" present in the outer solid continuous phase. However, it is preferred that the "extended release material" present in the inner solid particulate phase be different from the "extended release material" present in the inner solid particulate phase be different from the "extended release material" present in the outer solid continuous phase.

The term "high water solubility" or similar term when characterizing a drug, medicament or pharmaceutical for use in the formulation of the invention refers to a solubility in water at ambient temperature of at least about 50 mg/ml  $\rm H_2O$ , preferably at least about 100 mg/ml  $\rm H_2O$  or more, and more preferably greater than 150 mg/ml.

20

30

35

The term "limited window of absorption" or similar term when characterizing a drug, medicament or pharmaceutical for use in the formulation of the invention refers to an oral bioavailability of less than about 75%, usually less than about 60%, usually decreasing with increasing dose, and almost invariably having permeability/transit time limited absorption.

The biphasic controlled release system of the invention will include the inner solid particulate phase in a weight ratio to the outer solid continuous phase within the range from about 0.5:1 to about 4:1, preferably from about 0.8:1 to about 2:1.

The inner solid particulate phase will contain drug in an amount within the range from about 10 to about 98% by weight, preferably from about 15 to about 95% by weight, and hydrophilic polymers and/or hydrophobic polymers and/or

other hydrophobic material in an amount within the range from about 5 to about 95% by weight, preferably from about 7 to about 85% by weight, the above % being based on the weight of the inner solid particulate phase. Where 5 mixtures are employed, the hydrophilic polymer will be employed in a weight ratio to hydrophobic polymer and/or other hydrophobic material within the range from about 0.05:1 to about 19:1, preferably from about 0.1:1 to about 10:1.

10 The particles or granules of the inner solid particulate phase will have a mean particle size within the range from about 30  $\mu m$  to about 0.8 mm, and preferably from about 50  $\mu m$  to about 0.5 mm.

The outer solid continuous phase may contain mixtures of hydrophilic polymer and hydrophobic polymer and/or other hydrophobic material in a weight ratio of hydrophilic polymer to hydrophobic polymer or other hydrophobic material within the range from about 200:1 to about 0.05:1, preferably from about 100:1 to about 0.1:1.

15

20

25

30

35

Hydrophilic polymers which may be employed in the inner solid particulate phase and/or outer solid continuous phase include, but are not limited to hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, carboxymethylcellulose calcium, ammonium alginate, sodium alginate, potassium alginate, calcium alginate, propylene glycol alginate, alginic acid, polyvinyl alcohol, povidone, carbomer, potassium pectate, potassium pectinate, and the like.

Hydrophobic polymers which may be employed in the inner solid particulate phase and/or outer solid continuous phase include, but are not limited to ethyl cellulose, hydroxyethylcellulose, ammonio methacrylate copolymer (Eudragit RLTM or Eudragit RSTM), methacrylic acid copolymers (Eudragit LTM or Eudragit STM), methacrylic acid-acrylic acid ethyl ester copolymer (Eudragit L 100-5TM), methacrylic acid esters neutral copolymer (Eudragit NE

30D<sup>m</sup>), dimethylaminoethylmethacrylate-methacrylic acid esters copolymer (Eudragit E 100<sup>m</sup>), vinyl methyl ether/maleic anhydride copolymers, their salts and esters (Gantrez<sup>m</sup>).

Other hydrophobic materials which may be employed in the inner solid particulate phase and/or outer solid continuous phase include, but are not limited to waxes such as beeswax, carnauba wax, microcrystalline wax, and ozokerite; fatty alcohols such as cetostearyl alcohol, stearyl alcohol; cetyl alcohol and myristyl alcohol; and fatty acid esters such as glyceryl monostearate, glycerol monooleate, acetylated monoglycerides, tristearin, tripalmitin, cetyl esters wax, glyceryl palmitostearate, glyceryl behenate, and hydrogenated castor oil.

15

20

35

Where hydrophilic polymers and/or hydrophobic polymers are used in the inner solid particulate phase and/or the outer solid continuous phase, such polymers can be ionic or non-ionic, preferably ionic for the inner solid particulate phase and preferably non-ionic for the outer solid continuous phase.

Preferred ionic polymers for use in the inner solid particulate phase include sodium alginate, carbomer (Carbopol™), calcium carboxymethylcellulose, or sodium carboxymethylcellulose, xanthan gum, methacrylic acid-acrylic acid ethyl ester copolymer, dimethylaminoethylmethacrylate-methacrylic acid esters copolymer, cellulose acetate phthalate, hydroxypropylmethylcellulose trimellitate, and hydroxypropylmethylcellulose maleate, with sodium carboxymethylcellulose being particularly preferred.

Preferred non-ionic polymers for use in the outer solid continuous phase are those which assure rapid hydration of the outer solid continuous phase to minimize a variable and significant burst of drug, yet effectively control the release of drug being liberated from the discrete particles or granules forming the inner solid

particulate phase. The liberated drug will migrate through the non-ionic polymers forming the outer solid continuous phase before being released from the dosage form and being available for absorption. Preferred polymers for the outer solid phase with the appropriate hydration characteristics include hydroxypropylmethyl cellulose 2910 USP (hydroxypropylmethylcellulose with a methoxyl content of 19-24% and a hydroxypropyl content of 7-12%), viscosity grades ranging from about 4000 to about 100,000 cps and hydroxypropylmethylcellulose 2208 USP (hydroxypropyl-10 methylcellulose with a methoxyl content of 28-30% and a hydroxypropyl content of 7-12%), viscosity grades ranging from about 3 to about 150 cps, and microcrystalline cellulose. In particular preferred embodiments of the 15 outer solid phase, the above preferred polymers are used in admixture in weight ratios of hydroxypropylmethylcellulose 2910 USP:hydroxypropylmethylcellulose 2208 USP within the range from about 25:1 to about 50:1, preferably from about 30:1 to about 40:1.

20 Preferred biphasic controlled extended release delivery systems in accordance with the present invention are as follows.

A. <u>Inner Solid Particulate Phase</u>

25 (1) Metformin HCl (or other salt such as succinate or fumarate)

% by Weight of Inner\_ Solid Particulate Phase

55 to 98

(2) Polymer or Hydrophobic material: ethylcellulose or sodium carboxymethylcellulose or glyceryl monostearate (Average Particle Size of granules forming inner solid particulate 5 to 45

35 phase: 0.05 to 2.0 mm)

30

		% by weight of Outer_
	B. Outer Solid Continuous Phase	Solid Continuous Phase
	(1) Hydroxypropylmethyl-	60 to 100
	cellulose 2208USP	
5	(100,000 cps)	
	(2) Microcrystalline cellulose	0 to 30
	(3) Hydroxypropylmethyl	1 to 30
	cellulose 2910 USP (5 cps)	:•
	Weight Ratio of Inner Solid Phase:	0.5:1 to 1.5:1
10	Outer Solid Phase	
		% by Weight of Outer_
	C. Optional Ingredients	Solid Continuous Phase
	Lubricant - Mg Stearate	0.02 to 1

. 15

20

25

The preferred drug (having high water solubility) for use herein is metformin or pharmaceutically acceptable salts thereof, including the hydrochloride salt and dibasic salts such as metformin (2:1) fumarate and metformin (2:1) succinate as described in pending U.S. Application Serial No. (not yet available) filed December, 1997 (internal code LA19) which is incorporated herein by reference. Other biguanides may be used such as phenformin or buformin or pharmaceutically acceptable salts thereof.

Most preferred are the metformin hydrochloride salt, metformin (2:1) succinate salt, and metformin (2:1) fumarate salt.

Where desired, metformin or a salt thereof may be used in combination with another antihyperglycemic agent which may be administered orally in the same dosage form in accordance with the invention, a separate oral dosage form or by injection.

It is believed that the use of the metformin or salt thereof in combination with another anti-hyperglycemic agent produces antihyperglycemic results greater than that possible from each of these medicaments alone and greater

than the combined additive anti-hyperglycemic effects produced by these medicaments.

The other antihyperglycemic agent may be an oral antihyperglycemic agent preferably a sulfonyl urea such as 5 glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Patent No. 4,379,785), glipizide, gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATPdependent channel of the  $\beta$ -cells, with glyburide being preferred.

The metformin or salt thereof will be employed in a weight ratio to the sulfonyl urea in the range from about 300:1 to about 50:1, preferably from about 250:1 to about 75:1.

10

20

25

30

15 The oral antihyperglycemic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Patent No. 4,904,769) or miglitol (disclosed in U.S. Patent No. 4,639,436), which may be administered in a separate oral dosage form.

The metformin salt of the invention will be employed in a weight ratio to the glucosidase inhibitor within the range from about 300:1 to about 2:1, preferably from about 200:1 to about 25:1.

The metformin or salt thereof may be employed in combination with a thiazolidinedione oral anti-diabetic agent (which has an insulin sensitivity effect in NIDDM patients) such as troglitazone (Warner-Lambert's Rezulin®, disclosed in U.S. Patent No. 4,572,912), zorglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 5,594,016) Glaxo-Welcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer).

The metformin or salt thereof will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 75:1 to about 0.1:1, preferably from about 5:1 to about 0.5:1.

The sulfonyl urea and thiazolidinedione in amounts of less than about 150 mg oral anti-diabetic agent may be incorporated in a single tablet with the biphasic controlled release formulation of the invention as a separate rapidly dissolving layer.

The metformin or salt thereof may also be employed in combination with a non-oral antihyperglycemic agent such as insulin or with glucagon-like peptide-l (GLP-l) such as GLP-l(l-36) amide, GLP-l(7-36) amide, GLP-l(7-37) (as disclosed in U.S. Patent No. 5,614,492 to Habener, the disclosure of which is incorporated herein by reference), which may be administered via injection, or by transdermal or buccal devices.

In addition, in accordance with the present invention a method is provided for treating hyperglycemia including Type II diabetes (NIDDM) and/or Type I diabetes (IDDM) wherein a therapeutically effective amount of the biphasic formulatin of the invention containing metformin or a salt thereof, optionally in combination with another antihyperglycemic agent, is administered to a patient in need of treatment.

15

25-

Where present, the sulfonyl ureas, such as glyburide, glimepiride, glipyride, glipizide, glipizide, chlorpropamide and gliclazide and the glucosidase inhibitors acarbose or miglitol may be employed in formulations as described above and in amounts and dosing as indicated in the Physician's Desk Reference.

Where present, the thiazolidinedione anti-diabetic agent may be employed in amounts within the range from about 0.01 to about 2000 mg/day which may be administered in single or divided doses one to four times per day.

Where present insulin may be employed in formulations, amounts and dosing as indicated by the Physician's Desk Reference.

Where present GLP-1 peptides may be administered in oral buccal formulations, by nasal administration or parenterally as described in U.S. Patent Nos. 5,346,701

(TheraTech), 5,614,492 and 5,631,224 which are incorporated herein by reference.

The following additional type high water soluble drugs may be employed in the biphasic controlled release delivery system of the invention:

antihypertensives and antidepressants related to guanethidine (as disclosed in U.S. Patent No. 2,928,829) and related to guanoxyfen (as disclosed in BE612362);

antibiotics and viricides such as related to amidinomycin (as disclosed in JP 21,418); stallimycin (as disclosed in DE 1,039,198);

Arphamenine B (as disclosed in published European Patent Application 85/133550A2);

chitinovorin-A (as disclosed in published European Patent Application 85/150,378A2 and U.S. Patent No., 4,723,004);

streptomycin (as disclosed in U.S. Patent No. 2,868,779);

SB-59 (as disclosed in Justus Liebigs, Ann. Chem.

20 (1973) 7, lll2-ll40);
TAN-l057-A (as disclosed in U.S. Patent No.

4,971,965);

streptoniazid (as disclosed in J. Am. Chem. Soc. (1953) 75, 2261);

25 immunostimulants related to

ST-789 (as disclosed in published European Patent
Application 88/260588);

peptide hydrolase inhibitors related to nafamastat (as disclosed in U.S. Patent No.

30 4,454,338);

35

·5

10

gabexate (as disclosed in U.S. Patent No.

3,751,447);

sepimostat (as disclosed in U.S. Patent Nos.

4,777,182 and 4,820,730);

Factor Xa inhibitors related to

DX-9065a (as disclosed in published European Patent
Application 92/0540051);

anti-inflammatory agents related to paranyline as disclosed in U.S. Patent No. 2,877,269;

peptidyl aldehydes (as disclosed in WO94/13693);
 antianaphylactics related to GMCHA-TBP (Batebulast)
(as disclosed in U.S. Patent No. 4,465,851);

anti-ulcer agents related to benexate (as disclosed in U.S. Patent No. 4,348,410);

deoxyspergualin (as disclosed in U.S. Patent Nos. 10 4.518,532, 4.658,058 and 4.983,328); and arginine.

Other water-soluble drugs suitable for use herein include peptides preferably have a molecular weight from about 100 to 10,000, more preferably from about 100 to about 6,000 and having from 2 to 35 amino acid moieties.

Higher molecular weight peptides, even those with a molecular weight of above 10,000, up to about 50,000, may also be accommodated in biphasic formulations of the present invention.

Suitable small peptides have from about 2 to about 20 10, more preferably from about 2 to about 6 amino acid moieties. Preferred small peptides include the fibrinogen receptor antagonists (RGD containing peptides) which are tetrapeptides with an average molecular weight of about 600. These peptide antagonists are highly potent platelet aggregation inhibitors at plasma levels as low as 1

aggregation inhibitors at plasma levels as low as 1 pmol/mL. Preferred fibrinogen antagonists include the peptide cyclo(S,S)-Na-acetyl-Cys-(Na-methyl)Arg-Gly-Asp-Pen-NH<sub>2</sub> (Ali et al, EP 0341915, whose disclosure is herein incorporated by reference) and the peptide cyclo(S,S)-(2-

mercapto)benzoyl-(Na-methyl)Arg-Gly-Asp-(2-mercapto)phenylamide (EP 0423212, whose disclosure is herein
incorporated by reference). Other fibrinogen antagonists
useful in the present invention are those peptides
disclosed by Pierschbacher et al, WO 89/05150

30

(US/88/04403); Marguerie, EP 0275748; Adams et al, U.S. 4,857,508; Zimmerman et al, U.S. 4,683,291; Nutt et al, EP 0410537, EP 0410539, EP 0410540, EP 0410541, EP 0410767, EP

0410833, EP 0422937 and EP 0422938; Ali et al, EP 0372486; Ohba et al, WO 90/02751 (PCT/JP89/00926); Klein et al, U.S. 4,952,562; Scarborough et al, WO 90/15620 (PCT/US90/03417); Ali et al, PCT/US90/06514 and PCT/US92/00999; the peptide-like compounds disclosed by Ali et al, EP 0381033 and EP 0384362; and the RGD peptide cyclo-Na-acetyl-Cys-Asn-Dtc-Amf-Gly-Asp-Cys-OH (in which Dtc is 4,4'-dimethylthia-zolidine-5-carboxylic acid and Amf is 4-aminomethylphenyl-alanine).

The RGD peptide may be usefully included in the formulation of the invention in an amount up to about 600 mg/g of the hydrophilic phase or from 0.1 to 60 mg/g of the formulation.

Other peptides useful in the present invention include, but are not limited to, other RGD containing peptides such as those disclosed by Momany, U.S. 4,411,890 and U.S. 4,410,513; Bowers et al, U.S. 4,880,778, U.S. 4,880,777, U.S. 4,839,344; and WO 89/10933 (PCT/US89/01829); the peptide Ala-His-D-Nal-Ala-Trp-D-Phe-Lys-NH<sub>2</sub> (in which Nal represents β-naphthylalanine) and the peptides disclosed by Momany, U.S. 4,228,158, U.S. 4,228,157, U.S. 4,228,156, U.S. 4,228,155, U.S. 4,226,857, U.S. 4,224,316, U.S. 4,223,021, U.S. 4,223,020, U.S. 4,223,019 and U.S. 4,410,512.

Other suitable peptides include hexapeptides such as the growth hormone releasing peptide (GHRP) His-D-Trp-Ala-Trp-D-Phe-Lys-NH<sub>2</sub>, (Momany, U.S. 4,411,890, the disclosure of which is herein incorporated by reference in its entirety). This may usefully be included in an amount up to about 250 mg/g of the hydrophilic phase or from 0.1 to 25 mg/kg of the formulation.

Suitable larger polypeptides and proteins for use in the controlled release formulations of the present invention include insulin, calcitonin, elcatonin, calcitoningene related peptide and porcine somatostatin as well as analogs and homologs thereof. Other suitable larger polypeptides include those disclosed by

Pierschbacher et al, U.S. 4,589,881 (>30 residues); Bittle et al, U.S. 4,544,500 (20-30 residues); and Dimarchi et al, EP 0204480 (>34 residues).

Other type of compounds useful in the present invention include analogs or homologs of LHRH which display potent LH releasing activity or inhibit the activity of LHRH; analogs or homologs of HP5 which possesses hematopoetic activity; analogs or homologs of endothelin which possess hypotensive activity; analogs or homologs of 10 enkephalin which have antinociceptive activity; analogs or homologs of chlorecystokinin; analogs or homologs of cyclosporin A which have immunosuppressive activity; analogs or homologs of atrial natriuretic factor; peptidergic antineoplastic agents; analogs or homologs of 15 gastrin releasing peptide; analogs or homologs of somatostatin; gastrin antagonists; bradykinin antagonists; neurotensin antagonists; bombesin antagonists; oxytocin agonists and antagonists; vasopressin agonists and antagonists; hirudin analogs and homologs; analogs and 20 homologs of the cytoprotective peptidecyclolinopeptide; alpha MSH analogs; analogs, and homologs of MSH releasing factor (Pro-Leu-Gly-NH2); peptides which inhibit collagenase; peptides which inhibit elastase, peptides which inhibit renin; peptides which inhibit HIV protease; 25 peptides which inhibit angiotensin converting enzyme; peptides which inhibit chymases and tryptases and peptides which inhibit blood coagulation enzymes.

Other suitable drugs include non-peptide therapeutic agents such as antibiotics, antimicrobial agents, antineoplastic agents, cardiovascular and renal agents, anti-inflammatory, immunosuppressive and immunostimulatory agents and CNS agents.

30

35

Preferably, the water-soluble drug is metformin or salt thereof as described above.

The biphasic controlled release formulation of the present invention can be administered to various mammalian

species, such as dogs, cats, humans, etc., in need of such treatment.

The biphasic controlled release system of the invention can be incorporated in a conventional systemic dosage form, such as a tablet or capsule. The above dosage forms may also include the necessary physiologically acceptable carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like.

10

15

20

30

The dose administered must be carefully adjusted according to the age, weight, and condition of the patient, as well as the route of administration, dosage form and regimen, and the desired result. In general, the dosage forms of formulation containing metformin or salt thereof (whether by itself or with another antihyperglycemic agent) described above may be administered in amounts as described for metformin hydrochloride (Bristol-Myers Squibb Company's Glucophage®) as set out in the Physician's Desk Reference.

The combination of the metformin or salt thereof and the other antihyperglycemic agent may be formulated separately or, where possible, in a single formulation employing conventional formulation procedures.

The various formulations of the invention may optionally include one or more fillers or excipients in an amount within the range of from about 0 to about 90% by weight and preferably from about 1 to about 80% by weight such as lactose, sugar, corn starch, modified corn starch, mannitol, sorbitol, inorganic salts such as calcium carbonate and/or cellulose derivatives such as wood cellulose and microcrystalline cellulose.

One or more binders may be present in addition to or in lieu of the fillers in an amount within the range of from about 0 to about 35% and preferably from about 0.5 to about 30% by weight of the composition. Examples of such binders which are suitable for use herein include polyvinylpyrrolidone (molecular weight ranging from about 5000 to about 80,000 and preferably about 40,000), lactose,

starches such as corn starch, modified corn starch, sugars, gum acacia and the like as well as a wax binder in finely powdered form (less than 500 microns) such as carnauba wax, paraffin, spermaceti, polyethylenes or microcrystalline wax.

Where the composition is to be in the form of a tablet, it will include one or more tableting lubricants in an amount within the range of from about 0.2 to about 8% and preferably from about 0.5 to about 2% by weight of the composition, such as magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax and the like. Other conventional ingredients which may optionally be present include preservatives, stabilizers, antiadherents or silica flow conditioners or glidants, such as Syloid brand silicon dioxide as well as FD&C colors.

1.0

20

25

30

Tablets of the invention may also include a coating layer which may comprise from 0 to about 15% by weight of the tablet composition. The coating layer which is applied over the outer solid phase containing particles of inner solid phase embedded therein may comprise any conventional coating formulations and will include one or more filmformers or binders, such as a hydrophilic polymer like hydroxypropylmethylcellulose, and/or a hydrophobic polymer like methacrylic acid esters neutral polymer, ethyl cellulose, cellulose acetate, polyvinyl alcohol-maleic anhydride copolymers,  $\beta$ -pinene polymers, glyceryl esters of wood resins and the like and one or more plasticizers, such as triethyl citrate, diethyl phthalate, propylene glycol, glycerin, butyl phthalate, castor oil and the like. Both core tablets as well as coating formulations may contain aluminum lakes to provide color.

The film formers are applied from a solvent system containing one or more solvents including water, alcohols like methyl alcohol, ethyl alcohol or isopropyl alcohol, ketones like acetone, or ethylmethyl ketone, chlorinated hydrocarbons like methylene chloride, dichloroethane, and 1,1,1-trichloroethane.

Where a color is employed, the color will be applied together with the film former, plasticizer and solvent compositions.

It will be recognized by one of skill in the art that the amount of drug required for therapeutic effect on administration will, of course, vary with the agent chosen, the nature and severity of the condition and the animal undergoing treatment, and is ultimately at the discretion of the physician. Furthermore, the optimal quantity and spacing of individual dosages of a drug will be determined by the nature and extent of the condition being treated, the form, route and site of administration, the particular patient being treated and that such optima can be determined by conventional techniques. It will also be appreciated that the optimal course of treatment, this is, the number of doses given, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

15

20

25

As indicated, the preferred highly water-soluble drug will be metformin or a salt thereof, which will be employed in a dosage range from about 2 to about 43 mg/kg, preferably about 3 to about 36 mg/kg and more preferably from about 4.5 to about 30 mg/kg (or from about 150 to about 3000 mg, preferably from about 250 to about 2500 mg) on a regimen in single or 2 to 4 divided daily doses.

The biphasic controlled release formulation of the invention may be prepared in accordance with the following method of the invention.

A mixture of medicament (preferably metformin HCl) and hydrophilic polymer and/or hydrophobic polymer and/or other hydrophobic material are dispersed/dissolved in a suitable solvent such as water or an inert organic solvent such as ethanol, isopropanol, acetone or dichloromethane or appropriate mixtures of two or more thereof, to produce a substantially uniform granulation. The granulation is dried and passed through a 0.5 to 2 mm aperture screen to break down agglomerates.

The resulting dry granules are blended with hydrophilic polymer and/or hydrophobic polymer and/or other hydrophobic material. The resulting mix usually with lubricant is pressed into tablets or filled into capsules.

The finished dosage form is either a compressed tablet or a hard gelatin capsule, preferably a tablet. The tablet may be optionally film coated. The total amount of drug per dosage unit would be such as to offer a dosage form of convenient size for patients, but following ingestion would remain (or swell to, by hydration of the polymers used in the fabrication of the tablet) a size that does not easily pass through the pylorus (15mm or greater) when taken with a meal. As the tablet swells up to approximately three times its dry size following hydration, drug loads of up to 750 mg are possible, dependent upon the actual characteristics of the individual drug. Gradual erosion of the polymers of the formulation over a period of up to 15 hours ensures that the dosage form does not produce a gastrointestinal obstruction.

Useful metformin formulations of the invention show the following drug release characteristic when tested <u>in</u> vitro.

	Time (hours)	<u>% released</u>
25		28-39
	2	43-57
	3	53-70
	5	70-88
	· . 7	80-98
30	10	>85

15

20

The following Examples represent preferred embodiments of the invention.

# Example 1 Biphasic Metformin HCl Formulation

25g of ethylcellulose N10 NF was dissolved/ dispersed in 100 ml of 95% ethanol. This dispersion was gradually added to 500 g of metformin hydrochloride in a planetary mixer to produce a uniform damp granulation. granulation was dried at 55°C for one hour and passed through a 0.8mm aperture screen to break down agglomerates. The metformin-ethylcellulose granules (54lg) were blended 10 with 351.5g of hydroxypropylmethylcellulose 2208 USP (100,000 cps grade), l0g of hydroxypropylmethylcellulose 2910 USP (5 cps grade) and 100.5g of microcrystalline cellulose in a planetary mixer for 10 minutes. Finally this mix was lubricated with 1% w/w magnesium stearate and compressed into capsule shaped tablets, each containing 15 500mg metformin hydrochloride. When subjected to in vitro drug release testing, the following results were obtained.

	Time (hours)	<pre>% metformin released</pre>
20	1	38.1
	2	56.3
	3	69.5
	4	79.7
	5.	87.4
25	6	93.1
	7	97.7
	8	100

### Example 2

30 <u>Biphasic Metformin HCl Formulation</u>

35

5lg of sodium carboxymethylcellulose (Blanose 7HF) was mixed with 500g of metformin hydrochloride and granulated with 95% ethanol in a small planetary mixer. The damp granulation was passed through a 2mm aperture screen and then dried in an oven at 55°C for one hour. The dried granulation (530g) was blended with 344g of hydroxypropylmethylcellulose 2208 USP (100,000 cps grade),

9.5g of hydroxypropylmethylcellulose 2910 USP (5cps grade) and 100g of microcrystalline cellulose in a planetary mixer for 10 minutes. This blend was lubricated with 1% w/w magnesium stearate and compressed into capsule shaped tablets, each containing 500mg metformin hydrochloride. When the tablets were subjected to in vitro release testing the following results were obtained.

•	Time (hours)	% metformin released
10	. 1	35.3
•	2	51.4
	3	62.6
	4	70.7
	. 5	76.7
15	. 6	82.1
	7	85.3
	8	88.5
	10	92.6

20 <u>Example 3</u>

25

### Biphasic Metformin HCl Formulation

Metformin hydrochloride (502.5g) was mixed with sodium carboxymethylcellulose (Blanose 7HF) (50g) for five minutes in a small planetary mixer and sufficient purified water added with continued mixing to produce a damp granular mass. The wet granulation was dried at 60°C for 1 hour and then size reduced in a hammer mill. The granulation was dry blended with a mixture prepared from 385g of hydroxypropylmethylcellulose 2208 USP (100,000 cps grade), 10g of hydroxypropylmethylcellulose 2910 USP (5 cps grade) and 102g of microcrystalline cellulose in a planetary mixer for 10 minutes. Finally this mix was lubricated by mixing with 1% w/w magnesium stearate and compressed into capsule shaped tablets, each containing 0.5g of metformin hydrochloride. When tested for in vitro release of metformin the following results were obtained.

	Time (hours)			% metformin released	<u>1</u>
	1			33.1	
	. 2	-		47.6	
	3			57.5	
5	4			65.1	
	. 6			76.5	
	8			84.3	
	10		•	88.6	

10

15

20

25

30

### Example 4

### Biphasic Metformin HCl Formulation

a high shear mixer bowl and 199g of metformin hydrochloride was added and the mixer operated with impeller at 90 rpm and chopper at 215 rpm for 5 minutes. A further 796g of metformin hydrochloride was added gradually with continued mixing, maintaining the granulation at 70°C and with an increase in chopper speed first to 500 rpm for 13 minutes, then to 1000 rpm for a further 3 minutes. The bowl was then cooled to 60°C, the impeller speed was reduced to 20 rpm and the chopper speed increased to 2000 rpm. Cooling was continued with adjustment in impeller and chopper speed to eventually provide a cooled solid granulation. The cooled granulation was deagglomerated by passing through a 0.8mm screen.

540.5g of the granulation was blended with 350g of hydroxypropylmethylcellulose 2208 USP (100,000 cps grade), 10g hydroxypropylmethylcellulose 2910 USP (5 cps grade) and 100g of microcrystalline cellulose in a planetary mixer for 10 minutes. The blend was lubricated by blending with 1% w/w magnesium stearate and then compressed into capsule shaped tablets each containing 500mg metformin hydrochloride. When tested for in vitro release of metformin, the following results were obtained.

35

	Time (hours)	% metformin released
	1	32.4
	2	45.7
	3	55.8
5	4	63.7
	5	70.3
	6	75.7
•	8	83.3
	10	88.6
10		

10

# Example 5 Biphasic Metformin HCl Formulation

Tablets containing 500 mg metformin hydrochloride prepared according to Example 3 or Glucophage brand

15 metformin hydrochloride 500 mg tablets was dosed (2 x 500 mg tablets) to 24 patients immediately after dinner. Blood samples were taken at 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 20, 24 hours and analyzed for metformin. The mean plasma profile demonstrated useful modification of drug release in vivo relative to the immediate release formulation and with no impact on bioavailability in contrast to other metformin extended release formulations reported in the literature.

Interpatient variability in pharmacokinetic
25 parameters was acceptable as illustrated by the mean parameters (%CV) given in the table below:

Formulation	Cmax	AUC (inf)	Tmax*(hr)	%UR
	(ng/ml)	(ng.hr/ml)		·
Glucophase	1226(16)	10128(14)	3.5(1,5)	43.3(20)
Example 3	978 (13)	10483 (21)	5(4,8)	42.7(18)

<sup>\*</sup>median (min., max.)

30

The new formulations of the invention thus represent a useful advance in the administration of metformin hydrochloride to human in the treatment of diabetes.

### Example 6

### Preparation of Metformin (2:1) Fumarate

Metformin base (8.71 moles) (prepared from the hydrochloride salt via an ion-exchange column) was dissolved in methanol/H<sub>2</sub>O [5:1]. With stirring, a solution of fumaric acid (4.05 moles) in ethanol was added over a period of one hour under a nitrogen atmosphere at ambient temperature (~20°C). Crystallization began to occur immediately. After stirring the slurry for one hour at ambient temperature, the product was filtered off, washed with ethanol and dried under vacuum to afford the metformin (2:1) fumarate salt as a free-flowing white crystalline solid in 72 M% yield and melting point of 247-249°C.

The resulting metformin (2:1) fumarate slat had a solubility in water (mg/ml) of 140, a hygroscopicity measured at 95% relative humidity/25°C of less than 7% moisture uptake at 6 hours, and a low compaction susceptibility.

The so-formed metformin salt is used to prepare a biphasic controlled release formulation employing the procedure of Example 3.

### Example 7

25

30

15

20

### Preparation of Metformin (2:1) Succinate

Metformin base (8.95 moles) (prepared from the hydrochloride salt via an ion-exchange column) was dissolved in methanol/H<sub>2</sub>O [5:1]. With stirring, a solution of succinic acid (4.42 moles) in ethanol was added over one hour under a nitrogen atmosphere at ambient temperature (~20°). Crystallization of the salt commenced shortly after addition of the succinic acid solution. After stirring the slurry for an hour at ambient temperature, the product was filtered off, washed with ethanol and dried under vacuum to form the metformin (2:1) succinate salt as a free flowing white crystalline solid in 89 M% yield and melting point of 246-247°C.

The resulting metformin (2:1) succinate salt had a solubility in water (mg/ml) of 95, a hygroscopicity measured at 95% relative humidity/25°C of less than 1% moisture uptake at 30 minutes, and a low compaction susceptibility.

The so-formed metformin salt is used to prepare a biphasic controlled release formulation employing the procedure of Example 3.

### 10 REFERENCES

- Vidon, N., Chaussade, S., Noel, M.,
   Franchisseur, C., Huchet, B., Bernier, J.J. (1988),
   Diabetes Research and Clinical Practice, 4, 223-239.
- 2. Pentikainen, P.J. (1986), International Journal of Clinical Pharmacology, Therapy and Toxicology, 24, 213-220
  - 3. Watanabe, S., Kayano, M., Ishino, Y., Miyao, K. (1976), U.S. Patent 3,976,764.
- 4. Sheth, P., Tossounian, J.L. (1979), U.S. Patent 20 4,140,755.
  - 5. Sheth, P., Tossounian, J. L. (1978), U.S. Patent 4,126,672.
  - 6. Sheth, P., Tossounian, J. L. (1979), U.S. Patetn 4,167,558.
- 7. Dennis, A.B., Lee, K., Timmins, P. (1992), U.S.
   Patent 5,169,638.
  - 8. Franz, M.R., Oth, M.P. (1993), U.S. Patent 5,232,704.
    - 9. Ishikawa, M., Miyaka, Y., Watanabe, S. (1989),
- 30 U.S. Patent 4,844,905.
  - 10. Davis, S.S., Stockwell, A.F., Taylor, J.J., Hardy, J.G., Whalley, D.R., Wilson, C.G., Bechgaard, H., Christensen, F.N. (1986) Pharm. Res., 3, 208-213.
    - 11. Timmermans, J., Moes, A. (1994), J. Pharm.
- 35 Sci., 83, 18-24.
  - 12. Caldwell, L.J., Gardener, C.R., Cargill, R.C. (1988), U.S. Patent 4,767,627.

13. Urquart, J., Theeuwes, F. (1984), U.S. Patent 4,434,153.

- 14. Shell, J.W. (1990), U.S. Patent 5,007,790.
- 15. Shell, J.W. (1993), World Patent WO 9318755.
- 16. Shell, J.W. (1996), U.S. Patent 5,582,837.
- 17. Fisher, M.C., Morella, A.M. (1994), European Patent 609961.
- 18. Hansraj, B.R., Bashir, R.H. (1992), European Patent 502642.
- 10 19. Rollet, M. (1987), French Patent 2594693.
  - 20. Howard, S.A., Kotwal, P.M. (1997) U.S. Patent 5,645,858.
    - 21. Macrae, R.J., Smith J.S. (1997), World Patent WO 9718814.
- 15 22. Belenduik, G.W., McCarty, J.A., Rudnic, E.M. (1996), U.S. Patent 5,484,608.
  - 23. Bhatti, G.K., Edgren, D.E., Hatamkhani, Z.,
  - Wong, P.S., Wong, P.S.L. (1994), World Patent WO 9427589.
  - 24. Palepu, N.R., Venkatesh, G.M., (1997) European
- 20 Patent 701436.

5

### What is claimed is:

10

1. A pharmaceutical formulation comprising (1) an inner solid particulate phase, and (2) an outer solid continuous phase in which particles of the inner solid particulate phase are dispersed and embedded, the particles of the inner solid particulate phase comprising (a) a pharmaceutical having a high water solubility; and (b) an extended release material, and the outer solid continuous phase comprising an extended release material.

- 2. The pharmaceutical formulation as defined in Claim 1 which is a biphasic heterogeneous controlled release formulation which is designed to release pharmaceutical from the particles forming the inner solid particulate phase through the outer solid continuous phase into the upper gastrointestinal tract.
  - 3. The pharmaceutical formulation as defined in Claim 1 wherein the pharmaceutical is a biguanide antidiabetic agent.
- The pharmaceutical formulation as defined in
   Claim 3 wherein the biguanide is metformin or a pharmaceutically acceptable salt thereof.
  - 5. The pharmaceutical formulation as defined in Claim 4 wherein the pharmaceutical is metformin hydrochloride.
- 25 6. The pharmaceutical as defined in Claim 1 wherein the inner solid particulate phase is in the form of discrete individual particles or granules and the outer solid continuous phase is a substantially continuous matrix having individual particles forming the inner solid particulate phase embedded therein and dispersed throughout.
  - 7. The pharmaceutical formulation as defined in Claim 1 wherein the pharmaceutical has a solubility in water of at least about 100 mg/ml and a limited window of absorption in the upper gastrointestinal tract.
  - 8. The pharmaceutical formulation as defined in Claim 1 wherein the pharmaceutical present in the inner

solid particulate phase is metformin or a pharmaceutically acceptable salt thereof.

- 9. The pharmaceutical formulation as defined in Claim 1 wherein the inner solid particulate phase is present in a weight ratio to the outer solid continuous phase within the range from about 0.5:1, to about 4:1.
- 10. The pharmaceutical formulation as defined in Claim 1 wherein the pharmaceutical is present in the inner solid particulate phase in an amount within the range from about 10 to about 98% by weight of the inner solid particulate phase.

10

- 11. The pharmaceutical formulation as defined in Claim 1 wherein the extended release material present in the inner solid particulate phase comprises one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more other type hydrophobic materials; and the extended release material in the outer solid continuous phase comprises one or more hydrophilic polymers, one or more hydrophobic polymers and/or one or more other type hydrophobic materials.
  - 12. The pharmaceutical formulation as defined in Claim 11 wherein the extended release material present in the inner solid particulate phase comprises one or more ionic polymers and the extended release material present in the outer solid continuous phase comprises one or more non-ionic polymers.
- 13. The pharmaceutical formulation as defined in Claim 12 wherein the ionic polymer comprises sodium alginate, carbomer, calcium carboxymethylcellulose or sodium carboxymethylcellulose, and the non-ionic polymer comprises hydroxypropylmethylcellulose 2910 USP, viscosity grade ranging from about 4000 to about 100,000 cps and hydroxypropylmethyl cellulose 2208 USP viscosity grade ranging from about 3 to about 150 cps and/or microcrystalline collulose.
  - l4. The pharmaceutical formulation as defined in Claim 1 wherein the inner solid particulate phase has a

mean particle size within the range from about 30  $\mu m$  to about 0.8 mm.

- 15. The pharmaceutical formulation as defined in Claim I wherein the inner solid particulate phase comprises metformin, metformin hydrochloride, metformin succinate (2:1) salt or metformin fumarate (2:1) salt, and ethyl cellulose and/or sodium carboxymethyl cellulose and/or glycerylmonostearate and the outer solid continuous phase comprises hydroxypropylmethylcellulose 2208 USP (100,000 cps), and/or hydroxypropylmethylcellulose 2910 USP (5 cps) and/or microcrystalline cellulose.
  - 16. The pharmaceutical formulation as defined in Claim 1 wherein the pharmaceutical is a combination of metformin or a pharmaceutically acceptable salt thereof and another antihyperglycemic agent.

15

- 17. A method for preparing a biphasic controlled release delivery system, which comprises forming an inner solid particulate phase comprising individual particles comprising a pharmaceutical having a high water solubility and an extended release material and mixing the individual particles forming the inner solid particulate phase with an outer solid continuous phase comprising an extended release material to thereby disperse and embed the individual particles forming the inner solid particulate phase in the outer solid continuous phase.
  - 18. A biphasic controlled release delivery system formed by the method as defined in Claim 17.
- 19. A method for treating diabetes which comprises administering to a mammalian patient in need of treatment a therapeutically effective amount of the formulation as defined in Claim 4.

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/05233

A. CLASSIFICATION OF SUBJECT MATTER  IPC(6) :A61K 9/24  US CL :424/457  According to International Patent Classification (IPC) or to both national classification and IPC						
	DS SEARCHED	·				
Minimum de	ocumentation searched (classification system followed	by classification symbols)				
U.S. : 4	424/472		,			
Documentat	ion searched other than minimum documentation to the	extent that such documents are included	in the fields searched			
Electronic d	ata base consulted during the international search (na	me of data base and, where practicable,	search terms used)			
APS						
C. DOC	UMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.			
Y	US 5,645,858 A (KOTWAL ET AL.)	08 July 1997, see cols. 5-8.	1-19			
Y	WO 96/08243 A1 (MOECKEL ET AL disclosure.	.) 21 March 1996, see entire	1-19			
Y	EP 0 609 961 A1 (MORELLA ET examples and tables.	AL.) 10 August 1994, see	1-19			
		-				
			•			
		·				
Furth	l her documents are listed in the continuation of Box C	. See patent family annex.				
• Sp	pecial categories of cited documents;	"T" later document published after the inte data and not in conflict with the appl				
	comment defining the general state of the art which is not considered be of particular relevance	the principle or theory underlying the				
'B'	rlier document published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be considered.				
cit	ocusest which may throw doubts on priority claim(s) or which is ted to establish the publication data of another citation or other social reason (as specified)	"Y" document of particular relevance; th				
	comment referring to an oral disclosure, use, exhibition or other	considered to involve an inventive combined with one or more other suc being obvious to a person skilled in (	h documents, such combination			
	comeent published prior to the international filing data but later than a priority data claimed	"A" document member of the same paten	l family			
Date of the	actual completion of the international search	Date of mailing of the international sea	arch report			
03 JUNE	1999	<b>0</b> 7JUL 1999				
	mailing address of the ISA/US oner of Patents and Trademarks	Authorized officer  D. Laurence	To			
Washingto	n, D.C. 20231	PETER KULKOSKY aco /	_ <b>C</b>			

# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

### IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

### **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Buréau



AL

### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

	עםו	JNDER THE PATENT COOPERATION TREATY (PCT)
(51) International Patent Classification <sup>6</sup> : A61K 9/20	<b>A1</b>	<ul> <li>(11) International Publication Number: WO 99/4712.</li> <li>(43) International Publication Date: 23 September 1999 (23.09.99)</li> </ul>
<ul> <li>(21) International Application Number: PCT/USS</li> <li>(22) International Filing Date: 19 March 1999 (19)</li> <li>(30) Priority Data: 09/045,330 20 March 1998 (20.03.98)</li> <li>(71) Applicant: ANDRX PHARMACEUTICALS, INC. Suite 201, 4001 S.W. 47th Avenue, Fort Lauder 33314 (US).</li> <li>(72) Inventors: CHENG, Xiu, Xiu, Apartment 506, Rolling Hills Circle, Davie, FL 33328 (US). Chih-Ming; 10680 S.W. 40th Manor, Davie, F (US). JAN, Steve; 512 N.W. 120th Drive, Coral FL 33071 (US). CHOU, Joseph; 5755 N.W. 54 Coral Springs, FL 33067 (US).</li> <li>(74) Agent: ENDRES, Martin, P.; Hedman, Gibson &amp; P.C., 1185 Avenue of the Americas, New York, N (US).</li> </ul>	[US/US]  [US/US]  Gale, 1  3150 CHE  L 333  Sprin  kth Pla	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GI, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MV, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TTM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO pater (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasia patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GI, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CC, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  W. Published  With international search report.

(54) Title: CONTROLLED RELEASE ORAL TABLET HAVING A UNITARY CORE

### (57) Abstract

A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL AM AT AU AZ BA BB BE BF BC CA CF CCG CCH CCI CCM	Albania Armenia Austria Austria Azerbaijan Bosnia and Herzegovina Barbados Belgium Burkina Faso Bulgaria Benin Brazil Belarus Canada Central African Republic Congo Switzerland Côte d'Ivoire Cameroon	ES FI FR GA GB GE GH GN GR HU IE IL IS IT JP KE KG KP	Spain Finland France Gabon United Kingdom Georgia Ghana Guinea Greece Hungary Ireland Israel Iceland Italy Japan Kenya Kyrgyzstan Democratic People's Republic of Korea Republic of Korea	LS LT LU LV MC MD MG MK ML MN MR MR NE NL NO NZ PL PT	Lesotho Lithuania Luxembourg Latvia Monaco Republic of Moldova Madagascar The former Yugoslav Republic of Macedonia Mali Mongolia Mauritania Malawi Mexico Niger Netherlands Norway New Zealand Poland Portugal	SI SK SN SZ TD TG TJ TM TR TU UA UG US UZ VN YU ZW	Slovenia Slovakia Senegal Swaziland Chad Togo Tajikistan Turkmenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistan Viet Nam Yugoslavia Zimbabwe
			Republic of Korea		•		
CU CZ DE DK	Cuba Czech Republic Germany Denmark Estonia	KZ LC LI LK LR	Kazakstan Saint Lucia Liechtenstein Sri Lanka Liberia	RU SD SE SG	Russian Federation Sudan Sweden Singapore		

10

15

20

25

35

## CONTROLLED RELEASE ORAL TABLET HAVING A UNITARY CORE BACKGROUND OF THE INVENTION:

The present invention relates to controlled release unit dose formulations containing an antihyperglycemic drug. More specifically, the present invention relates to an oral dosage form comprising a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride or the metformin salts described in United States Patent Nos. 3,957,853 and 4,080,472 which are incorporated herein by reference.

In the prior art, many techniques have been used to provide controlled and extended-release pharmaceutical dosage forms in order to maintain therapeutic serum levels of medicaments and to minimize the effects of missed doses of drugs caused by a lack of patient compliance.

In the prior art are extended release tablets which have an osmotically active drug core surrounded by a semipermeable membrane. These tablets function by allowing a fluid such as gastric or intestinal fluid to permeate the coating membrane and dissolve the active ingredient so it can be released through a passageway in the coating membrane or if the active ingredient is insoluble in the permeating fluid, pushed through the passageway by an expanding agent such as a hydrogel. Some representative examples of these osmotic tablet systems can be found in United States Patent Nos. 3,845,770, 3,916,899, 4,034,758, United States Patent 4,077,407 and 4,783,337. 3,952,741 teaches an osmotic device wherein the active agent is released from a core surrounded by a semipermeable membrane only after sufficient pressure has developed within the membrane to burst or rupture the membrane at a 30 weak portion of the membrane.

The basic osmotic device described in the above cited patents have been refined over time in an effort to provide greater control of the release of the active ingredient. For example United States Patent Nos. 4,777,049 and 4,851,229 describe an osmotic dosage form comprising a

PCT/US99/06024 WO 99/47125

semipermeable wall surrounding a core. The core contains an active ingredient and a modulating agent wherein the modulating agent causes the active ingredient to be released through a passageway in the semipermeable membrane in a pulsed manner. Further refinements have included modifications to the semipermeable membrane surrounding the active core such as varying the proportions of the components that form the membrane, i.e United States Patent Nos. 5,178,867, 4,587,117 and 4,522,625 or increasing the number of coatings surrounding the active core, 5,650,170 and 4,892,739.

10

15

20

35

Although vast amounts of research has been performed on controlled or sustained release compositions and in particular on osmotic dosage forms, very little research has been performed in the area of controlled or sustained release compositions that employ antihyperglycemic drugs.

The limited work on controlled or sustained release formulations that employ antihyperglycemic drugs such as metformin hydrochloride has been limited to the combination of the antihyperglycemic drug and an expanding or gelling agent to control the release of the drug from the dosage This limited research is exemplified by the teachings of WO 96/08243 and by the GLUCOPHAGE® product which is a commercially available product from Bristol-Myers Squibb Co. containing metformin HCl.

It is reported in the 50th Edition of the Physicians' Desk Reference, copyright 1996, p. 753, that food decreases the extent and slightly delays the absorption of metformin delivered by the  ${\tt GLUCOPHAGE}^{\odot}$  dosage form. This decrease is 30 shown by approximately a 40% lower peak concentration and a 25% lower AUC in plasma and a 35 minute prolongation of time to peak plasma concentration following administration of a single GLUCOPHAGE $^{\odot}$  tablet containing 850 mg of metformin HCl with food compared to the similar tablet administered under fasting conditions.

It is an object of the present invention to provide a controlled or sustained release formulation for an

PCT/US99/06024 WO 99/47125

antihyperglycemic drug wherein the bioavailability of the drug is not decreased by the presence of food.

It is a further object of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that does not employ an expanding polymer.

It is also a further object of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that can provide continuous non-pulsating therapeutic levels antihyperglycemic drug to an animal or human in need of such treatment over a twelve hour to twenty-four hour period.

It is an additional object of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that obtains peak plasma levels approximately 8-12 hours after administration.

It is also an object of this invention to provide a controlled or sustained release pharmaceutical tablet having only a homogeneous osmotic core wherein the osmotic core component may be made using ordinary tablet compression techniques.

## SUMMARY OF THE INVENTION

10

15

20

- The foregoing objectives are met by a controlled 25 release dosage form comprising:
  - (a) a core comprising:
    - an antihyperglycemic drug; (i)
    - optionally a binding agent; and (ii)
- optionally an absorption enhancer; 30
  - (b) a semipermeable membrane coating surrounding the core; and
  - (c) at least one passageway in the semipermeable membrane.
- The dosage form of the present invention can provide therapeutic levels of the antihyperglycemic drug for twelve to twenty-four hour periods and does not exhibit a decrease 35 in bioavailability if taken with food. In fact, a slight

WO 99/47125

increase in the bioavailability of the antihypoglycemic drug is observed when the controlled release dosage form of the present invention is administered with food. preferred embodiment, the dosage form will be administered once a day, ideally with or after a meal and most preferably with or after the evening meal, and provide therapeutic levels of the drug throughout the day with peak plasma levels being obtained between 8-12 hours after administration.

10

20

25

30

35

# BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph which depicts the dissolution profile in simulated intestinal fluid (pH 7.5 phosphate (SGF) of the buffer) and simulated gastric fluid formulation described in Example 1 as tested according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm.

FIG. 2 is a graph which depicts the dissolution profile in simulated intestinal fluid (pH 7.5 phosphate simulated gastric fluid (SGF) formulation described in Example 2 as tested according to buffer) the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm.

FIG. 3 is a graph which depicts the dissolution profile in simulated intestinal fluid (pH 7.5 phosphate and simulated gastric fluid (SGF) formulation described in Example 3 as tested according to buffer) the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm.

FIG. 4 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 1 the in vivo metformin plasma profile of the commercially available metformin HCl product GLUCOPHAGE® under fasting conditions.

FIG. 5 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 2 the in vivo metformin plasma profile of the

PCT/US99/06024 WO 99/47125

commercially available metformin HCl product GLUCOPHAGE® under fasting conditions.

FIG. 6 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 2 and the in vivo metformin plasma profile of the commercially available metformin HCl product GLUCOPHAGE® under fed conditions.

FIG. 7 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 3 in vivo metformin plasma profile of the commercially available metformin HCl product GLUCOPHAGE® 10 under fed conditions (after breakfast).

FIG. 8 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 3 and the in vivo metformin plasma profile of commercially available metformin HCl product GLUCOPHAGE® under fed conditions (after dinner).

# DETAILED DESCRIPTION OF THE INVENTION

15

30

The term antihyperglycemic drugs as used in this specification refers to drugs that 20 controlling or managing noninsulin-dependent mellitus (NIDDM). Preferably, the antihyperglycemic drug is a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin 25 hydrochloride.

The binding agent may be any conventionally known pharmaceutically acceptable binder such as polyvinyl cellulose, hydroxyethyl hydroxypropyl cellulose, ethylcellulose, polymethacrylate, waxes and the like. Mixtures of the aforementioned binding agents may The preferred binding agents are water soluble such as polyvinyl pyrrolidone having a weight also be used. average molecular weight of 25,000 to 3,000,000. binding agent comprises approximately about 0 to about 40% of the total weight of the core and preferably about 3% to 35 about 15% of the total weight of the core.

10

20

30

The core may optionally comprise an absorption enhancer. The absorption enhancer can be any type of absorption enhancer commonly known in the art such as a fatty acid, a surfactant, a chelating agent, a bile salt or Examples of some preferred absorption mixtures thereof. enhancers are fatty acids such as capric acid, oleic acid and their monoglycerides, surfactants such as sodium lauryl sulfate, sodium taurocholate and polysorbate 80, chelating agents such as citric acid, phytic acid, ethylenediamine ethylene glycol-bis(ßand (EDTA) tetraacetic acid aminoethyl ether)-N,N,N,N-tetraacetic acid (EGTA). core comprises approximately 0 to about 20% of the absorption enhancer based on the total weight of the core and most preferably about 2% to about 10% of the total weight of the core.

The core of the present invention which comprises the antihyperglycemic drug, the binder which preferably is a pharmaceutically acceptable water soluble polymer and the absorption enhancer is preferably formed by wet granulating the core ingredients and compressing the granules with the addition of a lubricant into a tablet on a rotary press. The core may also be formed by dry granulating the core ingredients and compressing the granules with the addition of a lubricant into tablets or by direct compression.

Other commonly known excipients may also be included 25 into the core such as lubricants, pigments or dyes.

The homogeneous core is coated with a semipermeable membrane, preferably a modified polymeric membrane to form the controlled release tablet of the invention. semipermeable membrane is permeable to the passage of an external fluid such as water and biological fluids and is impermeable to the passage of the antihyperglycemic drug in Materials that are useful in forming the semipermeable membrane are cellulose esters, cellulose 35 diesters, cellulose triesters, cellulose ethers, cellulose cellulose acylate, cellulose diacylate, ester-ether, cellulose cellulose triacylate, cellulose acetate,

PCT/US99/06024 WO 99/47125

diacetate, cellulose triacetate, cellulose propionate, and cellulose acetate butyrate. Other suitable polymers are described in United States Patent Nos. 3,845,770, 3,916,899, 4,008,719, 4,036,228 and 4,11210 which are incorporated herein by reference. The most preferred semipermeable membrane material is cellulose acetate comprising an acetyl content of 39.3 to 40.3%, commercially available from Eastman Fine Chemicals.

10

25

35

an alternative embodiment, the semipermeable membrane can be formed from the above-described polymers and a flux enhancing agent. The flux enhancing agent increases the volume of fluid imbibed into the core to enable the dosage form to dispense substantially all of the antihyperglycemic drug through the passageway and/or the porous membrane. The flux enhancing agent can be a water soluble material or an enteric material. Some examples of 15 the preferred materials that are useful as flux enhancers are sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycol (PEG), propylene glycol, hydroxypropyl cellulose, hydroxypropyl methycellulose, hydroxypropyl methycellulose phthalate, cellulose acetate 20 phthalate, polyvinyl alcohols, methacrylic acid copolymers and mixtures thereof. The preferred flux enhancer is PEG 400.

The flux enhancer may also be a drug that is water such as metformin or its pharmaceutically acceptable salts or a drug that is soluble under intestinal soluble conditions. If the flux enhancer is a drug, the present dosage form has the added advantage of providing an 30 immediate release of the drug which is selected as the flux enhancer.

The flux enhancing agent comprises approximately 0 to about 40% of the total weight of the coating, most preferably about 2% to about 20% of the total weight of the The flux enhancing agent dissolves or leaches from the semipermeable membrane to form paths in the coating.

PCT/US99/06024 WO 99/47125

semipermeable membrane for the fluid to enter the core and dissolve the active ingredient.

The semipermeable membrane may also be formed with commonly known excipients such a plasticizer. commonly known plasticizers include adipate, azelate, enzoate, citrate, stearate, isoebucate, sebacate, triethyl citrate, tri-n-butyl citrate, acetyl tri-n-butyl citrate, and those described citric acid esters, Encyclopedia of Polymer Science and Technology, Vol. 10 (1969), published by John Wiley & Sons. The preferred plasticizers are triacetin, acetylated monoglyceride, grape 10 seed oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylfumarate, dibutylsuccinate, diethylmalate, dibutylsebacate, dioctylphthalate, triethylcitrate, tributylcitrate, glyceroltributyrate, and diethylmalonate, 15 the like. Depending on the particular plasticizer, amounts of from 0 to about 25%, and preferably about 2% to about 15% of the plasticizer can be used based upon the total weight of the coating. 20

As used herein the term passageway includes an aperture, orifice, bore, hole, weaken area or an erodible element such as a gelatin plug that erodes to form an osmotic passageway for the release of the antihyperglycemic drug from the dosage form. A detailed description of the passageway can be found in United States Patents such as 3,845,770, 3,916,899, 4,034,758, 4,077,407, 4,783,337 and 5,071.607.

25

30

35

Generally, the membrane coating around the core will comprise from about 1% to about 5% and preferably about 2% to about 3% based on the total weight of the core and coating.

In an alternative embodiment, the dosage form of the present invention may also comprise an effective amount of the antihyperglycemic drug that is available for immediate release. The effective amount of antihyperglycemic drug for immediate release may be coated onto the semipermeable

membrane of the dosage form or it may be incorporated into

In a preferred embodiment the dosage form will have the semipermeable membrane.

	In a preferror the following composition	n: <u>preferred</u>	Most Preferred
5	CORE: drug binder absorption enhancer	50-98% 0-40% 0-20%	75-95% 3-15% 2-10%
10	coating: semipermeable polymer flux enhancer	50-99% 0-40% 0-25%	75-95% 2-20% 2-15% according to the pre

The dosage forms prepared according to the present invention should exhibit the following dissolution profile when tested in a USP type 2 apparatus at 75 rpms in 900 ml 20 of simulated intestinal fluid (pH 7.5 phosphate buffer) and

20	at 37	°C:	preferred	Most Preferre
25	Time 2 4 8 12 16 20	(hours)	0-25% 10-45% 30-90% NTL 50% NTL 60% NTL 70%	0-15% 20-40% 45-90% NTL 60% NTL 70% NTL 80%
~ ^			Nation	s the

30

In the preparation of the tablets of the invention, NTL = NOT LESS THAN various conventional well known solvents may be used to prepare the granules and apply the external coating to the tablets of the invention. In addition, various diluents, excipients, lubricants, dyes, pigments, dispersants etc. which are disclosed in Remington's Pharmaceutical Sciences, 1995 Edition may be used to optimize the formulations of the invention.

40

## DESCRIPTION OF THE PREFERRED EMBODIMENTS EXAMPLE 1

A controlled release tablet containing 850 mg of metformin HCl and having the following formula is prepared as follows:

#### Core Ι 5 90.54% metformin HCl 4.38% povidone1, USP 4.58% sodium tribasic phosphate 0.5 % magnesium stearate

10

'approximate molecular weight = 50,000; dynamic viscosity (10%w/v solution at 20°C) = 5.5-8.5 m Pa s.

(a) Granulation The metformin HCl is delumped by passing it through a 40 mesh screen and collecting it in a clean, polyethylenelined container. The povidone, K-30, and sodium tribasic 15 phosphate are dissolved in purified water. The delumped metformin HCl is then added to a top-spray fluidized bed granulator and granulated by spraying the binding solution of povidone and sodium tribasic phosphate under the following conditions: inlet air temperature of 50-70°C; 20 atomization air pressure of 1-3 bars; and spray rate of

Once the binding solution is depleted, the granules 10-100 ml/min. are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After 30 blending, the granules are compressed on a rotary press fitted with 15/32" round standard concave punches (plain lower punch, upper punch with an approximately 1 mm indentation pin). 35

## (c) Seal Coating (optional)

PCT/US99/06024

WO 99/47125

10

20

30

The core tablet is seal coated with an Opadry material other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear, in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following exhaust air temperature atomization pressure of 28-40 psi; and spay rate of 10-15 The core tablet is coated with the sealing solution until a theoretical coating level of approximately 2% is obtained.

	II <u>Sustained Release Coating</u>	I 85%
	cellulose acetate (398-10) <sup>2</sup>	5%
	triacetin	10%
15	PEG 400	

2acetyl content 39.3 - 40.3%

### (d) Sustained Release Coating

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The clear coating solution is then sprayed onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately 3 bars; and spray rate of 120-150 ml/min. The sealed core tablet is coated until a theoretical coating level of approximately 3% is obtained.

The resulting tablet is tested in simulated intestinal fluid (pH 7.5) and simulated gastric fluid (SGF) according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm and found to have the following release profile:

	release profile:	% Released (SGF)	% Released (pH 7.5)
35	TIME (hours)	% Released \our 1	12
	2	27	82
	4	62	100
	8	82	100
	12		

88 105 16 92 108

The release profile in pH 7.5 and SGF of the sustained release product prepared in this Example is shown in Figure

5 1.

10

20

Figure 4 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example. Also shown in Figure 4 is the in vivo metformin plasma profile of GLUCOPHAGE®, a commercially available pharmaceutical product containing the drug metformin HCl.

#### EXAMPLE 2

A controlled release tablet containing 850 mg of metformin HCl and having the following formula is prepared

#### 15 as follows:

0	
I <u>Core</u>	88.555%
metformin HCl	
	6.368%
povidone3, USP	
	4.5778
	n 5 %
magnesium stearate	0.5
sodium lauryl sulfate magnesium stearate	4.577% 0.5 %

<sup>3</sup>approximate molecular weight = 1,000,000, dynamic viscosity  $(10\%w/v \text{ solution at } 20^{\circ}\text{C}) = 300-700 \text{ m Pa s.}$ 

10

15

#### Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90F, is dissolved in purified water. delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator granulated by spraying with the binding solution of the following conditions: inlet air povidone under atomization air pressure of 1-3 temperature of 50-70°C; bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. blending, the coated granules are compressed on a rotary press fitted with 15/32" round standard concave punches (plain lower punch, upper punch with an approximately 1 mm indentation pin).

### Seal Coating (optional)

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by dissolving the Opadry material, preferably Opadry Clear in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following exhaust air temperature of atomization pressure of 28-40 psi; and spay rate of 10-15 conditions: The core tablet is coated with the sealing solution until a theoretical coating level of approximately 2% is obtained.

25

II Sustained Release Coati	ng	
cellulose acetate (398-10)4		85%
		5%
triacetin	4,	10%
PEG 400		

5

10

20

30

35

facetyl content 39.3 - 40.3%

### (d) Sustained Release Coating

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The clear coating solution is then sprayed onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately 3 bars; and spray rate of 120-150 ml/min. The sealed core tablet is coated until a theoretical coating level of approximately 3% is obtained.

The resulting tablet is tested in simulated intestinal fluid (pH 7.5) and simulated gastric fluid (SGF) according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm and found to have the following release profile:

	release profile:	(SGF)	% Released (pH 7.5)
	TIME (hours)	% Released (SGF)	12
	2	29	27
25	4	55	52 71
	8	72	83
	12	81	91
	16	87	
	20	file in pH 7.5 and	SGF of the sustained

The release profile in pH 7.5 and SGF of the sustained release product prepared in this Example is shown in Figure

Figure 5 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example under fasting conditions. Figure 5 also shows the in vivo metformin plasma profile of the GLUCOPHAGE® product under fasting conditions.

Figure 6 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example

under fed conditions. Figure 6 also shows the in vivo metformin plasma profile of the GLUCOPHAGE® product under fed conditions.

Figures 5 and 6 clearly show that the dosage forms prepared in accordance with the present invention exhibit consistent bioavailability under both fed and fasting conditions while the GLUOPHAGE® product's bioavailability decreases in the presence of food.

EXAMPLE 3 10

15

20

35

A controlled release tablet containing 850 mg of metformin HCl and having the same formula as in Example 2 is prepared as described in Example 2 except that an additional hole was drilled on the plain side of the coated a diameter additional hole had The tablet. approximately 1 mm.

The resulting tablet is tested in simulated intestinal fluid (pH 7.5) and simulated gastric fluid (SGF) according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm and found to have the following release profile:

	release profile: TIME (hours)	% Released (SGF)	% Released (pH 7.5)
•	1 IMB (Jagas)	13	28
	2	27	63
	4 :	50	84
25	8	67	95
	12	84	102
	16	97	<b>—</b> • —
	20	and	SGF of the sustained

The release profile in pH 7.5 and SGF of the sustained release product prepared in this Example is shown in Figure 30 3.

Figure 7 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example when administered shortly after breakfast. Figure 7 also shows the in vivo metformin plasma profile of the GLUCOPHAGE® product administered shortly after breakfast.

Figure 8 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example Figure 8 also when administered shortly after dinner.

20

shows the in vivo metformin plasma profile of the  ${\tt GLUCOPHAGE}^{\scriptsize \textcircled{\scriptsize 0}}$  product administered shortly after dinner.

Table 1 is a summary of the bioavailability comparision data, test/reference ratio, shown in Figures 4-8 wherein the GLUCOPHAGE® product is the reference product in a two way crossover biostudy with n = 6.

	in a two way cross	TABLE 1		•	
· ·	Formula Figure Ex. 1 4	Study Fasting Fasting	<u>AUC</u> 0.202 0.369	<u>Cmax</u> 0.12 0.214	<u>Tmax</u> 2.15 1.73
10	Ex. 2 5 Ex. 2 6 Ex. 3 7	Fed (bkft) Fed (bkft) Fed (dinner)	0.628 0.797 0.850	0.305 0.528 0.751	1.94 1.82 2.00
. •	Ex. 3 8	. • • • • • • • • • • • • • • • • • • •		n. mires	4-8 sho

15 The results reported in Table 1 and Figures 4-8 show that dosage forms prepared in accordance with the present invention exhibit an increase in the bioavailability of the antihyperglycemic drug in the presence of food, especially when taken with or shortly after the evening meal.

While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention.

1. A controlled release pharmaceutical tablet comprising: We claim:

- a core comprising:
- an antihyperglycemic drug; (i)5
  - optionally a binding agent; and
  - (iii) optionally an absorption enhancer; and
  - (b) a semipermeable membrane coating covering said core;
- (c) at least one passageway in the semipermeable membrane. and 10
  - A controlled release pharmaceutical tablet as defined in claim 1 wherein the antihyperglycemic drug is a biguanide.

15

- A controlled release pharmaceutical tablet as defined in claim 2 wherein the antihyperglycemic drug is metformin or a pharmaceutically acceptable salt thereof.
- A controlled release pharmaceutical tablet as defined in claim 2 wherein the antihyperglycemic drug is buformin 20 or a pharmaceutically acceptable salt thereof.
  - A controlled release pharmaceutical tablet as defined in claim 1 wherein the binding agent is water soluble. 25
    - A controlled release pharmaceutical tablet as defined in claim I wherein the water soluble binding agent is hydroxypropyl pyrrolidone, hydroxyethyl cellulose, waxes or mixtures thereof.
  - 30
    - A controlled release pharmaceutical tablet as defined in claim 6 wherein the water soluble binding agent is polyvinyl pyrrolidone.

35

A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is selected from

the group consisting of fatty acids, surfactants, chelating agents, bile salts or mixtures thereof.

- 9. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is a fatty acid selected from the group consisting of capric acid, oleic acid or their monoglycerides.
- 10. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is a surfactant selected from the group consisting of sodium lauryl sulfate, sodium taurocholate and polysorbate 80.
  - 11. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is a chelating agent selected from the group consisting of citric acid, phytic acid, ethylene diamine tetraacetic acid and ethylene glycol-bis(ß-aminoethyl ether)-N,N,N,N-tetraacetic acid.
  - 20 12. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is a bile salt.
  - 13. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is sodium lauryl sulfate.
    - 14. A controlled release pharmaceutical tablet as defined in claim 1 wherein the semipermeable membrane around the core is a water insoluble cellulose derivative.
    - 15. A controlled release pharmaceutical tablet as defined in claim 14 wherein the water insoluble cellulose derivative in the membrane around the core is cellulose acetate.

35

30

16. A controlled release pharmaceutical tablet as defined in claim 1 wherein semipermeable membrane comprises a flux enhancer.

- 5 17. A controlled release pharmaceutical tablet as defined in claim 16 wherein the flux enhancer is sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycol, propylene glycol, hydroxypropyl cellulose, hydroxypropyl methycellulose, hydroxypropyl methycellulose, hydroxypropyl methycellulose acetate phthalate, polyvinyl alcohols, methacrylic acid copolymers or mixtures thereof.
- 18. A controlled release pharmaceutical tablet as defined in claim 17 wherein the flux enhancer is polyethylene glycol with an average molecular weight between 380 and 420.
- 19. A controlled release pharmaceutical tablet as defined
   20 in claim 1 wherein the semipermeable membrane comprises a plasticizer.

25

- 20. A controlled release pharmaceutical tablet as defined in claim 19 wherein the plasticizer is triacetin.
- 21. A controlled release pharmaceutical tablet as defined in claim 1 wherein at least two passageways are formed in the semipermeable membrane.
- 30 22. A controlled release pharmaceutical tablet as defined in claim 1 wherein the peak plasma level is obtained 8-12 hours after administration.
- 23. A controlled release pharmaceutical tablet as defined in claim 1 further comprising an effective amount of the antihyperglycemic drug coated onto the semipermeable membrane or mixed into the semipermeable membrane to

provide an immediate release of an effective amount of the antihyperglycemic drug.

A controlled release pharmaceutical tablet as defined in claim 1 wherein the core comprises: 5

50-98% of the drug;

0-40% of the binding agent; and

0-20% of the absorption enhancer; and the coating comprises:

50-99% of the polymer; 10

0-40% of the flux enhancer; and

0-25% of the plasticizer.

25. A controlled release pharmaceutical tablet as defined in claim 1 wherein the core comprises:

75-95% of the drug;

3-15% of the binding agent; and

2-10% of the absorption enhancer; and the coating comprises:

75-95% of the polymer; 20

2-20% of the flux enhancer;

2-15% of the plasticizer.

A controlled release pharmaceutical tablet as defined in claim 1 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml 25 of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37°C:


after 2 hours 0-25% of the drug is released;


after 4 hours 10-45% of the drug is released; after 8 hours 30-90% of the drug is released; after 12 hours not less than 50% of the drug is released; after 16 hours not less than 60% of the drug is released; and after 20 hours not less than 70% of the drug is

released. 35


A controlled release pharmaceutical tablet as defined in claim 1 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and

- 5 at 37°C:
  - after 2 hours 0-15% of the drug is released; after 4 hours 20-40% of the drug is released; after 8 hours 45-90% of the drug is released; after 12 hours not less than 60% of the drug is released;
- after 16 hours not less than 70% of the drug is released; and after 20 hours not less than 80% of the drug is released.
- A controlled release pharmaceutical tablet as defined in claim 1 that is administered with or shortly after the 15 evening meal.
  - controlled release antihyperglycemic tablet 29. comprising:
- a core consisting essentially of: 20
  - metformin or a pharmaceutically acceptable salt thereof:
    - (ii) a water soluble binding agent;
    - (iii) an absorption enhancer; and
- a semipermeable membrane coating covering said core (b) 25 comprising:
  - cellulose acetate; (i)
  - (ii) a flux enhancer; and
  - (iii) a plasticizer; and
- 30 (c) at least one passageway in the semipermeable membrane.
  - A controlled release pharmaceutical tablet as defined in claim 29 wherein the peak plasma level is obtained 8-12 hours after administration.





SUBSTITUTE SHEET (RULE 26) AUROBINDO EX. 1006, 123



SUBSTITUTE SHEET (RULE 26)






FIG. 4




--- ANDRX METFORMIN XL(P97450A) --- GLUCOPHAGE (MAH82)

FIG. 5




--- ANDRX METFORMIN XL(P97450A) --- GLUCOPHAGE (MAH82)

FIG. 6



--- ANDRX METFORMIN XL(P97450A-D) --- GLUCOPHAGE (MAH82)

FIG. 7



--- ANDRX METFORMIN XL(P97450A-D) --- GLUCOPHAGE (MAH82)

FIG. 8

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/06024

•	·		
	OR SUBJECT MATTER		
	FICATION OF SUBJECT MATTER		
PC(6) :A6	IK 9/20	al classification and IPC	
cording to la	1/464 sternational Patent Classification (IPC) or to both national	Vicesia	
nimum docu	SEARCHED mentation searched (classification system followed by cl	/	• .
	L/A6A	•	
	a searched other than minimum documentation to the exten	it that such documents are included in	the fields searched
cumentation	searched other than minimum documentation to		
	a base consulted during the international search (name o	f data base and, where practicable,	search terms used)
lectronic dat	a base consulted during -		
APS	•		
DOCL	IMENTS CONSIDERED TO BE RELEVANT		Relevant to claim No.
	Citation of document, with indication, where appropr	nate, of the relevant passages	Veterant to come
Category*	CHEROL OF THE PARTY A DAY	1000 col 1 lines 13-16:	1-30
Y,P	US 5,858,398 A (CHO) 12 JANUARY	col. 12. lines 13-29, col.	
	US 5,858,398 A (CHO) 12 JANOAR1 col. 3, lines 18-28; col. 11, lines 25-35; 15, lines 10,63; col. 16, lines 1-19; col.	18. lines 32-35; col. 19,	I
1	15 lines 10,63; col. 10, lines 1-15, col.	· •••	
	lines 67; col. 20 lines 1-5.		
		•	
		•	
	·		
		•	
	,		
		•	
1		•	
1.			
<b> </b>	the description of Box C.	See patent family annex	
Fu	rther documents are listed in the continuation of Box C.	•T• later document published after the date and not in conflict with the	
	Special categories of cited documents: document defining the general state of the art which is not considered	the principle of theory underly an	, =
٠٧.			; the claimed invention cannot b uidered to involve an inventive sta
•в•	earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is document which may throw doubt on priority claim(s) or which is	when the document is taken along	invention cannot b
•L•	aited to establish the publication	eye document of particular relevano considered to involve an inve	s; the claimed invention cannot be ntive step when the document r such documents, such combination
	special reason (as specified) document referring to an oral disclosure, use, exhibition or other	combined with one or more other being obvious to a person skille	
1.0.		document member of the same	
•р•	document published prior to the international filing date but later than the priority date claimed	Date of mailing of the internations	
Date of	the actual completion of the international search		
1		24 JUN 19	199
	PRIL 1999	Authorized officer D. Laurence	, .
Name	and mailing address of the ISA/US nissioner of Patents and Trademarks	THURMAN K. PAGE	- Zoo
D-v 1	act		, <u>J</u>
Wash	ington, D.C. 20231 ile No. (703) 305-3230	1 10.07=-	UROBINDO EX.

#### **PCT**

### WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



AM

#### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:	A1	(11) International Publication Number: WO 99/29314
A61K 31/155	AI	(43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/(1) (22) International Filing Date: 1 December 1998 (30) Priority Data: 08/986,586 8 December 1997 (08.12.) (71) Applicant: BRISTOL-MYERS SQUIBE (US/US); P.O. Box 4000, Princeton, NJ 08543- (72) Inventors: TIMMINS, Peter, 5 Heathbank Av Merseyside L61 4XD (GB). WINTER, William, Lake Road, Skaneateles, NY 13152 (US). SRISushil, K.; 9 Kayann Drive, Dayton, NJ 08RETNALL, Alison; 33 Sandon Road, Newtork (CH2 2EP (GB). WEI, Chenkou; 44 Win Princeton Junction, NJ 08550 (US). POWEL: 721 Cranbury Cross Road, North Brunswick	COMPAN-4000 (US) venue, Iri, J.; 2166 VASTAV 08810 (US) ton, Ches dsor Dri RS, Gera	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published  With international search report.
(US).  (74) Agents: RODNEY, Burton et al.; Bristol-Myers S pany, P.O. Box 4000, Princeton, NJ 08543-400		n-

(54) Title: NOVEL SALTS OF METFORMIN AND METHOD

#### (57) Abstract

Novel salts of the antidiabetic agent metformin are provided which are metformin salts of dibasic acids (2:1 molar ratio), preferably metformin (2:1) furnarate and metformin (2:1) succinate, which may be employed alone or in combination with another antihyperglycemic agent such as glyburide, for treating diabetes. A method for treating diabetes employing the novel metformin salt by itself or in combination with another antidiabetic agent is also provided.

#### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

ΑĹ	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	. LT	Lithuania	SK	Slovakia
AT	Austria .	FR	France	·LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	MC	Мопасо	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
СН	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	· PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal	*	
Cυ	Cuba	KZ	Kazakstan	RO	Romania		
cz	Czech Republic	LC	Saint Lucia	RU	Russian Federation		-
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

#### NOVEL SALTS OF METFORMIN AND METHOD

#### Field of the Invention

The present invention relates to salts of the anti-diabetic agent metformin, and more particularly to metformin salts of dibasic acids, preferably dibasic organic carboxylic acids, optionally in combination with other anti-diabetic agent and to a method employing such salts or combinations for treating diabetes.

10

15

20

25

#### Background of the Invention

The biguanide antihyperglycemic agent metformin is concurrently marketed in the U.S. in the form of its hydrochloride salt (Glucophage $^{TM}$ , Bristol-Myers Squibb Company).

Metformin hydrochloride is a cohesive white powder which is highly soluble in water (>300 mg/ml at ambient temperature), has a hygroscopicity measured at 95% relative humidity /25°C of greater than 20% moisture uptake at 6 hours, and a high compaction susceptibility. Accordingly, handling of metformin hydrochloride in a pharmaceutical manufacturing facility could present problems especially in high humidity environments. Furthermore, formulation of the metformin hydrochloride in a controlled release system is exceedingly difficult due, at least in part, to its extremely high water solubility.

The currently marketed metformin hydrochloride salt has a pronounced saline, bitter taste. Accordingly, it is usually marketed as a coated tablet where the coating is designed to mask any unpleasant taste. However, where the metformin hydrochloride salt is in the form of scored-divisible tablets, it will not usually have a coating or outer layer to mask the unpleasant taste.

Taste is of primary concern where the metformin

35 hydrochloride is to be formulated as a chewable tablet or
liquid indicated for children or adults who are not able to
swallow tablets.

In such cases, the unpleasant taste of the hydrochloride salt could lead to compliance problems.

The prior art is replete with references disclosing metformin salts of various organic or inorganic acids in a l:l molar ratio of metformin:acid. Thus, for example,

U.S. Patent No. 3,174,901 discloses phosphate, sulfate, hydrobromide, salicylate, maleate, benzoate, succinate, ethanesulfonate, fumarate and glycolate salts of metformin;

U.S. Patent No. 4,835,184 discloses the p-10 chlorophenoxyacetic acid salt of metformin;

French Patent Nos. 2320735 and 2037002 disclose the pamoate salt of metformin;

French Patent No. 2264539 and Japanese Patent No. 66008075 disclose the orotate salt of metformin;

15 French Patent No. 2275199 discloses the (4-chlorophenoxy)isobutyrate salt of metformin;

U.S. Patent No. 4,080,472 discloses the clofibrate salt of metformin;

U.S. Patent No. 3,957,853 discloses the acetylsalicylate salt of metformin;

20

25

30

35

French Patent No. 2220256 discloses the theophyllin-7-acetate salt of metformin;

German Patent Nos. 2357864 and 1967138 disclose the nicotinic acid salt of metformin;

U.S. Patent No. 3,903,141 discloses the adamantoate salt of metformin;

Japanese Patent No. 69008566 discloses the zinc-chlorophyllin salt of metformin;

Japanese Patent No. 64008237 discloses hydroxy acid salts of metformin, including salts of hydroxy aliphatic dicarboxylic acids such as mesotartaric acid, tartaric acid, mesoxalic acids, and oxidized maleates;

Japanese Patent No. 63014942 discloses the tannic acid salt of metformin;

Japanese Patent Nos. 87005905 and 61022071 disclose the 3-methyl-pyrazole-5-carboxylic acid (or other 5-members hetercycle carboxylic acid) salt of metformin;

Romanian Patent No. 82052 discloses sulfamido aryloxyalkyl carboxylic acid salts of metformin;

Soviet Union Patent No. 992512 discloses the trimethoxy benzoic acid salt of metformin;

U.S. Patent No. 4,028,402 discloses the dichloroacetic acid salt of metformin.

5

20

25

30

35

All of the above salts are formed of metformin: salt in a 1:1 molar ratio.

U.S. Patent No. 5,631,224 to Efendic et al issued May 20, 1997, discloses a combination of metformin with GLP-1(7-36) amide, or GLP-1(7-37) or a fragment thereof which retains GLP-1(7-37) activity.

#### Description of the Invention

In accordance with the present invention, novel salts of metformin are provided which retain equivalent antihyperglycemic activity to metformin hydrochloride, but which have improved handling properties as compared to metformin hydrochloride salt, including lower

hygroscopicity and better flow properties as well as reduced compaction susceptibility and reduced corrosiveness such as to tablet tooling. The novel salts of the invention will also have improved taste properties as compared to the hydrochloride salt thus enhancing patient compliance, especially where the novel salts are in the form of scored tablets, chewable tablets or liquids.

In addition, the novel salts of metformin of the invention are significantly less soluble in water than the hydrochloride salt and thus provide the opportunity for formulating metformin in controlled release systems which require less polymer excipients to achieve a desired metformin release rate.

The novel metformin salts of the invention are metformin salts of dibasic acids wherein the molar ratio of metformin:dibasic acid is 2:1.

The dibasic aid forming the novel salt with metformin is preferably a dibasic organic carboxylic acid

which includes saturated dicarboxylic acids such as succinic acid, malonic acid, glutaric acid, adipic acid, and pimelic acid and unsaturated dicarboxylic acids such as fumaric acid, maleic acid, and hydroxydicarboxylic acids such as malic acid, tartronic acid, and tartaric acid. Most preferred are the metformin (2:1) salt of succinic acid and the metformin (2:1) salt of fumaric acid.

The preferred metformin (2:1) fumarate salt of the invention is a free-flowing white crystalline solid which has a solubility in water at ambient temperature of 140 mg salt per ml water.

The preferred metformin (2:1) succinate salt of the invention is a free-flowing white powder which has a solubility in water at ambient temperature of 95 mg salt per ml water.

15

20

25

35

Moreover, metformin hydrochloride is a cohesive white powder which has a high solubility in water at ambient temperature of greater than 300 mg metformin per ml water.

The metformin (2:1) fumarate salt and metformin (2:1) succinate salt of the invention each has a low hygroscopicity measured at 95% relative humidity at 25°C of less than 7% moisture uptake at 6 hours; while metformin hydrochloride has a high hygroscopicity measured at 95% relative humidity of greater than 20% moisture uptake at 6 hours.

Furthermore, the metformin (2:1) salts of the invention have reduced compaction susceptibility (tendency of the salt to compact under its own weight) as compared to the high compaction susceptibility of the metformin hydrochloride salt which could cause problems in bulk transport.

Accordingly, the novel metformin (2:1) salts of the invention with their lower hygroscopicity and improved flow properties and reduced compaction susceptibility, provide substantial and unexpected benefits over metformin

hydrochloride in terms of handling during tabletting manufacture.

10

15

20

25

35

Surprisingly, it has also been found that the metformin (2:1) fumarate salt and the metformin (2:1) succinate salt have a substantially more tolerable taste as compared to the metformin hydrochloride salt. Accordingly, fumarate and succinate salts of the invention may be formulated as scored tablets, as well as chewable tablets or liquids without having an adverse effect on patient compliance.

The metformin (2:1) salts of dibasic acids of the invention are prepared employing conventional salt forming procedures. Thus, for example, the metformin base (which may be prepared from the hydrochloride using an ion-exchange column or other conventional technique) is dissolved in methanol or other suitable solvent and then admixed with a solution of the dibasic organic carboxylic acid, such as fumaric acid or succinic acid, in ethanol or other suitable solvent (in a 2:1 molar ratio metformin:dibasic acid). The desired salt crystallizes out and may be recovered by filtration, and dried to form a free flowing solid.

Still further in accordance with the invention, novel antihyperglycemic combinations are provided which include a metformin salt of a dibasic acid (2:1 molar ratio) in combination with another antihyperglycemic agent which may be administered orally or by injection.

The use of the metformin salt of the invention in combination with another anti-hyperglycemic agent produces antihyperglycemic results greater than that possible from each of these medicaments alone and greater than the combined additive anti-hyperglycemic effects produced by these medicaments.

The other antihyperglycemic agent may be an oral antihyperglycemic agent preferably a sulfonyl urea such as glyburide (also known as glibenclamide), glimepiride (disclosed in U.S. Patent No. 4,379,785), glipizide,

gliclazide or chlorpropamide, other known sulfonylureas or other antihyperglycemic agents which act on the ATP-dependent channel of the  $\beta$ -cells, with glyburide being preferred.

The metformin salt of the invention will be employed in a weight ratio to the sulfonyl urea in the range from about 300:1 to about 50:1, preferably from about 250:1 to about 75:1.

The oral antihyperglycemic agent may also be a glucosidase inhibitor such as acarbose (disclosed in U.S. Patent No. 4,904,769) or miglitol (disclosed in U.S. Patent No. 4,639,436).

The metformin salt of the invention will be employed in a weight ratio to the glucosidase inhibitor within the range from about 300:1 to about 2:1, preferably from about 200:1 to about 25:1.

15

30

The metformin salt of the invention may be employed in combination with a thiazolidinedione oral anti-diabetic agent (which has an insulin sensitivity effect in NIDDM patients) such as troglitazone (Warner-Lambert's Rezulin®, disclosed in U.S. Patent No. 4,572,912), zorglitazone (SKB), pioglitazone (Takeda), Mitsubishi's MCC-555 (disclosed in U.S. Patent No. 5,594,016) Glaxo-Welcome's GL-262570, englitazone (CP-68722, Pfizer) or darglitazone (CP-86325, Pfizer).

The metformin salt of the invention will be employed in a weight ratio to the thiazolidinedione in an amount within the range from about 75:1 to about 0.1:1, preferably from about 5:1 to about 0.5:1.

The novel metformin salt of the invention may also be employed in combination with a non-oral antihyper-glycemic agent such as insulin or with glucagon-like peptide-1 (GLP-1) such as GLP-1(1-36) amide, GLP-1(7-36) amide, GLP-1(7-37) (as disclosed in U.S. Patent No.

35 5,614,492 to Habener, the disclosure of which is incorporated herein by reference), which may be

administered via injection, orally, or by transdermal or buccal devices.

The novel metformin salts of the invention alone or in combination with another antihyper-glycemic agent may also be employed in combination with amylin.

In addition, in accordance with the present invention a method is provided for treating hyperglycemia including Type II diabetes (NIDDM) and/or Type I diabetes (IDDM) wherein a therapeutically effective amount of a metformin salt of a dibasic acid (2:1 molar ratio), optionally in combination with another antihyperglycemic agent, is administered to a patient in need of treatment.

Where present, the sulfonyl ureas, such as glyburide, glimepiride, glipyride, glipizide, chlorpropamide and gliclazide and the glucosidase inhibitors acarbose or miglitol may be employed in formulations, amounts and dosing as indicated in the Physician's Desk Reference.

Where present, the thiazolidinedione anti-diabetic agent may be employed in amounts within the range from about 0.01 to about 2000 mg/day which may be administered in single or divided doses one to four times per day.

Where present insulin may be employed in formulations, amounts and dosing as indicated by the Physician's Desk Reference.

20

25

35

Where present GLP-1 peptides may be administered in oral buccal formulations, by nasal administration or parenterally as described in U.S. Patent Nos. 5,346,701 (TheraTech), 5,614,492 and 5,631,224 which are incorporated herein by reference.

The novel metformin salts of the present invention are potent anti-hyperglycemic agents at least equivalent to metformin hydrochloride and can be administered to various mammalian species, such as dogs, cats, humans, etc., in need of such treatment in the same manner as metforin hydrochloride. These metformin salts can be administered systemically, preferably orally.

The metformin salts of the invention alone or in combination with one or more oral antihyperglycemic agents can be incorporated in a conventional systemic dosage form, such as a tablet, capsule, elixir or injectable

formulation. The above dosage forms will also include the necessary physiologically acceptable carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like. Oral dosage forms are preferred, although parenteral forms are quite satisfactory as well.

The dose administered must be carefully adjusted according to the age, weight, and condition of the patient, as well as the route of administration, dosage form and regimen, and the desired result. In general, the dosage forms of the metformin (2:1) salt of the invention (whether by itself or with another antihyperglycemic agent) described above may be administered in amounts as described for metformin hydrochloride (Bristol-Myers Squibb Company's Glucophage®) as set out in the Physician's Desk Reference.

15

20

25

The combination of the metformin salt of the invention and the other antihyperglycemic agent may be formulated separately or, where possible, in a single formulation employing conventional formulation procedures.

The various formulations of the invention may optionally include one or more fillers or excipients in an amount within the range of from about 0 to about 90% by weight and preferably from about 1 to about 80% by weight such as lactose, sugar, corn starch, modified corn starch, mannitol, sorbitol, inorganic salts such as calcium carbonate and/or cellulose derivatives such as wood cellulose and microcrystalline cellulose.

One or more binders may be present in addition to or in lieu of the fillers in an amount within the range of from about 0 to about 35% and preferably from about 0.5 to about 30% by weight of the composition. Examples of such binders which are suitable for use herein include polyvinylpyrrolidone (molecular weight ranging from about

5

10

15

20

25

30

35

5000 to about 80,000 and preferably about 40,000), lactose, starches such as corn starch, modified corn starch, sugars, gum acacia and the like as well as a wax binder in finely powdered form (less than 500 microns) such as carnauba wax, paraffin, spermaceti, polyethylenes or microcrystalline wax.

Where the composition is to be in the form of a tablet, it will include one or more tablet disintegrants in an amount within the range of from about 0.5 to about 10% and preferably from about 2 to about 8% by weight of the composition such as croscarmellose sodium, povidone, crospovidone, sodium starch glycolate, corn starch or microcrystalline cellulose as well as one or more tableting lubricants in an amount within the range of from about 0.2 to about 8% and preferably from about 0.5 to about 2% by weight of the composition, such as magnesium stearate, stearic acid, palmitic acid, calcium stearate, talc, carnauba wax and the like. Other conventional ingredients which may optionally be present include preservatives, stabilizers, anti-adherents or silica flow conditioners or glidants, such as Syloid brand silicon dioxide as well as FD&C colors.

Tablets of the invention may also include a coating layer which may comprise from 0 to about 15% by weight of the tablet composition. The coating layer which is applied over the tablet core may comprise any conventional coating formulations and will include one or more film-formers or binders, such as a hydrophilic polymer like hydroxy-propylmethyl cellulose and a hydrophobic polymer like ethyl cellulose, cellulose acetate, polyvinyl alcohol-maleic anhydride copolymers,  $\beta$ -pinene polymers, glyceryl esters of wood resins and the like and one or more plasticizers, such as triethyl citrate, diethyl phthalate, propylene glycol, glycerin, butyl phthalate, castor oil and the like. Both core tablets as well as coating formulations may contain aluminum lakes to provide color.

The film formers are applied from a solvent system containing one or more solvents including water, alcohols like methyl alcohol, ethyl alcohol or isopropyl alcohol, ketones like acetone, or ethylmethyl ketone, chlorinated hydrocarbons like methylene chloride, dichloroethane, and l,l,l-trichloroethane.

Where a color is employed, the color will be applied together with the film former, plasticizer and solvent compositions.

A preferred tablet composition of the invention will include from about 90 to about 97.5% by weight metformin (2:1) salt from about 2 to about 8% by weight providene, and from about 0.5 to about 2% by weight magnesium stearate.

10

15 The pharmaceutical composition of the invention may be prepared as follows. A mixture of the medicament and a fraction (less than 50%) of the filler where present (such as lactose), with or without color, are mixed together and passed through a #12 to #40 mesh screen. Filler-binder where present (such as microcrystalline cellulose), disintegrant (such as providone) are added and mixed. Lubricant (such as magnesium stearate) is added with mixing until a homogeneous mixture is obtained.

The resulting mixture may then be compressed into 25 tablets of up to 2 grams in size.

Where desired, the tablets of the invention may be formulated by a wet granulation techniques as disclosed in U.S. Patent No. 5,030,447 which is incorporated herein by reference.

The following examples represent preferred embodiments of the invention.

## Example 1 Preparation of Metformin (2:1) Fumarate

Metformin base (8.71 moles) (prepared from the

hydrochloride salt via an ion-exchange column) was
dissolved in methanol/H<sub>2</sub>O [5:1]. With stirring, a solution
of fumaric acid (4.05 moles) in ethanol was added over a
period of one hour under a nitrogen atmosphere at ambient
temperature (~20°C). Crystallization began to occur
immediately. After stirring the slurry for one hour at
ambient temperature, the product was filtered off, washed
with ethanol and dried under vacuum to afford the metformin
(2:1) fumarate salt as a free-flowing white crystalline
solid in 72 M% yield and melting point of 247-249°C.

The resulting metformin (2:1) fumarate salt had a solubility in water (mg/ml) of 140, a hygroscopicity measured at 95% relative humidity/25°C of less than 7% moisture uptake at 6 hours, and a low compaction susceptibility. Tabletting of the metformin (2:1) fumarate salt resulted in reduced corrosion of tablet tooling equipment as compared with the corresponding hydrochloride salt.

#### Example 2

#### Preparation of Metformin (2:1) Succinate

15

20

25

30

35

Metformin base (8.95 moles) (prepared from the hydrochloride salt via an ion-exchange column) was dissolved in methanol/ $H_2O$  [5:1]. With stirring, a solution of succinic acid (4.42 moles) in ethanol was added over one hour under a nitrogen atmosphere at ambient temperature (~20°C). Crystallization of the salt commenced shortly after addition of the succinic acid solution. After stirring the slurry for an hour at ambient temperature, the product was filtered off, washed with ethanol and dried under vacuum to form the metformin (2:1) succinate salt as

a free flowing white crystalline solid in 89 M% yield and melting point of 246-247°C.

The resulting metformin (2:1) succinate salt had a solubility in water (mg/ml) of 95, a hygroscopicity measured at 95% relative humidity/25°C of less than 1% moisture uptake at 30 minutes, and a low compaction susceptibility. Tabletting of the metformin (2:1) fumarate salt resulted in reduced corrosion of tablet tooling equipment as compared with the corresponding hydrochloride salt.

# Example 3 Preparation of Tablets Containing Metformin (2:1) Fumarate

15

10

Tablets of the following formulation were prepared as described below.

	<u>Ingredient</u>	Amount per	tablet (mg)
20	Metformin (2:1) fumarate	600.0	mg
	Microcrystalline cellulose NF	80.0	mg
	Croscarmellose sodium NF	45.0	mg
	Povidone USP	15.0	mg
	Magnesium Stearate NF	. 8.0	mg

. 25

30

In a planetary mixer metformin (2:1) fumarate was blended with half the microcrystalline cellulose and with the croscarmellose sodium. The povidone USP was dissolved in a suitable quantity of purified water and this solution was used to wet granulate the drug-excipient mixture. The granules were dried in an oven at 60°C to a moisture content of 1.5-2.5% w/w. In a V-cone blender the granules were mixed with the remaining microcrystalline cellulose and then with the magnesium stearate. The resulting mix was compressed into tablets using suitable capsule shaped tooling.

This formulation does not require introduction of additional moisture immediately prior to compression as is the case with metformin hydrochloride formulations in order to ensure trouble free tabletting.

The metformin fumarate salt has a less intense taste than metformin hydrochloride which means film coating of the final metformin fumarate tablet is not necessary.

#### Example 4

10 <u>Preparation of Tablets Containing Metformin</u>
(2:1) <u>Succinate</u>

Tablets of the following formulation are prepared as described below.

15

35

	Ingredient	Amount per	tablet (mg)
	Metformin (2:1) succinate	600.0	mg
	Microcrystalline cellulose NF	80.0	mg
	Croscarmellose sodium NF	45.0	mg
20	Hydroxypropylmethyl cellulose	15.0 mg	· .
	(5 cps) (HPMC) USP		
	Magnesium Stearate NF	8.0	mg

In a planetary mixer the metformin (2:1) succinate
is blended with half the microcrystalline cellulose and
with the croscarmellose sodium. The HPMC USP is dispersed
in a suitable quantity of purified water and this mixture
is used to wet granulate the drug-excipient mixture. The
granules are dried in an oven at 60°C to a moisture content
of 1.5-2.5% w/w. In a V-cone blender the granules are
mixed with the remaining microcrystalline cellulose and
then with the magnesium stearate. The resulting mix is
compressed into tablets using suitable capsule shaped
tooling.

This formulation does not require introduction of additional moisture immediately prior to compression as is

the case with metformin hydrochloride formulations in order to ensure trouble free tabletting.

#### Example 5

## Preparation of Tablets Containing Metformin (2:1) Fumarate and Glyburide

Tablets of the following formulation are prepared as described below.

10

30

5

	Ingredient	Amount per	tablet (mg)
	Metformin (2:1) fumarate	600.0	mg
,	Glyburide	5.0	mg
	Microcrystalline cellulose NF	80.0	mg
.15	Croscarmellose sodium NF	45.0	mg
	Povidone USP	15.0	mg
	Magnesium Stearate NF	8.0	mg .

In a planetary mixer metformin (2:1) fumarate is

20 blended with half the microcrystalline cellulose and with
the croscarmellose sodium. The povidone USP is dissolved
in a suitable quantity of purified water and this solution
is used to wet granulate the drug-excipient mixture. The
granules are dried in an oven at 60°C to a moisture content

25 of 1.5-2.5% w/w. In a V-cone blender the granules are
mixed with the remaining microcrystalline cellulose and
then with the magnesium stearate. The resulting mix is
compressed into tablets using suitable capsule shaped
tooling.

This formulation does not require introduction of additional moisture immediately prior to compression as is the case with metformin hydrochloride formulations in order to ensure trouble free tabletting, and the less intense taste of the fumarate salt means film coating of the final tablet may not be necessary.

30

# Example 6 Preparation of Tablets Containing Metformin (2:1) Succinate and Glyburide

Tablets of the following formulations are prepared as described below.

	Ingredient	Amount per tablet (mg)
	Metformin (2:1) succinate	600.0 mg
10	Glyburide	5.0 mg
	Microcrystalline cellulose NF	80.0 mg
	Croscarmellose sodium NF	45.0 mg
	Hydroxypropylmethyl	15.0 mg
	cellulose (5 cps) USP	
15	Magnesium Stearate NF	8.0 mg

In a planetary mixer metformin (2:1) succinate and glyburide are blended with half the microcrystalline cellulose and with the croscarmellose sodium. The HPMC USP is dissolved in a suitable quantity of purified water and this solution is used to wet granulate the drug-excipient mixture. The granules are dried in an oven at 60°C to a moisture content of 1.5-2.5% w/w. In a V-cone blender the granules are mixed with the remaining microcrystalline cellulose and then with the magnesium stearate. The resulting mix is compressed into tablets using suitable capsule shaped tooling.

This formulation does not require introduction of additional moisture immediately prior to compression as is the case with metformin hydrochloride formulations in order to ensure trouble free tabletting.

#### Example 7

# Preparation of Tablets Containing Metformin (2:1) Fumarate and Glipizide

Tablets of the following formulations are prepared as described below.

Amount per tablet (mg)
600.0 mg
5.0 mg
80.0 mg
45.0 mg
15.0 mg
8.0 mg

15

30

In a planetary mixer metformin (2:1) fumarate and glipizide are blended with half the microcrystalline cellulose and with the croscarmellose sodium. The povidone USP is dissolved in a suitable quantity of purified water and this solution is used to wet granulate the drug-excipient mixture. The granules are dried in an oven at 60°C to a moisture content of 1.5-2.5% w/w. In a V-cone blender the granules are mixed with the remaining microcrystalline cellulose and then with the magnesium stearate. The resulting mix is compressed into tablets using suitable capsule shaped tooling.

This formulation does not require introduction of additional moisture immediately prior to compression as is the case with metformin hydrochloride formulations in order to ensure trouble free tabletting.

30

# Example 8 Preparation of Tablets Containing Metformin (2:1) Succinate and Glipizide

Tablets of the following formulations were prepared as described below.

•	Ingredient	Amount per	tablet (mg)
	Metformin (2:1) succinate	600.0	mg
10	Glipizide	5.0	mg
	Microcrystalline cellulose NF	80.0	mg
	Croscarmellose sodium NF	45.0	mg
	Hydroxypropyl methyl	15.0	mg
	cellulose (5 cps) USP	,	
15	Magnesium Stearate NF	8.0	mg

In a planetary mixer metformin (2:1) succinate and glipizide are blended with half the microcrystalline cellulose and with the croscarmellose sodium. The HPMC USP is dissolved in a suitable quantity of purified water and this mixture is used to wet granulate the drug-excipient mixture. The granules are dried in an oven at 60°C to a moisture content of 1.5-2.5% w/w. In a V-cone blender the granules are mixed with the remaining microcrystalline cellulose and then with the magnesium stearate. The resulting mix is compressed into tablets using suitable capsule shaped tooling.

This formulation does not require introduction of additional moisture immediately prior to compression as is the case with metformin hydrochloride formulations in order to ensure trouble free tabletting.

WO 99/29314 PCT/US98/25104

#### Example 9

# Preparation of Chewable Tablets Containing Metformin (2:1) Fumarate Salt

5 Chewable tablets of the following formulation are prepared as described below.

	Ingredient	Amount per tablet (mg)
	Metformin (2:1) succinate	600.0 mg
10	Xylitol	450.0 mg
	Flavor, grape	0.5 mg
	Flavor, spice	0.5 mg
	Magnesium Stearate NF	10.0 mg

The metformin (2:1) fumarate is passed through a suitable wire mesh screen (600 micron aperture). The flavor ingredients are blended with the pre-screened xylitol and the resulting mix is added to the metformin (2:1) fumarate in a V-cone blender. The mixture is mixed for ten minutes. The magnesium stearate is added to the contents of the V-cone blender, passing the magnesium stearate through a 425 micron aperture screen. The mix is mixed for 5 minutes and compressed into flat faced bevel edged tablets using suitable tooling.

25

# Example 10 Preparation of Chewable Formulation of Metformin (2:1) Succinate Salt

30 Chewable tablets of the following formulation are prepared as described below.

	Ingredient	Amount per	tablet (mg)
	Metformin (2:1) succinate	600.0	mg
35	Xylitol	450.0	mg
	Flavor, raspberry	0.5	mg ·
	Magnesium Stearate NF	10.0	mg

WO 99/29314 PCT/US98/25104

The metformin (2:1) succinate is passed through a suitable wire mesh screen (600 micron aperture). The flavor ingredient is blended with the pre-screened xylitol and the resulting mix is added to the metformin (2:1) succinate in a V-cone blender. The mixture is mixed for ten minutes. The magnesium stearate is added to the contents of the V-cone blender, passing the magnesium stearate through a 425 micron aperture screen. The mix is mixed for 5 minutes and compressed into flat faced bevel edged tablets using suitable tooling.

#### Example 11

The following experiment was carried out to 15 determine moisture sorption/desorption profiles of metformin (2:1) fumarate salt and metformin (2:1) succinate salt compared to the moisture uptake properties of metformin hydrochloride salt.

The procedure employed was as follows:

20

25

The hygroscopicity of metformin salts was assessed by Dynamic Vapour Sorption (DVS), a means of rapidly assessing sample moisture uptake properties. Approximately 5 mg of sample is placed on a suitable microbalance sample pan in a controlled temperature environment (held at 30°C) and which is suitably tared against a separate blank pan. Both chambers are subjected to a controlled program of incremental increase in RH from 0% to 95% by means of a moisture saturated air/dry nitrogen variable mixture gas 30 stream. The weight increase of sample at each condition is recorded until a defined minimal rate of mass change is reached or a specified time period for equilibrium exceeded. A reverse cycle from 95% to 0% is performed immediately, allowing an absorption and desorption profile 35 to be generated and from which the hygroscopicity was determined.

WO 99/29314 PCT/US98/25104

The following moisture uptake at 95% relative humidity/25°C is observed.

	(1) metform	in hydrod	chloride	<u>Time</u>	<pre>% moisture uptake</pre>
5	•		•	30 min	1.2%
			· .	70 min	3.3%
				3 hours	10.0%
				6 hours	20.1%
				(did not	reach equilibrium)
10					
	(2) metform:	in (2:1)	fumarate	<u>Time</u>	% moisture uptake
				30 min	1.0%
			٠	70 min	2.0%
				3 hours	4.1%
15				6 hours	6.6%
			. * .	(did not	reach equilibrium)
	(3) metform	in (2:1)	succinate	Time	% moisture uptake
			:	30 min	0.27%
20	·			(reached	equilibrium)

In summary, the degree of moisture uptake for the salts tested were found to occur in the following rank order:

25

(1) metformin hydrochloride salt: 20% moisture content after 6 hours at 95% relative humidity at 25°C

30

(2) metformin (2:1) fumarate salt: 6.6% moisture after 6 hours at 95% relative humidity at  $25^{\circ}\text{C}$ 

(3) metformin (2:1) succinate:

0.27% equilibrium moisture content after 30 minutes at 95% relative humidity at 25°C.

5

From the above results, it is seen that metformin

10 hydrochloride salt absorbs substantially greater amounts of
moisture as compared to the metformin (2:1) fumarate salt
of the invention and the metformin (2:1) succinate salt of
the invention. Accordingly, the metformin (2:1) salts of
the invention will have improved handling properties during
tabletting as compared to the metformin hydrochloride salt.

25

35

What is claimed is:

- 1. A metformin salt of a dibasic acid in a molar ratio of 2 moles metformin to 1 mole dibasic acid.
- 2. The metformin salt as defined in Claim 1 wherein the dibasic acid is a dibasic organic carboxylic acid.
  - 3. The metformin salt as defined in Claim l which is metformin (2:1) fumarate.
  - 4. The metformin salt as defined in Claim 1 which is metformin (2:1) succinate.
- 5. The metformin salt as defined in Claim 1 which is metformin (2:1) malate.
  - 6. The metformin salt as defined in Claim 1 which is in the form of free flowing powder or crystals.
- 7. A metformin salt of a dibasic acid having a solubility in water (mg/ml) at ambient temperature of less than about 150 mg/ml.
  - 8. A metformin salt of a dibasic acid in the form of free flowing granules having a hygroscopicity measured at 95% relative humidity, 20°C of less than 7% moisture uptake at 6 hours.
  - 9. A pharmaceutical composition comprising a metformin salt as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.
  - 10. The pharmaceutical composition as defined in Claim 9 in the form of a tablet or capsule and the metformin salt is metformin fumarate or metformin succinate.
    - 11. The pharmaceutical composition as defined in Claim 9 further including another antihyperglycemic agent.
- 30 l2. The pharmaceutical composition as defined in Claim l1 wherein the other antihyperglycemic agent is glyburide or glipizide.
  - 13. A method for treating hyperglycemia which comprises administering to a patient in need of treatment a therapeutically effective amount of a metformin salt as defined in Claim 1.

- 14. The method as defined in Claim 13 wherein the metformin salt is administered with a therapeutically effective amount of another antihyperglycemic agent.
- 15. The method as defined in Claim 14 wherein the other antihyperglycemic agent is glyburide or glipizide.
- 16. A combination of a metformin salt of a dibasic acid in a molar ratio of 2 moles metformin to 1 mole dibasic acid, and another antihyperglycemic agent.
- 17. The combination as defined in Claim 16 wherein the metformin salt is metformin (2:1) fumarate or metformin (2:1) succinate.
  - 18. The combination as defined in Claim 16 wherein the other antihyperglycemic agent is a sulfonyl urea, a glucosidase inhibitor, a thiazolidinedione, a GLP-l peptide, and/or insulin.
  - 19. The combination ad defined in Claim 18 wherein the antihyperglycemic agent is glyburide, glipizide, glimepiride, acarbose, miglitol, troglitazone or insulin.
- 20. The combination as defined in Claim 16 which is 20 metformin (2:1) fumarate or metformin (2:1) succinate, and glyburide or glipizide.

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/1/S98/25104

	COURTS MICH OF CURITY MATTER	·	<u>l.</u>		<u> </u>	-
	SSIFICATION OF SUBJECT MATTER :A61K 31/155					
US CL	: 514/635					
	to International Patent Classification (IPC) or to both	national	classification an	id IPC		4
	DS SEARCHED	<del></del>		<del></del>		4
	ocumentation searched (classification system followed	d by clas	silication symbo	ols)		
<b>U.S</b> . :	514/635					
Documenta	tion searched other than minimum documentation to th	e extent th	at such docume	ents are included	in the fields searched	1
NONE					•	
	· · · · · · · · · · · · · · · · · · ·			·	<u> </u>	_
Electronic o	late base consulted during the international search (n	ame of da	ita base and, wi	here practicable	, search terms used)	
CAS ON	LINE, DERWENT					1 .
					•	
C. DOC	UMENTS CONSIDERED TO BE RELEVANT					7
Category*	Citation of document, with indication, where ap	propriate	of the relevant	passages	Relevant to claim No.	1
Α.	US 3,174,901 A (STERNE et al) 23	March	1965	the entire	1-20	1.
Α	document.	iviaiti	1 1700, 866	me entite	1-20	
	dodo		•			, ,
				:		
	<i>'</i>			•		
		<b>.</b>				
			-	i	·	
						,
•				•	·	
					·	
F	ner documents are listed in the continuation of Box C		Cun notant l	amily annex.		1 .
<u></u>		• <del>1</del> •	·	· · · · · · · · · · · · · · · · · · ·	160 1	_
	secial categories of cited documents:  becoment defining the general state of the art which is not considered.	•	date and not m c		ernational filing date or priority lication but eited to understand	
to	be of particular relevance	•X•	, .		e claimed invention cannot be	
	rlier document published on or after the international filing date securion which may throw doubts on priority claim(s) or which is			or cannot be conside	ered to involve an inventive step	
ci	ted to establish the publication date of another citation or other secial reason (as specified)	•Y•			e claimed invention cannot be	
	ocument referring to an oral disclosure, use, exhibition or other eans		combined with on		step when the document is the documents, such combination the art	
	ocument published prior to the international filing date but later than e priority date classical	٠٨٠	document membe	r of the same paten	d family	
	actual completion of the international search	Date of	mailing of the	international se	arch report	
19 JANU	ARY 1999		<b>03</b> F	FEB <b>1</b> 999	·	
Name and	mailing address of the ISA/US	Authori	zed officer		12	7
Box PCT	oner of Patents and Trademarks	ZOI	REH FAY	()	9	
Washingto Facsimile 1	on, D.C. 20231 No. (703) 305-3230	Telepho	-	) 308-123/5 A	£15	
L'acamine i	tti. (103) 303+3230	10.00	,	A	ÚRŎBINDO EX. 1	1006, 15 <sub>4</sub>

# This Page Is Inserted by IFW Operations and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

WELTORGANISATION FÜR GEIST Internationales Bür INTERNATIONALE ANMELDUNG VERÖFFENTLIC



INTERNATIONALE ZUSAMMENARBEIT AUF DEM (51) Internationale Patentklassifikation 6:

A1

(11) Internationale Veröffentlichungsnummer:

WO 96/08243

A61K 31/155, 9/20

(43) Internationales Veröffentlichungsdatum:

21. Marz 1996 (21.03.96)

(21) Internationales Aktenzeichen:

PCT/EP95/03610

(22) Internationales Anmeldedatum:

· 14. September 1995 (14.09.95) (81) Bestimmungsstaaten: AU, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SI, SK, UA, US, europäisches Patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

(30) Prioritätsdaten:

P 44 32 757.9

14. September 1994 (14.09.94) DE

Veröffentlicht

Mit internationalem Recherchenbericht.

(71) Anmelder (für alle Bestimmungsstaaten ausser US): BOEHRINGER MANNHEIM GMBH [DE/DE]; D-68298 Mannheim (DE).

(72) Erfinder; und

- (75) Erfinder/Anmelder (nur für US): MOECKEL, Jöm [DE/DE]; Am Baechenbuckel 24/1, D-69118 Heidelberg (DE). GABEL, Rolf-Dieter [DE/DE]; Kurpfalzring 96, D-68723 Schwetzingen (DE). WOOG, Heinrich [DE/DE]; Lindenstrasse 6, D-69514 Laudenbach (DE).
- (74) Anwälte: MINK, Reinhold usw.; Boehringer Mannheim GmbH, Patentabteilung, D-68298 Mannheim (DE).

(54) Title: PHARMACEUTICAL PREPARATION CONTAINING METFORMIN AND A PROCESS FOR PRODUCING IT

(54) Bezeichnung: PHARMAZEUTISCHE ZUBEREITUNG ENTHALTEND METFORMIN UND VERFAHREN ZU DEREN HER-STELLUNG

#### (57) Abstract

The present invention concerns pharmaceutical compounds containing metformin as an active substance and a hydrocolloidforming agent as a retardant, and (optionally) standard pharmaceutical auxiliary substances, the residual moisture content in the proposed pharmaceutical compound being 0.5-3 % by weight. The invention also concerns a process for producing pharmaceutical compounds containing metformin as an active substance and a hydrocolloid-forming agent as a retardant, and (optionally) standard pharmaceutical auxiliary substances. The proposed process is characterized by the fact that the active substance and retarding agent, or a portion thereof, are granulated with an aqueous solvent which can optionally contain a binder, and where appropriate the other portion of the retardant or other standard pharmaceutical auxiliaries are mixed with the granulate which is then dried until the residual moisture content is reduced to 0.5-3 % by weight.

#### (57) Zusammenfassung

Gegenstand der vorliegenden Erfindung sind pharmazeutische Zusammensetzungen enthaltend Metformin als Wirkstoff und einen Hydrokolloidbildner als Retardierungsmittel sowie gegebenenfalls pharmazeutisch übliche Hilfsstoffe, wobei die Restfeuchte in der pharmazeutischen Zusammensetzung 0,5-3 Gew.% beträgt. Die Erfindung betrifft ferner ein Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend Metformin als Wirkstoff und einen Hydrokolloidbildner als Retardierungsmittel sowie pharmazeutischen Zusammensetzungen enthaltend Metformin als Wirkstoff und einen Hydrokolloidbildner als Retardierungsmittel sowie gegebenenfalls weitere pharmazeutisch übliche Hilfsstoffe, dadurch gekennzeichnet, daß man den Wirkstoff und das Retardierungsmittel oder ein Teil davon mit einem wäßrigen, gegebenenfalls bindemittelhaltigen Lösungsmittel granuliert, gegebenenfalls den anderen Teil des Retardierungsmittels oder andere pharmazeutisch übliche Hilfsmittel dem Granulat zumischt, und anschließend das Granulat bis zu einer Restfeuchte von 0,5-3 Gew.-% trocknet.

## LEDIGLICH ZUR INFORMATION

Codes zur Identifizierung von PCT-Vertragsstaaten auf den Kopfbögen der Schriften, die internationale Anmeldungen gemäss dem PCT veröffentlichen.

Amir	amigar garan	•		MR	Mauretanien
	A	GA	Gabon	· MW	Malawi
AT	Osterreich	GB	Vereinigtes Königreich	NE	Niger
AU	Australien	GE	Georgian	NL	Niederlande
BB	Barbados	GN	Guines	NO	Norwegen
BE	Belgien	GR	Griechenland	NZ	Neusecland
BF	Burkina Faso	HU	Ungam	PL	Polen
BG	Bulgarien	IE.	irland	PT	Portugal
BJ	Benin	п	Italien	RO	Rumanien
BR	Brasilien	JP	Japan	RU	Russische Föderation
BY	Belarus	KE	Kenya	SD	Sudan
CA	Kanada	KG	Kirgisistan	SE SE	Schweden
CF	Zentrale Afrikanische Republik	КР	Demokratische Volksrepublik Korea	SE SI	Slowenien
CG	Kongo	KR	Republik Korea	SK	Slowakci
CH	Schweiz	ΚZ	Kasachstan	-	Senegal
CI	Cote d'Ivoire	u	Liechtenstein	SN	Tschad
CM	Kamerun	LK	Sri Lanka	TD	Togo
CN	China	LU	Luxemburg	TG	Tadachikistan
CS	Tschechoslowakei	LV	Lettland	TJ	Trinidad und Tobago
CZ	Tschechische Republik	MC	Monaco	TT	Ulcrane
DE	Deutschland	MD	Republik Moldau	UA	Vereinigte Staaten von Amerika
DK	Dänemark	MG	Madagaskar	US	
ES	Spanien	ML	Mali	UZ	Usbekistan
FI	Finnland	MN	Mongolei	VN	Vietnam
	Tlandah	1721.1	· v		

- 5 Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
- Die Erfindung betrifft pharmazeutische Zubereitungen enthaltend Metformin-Hydrochlorid (im folgenden auch Metformin genannt) als Wirkstoff und einen Hydrokolloidbildner als Retardierungsmittel und ein Verfahren zu deren Herstellung.
  - Es ist bekannt, daß Metformin-Hydrochlorid ein Biguanidderivat ist (1,1-Dimethylbiguanid-Monohydrochlorid), das oral antidiabetisch wirkt. Metformin-Retardtabletten sind mit 850 mg Metformin-Hydrochlorid pro Filmtablette (Glucophage® retard) auf dem Markt. Da sich Metformin im Gegensatz zu anderen Wirkstoffen als Reinsubstanz nicht verpressen läßt (die Masse zerfällt nach dem Komprimieren unverändert), wurde bei verpressen hochdosierten Retardtabletten auf gerüstbildende Hilfsstoffe wie Polyvinylacetat als Retardierungsmittel zurückgegriffen (Lipha, Fachinformation Glucophage®.
  - August 1991; Bundesverband der Pharmazeutischen Industrie e.V., Hrsg., Rote
    Liste 1993, Edition Cantor, Aulendorf 1993). Die Wirkungsweise solcher Gerüsttabletten beruht darauf, daß das gut wasserlösliche Metformin im Magen-Darm-Trakt pH-unabhängig aus der Tablette herausdiffundiert, während das Tablettengerüst mit Überzug weitgehend unverändert wieder ausgeschieden wird.
  - Der Nachteil der Verwendung solcher gerüstbildenden Hilfsstoffe wie Polyvinylacetat beruht jedoch darauf, daß sie insbesondere beim Granulationsvorgang mit organischen Lösungsmitteln verarbeitet werden müssen, wobei das organische Lösungsmittel möglichst wieder vollständig entfernt werden muß, bevor das Granulat zu komprimierten pharmazeutischen Darreichungsformen weiterverarbeitet und beispielsweise zu Tabletten verpreßt wird.
    - Aufgabe der Erfindung war es, eine verbesserte pharmazeutische Zusammensetzung für den Wirkstoff Metformin zur Verfügung zu stellen. Insbesondere sollte die Darreichungsform den Wirkstoff Metformin mit einem möglichst hohen Wirkstoffanteil und einem Retardierungsmittel enthalten, wobei das Retardierungsmittel eine kontrollierte

15

20

25

30

Freisetzung des Wirkstoffes bewirkt. Insbesondere sollte die neue pharmazeutische Zusammensetzung keine mit organischen Lösungsmittel zu verarbeitende Gerüstbildner enthalten, sondern auf Basis von wäßrig verarbeitbaren Substanzen aufgebaut sein. Diese pharmazeutischen Zusammensetzungen sollten gut bzw. leicht komprimierbar sein, so daß sie sich zur Herstellung von festen pharmazeutischen Darreichungsformen, wie z.B. Tabletten, Dragees oder Komprimaten zur Abfüllung in Kapseln eignen. Bei der Herstellung von Tabletten oder anderen Komprimaten sollte das Gesamtgewicht maximal etwa 1200 - 1300 mg betragen, um die Therapiesicherheit (Patienten-Compliance) nicht zu gefährden, da größere orale Darreichungsformen vom Patienten häufig nicht in der vorgeschriebenen Regelmäßigkeit eingenommen werden.

Außerdem stellte sich die Aufgabe, bei der Verarbeitung des Granulats für diese hochdosierten Darreichungsformen, insbesondere bei der Herstellung von Tabletten, das im Fall von Metformin besonders ausgeprägte wirkstoffbedingte Problem des Deckelns zu lösen, um Ausbeuteverluste während der Produktion und Beeinträchtigungen der pharmazeutischen Qualität zu vermeiden. Als Deckeln wird das Ablösen von verpreßter Masse in Schichten vom hergestellten Preßling während des Verpressens oder kurz danach bezeichnet (Schepky G. in: Bruchhausen F. von et al., Hrsg.; Hagers Handbuch der pharmazeutischen Praxis, Band 2, Methoden, 5. Aufl., Springer Verlag, Berlin 1991). Im Fall von Metfomin, insbesondere bei hochdosierten Wirkstoffgehalten im Granulat hat sich gezeigt, daß die Tendenz des Deckelns bei der Herstellung der Tabletten besonders hoch ist.

Die Ursachen für diese Tablettierprobleme können vielfältig und komplex sein. Deckeln kann ausgelöst werden durch ungenügende Bindemittelwirkung, zu geringe oder zu hohe Granulatfeuchtigkeit, ungeeignete Kristallformen, stark aerophile Stoffe, zu hohe Porosität, zu hohen Pulveranteil, zu starke interpartikulare Bindung zwischen den Granulatkörnern sowie durch ungeeignete Granulatformen. Als maschinenbedingte Faktoren können zu hohe Preßkraft, schlecht eingesetzte oder auch abgenutzte Werkzeuge, zu hohe Preßgeschwindigkeit und schlechte Entlüftung der Matrize (starrer Druck) zum Deckeln führen. Im Falle des Wirkstoffes Metformin hat sich jedoch gezeigt, daß die üblichen Möglichkeiten nicht ausreichen, um das Deckeln der Tablettiermasse befriedigend zu beherrschen. Bei der Herstellung der Tabletten konnte regelmäßig ein relativ hoher Anteil an fehlerhaften Tabletten festgestellt werden und die Tablettierung mußte aufgrund der hohen Ausschußraten abgebrochen werden.

25

35

Im vorliegenden Fall wird die Aufgabe der Erfindung gelöst, indem hochdosierte Metformin-haltige pharmazeutische Zusammensetzungen zur Verfügung gestellt werden, die als Retardierungsmittel einen Hydrokolloidbildner enthalten und die eine Restfeuchte in der pharmazeutischen Zusammensetzung von 0,5 - 3 Gew.-% aufweisen. Diese pharmazeutischen Zusammensetzungen können vorteilhaft unter Verwendung von wäßrigen Lösungsmitteln hergestellt werden, so daß organische Lösungsmittel nicht mehr benötigt werden. Außerdem sind diese Zusammensetzungen überraschenderweise gut komprimierbar. Sie eignen sich dadurch insbesondere zur Herstellung von festen pharmazeutischen Darreichungsformen, wie z.B. Tabletten, Dragees oder Kapseln, wobei diese mit Hilfe der üblichen Verarbeitungsmaschinen in technischem Maßstab und in guter Qualität sowie in hoher Ausbeute ohne größere Verluste infolge des unerwünschten Deckelns hergestellt werden können. Gegenstand der Erfindung ist demnach auch ein entsprechendes Verfahren zur Herstellung dieser festen Darreichungsformen, indem man die entsprechenden erfindungsgemäßen pharmazeutischen Zusammensetzungen in Form von Granulaten mit einer Restfeuchte von 0,5 - 3 Gew.-% einsetzt. Vorzugsweise beträgt die Restfeuche 1 - 2,5 Gew.-%, insbesondere 1,5 - 2 Gew.-%. 15

Überraschenderweise wurde ferner gefunden, daß im Falle des erfindungsgemäßen Granulats auf den sonst oft erforderlichen Zusatz von Feuchthaltemittel zur Einstellung einer konstanten Restfeuchte bis zum Komprimieren des Granulates verzichtet werden kann. Dies ist insbesondere deshalb vorteilhaft, da sich der Zusatz von Hilfsstoffen somit minimieren läßt und pharmazeutische Zusammensetzungen mit einem relativ hohen Wirkstoffgehalt erhalten werden. Außerdem haben diese Zusammensetzungen den Vorteil, daß sie für einen Zeitraum von zwei Tagen oder mehr (gerechnet von der Herstellung bis zur Verwendung des Granulates zur Tablettierung) bezüglich des Feuchtegehaltes lagerstabil sind, bevor sie komprimiert werden, ohne daß eine nachteilige Veränderung der Zusammensetzung feststellbar ist. Dies ist deshalb von Vorteil, da somit mehrere Teilansätze von Produktionschargen der pharmazeutischen Zusammensetzung hergestellt werden können, und diese dann zu einem späteren Zeitpunkt in einem gemeinsamen letzten Verfahrensschritt als preßfertige Masse abgemischt und zu festen pharmazeutischen Darreichungsformen verarbeitet werden können. 30

Weiterhin zeigte sich überraschenderweise, daß durch die Verwendung eines Hydrokolloidbildners insbesondere die für Metformin bekannte schlechte Komprimierbarkeit erstmals technisch in zufriedenstellender Weise beherrschbar war. Die erfindungsgemäße Lösung ermöglicht zudem, daß durch die Wahl des Hydrokolloidbildners als

Retardierungsmittel und bei geeigneter Führung des Herstellprozesses (Einhalten der kritischen Restfeuchte von 0,5 - 3 % Gew.-%, insbesondere von 1 - 2,5 Gew.-% bzw. 1,5 - 2 Gew.-%) die gewünschte Retardierung und Komprimierbarkeit gewährleistet sind, obwohl der Anteil des Hydrokolloidbildners an der Rezepturzusammensetzung außergewöhnlich niedrig ist. Dies ist um so überraschender, als der überwiegende Anteil der Rezeptur (etwa 70 - 95 Gew.-%) durch den Wirkstoff gebildet wird, dessen Wassersorptionsvermögen sehr gering ist (bei einer relativen Feuchte von 90 % bindet der reine Wirkstoff lediglich 0,04 Gew.-% Wasser).

Der Gewichtsanteil des Wirkstoffes in der hochdosierten pharmazeutischen Zusammensetzung liegt im Bereich von mindestens 70 Gew.-%, vorzugsweise 80 - 95 Gew.-%, bezogen auf die pharmazeutische Zusammensetzung. Der Wirkstoff kann in Form von 10 Säureadditionssalzen von anorganischen oder organischen Säuren, wie z.B. Salzsäure, Ameisensäure, Essigsäure, Äpfelsäure, Weinsäure oder Fumarsäure eingesetzt werden: Bevorzugt wird das Hydrochlorid-Salz eingesetzt.

Der Anteil der Hydrokolloidbildner an der pharmazeutischen Zusammensetzung beträgt bis zu 15 Gew.-%, vorzugsweise 4 - 10 Gew.-%, insbesondere etwa 6 - 8 Gew.-%. 15

Als Hydrokolloidbildner bzw. als hydrophile Quellstoffe im Sinne der Erfindung sind die üblichen hydrophilen Gelbildner geeignet, wie beispielsweise Cellulosederivate, Dextrine, Stärke, Polymere auf Kohlenhydratbasis, natürliche und hydrophile Gummen, Xanthane, Alginate, Gelatine, Polyacrylsäure, Polyvinylalkohol oder Polyvinylpyrrolidon. Im Falle der Cellulosederivate kommen bevorzugt die Alkyl- oder Hydroxyalkylcellulose-Derivate in Frage, wie z.B. Methylcellulose, Hydroxymethylcellulose, Hydroxyethylcellulose, Hydroxypropylcellulose, Methylhydroxyethylcellulose, Methylhydroxypropylcellulose oder Natriumcarboxymethylcellulose. In einer bevorzugten Ausführungsvariante der Erfindung kommt Methylhydroxypropylcellulose (MHPC) zum Einsatz. Die Hydrokolloidbildner können sowohl einzeln als auch in Gemischen von zwei oder mehreren 25 Kolloidbildnern verwendet werden. Als geeignete polymere Kolloidbildner auf Cellulosebasis können die üblichen für pharmazeutische Zwecke geeigneten Polymere mit unterschiedlichem Substitutionsgrad und/oder unterschiedlichem Molekulargewicht, entsprechend einem unterschiedlichen Viskositätsgrad der wäßrigen Lösung, eingesetzt 30 werden.

Die Verwendung von Hydrokolloidbildnern als Retardierungsmittel beruht auf der Eigenschaft der Hydrokolloidbildner, daß dieser bei Kontakt mit Freisetzungsmedium oder

Verdauungssästen unter Quellung eine Gelmatrix ausbildet, die unter Erosion den Wirksoff freisetzt. Das Zusammenwirken von Hydrokolloidbildner-Menge und Viskositätsgrad bestimmt dabei den Freisetzungsverlauf. So kann beispielsweise mit einem hohen Anteil (70 - 95 %, beogen auf das Kerngeweicht einer Tablette) von Polyvinylalkohol niedriger oder mittlerer Viskositätsstufe Riboflavin über mehrere Stunden retardiert werden (Möckel J E., Lippold B. C., Pharm. Research, 1993, 10, 1066 - 1070).

Die unter Verwendung der erfindungsgemäßen pharmazeutischen Zusammensetzung hergestellten komprimierten Darreichungsformen, wie beispielsweise Metformin-Retardtablettenkerne können zusätzlich mit einer Filmhülle versehen werden. Die Filmhülle kann einerseits eine zusätzliche Retardierung bewirken, indem solche Filmmaterialien 10 eingesetzt werden, die einen für diese Zwecke üblicherweise geeigneten Filmbildner darstellen. Andererseits kann die verwendete Filmhülle ein geschmacksneutralisierender Filmbildner sein, dem gegebenenfalls Farbstoffe zugesetzt werden können. Weiterhin ist beispielsweise auch der Einsatz von magensastresistenten Filmen möglich. Der Gewichtsanteil der Filmhülle bezogen auf die fertige Tablette liegt im üblichen Bereich von 15 0,3 - 3,0 Gew.-%, vorzugsweise von 0,8 - 1,2 Gew.%. Als Filmbildner kommen übliche Filmbildner, wie beispielsweise Ethylcellulose, Poly-(methylmethacrylat)-Derivate (Eudragit®), aber auch lösliche Cellulosederivate wie Methylhydroxypropylcellulose und Cellulosederivate zur Ausbildung magensaftresistenter Filme, wie Celluloseacetatphthalat oder Methylhydroxypropylcellulosephthalat in Frage. Bevorzugt wird 20 Ethylcellulose verwendet. Durch den gebildeten Film kann die Auflösung des Wirkstoffs verzögert werden. Als übliche Hilfsstoffe können in der Filmhülle Weichmacher, Porenbildner und Pigment enthalten sein.

Die erfindungsgemäße pharmazeutische Zusammensetzung kann auch zur Herstellung von komprimierten Kapselfüllmassen verwendet werden. Diese Komprimate bzw. kompaktierten Granulate können dann in handelsübliche Kapseln mittels geeigneter Vorrichtungen gefüllt werden. Im Vergleich zu den sonst üblichen Metformin-haltigen Kapselfüllmassen haben diese kompaktierten Granulate bei gleichem Wirkstoffgehalt bzw. gleicher Dosierung den Vorteil, daß aufgrund ihres geringeren Volumens kleinere Kapseln verwendet werden können, die leichter von dem Patienten geschluckt werden können.

Die erfindungsgemäßen pharmazeutischen Darreichungsformen, wie z.B. Tabletten, enthalten - neben dem Wirkstoff, dessen Anteil an der Darreichungsform im Bereich

von 70 - 95 Gew.-% liegen kann, (beispielsweise werden 850 mg der Wirkstoffes im Fall von Retardtabletten bevorzugt eingesetzt) und dem Retardierungsmittel - vorzugsweise 2 - 10 Gew.-% Bindemittel, bis zu 2 Gew.-%, vorzugsweise 0,1 - 0,3 Gew.-% Fließregulierungsmittel und bis zu 2 Gew.-%, vorzugsweise 0,4 - 1,1 Gew.-% Schmiermittel, jeweils bezogen auf das Gesamtgewicht der tablettierfertigen Masse bzw. des Tablettenkerns. Das Gewicht eines Tablettenkern liegt in der Regel zwischen 200 und 1300 mg, vorzugsweise im Bereich von weniger als 1200 mg, insbesondere von etwa 500 - 1000 mg. Als Fließregulierungsmittel kommen für die erfindungsgemäße Tablette übliche Mittel wie zum Beispiel kolloidales Siliciumdioxid in Frage. Als Schmiermittel sind beispielsweise Talkum oder Stearinsäure bzw. deren Alkali- oder Erdalkalisalze, insbesondere Magnesiumstearat, geeignet. Als Bindemittel können beispielsweise 10 Cellulosederivate, speziell Alkyl- und Hydroxyalkyl-Cellulosen, insbesondere Methylcellulose, Hydroxymethylcellulose, Hydroxyethylcellulose, Hydroxypropylcellulose, Methylhydroxyethylcellulose, Methylhydroxypropylcellulose, Natriumcarboxymethylcellulose u.a., Dextrine, Stärken, speziell lösliche Stärken, andere Polymere auf Kohlenhydratbasis wie z.B. Galaktomannane, natürliche Gummen wie Gummi arabicum, 15 Traganth, Sterculia, Acacia u.a., Xanthan, Alginate, Polyacrylsäure, Polyvinylalkohol und Polyvinylpyrrolidon eingesetzt werden. Bevorzugt wird Polyvinylpyrrolidon verwendet.

Die erfindungsgemäßen pharmazeutischen Darreichungsformen, wie z.B. Tabletten, werden hergestellt, indem man den Wirkstoff, das Retardierungsmittel oder einen Teil 20. des Retardierungsmittels und gegebenenfalls weitere Hilfsstoffe trocken miteinander vermischt, mit Wasser oder einer wäßrigen Lösung eines Bindemittels feucht granuliert, die tablettierfertige Masse bis zu einer gewünschten Restfeuchte trocknet und danach gegebenenfalls den anderen Teil des Retardierungsmittels oder andere pharmazeutische Hilfsstoffe dem Granulat zumischt, so daß in dem letzten Verfahrensschritt eine Rest-25 feuchte in der pharmazeutischen Zusammensetzung von 0,5 -3 Gew.-% erzielt wird. Die Bestimmung der Restfeuchte erfolgt nach bekannten analytischen Methoden der Aquametrie, beispielsweise durch die Bestimmung des Wassergehaltes mit Hilfe des Karl-Fischer-Reagenzes, oder anderen alternativen Bestimmungsverfahren. Bei der Feuchtgranulation kann auch ein Teil des Wirkstoffes, die verwendeten Hilfsstoffe sowie 30 das Retardierungsmittel ganz oder teilweise in Wasser gelöst oder suspendiert vorliegen. Gegebenenfalls können auch mit Wasser mischbare organische Lösungsmittel, wie beispielsweise Aceton oder niedere Alkohole, wie Methanol oder Ethanol zugesetzt werden

10

15

20

30

Die Einstellung der Restfeuchte erfolgt zweckmäßigerweise im Rahmen einer Trocknung im Wirbelschichtverfahren, wobei das feuchte Granulat so lange getrocknet wird, bis die gemessene Feuchtigkeit in der Abluft den zuvor im Rahmen einer Kalibrierung zur Restfeuchte im Trocknungsgut ermittelten Wert erreicht hat. Die so hergestellte Zusammensetzung wird anschließend in üblicher Weise zu pharmazeutischen Darreichungsformen verarbeitet und beispielsweise zu Tabletten verpreßt. Die Tabletten können mit üblichen Überzugsverfahren mit einem Film überzogen werden. Es wurde gefunden, daß die mit Hilfe des Hydrokolloidbildners eingestellte Restfeuchte von 0,5 - 3 Gew.-% gewährleistet, daß die tablettierfertige Masse über den gesamten, zur Herstellung großer Tabletten notwendigen Preßkraftbereich ohne Deckeln komprimierbar ist.

Der Wirkstoff kann ganz oder teilweise mit dem zur Retardierung eingesetzten Hydrokolloidbildner zu einem Granulat verarbeitet werden oder der Hydrokolloidbildner wird vollständig einem Hydrokolloidbildner-freien Granulat nach dessen Herstellung zugemischt. Eine zusätzlich bessere Tablettierbarkeit wird jedoch erreicht, wenn der Hydrokolloidbildner oder ein Teil davon mit dem Wirkstoff granuliert wird.

Das Überziehen der Tablette erfolgt nach üblichen Verfahren wie z. B. dem Dragierkessel- oder Wirbelbettverfahren.

Die erfindungsgemäßen retardierten Tabletten setzen Metformin über einen Zeitraum von 0,5 - 10 Stunden, vorzugsweise über 4 Stunden, kontrolliert frei (Abb. 1). Das Gewicht der Tabletten liegt dadurch, daß durch die Verwendung des Hydrokolloidbildners keine großen Mengen zusätzlicher Hilfsstoffe, insbesondere keine Feuchthaltemittel, wie z.B. Gycerol oder Sorbitol, notwendig sind, bei maximal 1200 mg, vorzugsweise unter 1000 mg.

Nachfolgend soll die Erfindung durch Ausführungsbeispiele verdeutlicht werden, ohne sie darauf einzuschränken.

Bei den folgenden Beispielen 1 - 6 wurde die Restfeuchte auf den erfindungsgemäßen Bereich eingestellt, bevor die pharmazeutische Zusammensetzung in Form einer preßfertigen Masse zu Tabletten verpreßt wurde. In den Beispielen 7 und 8 wurde die Restfeuchte auf einen Wert von weniger als 0,5 Gew.-% eingestellt. In diesen beiden Fällen mußte die Tablettierung aufgrund der hohen Verluste durch Deckeln abgebrochen werden.

#### Beispiel 1:

Hydrokolloidbildner: Methylhydroxypropylcellulose(MHPC). Der MHPC-Anteil kann variiert werden, z.B. von 40 - 95 mg.

Restfeuchte: 2.1 %

Bestandteile	Tablette [mg] [k	preßfertige Masse g/1 Mio St.]
Kern: Metformin-Hydrochlorid Methylhydroxypropylcellulose Polyvidon Magnesiumstearat  Kern gesamt:	850,00 60,00 38,00 <u>5,00</u> 953,00	850,00 60,00 38,00 <u>5,00</u> 953,00
Filmhülle: Methylhydroxypropylcellulose Ethylcellulose Macrogol Titandioxid Hülle gesamt:	20,00 12,00 4,00 4,00 40,00	20,00 12,00 4,00 <u>4,00</u> 40,00
<u>Filmtablette gesamt</u>	993,00	993,00

### Herstellung:

Die Herstellung des Granulats für eine Menge von etwa 1 Million Tabletten erfolgt in fünf Teilansätzen. Für jeden der fünf Teilansätze werden 170 kg Metformin-Hydrochlorid und 12 kg Methylhydroxypropylcellulose trocken miteinander gemischt und mit einer 10%igen wässrigen Bindemittellösung von Polyvidon in einem Mischer feucht granuliert. Danach wird das Granulat in einem Wirbelschichtgranulator getrocknet, bis es eine ausreichende Restfeuchte besitzt. Die fünf Teilansätze werden vereinigt und mit 5 kg Magnesiumstearat gemischt. Die preßfertige Masse wird tablettiert. Die Tablettenkerne werden im Dragierkessel mit dem Film beschriebener Zusammensetzung überzogen.

Bei der aufgeführten Rezeptur wird die Restfeuchte auf 2,1 % eingestellt. Die Tablettierung verläuft entsprechend problemlos, d.h. eine Deckeln der hergestellten Tablettenmasse kann nicht festgestellt werden.

5

## Beispiel 2:

Hydrokolloidbildner: Hydroxyethylcellulose

10 Restfeuchte: 2,0 %

<u>Bestandteile</u>	Tablette [mg] [k	preßfertige Masse g/1 Mio St.]
Kern: Metformin-Hydrochlorid Hydroxyethylcellulose Polyvidon Magnesiumstearat Kern gesamt:	850,00 70,00 40,00 	850,00 70,00 40,00 <u>5,00</u> 965,00
Filmhülle: Methylhydroxypropylcellulose Lactose Ethylcellulose Macrogol Titandioxid Hülle gesamt	5,00 5,00 10,00 3,00 3,00 26,00	5,00 5,00 10, 3,00 3,00 26,00
Filmtablette gesamt	991,00	991,00

Herstellung des Granulates und Weiterverarbeitung erfolgt analog zu Beispiel 1; die Tablettierung verläuft entsprechend problemlos.

15

## Beispiel 3:

Hydrokolloidbildner: Natriumcarboxymethylcellulose

Restfeuchte: 2,1 %.

Bestandteile		Tablette [mg]	preßfertige Masse (g/1 Mio St]
Kern: Metformin-Hydrochlorid Natriumcarboxymethylcellulose Polyvidon Magnesiumstearat	k Kern gesamt:	850,00 80,00 35,00 5,00 970,00	850,00 80,00 35,00 5,00 970,00
Filmhülle: Methylhydroxypropylcellulose Ethylcellulose Macrogol Titandioxid	Hülle gesamt:	5,00 10,00 4,00 3,00 22,00	5,00 10,00 4,00 3,00 22,00
Film	tablette gesamt:	992,00	992,00

Herstellung des Granulats und Weiterverarbeitung erfolgt analog Beispiel 1; die Tablettierung verläuft entsprechend problemlos

#### Beispiel 4:

Hydrokolloidbildner: Polyacrylsäure

Restfeuchte: 2,8 %

ı	۹	,		
۰		١		
	è			

<u>Bestandteile</u>		[mg]	preßfertige Masse g/1 Mio St]
Kern: Metformin-Hydrochlorid Polyacrylsäure Methylhydroxypopylcellulos Magnesiumstearat	e Kern gesamt:	850,00 60,00 30,00 <u>5,00</u> 945,00	850,00 60,00 30,00 <u>5,00</u> 945,00
Filmhülle: Methylhydroxypropylcellulo Ethylcellulose Macrogol Titandioxid	ose Hülle gesamt:	10,00 10,00 3,00 3,00 26,00	10,00 10,00 3,00 3,00 26,00
Fil	imtablette gesamt:	971,00	971,00

Herstellung und Weiterverarbeitung des Granulats erfolgt analog zu Beispiel 1.

Abweichend dient hier Methylhydroxypropylcellulose als Bindemittel. Die Tablettierung erfolgt problemlos.

### Beispiel 5:

5

Hydrokolloidbildner: Hydroxypropylcellulose

Restfeuchte: 1.95 %

Bestandteile	[mg]	Masse /1 Mio St]
Kern: Metformin-Hydrochlorid Hydroxypropylcellulose Polyvidon Magnesiumstearat Kern ge	850,00 60,00 40,00 	850,00 60,00 40,00 5,00 955,00
Filmhülle: Poly(ethylacrylat-methylmethacrylat)-	6,00*	6,00*
Dispersion 30%  Talk  Antischaummittel  Hülle g	1,20 <u>0,07</u> esamt: 7,27	1,20 <u>0,07</u> 7,27
Filmtablette g	gesamt: 962,270	962,270

<sup>\*</sup>Mengenangabe bezogen auf die Trockensubstanz

Herstellung und Weiterverarbeitung des Granulats erfolgt analog zu Beispiel 1.

10 Abweichend wird hier der Hydrokolloidbildner Hydroxypropylcellulose nicht mitgranuliert sondern dem fertigen Granulat trocken zugemischt.

### Beispiel 6:

5

Hydrokolloidbildner: Methylhydroxypropylcellulose

Restfeuchte: 2,0 %

Im folgenden Beispiel wird auf die Verwendung eines zusätzlichen Bindemittels ganz verzichtet, die eingesetzte Methylhydroxypropylcellulose übernimmt gleichzeitig die Funktion von Binde- und Retardierungsmittel.

Bestandteile	[mg]	preßfertige Masse g/1 Mio St.]
Kern: Metformin-Hydrochlorid Methylhydroxypropylcellulose Magnesiumstearat Kern gesamt:	850,00 100,00 <u>5,00</u> 955,00	850,00 100,00 <u>5,00</u> 955,00
Filmhülle: Methylhydroxypropylcellulose Ethylcellulose Macrogol Titandioxid Hülle gesamt	20,00 12,00 4,00 4,00 40,00	20,00 12,00 4,00 <u>4,00</u> 40,00
Filmtablette gesam	205.00	995,00

10

15

Die Herstellung des Granulats erfolgt in 5 Teilansätzen. Für jeden der fünf Teilansätze werden 170 kg des Wirkstoffs Metformin-Hydrochlorid mit 18 kg Methylhydroxy-propylcellulose im Wirbelschichtgranulierer vorgelegt. 2 kg Mehylhydroxypropylcellulose werden in 50 l Wasser gelöst. Die trockene Mischung wird mit der Bindemittelsung im Wirbelschichtgranulierer granuliert und anschließend getrocknet. Die fünf lösung im Wirbelschichtgranulierer granuliert und anschließend gemischt. Diese preßfertige Teilansätze werden vereinigt und mit 5 kg Magnesiumstearat gemischt. Diese preßfertige Masse wird tablettiert. Auf die Tablettenkerne wird im Dragierkessel der Film beschriebener Zusammensetzung aufgetragen.

## Beispiel 7

Hydrokolloidbildner: Methylhydroxypropylcellulose

Restfeuchte: 0,49 %

Bei der untenstehenden Rezeptur wurde eine Feuchte von 0,49 % erhalten. Aufgrund des zu hohen Verlustes durch Deckeln mußte die Tablettierung abgebrochen werden.

<u>Bestandteile</u>		Tablette [mg]
Kern: Metformin-Hydrochlorid Methylhydroxypropylcellulo Polyvidon Magnesiumstearat	se Kern gesamt	850,00 40,00 38,00 <u>5,00</u> 953,00
Filmhülle: Methylhydroxypropylcellul Ethylcellulose Macrogol Titandioxid	ose Hülle gesamt:	20,00 12,00 4,00 4,00 40,00
F	ilmtablette gesamt	993,00

## Beispiel 8

Hydrokolloidbildner: Gelatine

Restfeuchte: 0,48 %

5

Bei der untenstehenden Rezeptur wurde eine Feuchte von 0,48 % erhalten. Aufgrund des zu hohen Verlustes durch Deckeln mußte die Tablettierung abgebrochen werden.

Bestandteile	• •	[mg]
Kern: Metformin-Hydrochlorid		850,00
Lactose		70,00 40,00
Gelatine Siliciumdioxid, hochdispers		2,00 2,50
Magnesiumstearat	Kern gesamt:	964,50
Filmhülle: Methylhydroxypropylcellulose	e	10,00
Ethylcellulose Diethylphthalat		9,00 3,00
Titandioxid	Hülle gesamt:	<u>3,00</u> 25,00
Film	ntablette gesamt	989,5

10

#### **Patentansprüche**

- Pharmazeutische Zusammensetzung enthaltend Metformin als Wirkstoff und einen Hydrokolloidbildner als Retardierungsmittel sowie gegebenenfalls pharmazeutisch übliche Hilfsstoffe, wobei die Restfeuchte in der pharmazeutischen Zusammensetzung 0,5 - 3 Gew.-% beträgt.
- Pharmazeutische Zusammensetzung nach Anspruch 1, dadurch gekennzeichnet, daß der Wirkstoffgehalt von Metformin mindestens 70 % beträgt.
- Pharmazeutische Zusammensetzung nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß die Menge des Hydrokolloidbildners 4 15 Gew.-% beträgt.
- Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 3, dadurch gekennzeichnet, daß der Hydrokolloidbildner ausgewählt ist aus der Gruppe bestehend aus Cellulosederivaten, Dextrinen, Stärken, Polymeren auf Kohlenhydratbasis, natürliche Gummen, Xanthan, Alginate, Gelatine, Polyacrylsäure, Polyvinylalkohol und Polyvinylpyrrolidon.
- Pharmazeutische Zusammensetzung nach Anspruch 4, dadurch gekennzeichnet, daß der Hydrokolloidbildner ein Cellulosederivat ist, insbesondere eine Alkyl- oder Hydroxyalkylcellulose.
- 6. Pharmazeutische Zusammensetzung nach Anspruch 5, dadurch gekennzeichnet, daß der Hydrokolloidbildner ausgewählt ist aus Methylcellulose, Hydroxymethylcellulose, Hydroxypropylcellulose, Methylhydroxymethylcellulose ethylcellulose, Methylhydroxypropylcellulose oder Natriumcarboxymethylcellulose.
  - Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 6 enthaltend
     3 5 Gew.% Bindemittel, bis zu 2 Gew.% Fließregulierungsmittel und bis zu 2 Gew.% Schmiermittel.
- Pharmazeutische Zusammensetzung nach einem der Ansprüche 1 6 zur Herstellung von komprimierten festen pharmazeutischen Darreichungsformen, insbesondere Tabletten oder Komprimaten zur Abfüllung in Kapseln.
  - 9 Pharmazeutische Darreichungsform in Form von Tabletten oder Komprimaten zur Abfüllung in Kapseln enthaltend Metformin als Wirkstoff und einen Hydro-

30

- kolloidbildner als Retardierungsmittel mit einer Restfeuchte von 0,5 3 Gew.-% bezogen auf das Gewicht des Tablettenkerns oder der Kapselfüllmasse.
- 10. Pharmazeutische Darreichungsform nach Anspruch 9 in Form einer Tablette mit einem Endgewicht unter 1300 mg.
- Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend Metformin als Wirkstoff und einen Hydrokolloidbildner als Retardierungsmittel sowie gegebenenfalls weitere pharmazeutisch übliche Hilfsstoffe, dadurch gekennzeichnet, daß man den Wirkstoff und das Retardierungsmittel oder ein Teil davon mit einem wäßrigen, gegebenenfalls bindemittelhaltigen Lösungsmittel granuliert, gegebenenfalls den anderen Teil des Retardierungsmittels oder andere pharmazeutisch übliche Hilfsmittel dem Granulat zumischt, und anschließend das Granulat bis zu einer Restfeuchte von 0,5 3 Gew.% trocknet.
  - 12. Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß das Granulat zu Tabletten verpreßt wird, die anschließend gegebenenfalls mit einer Filmhülle überzogen werden.
    - 13. Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß das Granulat kompaktiert wird und in Kapseln abgefüllt wird.
    - 14. Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß als Hydrokolloidbildner Methylhydroxypropylcellulose eingesetzt wird.
  - Verfahren nach Anspruch 11, dadurch gekennzeichnet, daß man zur Herstellung des Granulats bis zu 2 Gew.-% Fließregulierungsmittel, bis zu 2 Gew.-% Schmiermittel und bis zu 5 Gew.-% Bindemittel einsetzt, bezogen auf die fertige pharmazeutische Zusammensetzung.
  - Verwendung von pharmazeutischen Zusammensetzungen nach einem der
     Ansprüche 1 8 zur Herstellung von komprimierten pharmazeutischen
     Darreichungsformen, insbesondere von Tabletten oder Komprimaten zur Abfüllung in Kapseln
    - 17. Verfahren zur Herstellung eines leicht komprimierbaren pharmazeutischen Granulates enthaltend Metformin als Wirkstoff und einen Hydrokolloidbildner als Retardierungsmittel, dadurch gekennzeichnet, daß das Granulat vor der Komprimierung auf eine Restfeuchte von 0,5 3 Gew.-% getrocknet wird.

# INTERNATIONAL SEARCH REPORT

Int onal Application No PCT/EP 95/03610

			7
	OF SUBJECT MATTER		1
CLASSIFICA	ATION OF SUBJECT MATTER 61K31/155 A61K9/20	•	
	ternational Patent Classification (IPC) or to both national classification and IPC		┤ :
According to Int	emational Patent Classification (1997)		
B. FIELDS SE	ARCHED mentation searched (classification system followed by classification symbols)		
IPC 6	A61K	•	
		abuded in the fields searched	$\neg$
	searched other than minimum documentation to the extent that such documents a	re included in the	
Documentation	Kation	_	
		etical search terms used)	
data	base consulted during the international search (name of data base and, where pra	icucai, sea di anno	
Electronic can	, (10.	•	- {
	·	·	
•			
	INTS CONSIDERED TO BE RELEVANT	Relevant to claim No.	
C. DOCUME	NTS CONSIDERED TO BE telegraphic appropriate, of the relevant passages.		
Category *	Citation of document, with the	1-4,8-10	1
	EP,A,O 283 369 (LIPHA, LYONNAISE	1 4,0 20	- 1
X	EP, A, O 283 369 (LIPTIX, ETGINIAL STREET PHARMACEUTIQUE, FR) 21		. \
	September 1988		
1	coo claims		
ļ .	see examples 1,111	1-4,8,11	٠
.	US,A,3 621 097 (J.F.SCOTT) 16 November	1-4,0,1-	- 1
Ä	US,A,3 621 097 (0:1:500:77	'	- 1
	1971   see claims 1-3		
	see examples 1,2,4		1
1			- 1
1			
		` l	•
	Pa Particulation of box C.	stent family members are listed in annex.	
F	desirents are listed in the continuation of box C.		
	categories of cited documents: T later d	locument published after the international filing date ionly date and not in conflict with the application but ionly date and not in rinciple or theory underlying the	
* <b>1</b>	state of the art which is not cited	(D RESOURCE THE PROPERTY OF PROPERTY OF PERSONS ASSESSMENT ASSESSMENT ASSESSMENT ASSESSMENT ASSESSMENT ASSESSMENT ASSESSMENT ASSESSM	
.V. qoo	andered to be of barticular relevance	ment of particular relevance; the Califico street to	
'E' earl	lier document but published on or a series invol	ve an inventive step when the document is taken according	
11.1 000		we an inventive step when the claimed invention ment of particular relevance, the claimed invention to be considered to involve an inventive step when the total combined with one or more other such document is combined with one or more other such document is combined with one or more other such document is combined to be person skilled.	
di	ation or other special reason (as specifics)  document of the special disclosure, use, exhibition or ment	ts, such combination being obvious to a person senies	•
.O. 90	cument relating an in th	ne art.  ment member of the same patent family	
P do	ter than the priority date claimed	of mailing of the international search report	
	and completion of the international search		
Date o	1	D 4. 01, 96	
	15 December 1995	honzed officer	
<b> </b>	Aug.	IMITED OFFICE	
Name	European Factor	Scarponi, U	
	NL 2280 HV Rigwijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Far (+31-70) 340-3016	Juli poniti	

## INTERNATIONAL SEARCH REPORT

Information on patent family members

Int ional Application No PCT/EP 95/03610

Patent document	Publication date	Patent family member(s)	date
cited in search report	21-09-88	FR-A- 261150	A 16-05-91
EP-A-283369		AU-B- 61013 AU-B- 127278 CA-A- 132860 DE-D- 388607 DE-T- 388607 DK-B- 1697 JP-A- 632306 ZA-A- 88015	08 08-09-86 19-04-94 75 20-01-94 75 14-04-94 13 23-01-95 28 27-09-88
US-A-3621097	16-11-71	NONE	

# INTERNATIONALER RECHERCHENBERICHT

Int ionales Aktenzeichen
PCT/EP 95/03610

	COUNCECEGENSTANDES	\ ·
A. KLASSIFI IPK 6	ZIERUNG DES ANMELDUNGSGEGENSTANDES A61K31/155 A61K9/20	
•	est au-Gharian und der IPK	
	rnationalen Patentklassifikation (IPK) oder nach der nationalen Klassifikation und der IPK	
Nach der Ince	CHIERTE GEBIETE  CHIERTE GEBIETE  CHIERTE GEBIETE  CHIERTE GEBIETE	
B. RECHER	CHIERTE GEBIETE  r Mindessprüfstoff (Klassifikationssystem und Klassifikationssymbole)  A C 1 K	l l
TPK 6	WOIV.	
	de recherchierten Gebiet	e fallen
	e aber nicht zum Mindestprüfstoff gehörende Veröffentlichungen, soweit diese unter die recherchierten Gebiet	
Recherchiert	g goer mein somi man	
	d out verwendet	e Suchbegriffe)
	r internationalen Recherche konsultierte elektronische Datenbank (Name der Datenbank- und evtl. verwendet	
Während de	r internationalen Recipiete and	
}	•	
1	·	
		- In No
C. ALS W	ESENTLICH ANGESEHENE UNTERLAGEN	Betr. Anspruch Nr.
Kategorie*	ESENTLICH ANGESEHENE UNTERLAGEN  Bezeichnung der Veröffentlichung, soweit erforderlich unter Angabe der in Betracht kommenden Teile	
Kaugom		1-4,8-10
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	EP, A, O 283 369 (LIPHA, LYONNAISE	
X	TANISTRIFILE PHARMACOURTS	
	21 Sentember 1900	
1	1 -i-ha Anchruche	
	siehe Beispiele 1,111	1-4,8,11
	US,A,3 621 097 (J.F.SCOTT) 16.November	1 .,=,
٨	US, A, 3 621 097 (0.11.000)	
1	1971 siehe Ansprüche 1-3	
	siehe Beispiele 1,2,4	
1	2 (Elle penet	
l l		
1		
1		
\	Siehe Anhang Patentfamili	
	Weitere Veröffentlichungen and der Forstebung von	ach dem internationalen Anmeldedatum Mentlicht worden ist und mit der
	entrehmen	ach dem internationalier value fer ffendicht worden ist und mit der nderin nur zum Verständnis des der Prinzips oder der ihr zugrundeliegenden
	Erindung zugrunden id	ndern nur zum Verstanduns des ingenden Prinzips oder der ihr zugrundeliegenden
	aber nicht als besonders occusionen am oder nach dem internationalen	er Bedeutung die beausprucht
,E, 4	Anmeldedaum veröffentlicht worden Prioritätsanspruch zweifdhaft er-	nd betrachtet werden
1.1.	Veröffentlichung, die geeignet ist das Veröffentlichungsdatum einer veröffentlichung von besonder	er Tätigkeit beruhend betrachtet
1	anderen im Recherchenbericht gehanderen Grund angegeben ist (wie kann nicht aus die Veröffendic	hung mit einer oder inchracht wird und
	ausgeführt) veronientlichte Offenbarung.	chmann naheliereim ist
,0,	Verollentichung die Ausstellung oder andere manddedahim, aber nach . A. Verollentlichung, die Mittplet	1 00 2410 41.
.ь.	Verollenutellung Prioritätsdatum verollenutelt worden Absendedatum des internation	Union Medica construction
Date	dem beansprüchen Printernationalen Recherche um des Abschlusses der internationalen Recherche 04.01.96	
•		
1	15. Dezember 1995  Bevollmächtigter Bedienstete	т
<u> </u>	Recherchenbehorde	
Na	Europaische	
	NL - 228 HV RIAWIN (18 1651 epo nl. 3Car pont)	
1	Fax (+31-70) 340-3016	

## INTERNATIONALER RECHERCHENBERICH I

Angaben zu Veröffentlich. gen, die zur selben Patentfamilie gehören

Int onales Aktenzeichen
PCT/EP 95/03610

Im Recherchenbericht ngeführtes Patentdokument	Datum der Veröffentlichung	Mitglied(er) der Patentfamilie	Datum der Veröffentlichung
EP-A-283369	21-09-88	FR-A- 2611500 AU-B- 610134 AU-B- 1272788 CA-A- 1328606 DE-D- 3886075 DE-T- 3886075 DK-B- 169713 JP-A- 63230628 ZA-A- 8801540	09-09-88 16-05-91 08-09-88 19-04-94 20-01-94 14-04-94 23-01-95 27-09-88 26-08-88
us-A-3621097	16-11-71	KEINE	


## RECEIVED CENTRAL FAX CENTER

pr

CLIFFORD M. DAVIDSON
LESLYE B. DAVIDSON
CARY S. KAPPEL
WILLIAM C. GEHRIS
MOREY B. WILDES
ROBERT J. PARADISO
ERIK R. SWANSON\*\*\*
THOMAS P. CANTY\*\*\*

FELIX L D'ARIENZO, IR.

DAVID G. KNASIAK
RICHARD V. ZANZALARI\*
BENJAMIN S. DIMARCO\*
FRANKLIN S. ABRAMS
MICHELLE I. BLAT\*\*
HEIDI M. STRUSE\*\*\*



NEW YORK
DAVIDSON, DAVIDSON & KAPPEL, LLC
485 SEVENTH AVENUE, 14TH FLOOR
NEW YORK, NY 10018
T. 212-736-1940
F. 212-736-2427
DDK@DDKPATENT.COM

FRANKFURT

TODK EUROPE

DAVIDSON, DAVIDSON & KAPPEL EUROPE, LLC
ARNDTSTRASSE 11
60325 FRANKFLIRT AM MAIN, GERMANY
T. +49 (69) 788 088-0
F. +49 (69) 788 088-29
FRANKFLIRT@DDKPATENT.COM
"ADMITTED IN NEW JERSEY ONLY
"ADMITTED IN CONNECTICUIT ONLY
""ADMITTED IN TEXAS & DISTRICT OF COLUMBIA

#### FACSIMILE TRANSMITTAL

FROM: Clifford M. Davidson

PAGES: 2 (including cover sheet)

DATE: November 19, 2003

Attorney Docket Nos.: 300.1012

#### PLEASE DELIVER THE FOLLOWING TO:

Recipients(s): T. Page

Fax Number: 1-703-308-4556

MESSAGE: Please see attached.

This transmission was sent from fax number (212) 736-2427. If you have any problems with your reception, please telephone the sender at (212) 736-1940 Ext. 231.

#### CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper with enclosures are being facsimile transmitted to the Patent and Trademark Office on the date shown

favel (

David G. Knasiak

belov

Date

CONFIDENTIALITY NOTICE: The documents accompanying this facsimile transmission contain confidential information belonging to the sender which is legally privileged. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this facsimile information is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone to arrange for return of the original documents to us.

IF THERE ARE ANY PROBLEMS WITH RECEPTION OF THIS FAX, PLEASE CALL OR FAX SENDER TO ADVISE. THANK YOU.

PTOL-413A (05-03) Approved for use through xx/xx/xxx, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Application: Respond of File	Ponse to ice Action PECEIVEL CENTRAL FAX CEIVEL
(AM(PM)	OFFICA RECEIVED CENTRAL FAX CEI
(AM(PM)	CENTRAL FAX CEI
	CENTRAL FAX CEI
e	1
	-
d Agreed	Not Agreed
[]	[]
[]	[]
[]	[]
[]	[]
to submit a written of this interview (3	
	[ ] [ ] [ ] [ ] advance of the into submit a written

This collection of information is required by 37 CFR 1.133. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 21 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office, U.S. Department of Commerce, P.O. Ban 1450, Alexandria, VA 22313-1450. DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

#### **FORM PTO-1083**

# COMMISSIONER FOR PATENTS P.O. Box 1450

Alexandria, VA 22313-1450



Docket No.: 300.1012

007.23.2003

TICH CENTER 1600/2900

In re application: Xiu Xiu Cheng, et al. Serial No.: 09/705,625

Filed:

November 3, 2000

For:

METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE

**METFORMIN** 

Sir:

[]

Transmitted herewith is an Amendment in the above-identified application.

Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.

Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27. 

No fee for additional claims is required. [X]

A filing fee for additional claims calculated as shown below, is required:

	(Col. 1)	(Col. 2)	_	SMA	LL E	NTITY		LARGE ENTITY
FOR:	REMAINING	HIGHEST		L RA	TE	FEE	<u>OR</u>	RATE FEE
	AFTER	PREVIOUSLY	PRESENT	_				
	AMENDMENT	PAID FOR	EXTRA	_				
TOTAL CLAIMS	* Minus	** =	0	x \$	9	\$		x \$ 18 \$
INDEP. CLAIMS	* Minus	*** =	0	x \$	42	\$		x \$ 84 \$
[ ] FIRST PRES	ENTATION OF	MULTIPLE DE	EP. CLAIM	+ \$	140	\$		+ \$280 \$
					т	OTAL: \$		OR TOTAL: \$

If the entry in Co. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

[]	Also transmitted herewith are: [ ] Petition for extension under 37 C.F.R. 1.136 (in duplicate) [ ] Other:
[ ]	Check(s) in the amount of <b>\$.00</b> is/are attached to cover:  [ ] Filing fee for additional claims under 37 C.F.R. 1.16  [ ] Petition fee for extension under 37 C.F.R. 1.136  [ ] Other:

The Commissioner is hereby authorized to charge payment of the following fees associated with this [X] communication or credit any overpayment to Deposit Account No. 50-0552.

Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by [X] check submitted herewith.

Any patent application processing fees under 37 C.F.R. 1.17. [X]

Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, [X] and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR

1.136.

Clifford M. Davidson, Reg. No. 32,728

DAVÍDŠON, DAVIDSON & KAPPEL 485 Seventh Avenue, 14th Floor

New York, New York 10018

Tel: (212) 736-1940 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with sufficient postage to the United States Postal Service as "first class mail" in an envelope addressed to "Commissioner for Patents, P.O. Box 1450,

VA 22313-1450" on



RECEIVED

0C730031012

TECH CENTER 1600/2900

UNITED STATES PATENT & TRADEMARK OFFICE

Re:

Application of:

Xiu Xiu Cheng, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods for Treating Diabetes Via **Administration Of Controlled Release** 

Metformin

Examiner: T. Ware

Art Unit: 1615

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 October 14, 2003

# AMENDMENT UNDER 37 C.F.R. § 1.111

Sir:

Reconsideration of the present application in view of the following amendments and remarks is respectfully requested.

#### I. **INTRODUCTORY COMMENTS**

In response to the Office Action mailed on July 14, 2003, please amend the abovereferenced application as provided in the section below entitled "AMENDMENTS TO THE CLAIMS."

# II. AMENDMENTS TO THE CLAIMS

Claim 1. (currently amended) A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of metformin or a pharmaceutically acceptable salt thereof and an effective amount of a controlled release carrier to control the release of said meformin or pharmaceutically acceptable salt thereof from said dosage form, wherein following oral administration of a single dose, the dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from 5.5 to 7.5 hours after administration following dinner; and the administration of the at least one metformin dosage form provides a mean AUC<sub>0.24</sub> of  $\frac{22590 \pm 3626 \text{ ng} \cdot \text{hr/ml}}{3626 \text{ ng} \cdot \text{hr/ml}}$  and a mean  $\frac{C_{max}}{3626 \text{ ng} \cdot \text{h$ 

Claims 2-3 (cancelled)

Claim 4. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from 6.0 to 7.0 hours after administration.

Claim 5. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form occurs at dinner time and provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from 5.5 to 7.0 hours after the administration.

Claim 6. (cancelled)

Claim 7. (previously presented) The method of claim 1, in which the administration of the at

least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of metformin from about 4.5 to about 13 hours.

Claim 8. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of metformin from about 5.5 to about 10 hours.

Claim 9.( previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is more than about 7 times the mean plasma level of said metformin at about 24 hours after administration.

Claim 10. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 7 times to about 14 times the plasma level of said metformin at about 24 hours after administration.

Claim 11. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 8 times to about 12 times the plasma level of said metformin at about 24 hours after administration.

# Claims 12 - 13. (cancelled)

Claim 14. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from at least 80% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.

Claim 15. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> that is from at least 90% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.

Claims 16-17. (cancelled)

Claim 18 (currently amended) The method of claim 161, in which the once-a-day dosage of the metformin is about 2000 mg, which is provided by two controlled release dosage forms containing about 1000 mg.

Claims 19 - 21. (cancelled)

Claim 22. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-\infty}$  of  $18277 \pm 2961$  ng·hr/ml and a mean  $C_{max}$  of  $1929 \pm 333$  ng/ml, for administration of a 1700 mg once-a-day dose of metformin.

Claims 23 - 25. (cancelled)

Claim 26. (previously presented) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $t_{1/2}$  from 2.8 to 4.4.

Claim 27. (previously presented) The method of claim 1, further comprising administering to said human patients at least one additional pharmaceutically active ingredient for treatment of NIDDM.

Claim 28. (previously presented) The method of claim 1, further comprising administering to said human patients an additional pharmaceutically active ingredient for treatment of NIDDM, said additional pharmaceutically active ingredient selected from the group consisting of a sulfonylurea, a glitazone or a second biguanide.

Claim 29. (previously presented) The method of claim 1, in which the dose of metformin comprises metformin hydrochloride.

Claim 30. (original) The method of claim 29, in which the once-a-day dose of metformin hydrochloride is about 1000 mg to about 2500 mg.

Claim 31. (original) The method of claim 29, in which the once-a-day dose of metformin hydrochloride is about 2000 mg to about 2500 mg meformin.

Claims 32-34. (cancelled)

Claim 35. (new) The method of claim 1, in which the once-a-day dose of metformin or pharmaceutically acceptable salt thereof is 2000 mg.

Claim 36. (new) The method of claim 1, in which the once-a-day dose of metformin or pharmaceutically acceptable salt thereof is 1000 mg.

Claim 37. (new) The method of claim 1, in which the once-a-day dose of metformin or pharmaceutically acceptable salt thereof is 500 mg.

# III. REMARKS

The undersigned gratefully acknowledges the Examiner's indication in the last Office Action that claim 25 would be allowable if rewritten in dependent form, which has been done by virtue of this amendment, without prejudice to applicants pursuing remaining subject matter in continuation applications. It is respectfully submitted that this amendment places the previously deemed allowable subject matter into condition for allowance.

### A. Status of the Claims

The Examiner indicated that Claim 25 would be allowable if rewritten in independent from including all of the limitations of the base claim and any intervening claims. Therefore, Claim 1 has been amended to incorporate Claim 25. It is respectfully submitted that no new matter has been added by virtue of this amendment.

Claims 1, 4-5, 7-11, 14-15, 26-31 and 35-37 are pending. Claims 12-13, 19-21, and 23-25 have been cancelled without prejudice by virtue of this amendment. Claims 1 and 18 have been amended without prejudice by virtue of this amendment. The Examiner indicated that Claim 25 would be allowable if rewritten in independent from including all of the limitations of the base claim and any intervening claims. Therefore, Claim 1 has been amended to incorporate Claim 25. It is respectfully submitted that no new matter has been added by virtue of this amendment.

New claims 35-37 have been added which are directed to particular dosage strengths to be administered via the method set forth in amended claim 1. Support for these different strengths is found throughout the specification, including page 7 lines 19-26; page 8, lines 3-9. Original claims as filed and as pending specifically call for dosage strengths of 1000 and 2000 mg metformin, among other strengths. In this regard, the Examiner is reminded that, as stated in the specification at page 7, lines 4-10, "a given plasma level (e.g.,  $C_{max}$ ) of metformin per

specified dose will be directly proportional to other doeses of metformin. Such proportional doses and plasma levels are contemplated to be within the scope of the invention and to be within the scope of the appended claims." Applicants point out that the previous amendment to claims 22 -25 was intended to clarify that the particular ranges of the claimed pharmacokinetic parameters (i.e., C<sub>max</sub> and AUC) were directed to the 2000 mg dose, and were not intended to limit the scope of the claims solely to a 2000 mg dosage strength.

# B. Claim objection

In the Office Action, claim 18 was objected to as depending from cancelled claim 17. Claim 18 has been amended to depend from claim 1. The Examiner is requested to withdrawal this objection.

# C. Rejection of Claim 18 under 35 U.S.C. §112, second paragraph

In the Office Action, claim 18 were rejected under 35 U.S.C. 112, second paragraph, as being indefinite. The Examiner notes that claim 18 depends from cancelled claim 17.

In response, claim 18 has been amended to depend from claim 1. Therefore, the Examiner is requested to withdrawal this rejection.

# D. Rejections of Claims 1, 4-5, 7-15, 18-24, and 26-31 under 35 U.S.C. 103(a) over Lewis et al. in combination with Chiao and Drug Facts and Comparisons OR Moeckel et al. in combination with Chiao and Drug Facts and Comparisons

Claims 1, 4-5, 7-15, 18-24, 26-31 were rejected under 35 U.S.C. 103(a) as being unpatentable over Lewis et al (WO 00/28989; hereafter '989) in combination with Chiao (Remington, 1995) and further in combination with Drug Facts and Comparisons (1999) OR Moeckel et al (5,955,106; hereafter '106) in combination with Chiao (Remington, 1995) and further in combination with Drug Facts and Comparisons (1999)."

The Examiner states that "it would have been obvious to one skilled in the art at the time of the invention to combine '989 with Chaio and DFC or '106 with Chiao and DFC with the motivation of providing controlled delivery of metformin over a desired period of time to lower blood glucose levels when an individual is in the fed state. Applicant's comments filed 3-4-03, Paper #11, stating that numerous controlled release technologies are well within the knowledge of pharmaceutical formulators having ordinary skill in the art and such pharmaceutical formulators know that controlled release can be manipulated, e.g., by varying the amount of controlled release carrier (among other things), to provide a formulation which upon *in vivo* testing will provide the Tmax range of the present invention (pages 8-9 of response), are also relied upon for supporting the above position.

In view of the amendment to claim 1, incorporating allowable claim 25 of the present application, the Examiner's rejection with respect to Claims 1, 4-5, 7-15, 18-24, and 26-31 under 35 U.S.C. 103(a) as being unpatentable over Lewis et al (WO 00/28989; hereafter '989) in combination with Chiao (Remington, 1995) and further in combination with Drug Facts and Comparisons (1999) OR Moeckel et al (5,955,106; hereafter '106) in combination with Chiao (Remington, 1995) and further in combination with Drug Facts and Comparisons (1999) is now moot. The Examiner is respectfully requested to remove this rejection.

# E. Rejections of Claims 1, 4-5, 7-15, 18-24, and 26-31 under 35 U.S.C. 103(a) over Cheng et al. in view of Drug Facts and Comparisons

Claims 1, 4-5, 7-15, 18-24, and 26-31 were rejected under 35 U.S.C. 103(a) as being unpatentable over Cheng et al (WO 99/47125; hereafter '125) in view of Drug Facts and Comparisons (1999).

The Examiner states that "it would have been obvious to one skilled in the art at the time of the invention to manipulate the release profile of '125 in accordance with the teachings in '770 and lower blood glucose levels accordingly with the motivation of providing controlled

delivery of metformin over a desired period of time and to administer the compositions at dinner or at a fed state with the motivation of regulating sugar levels.

In view of the present amendment, claims 32-34 of the present application have been canceled without prejudice rendering the Examiner's rejection moot. Therefore, the Examiner is respectfully requested to withdraw the rejection of claims 32-34 under 35 U.S.C. §102(b) for the above-referenced application.

In view of the amendment to claim 1, incorporating allowable claim 25 of the present application, the Examiner's rejection with respect to Claims 1, 4-5, 7-15, 18-24, and 26-31 under 35 U.S.C. 103(a) as being unpatentable over Cheng et al (WO 99/47125; hereafter '125) in view of Drug Facts and Comparisons (1999) is now moot. The Examiner is respectfully requested to remove this rejection.

# F. <u>Double Patenting Rejections</u>

Claims 1, 4-5, 7-15, and 18-31 were rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over the following:

claims 1-29 of U.S. Patent No. 6,099,859; claims 1-39 of U.S. Patent No. 6,284,275; and claims 1-4 of U.S. Patent No. of U.S. Patent no. 6,099,862.

In addition claims 1, 4-5, 7-15, and 18-31 were provisionally rejected over claims 1-29 of copending Application No. 09/726,193.

In response, Applicants will consider the filing of Terminal Disclaimers to obviate the double-patenting rejections upon indication from the Examiner that the claims are otherwise allowable.

# G. Conclusion

It is now believed that the above-referenced rejections and objections have been obviated and it is respectfully requested that the rejections and objections be withdrawn. It is believed that all claims are now in condition for allowance.

According to currently recommended Patent Office policy the Examiner is specifically authorized to contact the undersigned in the event that a telephonic interview will advance the prosecution of this application.

An early and favorable action is earnestly solicited.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Bv:

rd M. Davidson

Ræg. No. 32,728

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018

(212) 736-1940

by & aval 4 (sured)
Rey No. 45,991



# UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vigninia 22313-1450 www.uspto.gov

APPLICATION NO.	7	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/705,625 11/03/2000		Xiu Xiu Cheng	300.1012	6705	
23280	7590	07/14/2003			
	•	VIDSON & KAPPE		EXAMI	NER
485 SEVEN NEW YOR		ENUE, 14TH FLOOR 10018		WARE,	TODD
				ART UNIT	PAPER NUMBER
				1615	12
				DATE MAILED: 07/14/2003	( )

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
		09/705,625	CHENG ET AL.
	Office Action Summary	Examiner	Art Unit
•		Todd D Ware	1615
	The MAILING DATE of this communication app		heet with the correspondence address
Period fo	• •		25 - 110 VT (/0) 5D0M
THE I - Exter after - If the - If NO - Failu - Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period we to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however within the statutory minim will apply and will expire SIX cause the application to b	r, may a reply be timely filed um of thirty (30) days will be considered timely. ( (6) MONTHS from the mailing date of this communication. ecome ABANDONED (35 U.S.C. § 133).
1) 🖂	Responsive to communication(s) filed on <u>05 A</u>	April 2001	
2a)□	·	is action is non-fina	1
3)	Since this application is in condition for allowa		
ا_ارق	closed in accordance with the practice under	Ex parte Quayle, 1	935 C.D. 11, 453 O.G. 213.
Dispositi	on of Claims		
4)🖂	Claim(s) 1, 4-5, 7-15, and 18-31 is/are pendin	g in the applicatior	· ·
	4a) Of the above claim(s) is/are withdrav	vn from considerati	on.
5)	Claim(s) is/are allowed.		
6)⊠	Claim(s) 1, 4-5, 7-15, 18-24, and 26-31 is/are	rejected.	
7)⊠	Claim(s) 25 is/are objected to.		•
8)□	Claim(s) are subject to restriction and/or	election requirement	ent.
Applicati	on Papers		
<i>,</i> —	The specification is objected to by the Examiner		
10) 🔲 🗆	The drawing(s) filed on is/are: a)☐ accep	•	
	Applicant may not request that any objection to the		
11)	The proposed drawing correction filed on		
12)□ -	If approved, corrected drawings are required in rep The oath or declaration is objected to by the Exa		1.
<i>,</i> —		armirer.	
•	nder 35 U.S.C. §§ 119 and 120  Acknowledgment is made of a claim for foreign	priority under 35 L	1 S C & 119(a)-(d) or (f)
· —	Acknowledgment is made of a claim for foreign	priority under 55 c	7.3.0. g 113(a)-(d) 51 (1).
a)L	1. Certified copies of the priority documents	s have been receive	ad.
	<ul><li>2. Certified copies of the priority documents</li></ul>		
	<ul><li>3. Copies of the certified copies of the prior</li></ul>		
	application from the International Bur ee the attached detailed Office action for a list of	reau (PCT Rule 17	2(a)).
14)∐ A	cknowledgment is made of a claim for domestic	priority under 35	J.S.C. § 119(e) (to a provisional application).
	) ☐ The translation of the foreign language proceed to the compact of a claim for domestion		
Attachment	(s)		
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 N	terview Summary (PTO-413) Paper No(s)  ptice of Informal Patent Application (PTO-152)  her:
C Batant and To	ademark Office		AUROBINDO EX. 1006, 193

Application/Control Number: 09/705,625

Art Unit: 1615

# **DETAILED ACTION**

Receipt of request for extension of time (granted) and amendment/response all filed 3-4-03 is acknowledged. In view of Applicant's comments and the new grounds for rejection, the instant Office Action is non-final. Claims 2-3, 6, 16-17, and 32-34 have been canceled and claims 1, 4-5, 7-15, and 19-29 have been amended as requested. Claims 1, 4-5, 7-15, and 18-31 are pending.

# Claim Objections

 Claim 18 is objected to because of the following informalities: claim 18 depends from canceled claim 17. Appropriate correction is required.

# Claim Rejections - 35 USC § 112

- 2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

  The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 3. Claim 18 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- 4. Claim 18 depends from canceled claim 17.

Claim Rejections - 35 USC § 103

Application/Control Number: 09/705,625 Page 3

**Art Unit: 1615** 

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 7. Claims 1, 4-5, 7-15, 18-24, 26-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lewis et al (WO 00/28989; hereafter '989) in combination with Chiao (Remington, 1995) and further in combination with Drug Facts and Comparisons (1999) **OR** Moeckel et al (5,955,106; hereafter '106) in combination with Chiao (Remington, 1995) and further in combination with Drug Facts and Comparisons (1999).
- 8. '989 and '106 both teach controlled release metformin compositions but do not teach the exact release profile(s) of the instant claims.
- 9. Chiao is relied upon for teaching manipulation of controlled release formulations in achieving a desired release profile. Such manipulation can occur, for example, by

Page 4

Application/Control Number: 09/705,625

. . . . =

Art Unit: 1615

varying the controlled release carrier, amount of controlled release ingredients, or thickness of coating(s) of controlled release ingredients.

Drug Facts and Comparisons (DFC) is relied upon for teaching delivery of metformin in the presence or absence of food.

- 10. Accordingly, it would have been obvious to one skilled in the art at the time of the invention to combine '989 with Chiao and DFC or '106 with Chiao and DFC with the motivation of providing controlled delivery of metformin over a desired period of time to lower blood glucose levels when an individual is in the fed state. Applicant's comments filed 3-4-03, Paper # 11, stating that numerous controlled release technologies are well within the knowledge of pharmaceutical formulators having ordinary skill in the art and such pharmaceutical formulators know that controlled release technologies can be manipulated, e.g. by varying the amount of controlled release carrier (among other things), to provide a formulation which upon *in* vivo testing will provide the T<sub>max</sub> range of the present invention (pages 8-9 of response), are also relied upon for supporting the above position.
- 11. Claims 1, 4-5, 7-15, 18-24, 26-31 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cheng et al (WO 99/47125; hereafter '125) in view of Drug Facts and Comparisons (1999).
- 12. '125 teaches controlled release metformin compositions but does teach the exact release profile(s) of the instant claims. In addition, '125 discloses a semi-permeable membrane coating surrounding the core. '125 incorporates by reference US Patent No.

Page 5

Application/Control Number: 09/705,625

Art Unit: 1615

3,845,770 (hereafter '770) to further describe the passageway and therefore drug release from the formulations taught therein. Briefly, '770 teaches adjustment of the release profile through manipulation of the interaction between the semi-permeable membrane and passageway(s) of the device (see '770 at C 6, L 39 - C 7, L 21; C 12, L 57 - C 13, L 67).

- 13. Drug Facts and Comparisons (DFC) is relied upon for teaching delivery of metformin in the presence or absence of food.
- 14. Accordingly, it would have been obvious to one skilled in the art at the time of the invention to manipulate the release profile of '125 in accordance with the teachings in '770 and lower blood glucose levels accordingly with the motivation of providing controlled delivery of metformin over a desired period of time and to administer the compositions at dinner or at a fed state with the motivation of regulating sugar levels.

# **Double Patenting**

15. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Application/Control Number: 09/705,625 Page 6

Art Unit: 1615

16. Claims 1, 4-5, 7-15, and 18-31 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-29 of U.S. Patent No. 6,099,859. '859 teaches a semi-permeable membrane metformin formulation and incorporates US Patent No. 3,845,770 (hereafter '770) by reference to further describe the passageway and therefore drug release from the formulations taught therein. '770 teaches adjustment of the release profile through manipulation of the interaction between the semi-permeable membrane and passageway(s) of the device (see '770 at C 6, L 39 - C 7, L 21; C 12, L 57 - C 13, L 67). Accordingly, it would have been obvious to one skilled in the art at the time of the invention to manipulate the release profile of '125 in accordance with the teachings in '770 with the motivation of providing controlled delivery of metformin over a desired period of time.

17. Claims 1, 4-5, 7-15, and 18-31 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-39 of U.S. Patent No. 6,284,275. '275 teaches a semi-permeable membrane metformin formulation and incorporates US Patent No. 3,845,770 (hereafter '770) by reference to further describe the passageway and therefore drug release from the formulations taught therein. '770 teaches adjustment of the release profile through manipulation of the interaction between the semi-permeable membrane and passageway(s) of the device (see '770 at C 6, L 39 - C 7, L 21; C 12, L 57 - C 13, L 67). Accordingly, it would have been obvious to one skilled in the art at the time of the invention to manipulate the

Page 7

Application/Control Number: 09/705,625

Art Unit: 1615

release profile of '125 in accordance with the teachings in '770 with the motivation of providing controlled delivery of metformin over a desired period of time.

- 18. Claims 1, 4-5, 7-15, and 18-31 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 6,099,862. '862 teaches a semi-permeable membrane metformin formulation and incorporates US Patent No. 3,845,770 (hereafter '770) by reference to further describe the passageway and therefore drug release from the formulations taught therein. '770 teaches adjustment of the release profile through manipulation of the interaction between the semi-permeable membrane and passageway(s) of the device (see '770 at C 6, L 39 C 7, L 21; C 12, L 57 C 13, L 67). Accordingly, it would have been obvious to one skilled in the art at the time of the invention to manipulate the release profile of '125 in accordance with the teachings in '770 with the motivation of providing controlled delivery of metformin over a desired period of time.
- 19. Claims 1, 4-5, 7-15, and 18-31 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-29 of copending Application No. 09/726,193. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are within the scope (species) of the claims of Application No. 09/726,193 (genus).

Art Unit: 1615

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

# Allowable Subject Matter

20. Claim 25 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### Conclusion

21. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Todd D Ware whose telephone number is (703) 305-1700. The examiner can normally be reached on M-F, 8:30 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703)308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

tw July 10, 2003 THURMAN K. PAGE
SUPERVISORY FAVENT EXAMINER
TECHNOLOGY CENTER 1600

# Notice of References Cited

Application/Control No. 09/705,625

Applicant(s)/Patent Under leexamination CHENG ET AL. Art Unit

1615

Page 1 of 1

Examiner
Todd D Ware

**U.S. PATENT DOCUMENTS** 

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	Α	US-3,845,770	11-1974	Theeuwes et al.	424/427
*	В	US-5,955,106	09-1999	Moeckel et al.	424/464
*	С	US-6,099,859	08-2000	Cheng et al.	424/464
*	D	US-6,099,862	08-2000	Chen et al.	424/473
*	Ε	US-6,284,275	09-2001	Chen et al.	424/473
	F	US-			
	G	US			·
	Н	US-			
	1	US-			
	J	US-			·
	К	US-			
	Ľ	US-			
	М	US-			

#### **FOREIGN PATENT DOCUMENTS**

*	٠	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
*	N	WO 9947125 A1	09-1999	World Intellect	CHENG et al.	A61K 09/20
*	0	WO 0028989 A1	05-2000	World Intellect	Lewis et al	A61K 31/353
	Р					
	Q					
	R					
	S					·
	т					

#### **NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)								
*	U	Chiao, C. Sustained-Release Drug Delivery Systems Remington: the Science and Practice of Pharmacy, 1995, Mack Publishing Company, Easton, PA Pages 1660-1669.								
	٧									
	w									
	х	· ·								

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

RECEIVED

MAR 1 4 2003 --- 300,1012

# UNITED STATES PATENT AND TRADEMAREC PENTER 16

Re:

Application of:

Xiu Xiu Cheng, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods for Treating Diabetes Via

**Administration Of Controlled Release** 

Metformin

Examiner: T. Ware

Art Unit: 1615

# **INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents Washington, D.C. 20231

February 28, 2003

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R.§1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the documents listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application.

Applicants note that reference AM is being submitted in an envelope labeled "PROPRIETARY MATERIAL NOT OPEN TO PUBLIC. TO BE OPENED ONLY BY EXAMINER OR OTHER AUTHORIZED U.S. PATENT AND TRADEMARK OFFICE EMPLOYEE." as this material in the envelope is considered proprietary and is being submitted for consideration under MPEP §724 (8th Edition).

03/14/2003 RHARMON 00000001 09705625

01 FC:1806

180.00 OP

The biostudy (which resulted in the data submitted as reference AM) was performed using formulations prepared in accordance with U.S. Patent No. 6,099,859. It is noted that the exemplified formulations did <u>not</u> provide a T<sub>max</sub> between 8-12 hours except when the formulation prepared in accordance with Example 3 was administered at dinner. As set forth in the accompanying biostudy data, the mean T<sub>max</sub> values for the Examples of the '859 were as follows: Example 1 (fasting) 4.67 hours (*See*, *e.g.*, pages 1 and 3 of the biostudy); Example 2 (fasting) 4.33 hours (*See*, *e.g.*, pages 10 and 12 of the biostudy); Example 2 (fed a.m.) 6.80 hours (*See*, *e.g.*, pages 13, 14 and 16 of the biostudy); Example 3 (fed a.m.) 6.67 hours (*See*, *e.g.*, pages 4 and 6 the biostudy); Example 3 (Fed p.m.) 9.67 hours (*See*, *e.g.*, pages 17 and 20 of the biostudy). Therefore, the only instance that the T<sub>max</sub> was between 8-12 hours was Example 3 fed in the P.M. (at dinner).

1

In addition, pages 2, 5, 11, 15, 19 of the biostudy data includes plasma concentration v. time graphs and data for formulations prepared in accordance with Examples 1(fasting), 3 (fed), 2 (fasting), 2 (fed), and 3 (fed), respectively, of U.S. Patent No. 6,099,859; pages 8 and 9 of the biostudy data include plasma concentration v. time graphs and data for formulations prepared in accordance with Example 2 (fasting and fed) and Example 3 (fed a.m. and p.m.) of U.S. Patent No. 6,099,859; and pages 7 and 18 include plasma concentration v. time graphs and data for formulations prepared in accordance with Example 3 (fed a.m. and p.m.) of U.S. Patent No. 6,099,859.

This Information Disclosure Statement is being filed after a First Office Action but before a Final Office Action or Notice of Allowance. Pursuant to 37 C.F.R. § 1.98(c), a check for \$180.00 is enclosed to cover the required fee. However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Bv:

fford M. Davidson

Reg. No. 32,728

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940

														- 40
FORM PTO-1449 (REV. 7-80)									ATTY. DOCKET NO.: SERIAL 300.1012 SERIAL 09/705,6			馬山	ECE	
LIST OF PRIOR ART CITED BY APPLICANT								APPLICANT(S): Xiu Xiu CHENG, et al.  FILING DATE: GROUP: November 3, 2000 1615				1800		
(Use several sheets if necessary)								FILING DATE: November 3, 2000		GROUP: 1615	4: 1	35.61		
			<u>,                                      </u>					Ü	S. PATENT DOC					Ó
*EXAMINER INITIAL		DOC	UMEN	T NUME	BER				DATE	NAME	CLASS	SUBCLASS	FILING DAT	
	AA	6	4	7	5	5	2	1	11/05/2002	Timmins et al.	424	469	Sep. 16, 199	9
	AB													
	AC		<u> </u>											
	AD		ļ				ļ							
	AE			-		<u> </u>								
	AF	ļ <u> </u>					<u> </u>	l —						
		_		-		<u> </u>	$\vdash$							<u>.</u>
	AG	<u> </u>	l	<u> </u>			ــــــــــــــــــــــــــــــــــــــ	FOR	EIGN PATENT D	OCUMENTS			<del></del>	
				T AU 1841				FUR	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATI	ON
		DOC	UMEN	T NUM	BER				DATE	COUNTRY	CLASS	3000000	YES	NO
		ļ											1123	
	АН	<u> </u>	ļ											<u> </u>
	Al	<u>L</u>												ļ
	AJ					ļ	_							-
	AK				ļ									
	AL					<u> </u>		<u> </u>		<u> </u>				
					0	THER F	PRIOR	ART (In	cluding Author, T	itle, Date, Pertinent Pa	ges, Etc.)			
	AM	Andr	x Pilot I	Biostud	y Data	(20 pag	jes)			· -				
	AN						_							
	AO			_								<del></del>	·	
	AP													
	AQ													
	AR												· · · · · · · · · · · · · · · · · · ·	<del></del> -
	AS													
EXAMINER									,	DATE CONSIDERE	D			
*EXAMINER: Initia						ot citatio	on is in	conforn	nance with MPEF	P 609; Draw line through	n citation if not in o	onformance and n	ot considered. In	nclude

#### **FORM PTO-1083**

ASSISTANT COMMISSIONER FOR PATENTS Washington, DC 20231

In re application: Xiu Xiu Cheng, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE

**METFORMIN** 

Sir:

[]

Transmitted herewith is an Information Disclos	sure Statement in the above-identified application.
--	---

[ ] Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.

[ ] Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.

[X] No fee for additional claims is required.

A filing fee for additional claims calculated as shown below, is required:

	(Col. 1)	(Col. 2)		SMALL	ENTITY		LARGE EN	Τ.
FOR:	REMAINING	HIGHEST		RATE	FEE	<u>OR</u>	RATE	
	AFTER	PREVIOUSLY	PRESENT					
	AMENDMENT	PAID FOR	EXTRA	_				
TOTAL CLAIMS	* Minus	;** =	x0\$	1\$		x \$ 1	8   \$	
INDEP. CLAIMS	* Minus	;*** =	x0\$ 40	\$	$\perp$	x \$ 8	0   \$	
[ ] FIRST PRES	SENTATION OF	MULTIPLE DE	P. ELAIM	\$	1 1	+ \$27	0 \$	
			•					

TOTAL: \$ OR TOTAL:

[X] Also transmitted herewith are:

[ ] Petition for extension under 37 C.F.R. 1.136

[X] Other: Form PTO 1449 and accompanying reference; and Material Submitted for consideration under MPEP § 724

[X] Check(s) in the amount of \$180.00 is/are attached to cover:

[ ] Filing fee for additional claims under 37 C.F.R. 1.16

[ ] Petition fee for extension under 37 C.F.R. 1.136

[X] Other: Fee for submission of Information Disclosure Statement

[X] The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.

[X] Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.

[X] Any patent application processing fees under 37 C.F.R. 1.17.

Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension on time under 37 CFR 1.136.

Clifford M. Davidson, Reg. No. 32,728

DAVIDSON, DAVIDSON & KAPPEL, LLC

485 Seventh Avenue, 14th Floor New York, New York 10018

Tel: (212) 736-1940

Fax: (212) 736-2427

No.: 300.1012

FORM	PTO-108	3	Docket No.: 300.1012 Date: February 24, 2003
	FANT CO	MMISSIONER FOR PATENTS O 1	1_//
In re ap Serial N Filed: For:	•	Xiu Xiu Cheng, et al. (2) 09/705,625 November 3, 2000 METHODS FOR TREATING STABLETES VIA ADMINISTRATION OF METFORMIN	RECEIVED  MAR OF RELEASE  CH CENTER 1600
Sir:			• 1000/2900
Transm	nitted here	ewith is an Amendment in the above-identified application.	
[ ] [x] [ ]	Applicant No fee fo	ntity status under 37 C.F.R. 1.9 and 1.27 has been previously established ts assert small entity status under 37 C.F.R. 1.9 and 1.27. or additional claims is required. see for additional claims calculated as shown below, is required:	.t
	FOR: TOTAL INDEP. [ ] FI	CLAIMS * Minus*** =   x0\$ 40 \$   x \$ RST PRESENTATION OF MULTIPLE DEP. @LAIM\$ \$   + \$:	18 \$ 80 \$ 270 \$
		TOTAL: \$ OR	TOTAL: \$
[X]		nsmitted herewith are: on for extension under 37 C.F.R. 1.136 ::	
[X]	[] Filing	) in the amount of <b>\$110.00</b> is/are attached to cover: fee for additional claims under 37 C.F.R. 1.16 on fee for extension under 37 C.F.R. 1.136 :	
[ <b>X</b> ]		istant Commissioner is hereby authorized to charge payment of the follo ication or credit any overpayment to Deposit Account No. 50-0552.	wing fees associated with this
-	[X] A	Any filing fee under 37 C.F.R. 1.16 for the presentation of additional clair check submitted herewith.  Any patent application processing fees under 37 C.F.R. 1.17.  Any petition fees for extension under 37 C.F.R. 1.136 which are not paid	

Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.

Clifford M. Davidson, Reg. No. 32,728 DAVIDSON, DAVIDSON & KAPPEL, LLC

485 Seventh Avenue, 14<sup>th</sup> Floor New York, New York 10018

Tel: (212) 736-1940 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to "Assistant Commissioner for Patents, Washington, D.C. 20231" on February 24, 2003.

DAVIDSON DAVIDSON & KAPPEL, LLC

BY: In wed M Grand



# UNITED STATES PATENT & TRADEMARK OFFICE CHA

Re:

Application of:

Xiu Xiu Cheng, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods for Treating Diabetes Via Administration Of Controlled Release

Metformin

Examiner: T. Ware

Art Unit: 1615

Assistant Commissioner for Patents Washington, D.C. 20231

February 24, 2003

# AMENDMENT UNDER 37 C.F.R. § 1.111

Sir:

In response to the Office Action mailed on October 22, 2002, Applicants respectfully request reconsideration of the application in view of the following amendments and remarks.

# IN THE CLAIMS

Please <u>cancel</u> claims 2-3, 6, 16-17, and 32-34.

Please **amend** the claims as follows:

1. (Twice Amended) A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of metformin or a pharmaceutically acceptable salt thereof and an effective amount of a controlled release carrier to control the release of said meformin or pharmaceutically acceptable salt thereof from said dosage form, wherein following oral administration of a single dose, the dosage form provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from 5.5 to 7.5 hours after administration following dinner.



- 4. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from 6.0 to 7.0 hours after administration.
- 5. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form occurs at dinner time and provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from 5.5 to 7.0 hours after the administration.




- 7. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of metformin from about 4.5 to about 13 hours.
- 8. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of metformin from about 5.5 to about 10 hours.
- 9.(Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is more than about 7 times the mean plasma level of said metformin at about 24 hours after administration.
- 10. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 7 times to about 14 times the plasma level of said metformin at about 24 hours after administration.
- 11. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration ( $C_{max}$ ) of metformin

which is from about 8 times to about 12 times the plasma level of said metformin at about 24 hours after administration.

12. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1500 ng/ml to about 3000 ng/ml, for administration of a 2000 mg once-a day dose of metformin.

- 13. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration ( $C_{max}$ ) of metformin from about 1700 ng/ml to about 2000 ng/ml, for administration of a 2000 mg oncea-day dose of metformin.
- 14. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-24hr}$  from at least 80% of the mean  $AUC_{0-24}$  provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 15. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> that is from at least 90% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 16. (Amended) The method of claim 1, in which the once-a-day dose of the metformin is administered at dinner.



metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 33900 ng.hr/ml, for administration of a 2000 mg once-a-day dose of metformin.

20. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-24hr}$  from about 17200 ng.hr/ml to about 26500 ng.hr/ml, for administration of a 2000 mg once-a-day dose of metformin.

21. (Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 19800 ng.hr/ml to about 33900 ng.hr/ml, for administration of a 2000 mg once-a-day dose of metformin.

b5

- 22. (Twice Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-\infty}$  of  $18277 \pm 2961$  ng·hr/ml and a mean  $C_{max}$  of  $1929 \pm 333$  ng/ml, for administration of a 1700 mg once-a-day dose of metformin.
- 23. (Twice Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-\infty}$  of  $20335 \pm 4360$  ng·hr/ml and a mean  $C_{max}$  of from  $2053 \pm 447$  ng/ml, for administration of a 2000 mg once-a-day dose of metformin.
- 24. (Twice Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-24}$  of  $26818 \pm 7052$  ng·hr/ml and a mean  $C_{max}$  of  $2849 \pm 797$  ng/ml, for administration of a 2000 mg once-a-day dose of metformin.
- 25. (Twice Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-24}$  of  $22590 \pm 3626$  ng·hr/ml and a mean  $C_{max}$  of  $2435 \pm 630$  ng/ml on the first day of administration and a mean  $AUC_{0-24}$  of  $24136 \pm 7996$  ng·hr/ml and a mean  $C_{max}$  of  $2288 \pm 736$  ng/ml on the  $14^{th}$  day of administration, for administration of a 2000 mg once-a-day dose of metformin.



26. (Twice Amended) The method of claim 1, in which the administration of the at least one metformin dosage form provides a mean  $t_{1/2}$  from 2.8 to 4.4.

36

- 27. (Amended) The method of claim 1, further comprising administering to said human patients at least one additional pharmaceutically active ingredient for treatment of NIDDM.
- 28. (Amended) The method of claim 1, further comprising administering to said human patients an additional pharmaceutically active ingredient for treatment of NIDDM, said additional pharmaceutically active ingredient selected from the group consisting of a sulfonylurea, a glitazone or a second biguanide.
- 29. (Amended) The method of claim 1, in which the dose of metformin comprises metformin hydrochloride.

#### **REMARKS**

Reconsideration of the present application is respectfully requested. An early and favorable action on the merits is earnestly solicited.

# I. Status of the Claims

Claims 1, 4-5, 7-15, and 18-31 are pending; claims 2-3, 6, 16-17, and 32-34 have been cancelled without prejudice; and claims 1, 4-5, 7-15, and 19-29 have been amended without prejudice. It is respectfully submitted that no new matter has been added by virtue of this amendment.



# II. Rejection of Claims 1-31 under 35 U.S.C. §112, first paragraph

In the Office Action, claims 1-31 were rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The Examiner states that "[t]he instant specification fails to provide information that would allow the skilled artisan to practice the instant invention without undue experimentation." The Examiner directs the Applicants attention to *In re Wands*, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988) and the eight factors discussed therein when assessing if a disclosure would have required undue experimentation.

The Examiner notes that "these examples are neither exhaustive, nor define the class of compound required," and that "[t]he pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity." The Examiner further states that "the instant claims read on all antihyperglycemic drug compositions where the maximum plasma concentration occurs from 5.5-7.5 hours after administration, necessitating an exhaustive search for the embodiments suitable to practice the claimed invention."

In response and in order to advance the prosecution of the present application, claim 1 has been amended without prejudice to recite "metformin" in place of "antihyperglycemic drug." The claims of the present application are clearly enabled for metformin or a pharmaceutically acceptable salt thereof, and as amended, the present claims do not "read on all antihyperglycemic compositions".

In any event, Applicants are not required to exemplify every formulation which would be encompassed by the claim and it would be tremendously costly, inefficient and perhaps unethical to require manufacturing and testing of alternative formulations as apparently deemed necessary by the Examiner in the last Office Action. At the time the present application was filed, there were numerous controlled release technologies in the art, and testing for drug-plasma levels is routine in clinical studies.



Therefore, it is respectfully submitted that once the  $T_{max}$  range which provides for a useful dosage form has been established, other controlled release technologies known in the art can be manipulated and tested to achieve this  $T_{max}$  range without undue experimentation as discussed below.

# A. The Test for Enablement

It is well recognized that "[t]he test of enablement is whether one reasonably skilled in the art could make or use the invention from the disclosures in the patent coupled with information known in the art without undue experimentation." *United States v. Telectronics, Inc.*, 8 USPQ2d 1217, 1223 (Fed. Cir. 1988), cert. denied, 490 U.S. 8 USPQ2d at 1046 (1989). "The determination of what constitutes undue experimentation in a given case requires the application of a standard of reasonableness, having due regard for the nature of the invention and the state of the art." *In re Wands*, 8 USPQ2d at 1404 (*citations omitted*). The test is not merely quantitative, since a considerable amount of experimentation is permissible, if it is merely routine, or if the specification in question provides a reasonable amount of guidance with respect to the direction in which the experimentation should proceed." *Id. (Emphasis added)*. The very nature of pharmaceuticals requires both formulation work and clinical (in-vivo) evaluation, and therefore giving due regard for the nature of the invention, the amount of experimentation needed to prepare a suitable controlled release formulation using a technology other than that exemplified in the specification does not amount to undue experimentation.

### B. Dosage Forms and Plasma Profile of the Present Invention

In the Office Action the Examiner states that "Applicant fails to set forth the criteria that defines the dosage form or steps in the production of the composition that results in the dosage form having the instant claimed plasma profile," and that "Applicant fails to provide information allowing the skilled artisan to ascertain the plasma profile without undue experimentation."



The invention as claimed is directed to a method of treatment wherein a maximum plasma concentration is obtained at 5.5 to 7.5 hours after administration, irrespective of the particular technology employed in the controlled release dosage form. Certain representative examples of these formulations are provided in the present application, and it is explained have stated in the specification that a number of controlled release technologies are useful in order to obtain the claimed pharmacokinetic parameters of the present invention.

Examples 1-3 of the present application which are directed to a tablet formulation containing metformin HCl, a seal coating, and a sustained release coating. Example 3 of the present application described clinical studies which were conducted to evaluate formulations prepared in accordance with Examples 1-3, which together with the specification enable the claimed methods of lowering blood glucose levels in human patients with oral controlled release dosage forms of metformin or a pharmaceutically salt thereof which provide the T<sub>max</sub> values of the present invention. The Examiner's attention is respectfully directed to page 19, line 21 to page 20, line 14 which states the following:

Other controlled release technologies known to those skilled in the art can be used in order to achieve the controlled release formulations of the present invention, i.e., formulations which provide a mean  $T_{\text{max}}$  of the drug and/or other pharmacokinetic parameters described herein when orally administered to human patients. Such formulations can be manufactured as a controlled oral formulation in a suitable tablet or multiparticulate formulation known to those skilled in the art . . . .

In addition, at the time the application was filed, numerous controlled release technologies were well within the knowledge of pharmaceutical formulators having ordinary skill in the art. Such pharmaceutical formulators know that controlled release technologies can be manipulated, e.g., by varying the amount of controlled release carrier (among other things), to provide a formulation which upon in-vivo testing will provide the  $T_{max}$  range of the present invention. This fact is supported, e.g., by a simple review of patents discussed in the specification concerning formulation technologies, which patents provide ranges of ingredients. These ranges represent the acknowledgement of those skilled in the art that a certain amount of experimentation is considered to be necessary to manipulate a controlled release technology to

obtain a desired release pattern of the drug. Such release patterns are demonstrated by the (well-known) use of in-vitro dissolution testing, which is considered by pharmaceutical formulators of ordinary skill in the art to provide guidance as to which particular formulations might provide the desired in-vivo performance.

Next, it is well known to those of ordinary skill in the art that upon formulating prospective products which might be useful in humans, in-vivo clinical studies must be conducted to determine whether the prospective product actually provides the desired in-vivo performance. Plasma profiles are routinely obtained during clinical trials and in particular during phase I-III studies as indicated in J.T. Cartensen, <u>Pharmaceutical Principles of Solid Dosage</u>
<u>Forms</u>, 1993 (attached herewith).

It is respectfully submitted that none of the above steps, either separately or collectively, rise to the level of undue experimentation. Once the goal has been identified and has been attained (as in the present exemplified formulations set forth in the specification), it is respectfully submitted that a pharmaceutical formulator of ordinary skill in the art can manufacture prospective dosage forms for evaluation (to determine if they meet the required invivo parameters), a clinician of ordinary skill in the art can administer the dosage forms and draw blood at appropriate time intervals, and a pharmacokineticist of ordinary skill in the art can evaluate the in-vivo blood plasma results.

These steps represent a clear pattern followed by every pharmaceutical company in the world. There is no alternative short-cut known which is considered to be acceptable by government regulatory agencies (such as FDA). Since human experiments with pharmaceuticals are generally considered unethical if being done solely for patent purposes, the Examiner appears to be requiring this Applicant to conduct studies that are unethical, unnecessary and not legally required to support the rightful scope of Applicant's claims. Accordingly, it is earnestly requested that the Examiner remove this basis for rejection.

The Examiner is reminded that Applicants are not required to exemplify every formulation which would be encompassed by the claim. See, e.g., *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 84 (CCPA 1970); MPEP 2164.01(b) (8<sup>th</sup> Edition) ("As long as the specification discloses at least one method for making and using the claimed invention that bears a reasonable correlation to the entire scope of the claim, then the enablement requirement of 35 U.S.C. 112 is satisfied.").

In *Telectronics*, for example, the court found that "[s]ince one embodiment is admittedly disclosed in the specification, along with the general manner in which its current range was ascertained, we are convinced that other permutations of the invention could be practiced by those skilled in the art without undue experimentation." *Telectronics*, 8 USPQ2d at 1223 (citing SRI Int'l v. Matsushita Elec. Corp. of America, 775 F.2d 1107, 1121, 227 USPQ 577, 586 (Fed. Cir. 1985) (the law does not require an applicant to describe in his specification every conceivable embodiment of the invention)).

Therefore, it is respectfully submitted that by virtue of the present application Applicants have disclosed a  $T_{max}$  range which provides for a useful dosage form of metformin or a pharmaceutically acceptable salt thereof, and other controlled release technologies known in the art can be manipulated by one of ordinary skill in the art to achieve this  $T_{max}$  range without undue experimentation.

#### C. <u>U.S. Patent No. 6,099,859</u>

In the rejection, the Examiner states that "[i]n the instant case, the provided examples set forth dosage forms made according to a process where the dosage forms have the same composition as those of U.S. 6,099,859 ('859)." However, the Examiner notes that "'859 discloses that the peak plasma profile is approximately 8-12 hours after administration, whereas the instant specification/claims state that the dosage forms, which appear to have the same composition and process of making as '859, have a peak plasma profile of 5.5-7.5 hours."

- (1) The specification of '859 states in <u>a</u> preferred embodiment, that peak plasma levels are obtained between 8-12 hours after administration (See column 2, lines 50-55).
- (2) In actuality however, the exemplified formulations did <u>not</u> provide a  $T_{max}$  between 8-12 hours except when the formulation prepared in accordance with Example 3 was administered at dinner. As set forth in an Information Disclosure Statement which will subsequently be hand delivered to the Examiner, the mean  $T_{max}$  values for the Examples of the '859 were as follows: Example 1 (fasting) 4.67 hours; Example 2 (fasting) 4.33 hours; Example 2 (fed a.m.) 6.80 hours; Example 3 (fed a.m.) 6.67 hours; Example 3 (Fed p.m.) 9.67 hours. Therefore, the only instance the  $T_{max}$  was between 8-12 hours was Example 3 fed in the P.M. (at dinner).

The claims have now been amended to state the " $T_{max}$  of metformin at from 5.5 to 7.5 hours after single dose administration following dinner." The claims as now written are directed to methods and treatments which were <u>never</u> accomplished in the Examples of the '859 patent.

With respect to the Examiner's position that the provided examples of the present application set forth dosage forms made according to a process where the dosage forms have the same composition as those of U.S. 6,099,859 ('859), the Examiner's attention is respectfully directed to the fact that the formulations exemplified and tested in the present application are indeed different as the formulations of the Examples of the present application differ from those of the '859 by having two laser drilled holes, and the method achieved a different result than that reported in the '859 or achieved by clinical testing of Examples 1-3. However, it is respectfully submitted that one skilled in the art would be able to manipulate the processes and formulations of the '859 by other methods to obtain the claimed pharmacokinetic parameters of the present invention by routine experimentation.

Therefore, in view of the aforementioned, it is respectfully submitted that the formulations of the present invention are different than those of the '859 patent.

#### D. Conclusion

In the specification, Applicants have provided formulations, methods of making the formulations, and clinical studies of these formulations, that support the limitations (e.g.,  $T_{max}$  values) recited in the present claims. Further, the prior art is replete with controlled release technology and, as stated in the present application, a number of controlled release technologies can be used to manufacture formulations which provide the results recited in the present claims without undue experimentation. Therefore, the Examiner is respectfully requested to remove the 35 U.S.C. §112 rejection of the pending claims.

#### III. Rejection of Claims 22-25 under 35 U.S.C. 112, second paragraph

Claims 22-25 were rejected under 35 U.S.C. 112, second paragraph, on the grounds of indefiniteness.

Specifically, the Examiner states that "[r]ecitation of 'based on' in claims 22-25 is indefinite since it is unclear whether Applicant is claiming that the dose of administration for metformin is 'X' mg after an evening meal or whether another dose of metformin provides these limitations. In the event the AUC<sub>0-infinity</sub> for a particular dose of metformin is claimed, amendment with 'for administration' is suggested to overcome the instant rejection."

In response and for purposes of advancing the prosecution of the present application, claims 22-25 have been amended without prejudice to recite the term "for" administration rather than "based on" administration, as suggested by the Examiner.

In view of the actions taken, the Examiner is respectfully requested to remove the rejection of claims 22-25 under 33 U.S.C. 112, second paragraph.

# IV. Rejection of Claims 32-34 under 35 U.S.C. 102(b) as being anticipated by Cheng et al (WO 99/47125).

Claims 32-34 were rejected under 35 U.S.C. 102(b) "as being anticipated by Cheng et al (WO 99/47125; hereafter '125)". The Examiner states that "125 discloses controlled release antihyperglycemic dosage form that has the same composition taught by the specification as providing the instant mean fluctuation indexes."

In view of the present amendment, claims 32-34 of the present application have been canceled without prejudice rendering the Examiner's rejection moot. Therefore, the Examiner is respectfully requested to withdraw the rejection of claims 32-34 under 35 U.S.C. §102(b) for the above-referenced application.

#### V. Conclusion

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "<u>Version With Markings To Show Changes</u> Made."

It is now believed that the above-referenced rejections and objections have been obviated and it is respectfully requested that the rejections and objections be withdrawn. It is believed that all claims are now in condition for allowance.

According to currently recommended Patent Office policy the Examiner is requested to contact the undersigned in the event that a telephonic interview will advance the prosecution of this application.

An early and favorable action is earnestly solicited.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Bv:

Clifford M. Davidson Reg. No. 32,728

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940

#### **VERSION WITH MARKINGS TO SHOW CHANGES MADE**

#### IN THE CLAIMS

Claims 2-3, 6, 16-17, and 32-34 have been cancelled without prejudice.

The claims have been amended as follows:

- 1. (Twice Amended) A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of [at least one suitable antihyperglycemic agent] metformin or a pharmaceutically acceptable salt thereof and an effective amount of a controlled release carrier to control the release of said metformin or pharmaceutically acceptable salt thereof from said dosage form, wherein following oral administration of a single dose, the dosage form provides a mean time to maximum plasma concentration (T<sub>max</sub>) of [agent] metformin at from 5.5 to 7.5 hours after administration following dinner.
- 4. (Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from 6.0 to 7.0 hours after administration.
- 5. (Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form occurs at dinner time and provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from [about] 5.5 to 7.0 hours after the administration.
- 7. (Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma



concentration/time curve of [the drug] metformin from about 4.5 to about 13 hours.

- 8. (Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of [the drug] metformin from about 5.5 to about 10 hours.
- 9.(Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is more than about 7 times the mean plasma level of said metformin at about 24 hours after administration.
- 10. (Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration ( $C_{max}$ ) of metformin which is from about 7 times to about 14 times the plasma level of said metformin at about 24 hours after administration.
- 11. (Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration ( $C_{max}$ ) of metformin which is from about 8 times to about 12 times the plasma level of said metformin at about 24 hours after administration.
- 12. (Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1500 ng/ml to about 3000 ng/ml, for [based on] administration of a 2000 mg once-a day dose of metformin.
- 13. (Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1700 ng/ml to about 2000 ng/ml, for [based on] administration of a 2000 mg once-



a-day dose of metformin.


- 14. (Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from at least 80% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 15. (Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-24hr}$  that is from at least 90% of the mean  $AUC_{0-24}$  provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 19. (Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 33900 ng.hr/ml, for [based on] administration of a 2000 mg once-a-day dose of metformin.
- 20. (Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 26500 ng.hr/ml, for [based on] administration of a 2000 mg once-a-day dose of metformin.
- 21. (Amended) The method of claim [3] 1, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 19800 ng.hr/ml to about 33900 ng.hr/ml, for [based on] administration of a 2000 mg once-a-day dose of metformin.
- 22. (Twice Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0- $\infty$ </sub> of 18277 ± 2961 ng·hr/ml and a mean C<sub>max</sub> of 1929 ± 333 ng/ml, <u>for</u> [based on] administration of a 1700 mg once-a-day dose of metformin

#### [after an evening meal].

- 23. (Twice Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0- $\infty$ </sub> of 20335 ± 4360 ng·hr/ml and a mean C<sub>max</sub> of from 2053 ± 447 ng/ml, <u>for</u> [based on] administration of a 2000 mg once-a-day dose of metformin [after an evening meal].
- 24. (Twice Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24</sub> of 26818 ± 7052 ng·hr/ml and a mean C<sub>max</sub> of 2849 ± 797 ng/ml, <u>for</u> [based on] administration of a 2000 mg once-a-day dose of metformin [after an evening meal].
- 25. (Twice Amended) The method of claim [3]  $\underline{\mathbf{1}}$ , in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-24}$  of  $22590 \pm 3626$  ng·hr/ml and a mean  $C_{max}$  of  $2435 \pm 630$  ng/ml on the first day of administration and a mean  $AUC_{0-24}$  of  $24136 \pm 7996$  ng·hr/ml and a mean  $C_{max}$  of  $2288 \pm 736$  ng/ml on the  $14^{th}$  day of administration, <u>for</u> [based on] administration of a 2000 mg once-a-day dose of metformin [after an evening meal].
- 26. (Twice Amended) The method of claim [3]  $\underline{1}$ , in which the administration of the at least one metformin dosage form provides a mean  $[T_{1/2}]$   $\underline{t_{1/2}}$  from 2.8 to 4.4.
- 27. (Amended) The method of claim [3] 1, further comprising administering to said human patients at least one additional pharmaceutically active ingredient for treatment of NIDDM.
- 28. (Amended) The method of claim [3] 1, further comprising administering to said human patients an additional pharmaceutically active ingredient for treatment of NIDDM, said additional pharmaceutically active ingredient selected from the group consisting of a sulfonylurea, a glitazone or a second biguanide.

29. (Amended) The method of claim [3] 1, in which the dose of metformin comprises metformin hydrochloride.





Re:

Application of:

Xiu Xiu Cheng, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods for Treating Diabetes Via **Administration Of Controlled Release** 

Metformin

Examiner: T. Ware

Art Unit: 1615

# PETITION FOR EXTENSION UNDER 37 CFR 1.136(a)

**Assistant Commissioner for Patents** Washington, D.C. 20231

February 24, 2003

Sir:

Applicants petition the Assistant Commissioner for Patents to extend the time for response to the Office Action dated October 22, 2002 for one (1) month from January 22, 2003 to February 24, 2003.

A check in the amount of \$110.00 is enclosed to cover the one month extension fee. If it is determined that additional fees are due at this time, the Assistant Commissioner is hereby authorized to charge said fees to Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

03/06/2003 ZJUHAR1 00000108 09705625

01 FC:1251

110.00 GP

ord M. Davidson

Reg. No. 32,728

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/705,625 11/03/2000		Xiu Xiu Cheng	300.1012	6705
23280	7590 10/22/2002			
	, DAVIDSON & KA	EXAMINER		
485 SEVENT NEW YORK,	H AVENUE, 14TH FLO NY 10018	OOR	WARE,	TODD
			ART UNIT	PAPER NUMBER
			1615	
			DATE MAILED: 10/22/2002	. 9

Please find below and/or attached an Office communication concerning this application or proceeding.

·	Application N .	Applicant(s)
Office Action Summary	09/705,625	CHENG ET AL.
Onice Action Canimary	Examiner Todd D.Ware	Art Unit
The MAILING DATE of this communication ap	Todd D Ware	
Period for Reply	pears on the bover shoot that the	
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.  after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a rep  - If NO period for reply is specified above, the maximum statutory period  - Failure to reply within the set or extended period for reply will, by statute  - Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).  Status	136(a). In no event, however, may a reply be till by within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from a, cause the application to become ABANDON	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on <u>08</u> .	<u>July 2002</u> .	
2a) ☐ This action is <b>FINAL</b> . 2b) ☑ The	nis action is non-final.	•
3) Since this application is in condition for allow closed in accordance with the practice under Disposition of Claims	ance except for formal matters, p Ex parte Quayle, 1935 C.D. 11,	prosecution as to the merits is 453 O.G. 213.
4) Claim(s) <u>1-34</u> is/are pending in the application	1.	
4a) Of the above claim(s) is/are withdra		
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-34</u> is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claim(s) are subject to restriction and/o	or election requirement.	
Application Papers		
9)☐ The specification is objected to by the Examine		
10)☐ The drawing(s) filed on is/are: a)☐ acce		
Applicant may not request that any objection to the	<del>-</del>	
11) The proposed drawing correction filed on		oved by the Examiner.
If approved, corrected drawings are required in re	• •	
12) The oath or declaration is objected to by the Ex	aminer.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. § 119(	a)-(a) or (t).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority document		San Ma
2. Certified copies of the priority document		
<ul> <li>3. Copies of the certified copies of the prio application from the International Bu</li> <li>* See the attached detailed Office action for a list</li> </ul>	reau (PCT Rule 17.2(a)).	_
14) Acknowledgment is made of a claim for domest	ic priority under 35 U.S.C. § 119(	e) (to a provisional application).
a) ☐ The translation of the foreign language pro	• •	
Attachment(s)		
Notice of References Cited (PTO-892)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)

Art Unit: 1615

# **DETAILED ACTION**

Receipt of request for extension of time (granted), amendment and terminal disclaimer all filed 7-8-02 is acknowledged. Claims 1, 2, 3, 22, 23, 25, 26 have been amended as requested. Claims 1-34 are pending. Based upon the new grounds for rejection, the instant Office Action is "non-final."

#### Claim Rejections - 35 USC § 112

- 1. The following is a quotation of the first paragraph of 35 U.S.C. 112:
  - The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
- 2. Claims 1-31 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
- 3. The instant specification fails to provide information that would allow the skilled artisan to practice the instant invention without undue experimentation. Attention is directed to *In re Wands*, 8 USPQ2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing *Ex parte Forman*, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors:
  - 1) the quantity of experimentation necessary,

Art Unit: 1615

2) the amount of direction or guidance provided,

- 3) the presence of absence of working examples,
- 4) the nature of the invention,
- 5) the state of the prior art,
- 6) the relative skill of those in the art
- 7) the predictability of the art, and
- 8) the breadth of the claims.

Applicant fails to set forth the criteria that defines the dosage form or steps in the production of the composition that results in the dosage form having the instant claimed plasma profile. Additionally, Applicant fails to provide information allowing the skilled artisan to ascertain the plasma profile without undue experimentation. In the instant case, the provided examples set forth dosage forms made according to a process where the dosage forms have the same composition as those of US 6,099,859 ('859). However, '859 discloses that the peak plasma profile is approximately 8-12 hours after administration, whereas the instant specification/claims state that the dosage forms, which appear to have the same composition and process of making as '859, have a peak plasma profile of 5.5-7.5 hours. It is noted that these examples are neither exhaustive, nor define the class of compounds required. The pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. The instant claims read on all antihyperglycemic drug compositions where the maximum plasma concentration occurs from 5.5-7.5 hours after administration, necessitating an exhaustive search for the embodiments suitable to practice the claimed

Art Unit: 1615

invention. Applicants fail to provide information sufficient to practice the claimed invention, absent undue experimentation.

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

- 5. Claims 22-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- 6. Recitation of "based on" in claims 22-25 is indefinite since it is unclear whether Applicant is claiming that the dose of administration for metformin is "X" mg after an evening meal or whether another dose of metformin provides these limitations. In the event the AUC<sub>0-infinity</sub> for a particular dose of metformin is claimed, amendment with "for administration" is suggested to overcome the instant rejection.

# Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 8. Claims 32-34 are rejected under 35 U.S.C. 102(b) as being anticipated by Cheng et al (WO 99/47125; hereafter '125).

Art Unit: 1615

9. '125 discloses controlled release antihyperglycemic dosage form that has the same composition taught by the specification as providing the instant mean fluctuation indexes.

### Response to Arguments

10. Applicant's arguments filed 7-8-02 have been fully considered but they are not persuasive. Applicant argues that the dosage forms of '125 do not disclose the same plasma profiles as in instant claims 1-31, however, the instant claims are not limited to plasma profiles. It is again submitted that the instant dosage forms are the same as those of '125 and that they would have the same mean fluctuation index.

#### Conclusion

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Todd D Ware whose telephone number is (703) 305-1700. The examiner can normally be reached on M-F, 8:30 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703)308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Application/Control Number: 09/705,625

**Art Unit: 1615** 

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

tw

October 20, 2002

Page 6

**FORM PTO-1083** 

ASSISTANT COMMISSIONER FOR PATENTS O

Washington, DC 20231

In re application: Chih-Ming Chen, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE

**METFORMIN** 

Sir:

[X]

RECEIVED

Docket No.: 300.1012

Date: July 1, 2002

Transmitted herewith is an Amendment in the above-identified application.

JUL 1 5 2002

TOTAL:

Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established. TECH CENTER 1600/2900 Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27. []

No fee for additional claims is required. [X]

A filing fee for additional claims calculated as shown below, is required: []

	(Col. 1)	(Col. 2)	_	SMALL	ENTITY		ENTITY
FOR:	REMAINING	HIGHEST	_	RATE	FEE	OR RATE	FEE
1	AFTER	PREVIOUSLY	PRESENT	그			•
	AMENDMENT	PAID FOR	EXTRA	1			COPY OF FAPERS
TOTAL CLAIMS	* Minus	** =	x0\$	9 \$	<u> </u>  x	\$ 18 \$	- ORIGINALLY FILED
INDEP. CLAIMS	* Minus	*** =	x0\$ 4	10 \$	<u>l</u>	\$ 80   \$	OMGINALLY FILED
FIRST PRES	SENTATION OF	MULTIPLE DE	P. ELAIN	\$ \$	$\perp$ 1+	\$270 \$	
					<del></del>		THE RESERVE THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TRANSPORT OF THE PERSON NAMED IN COLUMN TWO IS NOT THE PERSON NAMED IN COLUMN TWO IS NAMED IN COLUMN TWO

TOTAL:

Also transmitted herewith are:

[X] Petition for extension under 37 C.F.R. 1.136 (in duplicate)

[X] Other: Version With Markings to Show Changes Made and Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection over a Pending **Second Application** 

Check(s) in the amount of \$1030.00 is/are attached to cover: [X]

[ ] Filing fee for additional claims under 37 C.F.R. 1.16

[X] Petition fee for extension under 37 C.F.R. 1.136

[X] Other: Terminal Disclaimer Fee

The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this [X] communication or credit any overpayment to Deposit Account No. 50-0552.

Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by [X] check submitted herewith.

Any patent application processing fees under 37 C.F.R. 1.17. [X]

Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, [X] and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR

1.136.

Robert J. Paradiso, Reg. No. 41,240 DAVIDSON, DAVIDSON & KAPPEL, LLC

485 Seventh Avenue, 14th Floor New York, New York 10018

Tel: (212) 736-1940 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to "Assistant Commissioner for Patents. Washington, D.C. 20231 on July 1, 2002.

DAVIDSON, DAVIDSON & KAPPEL, LLC

AUROBINDO EX. 1006, 235



300.1012

# RECEIV

Re:

Application of:

Chih-Ming Chen, et al.

JUL 1 5 2002

Serial No.:

09/705,625

November 3, 2000

TECH CENTER 1600/2900

For:

Filed:

Methods For Treating Diabetes Via Administartion Of Controlled Release

Metformin

Examiner: T. Ware

Art Unit: 1615

COPY OF FAPERS ORIGINALLY FILED

Assistant Commissioner for Patents

July 1, 2002

Washington, D.C. 20231

# AMENDMENT UNDER 37 C.F.R. §1.111

Sir:

In response to the Office Action dated December 31, 2001, please enter the following amendments and remarks:

#### IN THE CLAIM

Please amend the claims as follows:

A method for lowering blood glucose levels in human patients needing treatment for noninsulin-dependent diabetes mellitus (NIDDM), comprising orally admirastering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of at least one suitable antihyperglycemic agent or a pharmaceutically acceptable salt thereof and a controlled release carrier, wherein the dosage form provides a mean time to maximum plasma concentration  $(T_{max})$  of the agent at from 5.5 to 7.5 hours after administration.



2. The method of claim 1 wherein said at least one antihyperglycemic agent is a biguanide.

3. The method of claim 2 wherein said biguanide is metformin or a pharmaceutically acceptable salt thereof.

23 Ph 23

The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0-\infty}$  of  $18277 \pm 2961$  ng·hr/ml and a mean  $C_{max}$  of  $1929 \pm 333$  ng/ml, based on administration of a 1700 mg once-a-day dose of metformin after an evening meal.

- The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0...}$  of 20335 ± 4360 ng hr/ml and a mean  $C_{max}$  of from 2053 ± 447 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin after an evening meal.
- The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0.24}$  of 26818  $\pm$  7052 ng·hr/ml and a mean  $C_{max}$  of 2849  $\pm$  797 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin after an evening meal.
- 25. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean  $AUC_{0.24}$  of  $22590 \pm 3626$  ng·hr/ml and a mean  $C_{max}$  of  $2435 \pm 630$  ng/ml on the first day of administration and a mean  $AUC_{0.24}$  of  $24136 \pm 7996$  ng·hr/ml and a mean  $C_{max}$  of  $2288 \pm 736$  ng/ml on the  $14^{th}$  day of administration, based on administration of a 2000 png once-a-day dose of metformin after an evening meal.
- The method of claim 3/ in which the administration of the at least one metformin dosage form provides a mean  $T_{1/2}$  from 2.8 to 4.4.

#### **REMARKS**

The undersigned attorney gratefully acknowledges the courtesies extended by Examiner Spear and Examiner Ware during the personal interview conducted at the United States Patent and Trademark Office on March 21, 2002.

### I. Status of the Claims

Claims 1-34 are pending. Claims 1-3 and 22-26 have been amended. Support for the amendments to claims 1-3 are found in the original specification as filed, e.g., at page 4, lines 12-15; Support for the amendment to claim 22 is found in the original specification as filed, e.g., at page 28, table 1; support for the amendment to claim 23 is found in the original specification as filed, e.g., at page 30, table 3; support for the amendment to claim 24 is found in the original specification as filed, e.g., at page 35, table 6; support for the amendment to claim 25 is found in the original specification as filed, e.g., at page 32, table 5; support for the amendment to claim 26 is found in the original specification as filed, e.g., at page 28, table 1. It is respectfully submitted that no new matter has been added by virtue of this amendment.

#### II. Information Disclosure Statement

In the Office Action, it was indicated that the Information Disclosure Statement filed on September 19, 2001 did not comply with 37 C.F.R. 1.98(a)(2). As discussed during the interview, it appears that the cited references became disassociated with the file and copies of the references cited in the Information Disclosure Statement will be resubmitted by hand delivery.

#### III. Rejections Under 35 U.S.C. § 112

In the Office Action, claims 4-31 were rejected as being indefinite on the grounds that "claims 4-31 require the method of claim 3, however claim 3 is a composition claims." In response, claim 3 has been amended to properly recite a method.

In the Office Action, claims 22-26 were rejected as being indefinite on the grounds that the claims are "omnibus type claims." In response, claims 21-25 have been amended as not to make reference to the Figures of the application.

In view of the actions taken, it is respectfully requested that the rejections under 35 U.S.C. § 112 be withdrawn.

# IV. Rejections Under 35 U.S.C. § 102 and 35 U.S.C. § 103

In the Office Action, claims 1-15 and 19-34 were rejected as being anticipated and obvious over WO 00/28989 ("Lewis et al."), on the grounds that Lewis et al. "discloses controlled release metformin compositions [and] does not explicitly disclose the functional limitations of the instant claims, however since the formulations of [Lewis et al.] are substantially the same, it appears that the instant claimed functional limitations are inherent within [Lewis et al.]"

Claims 1-15 and 19-34 were rejected as being anticipated and obvious over U.S. Patent No. 5,955,106 ("Moeckel et al."), stating that Moeckel et al. "is relied upon for the same reasons set forth in the [Lewis et al.] rejections".

Claims 1-15 and 19-34 were rejected as being anticipated and obvious over WO 99/47125 ("Cheng et al."), on the grounds that Cheng et al. "is relied upon for the same reasons set forth in the [Lewis et al.] rejections ... [and Cheng et al.] discloses a semi-permeable membrane coating surrounding the core."

Claims 16-18 were rejected on the grounds of obviousness over the Lewis reference, the Moeckel reference or the Cheng reference, in view of Drug Facts and Comparisons (1999) which "is relied upon for teaching delivery of metformin in the presence or absence of food."

With respect to rejections under the doctrine of inherency, it is noted that as set forth in the MPEP, 8th edition, section 2122, the fact that a certain result or characteristic may occur or be present in the prior art is not sufficient to establish the inherency of that result or characteristic. In re Rijckaert, 9 F.3d 1531, 1534, 28 USPQ2d 1955, 1957 (Fed. Cir. 1993) (reversed rejection because inherency was based on what would result due to optimization of conditions, not what was necessarily present in the prior art); In re Oelrich, 666 F.2d 578, 581-82, 212 USPQ 323, 326 (CCPA 1981). "To establish inherency, the extrinsic evidence 'must make clear that the missing descriptive matter is necessarily present in the thing described in the reference, and that it would be recognized by one of ordinary skill. Inherency, however, may not be established by probabilities or possibilities. The mere fact that a certain thing may result from a given set of circumstances is not sufficient.' "In re Robertson, 169 F.3d 743, 745, 49 USPQ2d 1949, 1950-51 (Fed. Cir. 1999).

It is further set forth in the MPEP, 8th edition, section 2122 that "[i]n relying upon the theory of inherency, the examiner must provide a basis in fact and/or technical reasoning to

reasonably support the determination that the alleged inherent characteristic <u>necessarily</u> flows from the teachings of the applied prior art." Ex parte Levy, 17 USPQ2d 1461, 1464 (Bd. Pat. App. And Inter. 1990) (emphasis in original).

Further, as discussed during the interview, the Federal Circuit stated the following in Continental Can Co. USA, Inc. v. Monsanto Co., 948 F.2d 1264, 1268-69, 20 U.S.P.Q.2d 1746, 1749 (Fed. Cir. 1991):

Inherency, however, may not be established by probabilities or possibilities. The mere fact that a certain thing may result from a given set of circumstances is not sufficient. If, however, the disclosure is sufficient to show that the natural result flowing from the operation as taught would result in the performance of the questioned function, it seems to be well settled that the disclosure should be regarded as sufficient.

In view of the above discussion on the doctrine of inherency, the references cited by the Examiner are discussed below:

#### THE CHENG REFERENCE

The rejection of claims 1-15 and 19-34 on the grounds of anticipation and obviousness over WO 99/47125 ("Cheng et al.") is respectfully traversed as the Cheng reference has not been fully considered in its entirety.

As stated at page 3, lines 14-17 and at page 4, lines 6-9 of the Cheng reference, the formulations disclosed therein provide a controlled or sustained release formulation for an antihyperglycemic drug that obtain peak plasma levels approximately 8-12 hours after administration. Therefore, the administration of formulations which provide a  $T_{max}$  of the agent at from 5.5 to 7.5 hours after administration as recited in the present claims cannot be inherent by the administration of formulations disclosed in the Cheng reference. Further, the Cheng reference does not provide motivation to one skilled in the art to modify the formulations therein to obtain a  $T_{max}$  of the agent other than that which is specifically taught in the reference, i.e., a  $T_{max}$  of 8 to 12 hours.

In view of the arguments presented, the Examiner is respectfully requested to remove the anticipation and obviousness rejections over the Cheng reference.

#### THE LEWIS REFERENCE

The rejection of claims 1-15 and 19-34 on the grounds of anticipation and obviousness over WO 00/28989 ("Lewis et al.") is respectfully traversed.

As set forth in the MPEP, 8<sup>th</sup> edition, section 2112.02, under the principles of inherency, if a prior art device, in its normal and usual operation, would necessarily perform the method claimed, then the method claimed will be considered to be anticipated by the prior ar6t device. When the prior art device is the same as a device described in the specification for carrying out the claimed method, it cab be assumed that the device will inherently perform the claimed process. In re King, 801 F.2d 1324, 231 USPQ 136 (Fed. Cir. 19867).

The exemplified formulations of the Lewis reference are Examples 1-7 on pages 10-12. Example 1 describes a single or bilayer tablet comprising 4 or 8 mg of Compound I (an insulin sensitizer) and 1000 to 1500 mg of metformin HCl coated with an enteric coating of Eudragit L30 D-55, triethyl citrate and talc Alphafil 500 in the described percentages; Example 2 describes the single or bilayer tablets of Example 1 coated with a semi-permeable membrane of Eudragit RS30D, triethyl citrate and talc in the described percentages; Example 3 describes a non-disintegrating matrix single layer tablet of Compound I, metformin HCl and the described excipients in the described amounts, and a bilayer tablet to provide sustained release of Compound I and immediate release of metformin HCl with the described excipients in the described amounts; Example 4 describes a single and trilayer tablet of Compound I and metformin HCl with the described excipients in the described amounts; Example 5 describes a single layer tablet of Compound I and metformin HCl with the described excipients in the described amounts; Example 6 describes a single and bilayer tablet of Compound I and metformin HCl with the described excipients in the described amounts; and Example 7 describes a capsule containing multiple pellet cores having Compound I, metformin HCl with the described excipient in the described amounts.

The examples of the present specification teach formulations which comprise a core comprising metformin or a salt thereof, a membrane surrounding the core, and at least one passageway in the membrane, the formulations providing a mean  $T_{max}$  from 5.5 to 7.5 hours after administration. Given the benefit of the information provided by the present specification, one skilled in the art would be able to modify other controlled release technologies in order to achieve these pharmacokinetic parameters.

As demonstrated above, the examples of the present application and the examples of the Lewis reference are directed to different controlled release technologies by virtue of their different ingredients, structure and methods of manufacture and it cannot be assumed that the prior art formulation would inherently perform the claimed method. Accordingly, a *prima facie* case of anticipation or obviousness based on inherency has not been established in the Office Action as there has not been provided a basis in fact and/or technical reasoning to reasonably support the determination that the prior art formulation would <u>necessarily</u> perform the method claimed.

Further, the Office Action has not taken into account the fact that there is no teaching in the Lewis reference to administer a formulation to arrive at the claimed  $T_{max}$  as recited in the present claims, nor does Lewis provide any motivation to one skilled in the art to achieve this parameter using the formulations described therein. In fact, it is respectfully submitted that as Lewis is silent as to the  $T_{max}$  of their formulations, one skilled in the art would be motivated to administer a formulation to achieve a  $T_{max}$  from an antihyperglycemic agent controlled release formulation which is known in the art, (e.g., a  $T_{max}$  of 8-12 hours as taught in the Cheng reference). It is pointed out that the present claims do not recite an all encompassing range of  $T_{max}$ , but rather a particular subset which is not taught or obvious over the prior art.

In view of the arguments presented, the Examiner is respectfully requested to remove the anticipation and obviousness rejections over the Lewis reference.

#### THE MOECKEL REFERENCE

The rejection of claims 1-15 and 19-34 on the grounds of anticipation and obviousness over U.S. Patent No. 5,955,106 ("Moeckel et al.") is respectfully traversed.

At the very least, the Moeckel reference does not teach or suggest administration of the formulations described therein on a once-a-day basis as recited in the present claims.

Further, the same arguments set forth above with respect to the Lewis reference are applicable to the Moeckel reference.

The exemplified formulations of the Moeckel reference are Examples 1-7 on columns 5-9 of the patent. Example 1 describes a process of preparing a formulation with a core of metformin hydrochloride, methylhydroxypropylcellulose, polyvidone and magnesium stearate in the specified amounts with a film envelope of methylhydroxypropylcellulose, ethylcellulose,

Macrogol and titanium dioxide in the specified amounts; Example 2 describes a process of preparing a formulation with a core of metformin hydrochloride, hydroxyethylcellulose, polyvidone and magnesium stearate in the specified amounts with a film envelope of methylhydroxypropyl-cellulose, lactose, ethylcellulose, Macrogol and titanium dioxide in the specified amounts; Example 3 describes a process of preparing a formulation with a core of metformin hydrochloride, sodium carboxy methyl cellulose, polyvidone and magnesium stearate in the specified amounts with a film envelope of methylhydroxypropylcellulose, ethylcellulose, Macrogol and titanium dioxide in the specified amounts; Example 4 describes a process of preparing a formulation with a core of metformin hydrochloride, polyacrylic acid, methylhydroxypropylcellulose, and magnesium stearate in the specified amounts with a film envelope of methylhydroxypropylcellulose, ethylcellulose, Macrogol and titanium dioxide in the specified amounts; Example 5 describes a process of preparing a formulation with a core of metformin hydrochloride, hydroxypropyl-cellulose, polyvidone and magnesium stearate in the specified amounts with a film envelope of poly(ethylacrylate-methylacrylate, talcum and antifoaming agent in the specified amounts; Example 6 describes a process of preparing a formulation with a core of metformin hydrochloride, methylhydroxypropylcellulose and magnesium stearate in the specified amounts with a film envelope of methylhydroxypropylcellulose, ethylcellulose, Macrogol and titanium dioxide in the specified amounts; and Example 7 describes a process of preparing a formulation with a core of metformin hydrochloride, methylhydroxypropylcellulose, polyvidone and magnesium stearate in the specified amounts with a film envelope of methylhydroxypropylcellulose, ethylcellulose, Macrogol and titanium dioxide in the specified amounts.

As set forth above, the Examples of the present specification teach formulations which comprise a core comprising metformin or a salt thereof, a membrane surrounding the core, and at least one passageway in the membrane, the formulations providing the claimed pharmacokinetic parameter of a mean  $T_{max}$  from 5.5 to 7.5 hours after administration.

Accordingly, the examples of the present application and the examples of the Moeckel reference are directed to different controlled release technologies by virtue of their different ingredients, structure and methods of manufacture. Accordingly, a *prima facie* case of anticipation or obviousness based on inherency has not been established as the Office Action has not provided a basis in fact and/or technical reasoning to reasonably support the determination

that the prior art formulation would <u>necessarily</u> perform the method claimed.

Further, the Office Action has not taken into account the fact that there is no teaching in the Moeckel reference to arrive at the claimed  $T_{max}$  as recited in the present claims, nor does Moeckel provide any motivation to one skilled in the art to achieve this parameter using the formulations described therein. In fact, it is respectfully submitted that as Moeckel is silent as to the  $T_{max}$  of their formulations, one skilled in the art would be motivated to achieve a  $T_{max}$  from a biguanide controlled release formulation which is known in the art, (e.g., a  $T_{max}$  of 8-12 hours as taught in the Cheng reference). As stated above with respect to the Lewis reference, it is pointed out that the present claims do not recite an all encompassing range of  $T_{max}$ , but rather a particular subset which is not taught or obvious over the prior art.

In view of the arguments presented, the Examiner is respectfully requested to remove the anticipation and obviousness rejections over the Moeckel reference.

#### DRUG FACTS AND COMPARISONS

The rejection of claims 16-18 on the grounds of obviousness over the Lewis reference, the Moeckel reference or the Cheng reference, in view of Drug Facts and Comparisons (1999) is respectfully traversed.

This rejection is respectfully traversed as this reference fails to cure the deficiencies of the Lewis reference, the Moeckel reference and the Cheng reference as presented above. Namely, Drug Facts and Comparisons does not provide motivation to achieve a method of administering an antihyperglycemic formulation to provide a mean  $T_{max}$  from 5.5 to 7.5 hours of the agent after administration

# V. <u>Double Patenting Rejections</u>

Claims 1-34 were provisionally rejected under the judicially created doctrine of obviousness type double patenting as being unpatentable over claims 1-42 of copending application serial number no. 09/705,630.

In response, in order to expedite the issuance of a patent, a terminal disclaimer is submitted herewith over this copending application. Applicants note that the obviation of an obvious-type double patenting rejection by the filing of a terminal disclaimer is not an admission, acquiescence, or estoppel on the merits of an issue of obviousness. See Quad Environmental

Technologies Corp. v. Union Sanitary District, 946 F.2d 870, 873-74, 20 U.S.P.Q.2d 1392, 1394-95 (Fed. Cir. 1991).

Claims 1-34 were rejected under the judicially created doctrine of obviousness type double patenting as being unpatentable over claims 1-29 of U.S. Patent no. 6,099,859; claims 1-39 of U.S. Patent No. 6,284,275; claims 1-4 of U.S. Patent No. 6,099,862. In the Office action, it was stated with respect to each reference that "[a]lthough the conflicting claims are not identical, they are not patentably distinct from each other because the claims are directed to limitations that are in a genus-species relationship and the functional limitations of the instant claims would be inherent in [the reference]." Further, claims 1-34 were provisionally rejected under obviousness type double patenting as being unpatentable over claims 1-54 of copending application no. 09/594,637 and over claims 1-29 of copending application no. 09/726,193 on the grounds that "the method claims disclose the compositions".

These rejections are respectfully traversed. It is submitted that the claimed pharmacokinetic parameter of a mean  $T_{max}$  of 5.5 to 7.5 hours after administration as recited in the present claims are not obvious in view of the claims of the cited references. As discussed during the interview, although formulations encompassed by the claims of these references  $\underline{may}$  provide a  $T_{max}$  of between 5.5 to 7.5, the claimed pharmacokinetic parameters  $\underline{do}$  not necessarily  $\underline{flow}$  from formulations encompassed by these claims. Therefore, the Examiner is requested to remove these rejections.

# VI. Conclusion

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "Version With Markings To Show Changes Made."

It is now believed that the above-referenced rejections and objections have been obviated and it is respectfully requested that the rejections and objections be withdrawn. It is believed that all claims are now in condition for allowance.



According to currently recommended Patent Office policy the Examiner is specifically authorized to contact the undersigned in the event that a telephonic interview will advance the prosecution of this application.

An early and favorable action is earnestly solicited.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Bv:

Robert J. Paradiso

Reg. No. 41,240

Davidson, Davidson & Kappel, LLC Patents, Trademarks and Copyrights 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940



#### Version With Markings To Show Changes Made

#### IN THE CLAIMS

The following claim has been amended as follows:

- 1. (Amended) A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of at least one suitable antihyperglycemic agent or a pharmaceutically acceptable salt thereof and a controlled release carrier, wherein the dosage form provides a mean time to maximum plasma concentration (T<sub>max</sub>) of [metformin] the agent at from 5.5 to 7.5 hours after administration.
- 2. (Amended) The [controlled release dosage form] method of claim 1 wherein said at least one antihyperglycemic agent is a biguanide.
- 3. (Amended) The [controlled release dosage form] method of claim 2 wherein said biguanide is metformin or a pharmaceutically acceptable salt thereof.
- 22. (Amended) The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0...</sub> of 18277 ± 2961 ng·hr/ml and a mean C<sub>max</sub> of 1929 ± 333 ng/ml [a mean plasma concentration-time profiles of metformin substantially as set forth in FIG. 1], based on administration of a 1700 mg once-a-day dose of metformin after an evening meal.
- 23. (Amended) The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0...</sub> of 20335 ± 4360 ng·hr/ml and a mean C<sub>max</sub> of from 2053 ± 447 ng/ml [a mean plasma concentration-time profiles of metformin substantially as set forth in FIG. 2], based on administration of a 2000 mg once-a-day dose of metformin after an evening meal.

- 24. (Amended) The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0.24</sub> of 26818 ± 7052 ng·hr/ml and a mean C<sub>max</sub> of 2849 ± 797 ng/ml [a mean plasma concentration-time profiles of metformin substantially as set forth in FIG. 4], based on administration of a 2000 mg once-a-day dose of metformin after an evening meal [at dinner].
- 25. (Amended) The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0.24</sub> of 22590 ± 3626 ng·hr/ml and a mean C<sub>max</sub> of 2435 ± 630 ng/ml on the first day of administration and a mean AUC<sub>0.24</sub> of 24136 ± 7996 ng·hr/ml and a mean C<sub>max</sub> of 2288 ± 736 ng/ml on the 14<sup>th</sup> day of administration [a mean plasma concentration-time profiles of metformin substantially as set forth in FIG. 6], based on administration of a 2000 mg once-a-day dose of metformin after an evening meal [at breakfast].
- 26. (Amended) The method of claim 22 [3], in which the administration of the at least one metformin dosage form provides a mean T<sub>1/2</sub> from 2.8 to 4.4 [about mean plasma glucose concentration-time profiles substantially as set forth in FIG. 5, based on administration of a 2000 mg once-a-day dose of metformin at dinner].

# TÉRMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION OVER A PENDING-SECOND APPLICATION

Docket No. 300.1012

			OIPE			<u> </u>
In re Applic Application Filed:	No. 09/70	Ming CHEN, et al. 5,625 mber 3, 2000	JUL 0 8 2002	S S S S S S S S S S S S S S S S S S S		ER 1600/2900
	THODS FOR TRE	ATING DIABETE	YIA ADMINIS	TRATION OF CONTR	OLLED RELEASE	900
any patent defined in 3 granted on The owner such period	the instant applicate granted on the instant on the ins to 15 U.S.C. 154 to 15 pending second A hereby agrees that it and any part of that it and any part of the property of the it and any part of the instant of the ins	ion hereby disclain tant application, who so and 173 as shore polication Number tany patent so granted on the	hich would exten tened by any terr 09/705, inted on the insta e second applica	vided below, the termid beyond the expiration in all disclaimer filed programs of the filed on t	on date of the full starior to the grant of ar November 3, 2 enforceable only for ned. This agreemer	tutory term ny patent g 2000 and during
application of any pate in the even invalid by a 1.321, has	that would extend nt granted on the s t that any such gra a court of compete all claims cancelle	to the expiration da second application, nted patent: expire ent jurisdiction, is sed by a reexamina	ate of the full statu as shortened by es for failure to pa statutorily disclain ation certificate, is	ne terminal part of any utory term as defined in any terminal disclaime ay a maintenance fee, ned in whole or termin is reissued, or in any is sclaimer filed prior to its	n 35 U.S.C. 154 to 19 er filed prior to the pa is held unenforceab nally disclaimed und manner terminated p	56 and 173 atent grant, le, is found er 37 CFR
Check eithe	er box 1 or 2, if app	ropriate.				
1.	For submissions agency, etc.), the	on behalf of an undersigned is em	organization (e. npowered to act o	g., corporation, partne n behalf of the organiz	ership, university, g ation.	overnment
				nowledge are true and		

willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

2. 

The undersigned is an attorney of record.

COPY OF FAPERS
OPTIGINALLY FILED

3		Owner/applicant is		Small entity	$\boxtimes$	Large entity	
Т	he	terminal disclaimer fee u	nder	37 CFR 1.20(d) is		\$110.00	and is to be paid as follows:
$\boxtimes$	3	A check in the amount of	the f	ee is enclosed.			
X		The Commissioner is here to Deposit Account Numb		authorized to charg 50-0552			nay be required, or credit any overpaymer copy of this sheet is enclosed.

PTO suggested wording for terminal disclaimer was

ung garaged.	☐ Afanged (if changed, a	an explanat	ion should be supplied
/ H //.	Parodin	Dated:	Culut, X
Siknatur	e /		Certify that this docu
Name and Address of F	erson Signing		on that this document

Robert J. Paradiso, Reg. No. 41,240 Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 212-736-1940

7/12/2002 AOSHAN1 00000061 09705625

2 FC:148 110.00 OP

1 Certify that this document and fee is being deposited on with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

AURUBINDU EX<sub>22</sub>, 1000, 24

Copyright 1995 Legalsoft

PETITION FOR E	XTENSION OF TIME UN (Large Entity)	NDER 37 CFI	R 1.136(a)	Docket No. 300.1012
In Re Application Of: 9	Chih-Ming CHEN, et al.			
Serial No. 09/705,025MAPX	Filing Date November 3, 2000		Examiner T. Ware	Group Art Unit 1615
Invention: METHODS	FOR TREATING DIABETES	S VIA ADMINIS	TRATION OF CONT	RECEIVE
				JUL 1 5 2002
	TO THE ASSISTANT C	<u>OMMISSIONEF</u>	R FOR PATENTS:	TECH CENTER 1600/2
	the provisions of 37 CFR 1.136 $\frac{31,2001}{e}$ above-identified app		e period for filing a res	ponse to the Office Action
The requested extension  One month	is as follows (check time peri	od desired): Three months	☐ Four months	☐ Five months
from:	March 31, 2002  Date	until:	June 30, 2002 Date	
The Commissione	ount of the fee is enclosed. r is hereby authorized to charg	and is to be pa		COPY OF FAPERS ORIGINALLY FILED credit any
A duplicate copy of If an additional extends any additional feet	eposit Account No.  f this sheet is enclosed.  ension of time is required, please which may be required to Defer this sheet is enclosed.			d charge
JA J	. Varostro	_ Dated: J	uly 1, 2002	
Robert J. Paradiso, Reg. Davidson, Davidson & Ka 485 Seventh Avenue, 14th	ppel, LLC			
New York, New York 100 212-736-1940			on first class mail under 37 C	ent and fee is being deposite with the U.S. Postal Service .F.R. 1.8 and is addressed to t for Patents, Washington, D.
12/2002 AOSMAN1 00000061 09 FC:117	1705625 920.00 pp		20231.	
	≁cα∙αα ñh,		Signature of Person	n Mailing Correspondence
cc:			Typed or Printed Name of	Person Mailing Correspondence



# United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	TION NO. FILING DATE FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/705,625	11/03/2000	Xiu Xiu Cheng	300.1012	6705
23280	7590 12/31/2001			
	, DAVIDSON & KAP	EXAMINER		
485 SEVENT NEW YORK,	H AVENUE, 14TH FLOONY 10018	OR	WARE,	TODD
			ART UNIT	PAPER NUMBER
			1615 DATE MAILED: 12/31/2001	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/705,625	CHENG ET AL.				
Office Action Summary	Examiner	Art Unit				
	Todd D Ware	1615				
Th MAILING DATE of this communication app	ars on the cover sheet with the c	orrespondence address				
Period for Reply		÷				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).  Status	6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from to cause the application to become ABANDONED	nely filed s will be considered timely. the mailing date of this communication. O (35 U.S.C. § 133).				
1) Responsive to communication(s) filed on <u>05 A</u>	<u>pril 2001</u> .					
2a)  This action is <b>FINAL</b> . 2b)  Thi	s action is non-final.					
3) Since this application is in condition for allowa closed in accordance with the practice under be	nce except for formal matters, pr Ex <i>parte Quayle</i> , 1935 C.D. 11, 4	osecution as to the merits is 53 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1-34 is/are pending in the application.						
4a) Of the above claim(s) is/are withdraw	n from consideration.					
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-34</u> is/are rejected.						
7)⊠ Claim(s) <u>2 and 3</u> is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9) The specification is objected to by the Examiner						
10) The drawing(s) filed on is/are: a) accep						
Applicant may not request that any objection to the						
11) The proposed drawing correction filed on		ved by the Examiner.				
If approved, corrected drawings are required in rep						
12) ☐ The oath or declaration is objected to by the Exa	aminer.					
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)	)-(a) or (t).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents		No				
2. Certified copies of the priority documents						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>						
14) ☐ Acknowledgment is made of a claim for domestic	c priority under 35 U.S.C. § 119(e	e) (to a provisional application).				
a) ☐ The translation of the foreign language provisional application has been received.  15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449) Paper No(s)</li> </ol>	5) Notice of Informal F	/ (PTO-413) Paper No(s) Patent Application (PTO-152)				
S. Patent and Trademark Office		LIDODINDO EV 1000 0E0				



Art Unit: 1615

# **DETAILED ACTION**

Receipt of declaration and fee filed 4-5-01 is acknowledged. Claims 1-34 are pending.

# Claim Objections

1. Claims 2 and 3 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim:

Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 1 requires a Tmax for metformin at 5.5 to 7.5 hours. Claim 2 broadens the scope of claim 1 to the class biguanides and claim 3 requires the active agent to be metformin, however, claim 1 already requires metformin.

# Claim Rejections - 35 USC § 112

- 2. The following is a quotation of the second paragraph of 35 U.S.C. 112:
  The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
- 3. Claims 4-31 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 4-31 require the method of claim 3, however claim 3 is a composition claim.



Art Unit: 1615

4. Claims 22-26 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite in that they fail to point out what is included or excluded by the claim language. These claims are omnibus type claims.

# Claim Rejections - 35 USC § 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

6. Claims 1-15, 19-34 are rejected under 35 U.S.C. 102(a) as being anticipated by Lewis et al (WO 00/28989; hereafter '989).



Art Unit: 1615

'989 discloses controlled release metformin compositions. '989 does not explicitly disclose the functional limitations of the instant claims, however since the formulations of '989 are substantially the same, it appears that the instant claimed functional limitations are inherent within '989. Therefore, the burden is shifted to applicants to demonstrate a difference between '989 and the instant claims (*In re Swinehart*, 169 USPQ 226 and *In re Fitzgerald* 205 USPQ 594).

7. Claims 1-15, 19-34 are rejected under 35 U.S.C. 102(b) as being anticipated by Cheng et al (WO 99/47125; hereafter '125).

'125 discloses controlled release metformin compositions and is relied upon for the same reasons set forth in the previous 35 U.S.C. 102(a) rejections as being anticipated by Lewis et al (WO 00/28989; hereafter '989).

8. Claims 1-15, 19-34 are rejected under 35 U.S.C. 102(b) as being anticipated by Moeckel et al (5,955,106; hereafter '106).

'106 discloses controlled release metformin compositions and is relied upon for the same reasons set forth in the previous 35 U.S.C. 102(a) rejections as being anticipated by Lewis et al (WO 00/28989; hereafter '989).

# Claim Rejections - 35 USC § 103

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:



Art Unit: 1615

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

- 10. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).
- 11. Claims 1-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lewis et al (WO 00/28989; hereafter '989) or Cheng et al (WO 99/47125; hereafter '125) or Moeckel et al (5,955,106; hereafter '106) each alone or each in combination with Drug Facts and Comparisons (1999).

'989, '125, and '106 all teach controlled release metformin compositions. 'They do not explicitly teach the functional limitations of the instant claims, however since the formulations of these references are substantially the same, it appears that the instant claimed functional limitations are inherent. Therefore, the burden is shifted to applicants to demonstrate a difference between the prior art and the instant claims (*In re Swinehart*, 169 USPQ 226 and *In re Fitzgerald* 205 USPQ 594). Varying amounts of ingredients, such as dose, or administration in two dosage forms would have been



Art Unit: 1615

obvious to one skilled in the art at the time of the invention to provide a greater or lesser drug effect or, in the case of administration in two dosage forms, to administer a large dose in smaller tablets. '989, '125, and '106 do not teach the limitations of claims 16-17.

Drug Facts and Comparisons (DFC) is relied upon for teaching delivery of meformin in the presence or absence of food.

Accordingly, it would have been obvious to one skilled in the art at the time of the invention to administer the compositions at dinner or at a fed state with the motivation of regulating sugar levels.

12. Claims 1-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chen et al (6,270,805; hereafter '805) alone or in combination with Drug Facts and Comparisons (1999).

'805 discloses controlled release metformin compositions. '805 does not explicitly disclose some of the functional limitations of the instant claims, however since the formulations of '805 are substantially the same, it appears that the instant claimed functional limitations are inherent within '106. Therefore, the burden is shifted to applicants to demonstrate a difference between '106 and the instant claims (*In re Swinehart*, 169 USPQ 226 and *In re Fitzgerald* 205 USPQ 594). Varying amounts of ingredients, such as dose would have been obvious to one skilled in the art at the time of the invention to provide a greater or lesser drug effect.





Art Unit: 1615

# **Double Patenting**

13. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

- 14. Claims 1-34 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-29 of U.S. Patent No. 6,099,859. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims are directed to limitations that are in a genus-species relationship and the functional limitations of the instant claims would be inherent in '859.
- 15. Claims 1-34 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-39 of U.S. Patent No. 6,284,275. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims are directed to limitations that are in a genus-species relationship and the functional limitations of the instant claims would be



Art Unit: 1615

inherent in '275. Also, buformin is an adjacent homolog of metformin and therefore metformin is obvious over buformin.

- 16. Claims 1-34 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4 of U.S. Patent No. 6,099,862. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims are directed to limitations that are in a genus-species relationship and the functional limitations of the instant claims would be inherent in '275.
- 17. Claims 1-34 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-42 of copending Application No. 09/705,630. Although the conflicting claims are not identical, they are not patentably distinct from each other because the method claims disclose the compositions.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

18. Claims 1-34 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-29 of copending Application No. 09/726,193. Although the conflicting claims are not identical,



**Art Unit: 1615** 

they are not patentably distinct from each other because the method claims disclose the compositions.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

19. Claims 1-34 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-54 of copending Application No. 09/594,637. Although the conflicting claims are not identical, they are not patentably distinct from each other because the method claims disclose the compositions.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

## Conclusion

20. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Todd D Ware whose telephone number is (703) 305-1700. The examiner can normally be reached on M-F, 8:30 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703)308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.





Page 10

Application/Control Number: 09/705,625

Art Unit: 1615

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

tw December 21, 2001

THURZOAN K. PAGE
TO PATENT EXAMINER
1600

# Notice of References Cited

Application/Control No.

09/705,625

Examiner

Todd D Ware

plicant(s)/Patent Under examination (standard processes and several points of the points of the plicant(s)/Patent Under examination (standard processes and several points of the plicant(s)/Patent Under examination (standard processes and several points of the plicant(s)/Patent Under examination (standard processes and several points of the plicant(s)/Patent Under examination (standard processes and several points of the plicant(s)/Patent Under examination (standard processes and several points of the plicant(s)/Patent Under examination (standard processes and several points of the plicant(s)/Patent Under examination (standard processes and several points of the plicant points of

#### **U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	Α	US-6,284,275	09-2001	Chen et al	424/473
	В	US-6,270,805	08-2001	Chen et al	424/497
	С	US-6,099,862	08-2000	Chen et al	424/473
	D	US-6,099,859	08-2000	Cheng et al	424/464
	E	US-5,955,106	09-1999	Moeckel et al	424/464
٠.,	F	US-			
	G	US-			
	Н	US-			
	ı	US-			
	J	US-			
	К	US-			
	L	US-			
	М	US-			

#### **FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 00/28989	05-2000	WIPO	Lewis et al	
	0	WO 99/47125	09-1999	WIPO	Cheng et al	
	Р					
	Q					
	R					
	s					
	Т					

## NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Drug Facts and Comparisons Page 635-642 1999
	٧	
	w	
	х	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

**Notice of References Cited** 

Part of Paper No. 4

# **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

51) International Patent Classification <sup>6</sup> : A61K 9/20	A1	<ul> <li>(11) International Publication Number: WO 99/47125</li> <li>(43) International Publication Date: 23 September 1999 (23.09.99)</li> </ul>
21) International Application Number: PCT/US  22) International Filing Date: 19 March 1999 (20.03.98)  30) Priority Data: 09/045,330 20 March 1998 (20.03.98)  71) Applicant: ANDRX PHARMACEUTICALS, INC. Suite 201, 4001 S.W. 47th Avenue, Fort Laude 33314 (US).  72) Inventors: CHENG, Xiu, Xiu; Apartment 506, Rolling Hills Circle, Davie, FL 33328 (US). Chih-Ming; 10680 S.W. 40th Manor, Davie, (US). JAN, Steve; 512 N.W. 120th Drive, Cora FL 33071 (US). CHOU, Joseph; 5755 N.W. 5 Coral Springs, FL 33067 (US).  74) Agent: ENDRES, Martin, P.; Hedman, Gibson & P.C., 1185 Avenue of the Americas, New York, (US).	[US/Usrdale, ] 3150 CHE FL 333 I Sprin 4th Pla	BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GI GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KI LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, T TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO pater (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasia patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Europea patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GI IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CI CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  Published  With international search report.

(54) Title: CONTROLLED RELEASE ORAL TABLET HAVING A UNITARY CORE

(57) Abstract

A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.

Jame as \$ 6099859

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

						SI	Slovenia
AL	Albania	ES	Spain	LS	Lesotho	SK	Slovakia
AM	Armenia	FI	Finland	LT	Lithuania		
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	ĦU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	Œ	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belanus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	Li	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
BE	Estonia Estonia	LR	Liberia	SG	Singapore		

# CONTROLLED RELEASE ORAL TABLET HAVING A UNITARY CORE BACKGROUND OF THE INVENTION:

The present invention relates to controlled release unit dose formulations containing an antihyperglycemic drug. More specifically, the present invention relates to an oral dosage form comprising a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride or the metformin salts described in United States Patent Nos. 3,957,853 and 4,080,472 which are incorporated herein by reference.

In the prior art, many techniques have been used to provide controlled and extended-release pharmaceutical dosage forms in order to maintain therapeutic serum levels of medicaments and to minimize the effects of missed doses of drugs caused by a lack of patient compliance.

In the prior art are extended release tablets which have an osmotically active drug core surrounded by a semipermeable membrane. These tablets function by allowing a fluid such as gastric or intestinal fluid to permeate the coating membrane and dissolve the active ingredient so it can be released through a passageway in the coating membrane or if the active ingredient is insoluble in the permeating fluid, pushed through the passageway by an expanding agent such as a hydrogel. Some representative examples of these osmotic tablet systems can be found in United States Patent Nos. 3,845,770, 3,916,899, 4,034,758, United States Patent No. 4,077,407 and 4,783,337. 3,952,741 teaches an osmotic device wherein the active agent is released from a core surrounded by a semipermeable membrane only after sufficient pressure has developed within the membrane to burst or rupture the membrane at a weak portion of the membrane.

The basic osmotic device described in the above cited patents have been refined over time in an effort to provide greater control of the release of the active ingredient. For example United States Patent Nos. 4,777,049 and 4,851,229 describe an osmotic dosage form comprising a

1

10

15

20

25

30

semipermeable wall surrounding a core. The core contains an active ingredient and a modulating agent wherein the modulating agent causes the active ingredient to be released through a passageway in the semipermeable membrane in a pulsed manner. Further refinements have included modifications to the semipermeable membrane surrounding the active core such as varying the proportions of the components that form the membrane, i.e United States Patent Nos. 5,178,867, 4,587,117 and 4,522,625 or increasing the number of coatings surrounding the active core, i.e 5,650,170 and 4,892,739.

Although vast amounts of research has been performed on controlled or sustained release compositions and in particular on osmotic dosage forms, very little research has been performed in the area of controlled or sustained release compositions that employ antihyperglycemic drugs.

The limited work on controlled or sustained release formulations that employ antihyperglycemic drugs such as metformin hydrochloride has been limited to the combination of the antihyperglycemic drug and an expanding or gelling agent to control the release of the drug from the dosage form. This limited research is exemplified by the teachings of WO 96/08243 and by the GLUCOPHAGE® product which is a commercially available product from Bristol-Myers Squibb Co. containing metformin HCl.

It is reported in the 50th Edition of the Physicians' Desk Reference, copyright 1996, p. 753, that food decreases the extent and slightly delays the absorption of metformin delivered by the GLUCOPHAGE® dosage form. This decrease is shown by approximately a 40% lower peak concentration and a 25% lower AUC in plasma and a 35 minute prolongation of time to peak plasma concentration following administration of a single GLUCOPHAGE® tablet containing 850 mg of metformin HCl with food compared to the similar tablet administered under fasting conditions.

It is an object of the present invention to provide a controlled or sustained release formulation for an

10

15

20

25

30

antihyperglycemic drug wherein the bioavailability of the drug is not decreased by the presence of food.

It is a further object of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that does not employ an expanding polymer.

It is also a further object of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that can provide continuous and non-pulsating therapeutic levels of an antihyperglycemic drug to an animal or human in need of such treatment over a twelve hour to twenty-four hour period.

It is an additional object of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that obtains peak plasma levels approximately 8-12 hours after administration.

It is also an object of this invention to provide a controlled or sustained release pharmaceutical tablet having only a homogeneous osmotic core wherein the osmotic core component may be made using ordinary tablet compression techniques.

#### SUMMARY OF THE INVENTION

10

15

20

30

The foregoing objectives are met by a controlled release dosage form comprising:

- (a) a core comprising:
  - (i) an antihyperglycemic drug;
  - (ii) optionally a binding agent; and
- (iii) optionally an absorption enhancer;
- (b) a semipermeable membrane coating surrounding the core; and
- (c) at least one passageway in the semipermeable membrane.

The dosage form of the present invention can provide therapeutic levels of the antihyperglycemic drug for twelve to twenty-four hour periods and does not exhibit a decrease in bioavailability if taken with food. In fact, a slight

3

increase in the bioavailability of the antihypoglycemic drug is observed when the controlled release dosage form of the present invention is administered with food. In a preferred embodiment, the dosage form will be administered once a day, ideally with or after a meal and most preferably with or after the evening meal, and provide therapeutic levels of the drug throughout the day with peak plasma levels being obtained between 8-12 hours after administration.

10

15

20

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a graph which depicts the dissolution profile in simulated intestinal fluid (pH 7.5 phosphate buffer) and simulated gastric fluid (SGF) of the formulation described in Example 1 as tested according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm.

FIG. 2 is a graph which depicts the dissolution profile in simulated intestinal fluid (pH 7.5 phosphate buffer) and simulated gastric fluid (SGF) of the formulation described in Example 2 as tested according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm.

FIG. 3 is a graph which depicts the dissolution profile in simulated intestinal fluid (pH 7.5 phosphate buffer) and simulated gastric fluid (SGF) of the formulation described in Example 3 as tested according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm.

FIG. 4 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 1 and the in vivo metformin plasma profile of the commercially available metformin HCl product GLUCOPHAGE® under fasting conditions.

FIG. 5 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 2 and the in vivo metformin plasma profile of the

4

commercially available metformin HCl product GLUCOPHAGE® under fasting conditions.

FIG. 6 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 2 and the in vivo metformin plasma profile of the commercially available metformin HCl product GLUCOPHAGE® under fed conditions.

FIG. 7 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 3 and the in vivo metformin plasma profile of the commercially available metformin HCl product GLUCOPHAGE® under fed conditions (after breakfast).

FIG. 8 is a graph depicting the in vivo metformin plasma profile of the formulation described in Example 3 and the in vivo metformin plasma profile of the commercially available metformin HCl product GLUCOPHAGE® under fed conditions (after dinner).

## DETAILED DESCRIPTION OF THE INVENTION

10

15

35

The term antihyperglycemic drugs as used in this specification refers to drugs that are useful in controlling or managing noninsulin-dependent diabetes mellitus (NIDDM). Preferably, the antihyperglycemic drug is a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride.

The binding agent may be any conventionally known pharmaceutically acceptable binder such as polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxyethyl cellulose, ethylcellulose, polymethacrylate, waxes and the like. Mixtures of the aforementioned binding agents may also be used. The preferred binding agents are water soluble such as polyvinyl pyrrolidone having a weight average molecular weight of 25,000 to 3,000,000. The binding agent comprises approximately about 0 to about 40% of the total weight of the core and preferably about 3% to about 15% of the total weight of the core.

5

The core may optionally comprise an absorption enhancer. The absorption enhancer can be any type of absorption enhancer commonly known in the art such as a fatty acid, a surfactant, a chelating agent, a bile salt or mixtures thereof. Examples of some preferred absorption enhancers are fatty acids such as capric acid, oleic acid and their monoglycerides, surfactants such as sodium lauryl sulfate, sodium taurocholate and polysorbate 80, chelating agents such as citric acid, phytic acid, ethylenediamine (EDTA) and qlycol-bis(ßtetraacetic acid ethylene aminoethyl ether) - N, N, N, N-tetraacetic acid (EGTA). core comprises approximately 0 to about 20% of the absorption enhancer based on the total weight of the core and most preferably about 2% to about 10% of the total weight of the core.

The core of the present invention which comprises the antihyperglycemic drug, the binder which preferably is a pharmaceutically acceptable water soluble polymer and the absorption enhancer is preferably formed by wet granulating the core ingredients and compressing the granules with the addition of a lubricant into a tablet on a rotary press. The core may also be formed by dry granulating the core ingredients and compressing the granules with the addition of a lubricant into tablets or by direct compression.

Other commonly known excipients may also be included into the core such as lubricants, pigments or dyes.

The homogeneous core is coated with a semipermeable membrane, preferably a modified polymeric membrane to form the controlled release tablet of the invention. The semipermeable membrane is permeable to the passage of an external fluid such as water and biological fluids and is impermeable to the passage of the antihyperglycemic drug in Materials that are useful in forming the the core. semipermeable membrane are cellulose esters, cellulose diesters, cellulose triesters, cellulose ethers, cellulose ester-ether, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose

6

#### SUBSTITUTE SHEET (RULE 26)

10

15

20

25

30

diacetate, cellulose triacetate, cellulose acetate propionate, and cellulose acetate butyrate. Other suitable polymers are described in United States Patent Nos. 3,845,770, 3,916,899, 4,008,719, 4,036,228 and 4,11210 which are incorporated herein by reference. The most preferred semipermeable membrane material is cellulose acetate comprising an acetyl content of 39.3 to 40.3%, commercially available from Eastman Fine Chemicals.

In an alternative embodiment, the semipermeable membrane can be formed from the above-described polymers and a flux enhancing agent. The flux enhancing agent increases the volume of fluid imbibed into the core to enable the dosage form to dispense substantially all of the antihyperglycemic drug through the passageway and/or the porous membrane. The flux enhancing agent can be a water soluble material or an enteric material. Some examples of the preferred materials that are useful as flux enhancers are sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycol (PEG), propylene glycol, hydroxypropyl cellulose, hydroxypropyl methycellulose, hydroxypropyl methycellulose phthalate, cellulose acetate phthalate, polyvinyl alcohols, methacrylic acid copolymers and mixtures thereof. The preferred flux enhancer is PEG 400.

The flux enhancer may also be a drug that is water soluble such as metformin or its pharmaceutically acceptable salts or a drug that is soluble under intestinal conditions. If the flux enhancer is a drug, the present dosage form has the added advantage of providing an immediate release of the drug which is selected as the flux enhancer.

The flux enhancing agent comprises approximately 0 to about 40% of the total weight of the coating, most preferably about 2% to about 20% of the total weight of the coating. The flux enhancing agent dissolves or leaches from the semipermeable membrane to form paths in the

7

10

15

20

25

30

PCT/US99/06024 WO 99/47125

semipermeable membrane for the fluid to enter the core and dissolve the active ingredient.

The semipermeable membrane may also be formed with commonly known excipients such a plasticizer. 5 commonly known plasticizers include adipate, azelate, enzoate, citrate, stearate, isoebucate, sebacate, triethyl citrate, tri-n-butyl citrate, acetyl tri-n-butyl citrate, citric acid esters, and those described in Encyclopedia of Polymer Science and Technology, Vol. 10 The preferred (1969), published by John Wiley & Sons. plasticizers are triacetin, acetylated monoglyceride, grape seed oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, dibutylsebacate, diethylmalonate, dioctylphthalate, triethylcitrate, tributylcitrate, glyceroltributyrate, and the like. Depending on the particular plasticizer, amounts of from 0 to about 25%, and preferably about 2% to about 15% of the plasticizer can be used based upon the total weight of the coating.

As used herein the term passageway includes an aperture, orifice, bore, hole, weaken area or an erodible element such as a gelatin plug that erodes to form an osmotic passageway for the release of the antihyperglycemic drug from the dosage form. A detailed description of the passageway can be found in United States Patents such as 3,845,770, 3,916,899, 4,034,758, 4,077,407, 4,783,337 and 5,071,607.

Generally, the membrane coating around the core will comprise from about 1% to about 5% and preferably about 2% to about 3% based on the total weight of the core and coating.

In an alternative embodiment, the dosage form of the present invention may also comprise an effective amount of the antihyperglycemic drug that is available for immediate The effective amount of antihyperglycemic drug release. for immediate release may be coated onto the semipermeable

8

#### SUBSTITUTE SHEET (RULE 26)

10

15

20

30

membrane of the dosage form or it may be incorporated into the semipermeable membrane.

In a preferred embodiment the dosage form will have the following composition:

5		Preferred	Most Preferred
10	CORE: drug binder absorption enhancer	50-98% 0-40% 0-20%	75-95% 3-15% 2-10%
15	coating: semipermeable polymer flux enhancer plasticizer	50-99% 0-40% 0-25%	75-95% 2-20% 2-15%

The dosage forms prepared according to the present invention should exhibit the following dissolution profile when tested in a USP type 2 apparatus at 75 rpms in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37°C:

		Preferred	Most Preferred
	Time (hours)		
	2	0-25%	0-15%
25	4	10-45%	20-40%
	8	30-90%	45-90%
	12	NTL 50%	NTL 60%
	16	NTL 60%	NTL 70%
	20	NTL 70%	NTL 80%
30			

NTL = NOT LESS THAN

In the preparation of the tablets of the invention, various conventional well known solvents may be used to prepare the granules and apply the external coating to the tablets of the invention. In addition, various diluents, excipients, lubricants, dyes, pigments, dispersants etc. which are disclosed in Remington's Pharmaceutical Sciences, 1995 Edition may be used to optimize the formulations of the invention.

40

20

# DESCRIPTION OF THE PREFERRED EMBODIMENTS EXAMPLE 1

9

A controlled release tablet containing 850 mg of metformin HCl and having the following formula is prepared as follows:

#### 5 I Core

metformin HCl	90.54%
povidone <sup>1</sup> , USP	4.38%
sodium tribasic phosphate	4.58%
magnesium stearate	0.5 %

10

15

25

<sup>1</sup>approximate molecular weight = 50,000; dynamic viscosity  $(10\%\text{w/v solution at } 20^{\circ}\text{C}) = 5.5-8.5 \text{ m Pa s.}$ 

#### (a) Granulation

The metformin HCl is delumped by passing it through a 40 mesh screen and collecting it in a clean, polyethylenelined container. The povidone, K-30, and sodium tribasic phosphate are dissolved in purified water. The delumped metformin HCl is then added to a top-spray fluidized bed granulator and granulated by spraying the binding solution of povidone and sodium tribasic phosphate under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with 15/32" round standard concave punches (plain lower punch, upper punch with an approximately 1 mm indentation pin).

## (c) Seal Coating (optional)

10

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear, in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spay rate of 10-15 ml/min. The core tablet is coated with the sealing solution until a theoretical coating level of approximately 2% is obtained.

	II <u>Sustained Release Coating</u>	
	cellulose acetate (398-10) <sup>2</sup>	85%
	triacetin	5%
.5	PEG 400	10%

<sup>&</sup>lt;sup>2</sup>acetyl content 39.3 - 40.3%

10

1

#### (d) Sustained Release Coating

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The clear coating solution is then sprayed onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately 3 bars; and spray rate of 120-150 ml/min. The sealed core tablet is coated until a theoretical coating level of approximately 3% is obtained.

The resulting tablet is tested in simulated intestinal fluid (pH 7.5) and simulated gastric fluid (SGF) according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm and found to have the following release profile:

35	TIME (hours)	% Released (SGF)	% Released (pH 7.5)
	2	9	12 、
	4	27	32
	8	62	82
	12	82	100

11

 16
 88

 20
 92

 108

The release profile in pH 7.5 and SGF of the sustained release product prepared in this Example is shown in Figure

Figure 4 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example. Also shown in Figure 4 is the in vivo metformin plasma profile of GLUCOPHAGE $^{\oplus}$ , a commercially available pharmaceutical product containing the drug metformin HCl.

#### EXAMPLE 2

A controlled release tablet containing 850 mg of metformin HCl and having the following formula is prepared 15 as follows:

#### I Core

5

10

metformin HCl	88.555%
povidone <sup>3</sup> , USP	6.368%
sodium lauryl sulfate	4.577%
magnesium stearate	0.5 %

approximate molecular weight = 1,000,000, dynamic viscosity
(10%w/v solution at 20°C) = 300-700 m Pa s.

#### (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90F, is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the coated granules are compressed on a rotary press fitted with 15/32" round standard concave punches (plain lower punch, upper punch with an approximately 1 mm indentation pin).

#### (c) Seal Coating (optional)

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spay rate of 10-15 ml/min. The core tablet is coated with the sealing solution until a theoretical coating level of approximately 2% is obtained.

35

10

15

20

25

II <u>Sustained Re</u>	<u>lease Coating</u>	
cellulose acetate	(398-10)4	85%
triacetin		5%
PEG 400		10%

5

20

4acetyl content 39.3 - 40.3%

#### (d) Sustained Release Coating

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The clear coating solution is then sprayed onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately 3 bars; and spray rate of 120-150 ml/min. The sealed core tablet is coated until a theoretical coating level of approximately 3% is obtained.

The resulting tablet is tested in simulated intestinal fluid (pH 7.5) and simulated gastric fluid (SGF) according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm and found to have the following release profile:

	TIME (hours)	<pre>% Released (SGF)</pre>	% Released (pH 7.5)
	2	13	12
25	4	29	27
	8	55	52
	12	72	71
	16	81	83
	20	87	91

The release profile in pH 7.5 and SGF of the sustained release product prepared in this Example is shown in Figure 2.

Figure 5 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example under fasting conditions. Figure 5 also shows the in vivo metformin plasma profile of the GLUCOPHAGE® product under fasting conditions.

Figure 6 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example

14

under fed conditions. Figure 6 also shows the in vivo metformin plasma profile of the GLUCOPHAGE® product under fed conditions.

Figures 5 and 6 clearly show that the dosage forms prepared in accordance with the present invention exhibit consistent bioavailability under both fed and fasting conditions while the GLUOPHAGE® product's bioavailability decreases in the presence of food.

#### 10 EXAMPLE 3

15

20

30

35

A controlled release tablet containing 850 mg of metformin HCl and having the same formula as in Example 2 is prepared as described in Example 2 except that an additional hole was drilled on the plain side of the coated tablet. The additional hole had a diameter of approximately 1 mm.

The resulting tablet is tested in simulated intestinal fluid (pH 7.5) and simulated gastric fluid (SGF) according to the procedure described in United States Pharmacopeia XXIII, Apparatus 2 @ 75 rpm and found to have the following release profile:

	TIME (hours)	<pre>% Released (SGF)</pre>	<pre>% Released (pH 7.5)</pre>
	2	13	14
	4	27	28
25	8	50	63
	12	67	84
	16	84	95
	20	97	102

The release profile in pH 7.5 and SGF of the sustained release product prepared in this Example is shown in Figure 3.

Figure 7 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example when administered shortly after breakfast. Figure 7 also shows the in vivo metformin plasma profile of the GLUCOPHAGE® product administered shortly after breakfast.

Figure 8 depicts the in vivo metformin plasma profile of the sustained release product prepared in this Example when administered shortly after dinner. Figure 8 also

shows the in vivo metformin plasma profile of the GLUCOPHAGE® product administered shortly after dinner.

Table 1 is a summary of the bioavailability comparision data, test/reference ratio, shown in Figures 4-8 wherein the GLUCOPHAGE® product is the reference product in a two way crossover biostudy with n = 6.

TA	$_{\mathtt{BL}}$	E	1

	<u>Formula</u>	<u>Figure</u>	Study	<u>AUC</u>	<u>Cmax</u>	<u>Tmax</u>
	Ex. 1	4	Fasting	0.202	0.12	2.15
10	Ex. 2	5	Fasting	0.369	0.214	1.73
	Ex. 2	6	Fed (bkft)	0.628	0.305	1.94
	Ex. 3	7	Fed (bkft)	0.797	0.528	1.82
	Ex. 3	8	Fed (dinner)	0.850	0.751	2.00

bkft = breakfast

20

The results reported in Table 1 and Figures 4-8 show that dosage forms prepared in accordance with the present invention exhibit an increase in the bioavailability of the antihyperglycemic drug in the presence of food, especially when taken with or shortly after the evening meal.

While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention.

We claim:

1. A controlled release pharmaceutical tablet comprising:

- (a) a core comprising:
  - (i) an antihyperglycemic drug;
  - (ii) optionally a binding agent; and
  - (iii) optionally an absorption enhancer; and
- (b) a semipermeable membrane coating covering said core;and
- 10 (c) at least one passageway in the semipermeable membrane.
  - 2. A controlled release pharmaceutical tablet as defined in claim 1 wherein the antihyperglycemic drug is a biguanide.

15

5

- 3. A controlled release pharmaceutical tablet as defined in claim 2 wherein the antihyperglycemic drug is metformin or a pharmaceutically acceptable salt thereof.
- 20 4. A controlled release pharmaceutical tablet as defined in claim 2 wherein the antihyperglycemic drug is buformin or a pharmaceutically acceptable salt thereof.
- A controlled release pharmaceutical tablet as defined
   in claim 1 wherein the binding agent is water soluble.
  - 6. A controlled release pharmaceutical tablet as defined in claim 1 wherein the water soluble binding agent is polyvinyl pyrrolidone, hydroxypropyl cellulose,
- 30 hydroxyethyl cellulose, waxes or mixtures thereof.
  - 7. A controlled release pharmaceutical tablet as defined in claim 6 wherein the water soluble binding agent is polyvinyl pyrrolidone.

35

8. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is selected from

the group consisting of fatty acids, surfactants, chelating agents, bile salts or mixtures thereof.

- 9. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is a fatty acid selected from the group consisting of capric acid, oleic acid or their monoglycerides.
- 10. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is a surfactant selected from the group consisting of sodium lauryl sulfate, sodium taurocholate and polysorbate 80.
- 11. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is a chelating agent selected from the group consisting of citric acid, phytic acid, ethylene diamine tetraacetic acid and ethylene glycol-bis(ß-aminoethyl ether)-N,N,N,N-tetraacetic acid.
- 20 12. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is a bile salt.
  - 13. A controlled release pharmaceutical tablet as defined in claim 1 wherein the absorption enhancer is sodium lauryl sulfate.
    - 14. A controlled release pharmaceutical tablet as defined in claim 1 wherein the semipermeable membrane around the core is a water insoluble cellulose derivative.

30

25

15. A controlled release pharmaceutical tablet as defined in claim 14 wherein the water insoluble cellulose derivative in the membrane around the core is cellulose acetate.

16. A controlled release pharmaceutical tablet as defined in claim 1 wherein semipermeable membrane comprises a flux enhancer.

- 17. A controlled release pharmaceutical tablet as defined in claim 16 wherein the flux enhancer is sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycol, propylene glycol, hydroxypropyl cellulose, hydroxypropyl methycellulose, hydroxypropyl methycellulose phthalate, cellulose acetate phthalate, polyvinyl alcohols, methacrylic acid copolymers or mixtures thereof.
- 18. A controlled release pharmaceutical tablet as defined in claim 17 wherein the flux enhancer is polyethylene glycol with an average molecular weight between 380 and 420.
- 19. A controlled release pharmaceutical tablet as defined20 in claim 1 wherein the semipermeable membrane comprises a plasticizer.
  - 20. A controlled release pharmaceutical tablet as defined in claim 19 wherein the plasticizer is triacetin.

25

- 21. A controlled release pharmaceutical tablet as defined in claim 1 wherein at least two passageways are formed in the semipermeable membrane.
- 30 22. A controlled release pharmaceutical tablet as defined in claim 1 wherein the peak plasma level is obtained 8-12 hours after administration.
- 23. A controlled release pharmaceutical tablet as defined in claim 1 further comprising an effective amount of the antihyperglycemic drug coated onto the semipermeable membrane or mixed into the semipermeable membrane to

19

provide an immediate release of an effective amount of the antihyperglycemic drug.

24. A controlled release pharmaceutical tablet as defined in claim 1 wherein the core comprises:

50-98% of the drug;

0-40% of the binding agent; and

0-20% of the absorption enhancer; and the coating comprises:

10 50-99% of the polymer;

0-40% of the flux enhancer; and

0-25% of the plasticizer.

25. A controlled release pharmaceutical tablet as defined
15 in claim 1 wherein the core comprises:

75-95% of the drug;

3-15% of the binding agent; and

2-10% of the absorption enhancer; and the coating comprises:

20 75-95% of the polymer;

2-20% of the flux enhancer; and

2-15% of the plasticizer.

26. A controlled release pharmaceutical tablet as defined in claim 1 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37°C:

after 2 hours 0-25% of the drug is released;

- 30 after 4 hours 10-45% of the drug is released;
  - after 8 hours 30-90% of the drug is released;

after 12 hours not less than 50% of the drug is released; after 16 hours not less than 60% of the drug is released;

and after 20 hours not less than 70% of the drug is

35 released.


27. A controlled release pharmaceutical tablet as defined in claim 1 that exhibits the following dissolution profile when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and

after 2 hours 0-15% of the drug is released; after 4 hours 20-40% of the drug is released; after 8 hours 45-90% of the drug is released; after 12 hours not less than 60% of the drug is released;


- 10 after 16 hours not less than 70% of the drug is released; and after 20 hours not less than 80% of the drug is released.
- 28. A controlled release pharmaceutical tablet as defined in claim 1 that is administered with or shortly after the evening meal.
  - 29. A controlled release antihyperglycemic tablet comprising:
- 20 (a) a core consisting essentially of:
  - (i) metformin or a pharmaceutically acceptable salt
    thereof;
    - (ii) a water soluble binding agent; and
    - (iii) an absorption enhancer; and
- 25 (b) a semipermeable membrane coating covering said core comprising:
  - (i) cellulose acetate;
  - (ii) a flux enhancer; and
  - (iii) a plasticizer; and
- 30 (c) at least one passageway in the semipermeable membrane.
  - 30. A controlled release pharmaceutical tablet as defined in claim 29 wherein the peak plasma level is obtained 8-12 hours after administration.

35


5 at 37°C:




SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)



→ ANDRX METFORMIN XL(P97444) --- GLUCOPHAGE (MAH82)


FIG. 4

5/6



--- ANDRX METFORMIN XL(P97450A) --- GLUCOPHAGE (MAH82)

FIG. 5




--- ANDRX METFORMIN XL(P97450A) --- GLUCOPHAGE (MAH82)

FIG. 6


SUBSTITUTE SHEET (RULE 26)

6/6



→ ANDRX METFORMIN XL(P97450A-D) --- GLUCOPHAGE (MAH82)

FIG. 7



→ ANDRX METFORMIN XL(P97450A-D) --- GLUCOPHAGE (MAH82)

FIG. 8

## SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/06024

	SSIFICATION OF SUBJECT MATTER A61K 9/20		
IIS CL	424/464	when the standard and IDC	
	o International Patent Classification (IPC) or to both a	auonai classification and IPC	
	DS SEARCHED ocumentation searched (classification system followed	by classification symbols)	
	424/464	. <b>0</b> , <b>0.0000</b>	
Documentat	ion searched other than minimum documentation to the	extent that such documents are include	ed in the fields searched
Electronic d	ata base consulted during the international search (na	me of data base and, where practicab	le, search terms used)
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where ap	propriate, of the relevant passages	Relevant to claim No.
Y,P	US 5,858,398 A (CHO) 12 JANUAR col. 3, lines 18-28; col. 11, lines 25-315, lines 10,63; col. 16, lines 1-19; colines 67; col. 20 lines 1-5.	15; col. 12, lines 13-29, col	
			<u> </u>
Furt	ner documents are listed in the continuation of Box C	. See patent family annex.	
1	social categories of cited documents: coment defining the general state of the art which is not considered	"I" later document published after the data and not in conflict with the a the principle or theory underlying	pplication but cited to understand
<b>1</b> 0	be of particular relevance riter document published on or after the international filing data	"X" document of particular relovance; considered novel or cannot be cons	the claimed invention cannot be
"L" du	comment which may throw doubts on priority claim(s) or which is	when the document is taken alone	
ei sp	and to establish the publication data of another estation or other estation content of the state	'Y' document of particular relevance; considered to involve an invent	ive step when the document is
	comment referring to an oral disclosure, use, exhibition or other eans	combined with one or more other to being obvious to a person skilled	such documents, such combination in the art
	ocument published prior to the international filing date but later than a priority data claimed	'&' document member of the same pa	tent femily
	actual completion of the international search	Date of mailing of the international	search report
21 APRIL 1999 24 JUN 1999			
Commission Box PCT	mailing address of the ISA/US oner of Patents and Trademarks on, D.C. 20231	Authorized officer THURMAN K. PAGE	For
	No. (703) 305-3230	Telephone No. (703) 308-1235	

Form PCT/ISA/210 (second sheet)(July 1992)+

### **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61K 31/353, 31/4439, 9/32, 9/52, 45/06, A61P 3/10		(11) International Publication Number:	WO 00/28989	
		(43) International Publication Date:	25 May 2000 (25.05.00)	
(21) International Application Number: PCT/E	P99/087	RE, Vincenzo [GB/GB]; Smith	Kline Beecham Pharmaceu-	

8 November 1999 (08.11.99)

(30) Priority Data:

(22) International Filing Date:

9824866.9	12 November 1998 (12.11.98)	GB
9824867.7	12 November 1998 (12.11.98)	GB
9824869.3	12 November 1998 (12.11.98)	GB
9912193.1	25 May 1999 (25.05.99)	GB
9912190.7	25 May 1999 (25.05.99)	GB
9912191.5	25 May 1999 (25.05.99)	GB
	• • •	

(71) Applicant (for all designated States except US): SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

#### (72) Inventors; and

(75) Inventors/Applicants (for US only): LEWIS, Karen [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). LILLIOTT, Nicola, Jayne [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). MACKENZIE, Donald, Colin [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

RE, Vincenzo [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(74) Agent: RUTTER, Keith; SmithKline Beecham Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN INSULIN SENSITISER AND ANOTHER ANTIDIABETIC AGENT

### (57) Abstract

A pharmaceutical composition, which composition comprises: an insulin sensitiser and another antidiabetic agent and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetes agent, and the use of such composition in medicine.

### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

٩L	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
LM.	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
<b>λ</b> Τ	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
λZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
3B	Barbados	GH	Ghana	MG	Madagascar	ŢJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	ſL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	LS	Iceland	MW	Malawi	US	United States of America
CA	Canada	rT.	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NB	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK ·	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN INSULIN SENSITISER AND ANOTHER ANTIDIABETIC AGENT

This invention relates to a novel composition, in particular to a modified release composition and its use in medicine, especially its use for the treatment of diabetes mellitus, preferably Type 2 diabetes, and conditions associated with diabetes mellitus.

Alpha glucosidase inhibitor antihyperglycaemic agents (or alpha glucosidase inhibitors) and biguanide antihyperglycaemic agents (or biguanides) are commonly used in the treatment of Type 2 diabetes. Acarbose, voglibose, emiglitate and miglitol are examples of alpha glucosidase inhibitors.1,1 - Dimethylbiguanidine (or metformin) is a particular example of a biguanide.

Insulin secretagogues are compounds that promote increased secretion of insulin by the pancreatic beta cells. The sulphonylureas are well known examples of insulin secretagogues. The sulphonylureas act as hypoglycaemic agents and are used in the treatment of Type 2 diabetes. Examples of sulphonylureas include glibenclamide (or glyburide), glipizide, gliclazide, glimepiride, tolazamide and tolbutamide.

European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and hypolipidaemic activity. One particular thiazolidinedione disclosed in EP 0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter 'Compound (I)'). WO94/05659 discloses certain salts of Compound (I) including the maleate salt at example 1 thereof.

Compound (I) is an example of a class of anti-hyperglycaemic agents known as 'insulin sensitisers'. In particular Compound (I) is a thiazolidinedione insulin sensitiser.

European Patent Applications, Publication Numbers: 0008203, 0139421, 0032128, 0428312, 0489663, 0155845, 0257781, 0208420, 0177353, 0319189, 0332331, 0332332, 0528734, 0508740; International Patent Application, Publication Numbers 92/18501, 93/02079, 93/22445 and United States Patent Numbers 5104888 and 5478852, also disclose certain thiazolidinedione insulin sensitisers.

Another series of compounds generally recognised as having insulin sensitiser activity are those typified by the compounds disclosed in International Patent Applications, Publication Numbers WO93/21166 and WO94/01420. These compounds are herein referred to as 'acyclic insulin sensitisers'. Other examples of acyclic insulin sensitisers are those disclosed in United States Patent Number 5232945 and International Patent Applications, Publication Numbers WO92/03425 and WO91/19702.

Examples of other insulin sensitisers are those disclosed in European Patent Application, Publication Number 0533933, Japanese Patent Application Publication Number 05271204 and United States Patent Number 5264451.

The above mentioned publications are incorporated herein by reference.

٤

5

10

15

20

25

30

35

-

It is now indicated that certain modified release pharmaceutical compositions allow administration of a single daily dose of Compound (I) and another antidiabetic agent, such as an alpha glucosidase inhibitor, a biguanide or an insulin secretagogue, to provide an advantageous delivery of drug for maintaining effective glycaemic control with no observed adverse side effects. Such modified release is therefore considered to be particularly useful for the delivery of insulin sensitisers in combination with other antidiabetic agents for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus.

Accordingly, the invention provides a pharmaceutical composition, suitable for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus in a mammal, such as a human, which composition comprises: an insulin sensitiser, such as Compound (I), and another antidiabetic agent, such as an alpha glucosidase inhibitor, a biguanide or an insulin secretagogue, and a pharmaceutically acceptable carrier therefor, wherein the composition is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetic agent.

In another aspect, the invention provides a modified release pharmaceutical composition, suitable for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus in a mammal, such as a human, which composition comprises: an insulin sensitiser, such as Compound (I), and another antidiabetic agent, such as an alpha glucosidase inhibitor, a biguanide or an insulin secretagogue, and a pharmaceutically acceptable carrier therefor, wherein the carrier is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetic agent

Suitably, the release of both the insulin sensitiser and the other antidiabetic agent is modified.

However, it is envisaged that the release of only the insulin sensitiser is modified. It is also envisaged that the release of only the other antidiabetic agent is modified. The remaining active agent would of course be subject to non-modified release.

Suitably, the modified release is delayed, pulsed or sustained release.

In one aspect the modified release is a delayed release.

Delayed release is conveniently obtained by use of a gastric resistant formulation such as an enteric formulation, such as a tablet coated with a gastric resistant polymer, for example Eudragit L100-55. Other gastric resistant polymers include methacrylates, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phtahlate, in particular, Aquateric, Sureteric, HPMCP-HP-55S.

The enteric coated tablet may be a single layer tablet, where the active agents are admixed prior to compression into tablet form, or a multi-layer tablet, such as a bi-or tri-layer tablet, wherein each active agent is present in a discrete layer within the compressed

5

10

15

20

25

30

tablet form. The discrete table layers can be arranged as required to provide modified or non-modified release of each active agent.

In a further aspect the modified release is a sustained release, for example providing effective release of active agents over a time period of up to 26 hours, typically in the range of 4 to 24 hours.

Sustained release is typically provided by use of a sustained release matrix, usually in tablet form, such as disintegrating, non-disintegrating or eroding matrices.

Sustained release is suitably obtained by use of a non disintegrating matrix tablet formulation, for example by incorporating Eudragit RS into the tablet. Alternative non disintegrating matrix tablet formulations are provided by incorporating methacrylates, cellulose acetates, hydroxypropyl methylcellulose phtahlate, in particular Eudragit L and RL, Carbopol 971P, HPMCP-HP-55S into the tablet.

Sustained release is further obtained by use of a disintegrating matrix tablet formulation, for example by incorporating methacrylates, methylcellulose, in particular Eudragit L, Methocel K4M into the tablet.

Sustained release can also be achieved by using a semi-permeable membrane coated tablet for example by applying methacrylates, ethylcellulose, cellulose acetate, in particular Eudragit RS, Surelease to the tablet.

Sustained release can also be achieved by using a multi layer tablet, where each active ingredient is formulated together or as a separate layer, for example as a matrix tablet, with the other layers providing further control for sustained release of either one or both active agents.

In yet a further aspect the modified release is a pulsed release, for example providing up to 4, for example 2, pulses of active agent per 24 hours.

One form of pulsed release is a combination of non-modified release of active agent and delayed release.

Suitable modified release includes controlled release. The composition of the invention also envisages a combination of pulsed, delayed and/or sustained release for each of the active agents, thereby enabling for example the release of the reagents at different times. For example, where the composition comprises an insulin sensitiser and a biguanide, such as metformin, the composition can be arranged to release the metformin overnight.

A suitable alpha glucosidase inhibitor is acarbose.

Other suitable alpha glucosidase inhibitors are emiglitate and miglitol. A further suitable alpha glucosidase inhibitor is voglibose.

Suitable biguanides include metformin, buformin or phenformin, especially metformin.

Suitable insulin secretagogues include sulphonylureas.

10

15

20

25

30

Suitable sulphonylureas include glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide. Further sulphonylureas include acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopyamide and glycylamide. Also included is the sulphonylurea glipentide.

Further suitable insulin secretagogues include repaglinide. An additional insulin secretagogue is nateglinide.

A preferred thiazolidinedione insulin sensitiser is Compound (I).

Other suitable thiazolidinedione insulin sensitisers include (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone).

A particular thiazolidinedione insulin sensitiser is 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone).

A particular thiazolidinedione insulin sensitiser is (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone).

Suitable dosages, preferably unit dosages, of the insulin sensitiser and the other antidiabetic agent, such as the alpha glucosidase inhibitor, a biguanide or insulin secretagogue, include the known permissible doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications.

The dosages of each particular active agent in any given composition can as required vary within a range of doses known to be required in respect of accepted dosage regimens for that compound. Dosages of each active agent can also be adapted as required to take into account advantageous effects of combining the agents as mentioned herein.

In one particular aspect, the composition comprises 2 to 12 mg of Compound (I). Suitably the composition comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound (I).

Particularly, the composition comprises 2 to 4, 4 to 8 or 8 to 12 mg of Compound (I).

Particularly, the composition comprises 2 to 4mg of Compound (I). Particularly, the composition comprises 4 to 8mg of Compound (I).

5

10

15

20

25

30

Particularly, the composition comprises 8 to 12 mg of Compound (I).

Preferably, the composition comprises 2 mg of Compound (I).

Preferably, the composition comprises 4 mg of Compound (I).

Preferably, the composition comprises 8 mg of Compound (I).

Suitable unit dosages of other insulin sensitisers include from 100 to 800mg of troglitazone such as 200, 400, 600 or 800mg or from 5 to 50mg, including 10 to 40mg, of pioglitazone, such as 20, 30 or 40 mg and also including 15, 30 and 45mg of pioglitazone.

As indicated above the unit doses of the additional antidiabetic agents including the alpha glucosidase inhibitor, the biguanide and the insulin secretagogue include those found in the reference texts mentioned herein and include the doses set out below.

For the alpha glucosidase inhibitor, a suitable amount of acarbose is in the range of from 25 to 600 mg, including 50 to 600 mg, for example 100mg or 200mg.

For the biguanide, a suitable dosage of metformin is between 100 to 3000mg, for example 250, 500mg, 850mg or 1000mg.

For the insulin secretagogue, a suitable amount of glibenclamide is in the range of from 2.5 to 20 mg, for example 10mg or 20mg; a suitable amount of glipizide is in the range of from 2.5 to 40 mg; a suitable amount of gliclazide is in the range of from 40 to 320 mg; a suitable amount of tolazamide is in the range of from 100 to 1000 mg; a suitable amount of tolbutamide is in the range of from 1000 to 3000 mg; a suitable amount of chlorpropamide is in the range of from 100 to 500 mg; and a suitable amount of gliquidone is in the range of from 15 to 180 mg. Also a suitable amount of glimepiride is 1 to 6mg and a suitable amount of glipentide is 2.5 to 20mg.

A suitable amount of repaglinide is in the range of from 0.5mg to 20mg, for example 16mg. Also a suitable amount of nateglinide is 90 to 360mg, for example 270mg.

The compounds mentioned herein, in particular the thiazolidinediones such as Compound (I), may exist in one of several tautomeric forms, all of which are encompassed by the invention as individual tautomeric forms or as mixtures thereof. The compounds mentioned herein may contain one or more chiral carbon atoms and hence can exist in two or more stereoisomeric forms, all of which are encompassed by the invention either as individual isomers or as mixtures of isomers, including racemates.

It will be understood that the insulin sensitiser, such as Compound (I) and the other antidiabetic agent are in a pharmaceutically acceptable form, including pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate to the relevant pharmaceutically active agent chosen. In certain instances herein the names used for the antidiabetic agent may relate to a particular pharmaceutical form of the relevant active agent: It will be understood that all

5

10

15

20

25

30

pharmaceutically acceptable forms of the active agents per se are encompassed by this invention.

Suitable pharmaceutically acceptable forms of the insulin sensitiser and other antidiabetic agent depend upon the particular agent used but included are known pharmaceutically acceptable forms of the particular agent chosen. Such derivatives are found or are referred to in standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) and the above mentioned publications. For example, a particular form of metformin is metformin hydrochloride, a particular form of repaglinide is a benzoic acid salt form and a particular form of tolbutamide is a sodium salt form.

Suitable pharmaceutically acceptable forms of Compound (I) include those described in EP 0306228 and WO94/05659, especially pharmaceutically acceptable salted or solvated forms. A preferred pharmaceutically acceptable salt form of Compound (I) is a maleate. A preferred pharmaceutically acceptable solvated form of Compound (I) is a hydrate. A preferred form of pioglitazone is as the hydrochloride salt.

The insulin sensitiser or the alpha glucosidase inhibitor antihyperglycaemic agent of choice is prepared according to known methods, such methods are found or are referred to in standard reference texts, such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or as described in the above mentioned publications.

Compound (I) or, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, may be prepared using known methods, for example those disclosed in EP 0306228 and WO94/05659. The disclosures of EP 0306228 and WO94/05659 are incorporated herein by reference.

When used herein the term 'conditions associated with diabetes' includes those conditions associated with the pre-diabetic state, conditions associated with diabetes mellitus itself and complications associated with diabetes mellitus.

When used herein the term 'conditions associated with the pre-diabetic state' includes conditions such as insulin resistance, including hereditary insulin resistance, impaired glucose tolerance and hyperinsulinaemia.

Conditions associated with diabetes mellitus itself include hyperglycaemia, insulin resistance, including acquired insulin resistance and obesity. Further conditions associated with diabetes mellitus itself include hypertension and cardiovascular disease, especially atherosclerosis and conditions associated with insulin resistance. Conditions

10

15

20

25

30

associated with insulin resistance include polycystic ovarian syndrome and steroid induced insulin resistance and gestational diabetes.

'Complications associated with diabetes mellitus' includes renal disease, especially renal disease associated with Type 2 diabetes, neuropathy and retinopathy.

Renal diseases associated with Type 2 diabetes include nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.

5

10

15

20

25

30

35

As used herein the term 'pharmaceutically acceptable' embraces both human and veterinary use: for example the term 'pharmaceutically acceptable' embraces a veterinarily acceptable compound.

For the avoidance of doubt, unless other wise stated, when reference is made herein to scalar amounts, including mg amounts, of the active compound such as Compound (I), in a pharmaceutically acceptable form, the scalar amount referred to is made in respect of the active compound *per se*: For example 2 mg of Compound (I) in the form of the maleate salt is that amount of maleate salt which provides 2 mg of Compound (I).

Diabetes mellitus is preferably Type 2 diabetes.

Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (Hb A1c). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Schweiz. med. Wschr. 101 (1971), 345 and 390 and Frank P., 'Monitoring the Diabetic Patent with Glycosolated Hemoglobin Measurements', Clinical Products 1988.

In a preferred aspect, the dosage level of each of the active agents when used in accordance with the treatment of the invention will be less than would have been required from a purely additive effect upon glycaemic control.

There is also an indication that the treatment of the invention will effect an improvement, relative to the non-modified release of the individual agents, in the levels of advanced glycosylation end products (AGEs), leptin and serum lipids including total cholesterol, HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof, in particular an improvement in serum lipids including total cholesterol, HDL-cholesterol including improvements in the ratios thereof.

Usually the compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration.

In a further aspect the invention also provides a process for preparing a pharmaceutical composition, suitably for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus in a mammal, such as a

human, which composition comprises an insulin sensitiser, such as Compound (I), and another antidiabetic agent, such as an alpha glucosidase inhibitor, a biguanide or an insulin secretagogue, and a pharmaceutically acceptable carrier therefor, which process comprises formulating the insulin sensitiser, the other antidiabetic agent and the pharmaceutically acceptable carrier so as to enable a modified release of at least one of the insulin sensitiser and the other antidiabetic agent.

In a further aspect, the invention provides a process for preparing a modified release pharmaceutical composition, suitably for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus in a mammal, such as a human, which composition comprises an insulin sensitiser, such as Compound (I) and another antidiabetic agent, such as an alpha glucosidase inhibitor, a biguanide or an insulin secretagogue and a pharmaceutically acceptable carrier therefor, which process comprises formulating the insulin sensitiser, the other antidiabetic agent and the pharmaceutically acceptable carrier so as to enable a modified release of at least one of the insulin sensitiser and the other antidiabetic agent.

The compositions are formulated to provide the modified release of active agents according to the appropriate methods required, for example those disclosed in Sustained and Controlled Release Drug Delivery Systems, Editor Joe R Robinson, Volume 7, published by Marcel Dekker under the title Drugs and the Pharmaceutical Sciences,

Controlled Drug Delivery, 2nd Edition' edited by Joe Robinson and Vince Lee, Marcel Dekker, 1987 and 'Drug Delivery to the Gastrointestinal Tract' Editors: J G Hardy, S S. Davis and C G Wilson also with reference to texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.),

Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) and Harry's Cosmeticology (Leonard Hill Books).

Preferably, the compositions are in unit dosage form. Unit dosage presentation forms for oral administration may be in tablet or capsule form and may as necessary contain conventional excipients such as binding agents, fillers, lubricants, glidants, disintegrants and wetting agents.

Examples of binding agents include acacia, alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, dextrates, dextrin, dextrose, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminium silicate, maltodextrin, methyl cellulose, polymethacrylates, polyvinylpyrrolidone, pregelatinised starch, sodium alginate, sorbitol, starch, syrup, tragacanth.

Examples of fillers include calcium carbonate, calcium phosphate, calcium sulphate, carboxymethylcellulose calcium, carboxymethylcellulose sodium, compressible

5

10

15

30

sugar, confectioner's sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, dibasic calcium phosphate, fructose, glyceryl palmitostearate, glycine, hydrogenated vegetable oil-type 1, kaolin, lactose, maize starch, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, microcrystalline cellulose, polymethacrylates, potassium chloride, powdered cellulose, pregelatinised starch, sodium chloride, sorbitol, starch, sucrose, sugar spheres, talc, tribasic calcium phosphate, xylitol.

Examples of lubricants include calcium stearate, glyceryl monostearate, glyceryl palmitostearate, magnesium stearate, microcrystalline cellulose, sodium benzoate, sodium chloride, sodium lauryl sulphate, stearic acid, sodium stearyl fumarate, talc, zinc stearate.

Examples of glidants include colloidal silicon dioxide, powdered cellulose, magnesium trisilicate, silicon dioxide, talc.

Examples of disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium, colloidal silicon dioxide, croscarmellose sodium, crospovidone, guar gum, magnesium aluminium silicate, microcrystalline cellulose, methyl cellulose, polyvinylpyrrolidone, polacrilin potassium, pregelatinised starch, sodium alginate, sodium lauryl sulphate, sodium starch glycollate.

An example of a pharmaceutically acceptable wetting agent is sodium lauryl sulphate.

As required the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.

No adverse toxicological effects are expected for the compositions of the invention in the above mentioned dosage ranges.

5

10

15

20

### **EXAMPLES COMPRISING AN INSULIN SENSITISER AND A BIGUANIDE**

### Example 1, Delayed Release Composition

Delayed release is achieved by coating single or bilayer tablets comprising 4mg or 8mg of Compound (I) as pure free base (pfb) and 500, preferably, or 1000 or 1500mg of metformin HCl with Eudragit L100-55, a gastric resistant polymer

10 The enteric coat consists of:

	%W/W
Eudragit L30 D-55 (30% aqueous dispersion)	76.8
Triethyl Citrate	7.7
Talc Alphafil 500	15.5

# Example 2, Sustained release by use of a semi-permeable membrane

The semi-permeable membrane consists of:

20

15

5

	%w/w
Eudragit RS30D (30% aqueous dispersion)	90
Triethyl Citrate	1
Talc	9

25

This membrane is applied to a single or bilayer tablets each comprising 4mg or 8mg of Compound (I) and 500, preferably, or 1000 or 1500mg of metformin HCl

### Example 3, Sustained Release by use of a non disintegrating matrix tablet

30

A matrix tablet is formed by tabletting the following mixture as:

(a) a single layer tablet:

		mg/ta	blet
35	Compound (I)	4	(pfb)
	Metformin HCl	500	
	Eudragit L100-55	150	
	Lactose monohydrate	50	
	Eudragit RS powder to	1000	

40

(b) a bilayer tablet to provide sustained release of Compound I and immediate (i.e non-modified) release of metformin HCl.

	Layer A	mg/tablet
45	Compound (I)	4 (pfb)

-10-

Eudragit L100-55 150 Lactose monohydrate 50 Eudragit RS powder to 500

5 <u>Layer B</u> mg/tablet

Metformin HCl 500 Polyvinyl pyrollidone 15 Magnesium stearate to 520

# 10 Example 4, Sustained Release by use of a Mixed Eudragit matrix tablet

A matrix tablet is formed by tabletting the following mixture as:

### (a) a single layer tablet:

15 mg/tablet
Compound (I) 4 (pfb)
Metformin HCl 500
Eudragit L100-55 74
Eudragit RS powder 18.5

20 Colloidal Silicon dioxide 2.6 Magnesium stearate 3.25

Lactose monohydrate to 650

## (b) a trilayer tablet:

25 Layer A mg/tablet
Compound (I) 4 (pfb)
Eudragit L100-55 74
Eudragit RS powder 18.5
Colloidal Silicon dioxide 0.6
30 Magnesium stearate 1.5

Magnesium stearate 1.5

Lactose monohydrate to 150

Layer B mg/tablet
Metformin HCl 250
35 Eudragit L100-55 74

Eudragit RS powder to 345

Layer C mg/tablet

Metformin HCl 250

40 Polyvinyl pyrrolidone 7.5

Magnesium stearate to 260

### Example 5, Sustained Release by use of a disintegrating matrix tablet

A matrix tablet is formed by tabletting the following mixture as a single layer tablet:

5 mg/tablet
Compound (I) 4 (pfb)
Metformin HCl 500
Eudragit L100-55 74
Methocel K4M 18.5
10 Colloidal Silicon dioxide 2.6
Magnesium stearate 3.25
Lactose monohydrate to 650

## 15 Example 6, Sustained Release by use of a Mixed Carbopol matrix tablet

A matrix tablet is formed by tabletting the following mixture as single or bilayer tablet:

	Ti matrix tablet is formed by tableting in	mg/tablet
	Compound (I)	4 (pfb)
20	Metformin HCl	500
	Anhydrous dibasic calcium phosphate	35.7
	Carbopol 971P	22.5
	Carbopol 974P	7.5
	Talc	0.75
25	Lactose monohydrate to	650

# Example 7, Delayed Release Composition

A capsule containing multiple pellet cores is formed using the following mixture:

30	•	mg/capsule
	Compound (I)	4 (pfb)
	Metformin HCl	500
	Microcrystalline cellulose to	650

Delayed release can be achieved by coating the pellet cores with Eudragit L100-55, a gastric resistant polymer as in example 1.

# EXAMPLES COMPRISING AN INSULIN SENSITISER AND AN INSULIN SECRETAGOGUE

## Example 1, Delayed Release Composition

Delayed release can be achieved by coating single or bilayer tablets comprising 4mg or 8mg of Compound (I) as pure free base (pfb) and 2.5, 10 or 20 mg of glibenclamide with Eudragit L100-55, a gastric resistant polymer

The enteric coat consists of:

%w/w
15 Eudragit L30 D-55 (30% aqueous dispersion) 76.8
Triethyl Citrate 7.7
Talc Alphafil 500 15.5

# Example 2, Sustained Release by use of a matrix tablet (single layer)

20

25

A matrix tablet is formed by tabletting the following mixture as a single layer tablet:

mg/tablet
Compound (I) 8 (pfb)
glibenclamide 10
Eudragit L100-55 150 .
Lactose monohydrate 50

Eudragit RS powder to 500

# 30 Example 3, Sustained Release and Non-modifie Release by use of a matrix tablet (bilayer)

A matrix tablet is formed by tabletting the following mixture as a bilayer tablet to provide sustained release of Compound I and immediate (i.e non-modified) release of glibenclamide:

35

40

45

Layer Amg/tabletCompound (I)8 (pfb)Eudragit L100-55150Lactose monohydrate50Eudragit RS powder to:500

Layer Bmg/tabletGlibenclamide10Polyvinylpyrrolidone12.5Sodium starch glycolate10

Lactose monhydrate to 250

# 5 Example 4, Sustained release by use of a semi-permeable membrane

The semi-permeable membrane consists of:

Eudragit RS30D (30% aqueous dispersion) 90
10 Triethyl Citrate 1
Talc 9

This membrane is applied to a single or multi layer tablet each comprising 4mg or 8mg Compound (I) (pfb) and 2.5, 10 (preferably) or 20mg Glibenclamide.

Example 5, Sustained Release by use of a Mixed Eudragit matrix tablet

A matrix tablet is formed by tabletting the following mixture as:

20 (a) a single layer tablet:

15

25

mg/tablet
Compound (I) 8 (pfb)
Glibenclamide 10
Eudragit L100-55 74
Eudragit RS powder 18.5
Colloidal Silicon dioxide 0.6
Magnesium stearate 1.5
Lactose monohydrate to 150

30 (b) a bilayer tablet:

Layer A mg/tablet
Compound (I) 8 (pfb)
Eudragit L100-55 74

35 Eudragit RS powder 18.5
Colloidal Silicon dioxide 0.6
Magnesium stearate 1.5
Lactose monohydrate to 150

40 <u>Layer B</u> mg/tablet

Glibenclamide 10 Eudragit L100-55 74 Eudragit RS powder 18.5

Colloidal Silicon dioxide 0.6 Magnesium stearate 1.5 Lactose monohydrate to 150

# 5 Example 6, Sustained Release by use of a Mixed Carbopol matrix tablet

A matrix tablet is formed by tabletting the following mixture as single or bilayer tablet:

		mg/table
	Compound (I)	8 (pfb)
10	Glibenclamide	10
	Anhydrous dibasic calcium phosphate	35.7
	Carbopol 971P	22.5
	Carbopol 974P	7.5
	Talc	0.75
15	Lactose monohydrate to	150

### Example 7, Delayed Release Composition

A capsule containing multiple pellet cores is formed using the following mixture:

20		mg/capsule
	Compound (I)	8 (pfb)
	Glibenclamide	10
	Microcrystalline cellulose	133.5
	Lactose monohydrate to	267

25

Delayed release can be achieved by coating the pellet cores with Eudragit L100-55, a gastric resistant polymer as in example 1.

30

# EXAMPLES COMPRISING AN INSULIN SENSITISER AND AN ALPHA GLUCOSIDASE INHIBITOR.

### 35 Example 1, Delayed Release Composition

Delayed release can be achieved by coating single or bilayer tablets comprising 4mg or 8mg of Compound (I) as pure free base (pfb) and 100mg acarbose with Eudragit L100-55, a gastric resistant polymer

40

The enteric coat consists of:

%w/w
 Eudragit L30 D-55 (30% aqueous dispersion)
 Triethyl Citrate
 Talc Alphafil 500
 %w/w
 76.8
 7.7
 15.5

5

### Example 2, Sustained Release by use of a matrix tablet

A matrix tablet is formed by tabletting the following mixture as:

10 (a) a single layer tablet:

mg/tablet
Compound (I) 8 (pfb)
Acarbose 100
Eudragit L100-55 150
Lactose monohydrate 50
Eudragit RS powder to 600

(b) a bilayer tablet to provide sustained release of Compound (I) and non modified (i.e immediate) release of acarbose :

20

25

15

Layer Amg/tabletCompound (I)8 (pfb)Eudragit L100-55150Lactose monohydrate50Eudragit RS powder to500

	Layer B	mg/tablet
	Acarbose	100
	Microcrystalline cellulose	134
30	Starch	12.5
	Colloidal silicon dioxide	1.25
	Magnesium stearate to	250

35

# Example 3, Sustained release by use of a semi-permeable membrane

The semi-permeable membrane consists of:

40 %w/w
Eudragit RS30D (30% aqueous dispersion) 90
Triethyl Citrate 1
Talc 9

This membrane is applied to a single or multi layer tablets each comprising 4mg or 8mg Compound (I) (pfb) and 100mg Acarbose

# Example 4, Sustained Release by use of a Mixed Eudragit matrix tablet

A matrix tablet is formed by tabletting the following mixture as:

## (a) a single layer tablet:

5

mg/tablet
10 Compound (I) 8 (pfb)
Acarbose 100
Eudragit L100-55 74

Eudragit L100-55 74
Eudragit RS powder 18.5
Colloidal Silicon dioxide 1

15 Magnesium stearate 2.5 Lactose monohydrate to 250

### (b) a bilayer tablet:

Layer A mg/tablet

20 Compound (I) 8 (pfb)

Eudragit L100-55 74

Eudragit RS powder 18.5

Colloidal Silicon dioxide 0.6

Magnesium stearate 1.5

25 Lactose monohydrate to 150

Layer B mg/tablet
Acarbose 100
Eudragit L100-55 74

30 Eudragit RS powder 18.5
Colloidal Silicon dioxide 0.6
Magnesium stearate 1.5
Lactose monohydrate to 250

### 35 Example 5, Sustained Release by use of a Disintegrating matrix tablet

A matrix tablet is formed by tabletting the following mixture as a single layer tablet:

mg/tablet

Compound (I) 8 (pfb)
40 Acarbose 100
Eudragit L100-55 74

Methocel K4M 18.5

Colloidal Silicon dioxide 1
Magnesium stearate 2.5
Lactose monohydrate to 250

5

## Example 6, Sustained Release by use of a Mixed Carbopol matrix tablet

A matrix tablet is formed by tabletting the following mixture as a single or bilayer tablet:

	, ,	mg/tablet
10	Compound (I)	8 (pfb)
	Acarbose	100
	Anhydrous dibasic calcium phosphate	35.7
	Carbopol 971P	22.5
	Carbopol 974P	7.5
15	Talc	0.75
	Lactose monohydrate to	250

# Example 7, Delayed Release Composition

A capsule containing multiple pellet cores is formed using the following mixture:

20	mg/capsule

Compound (I)	8 (pfb)
Acarbose	100
Microcrystalline cellulose	133.5
Lactose monohydrate to	267

25

Delayed release can be achieved by coating the pellet cores with Eudragit L100-55, a gastric resistant polymer as in example 1.

### Claims:

A pharmaceutical composition, which composition comprises: an insulin
 sensitiser and another antidiabetic agent and a pharmaceutically acceptable carrier
 therefor, wherein the composition is arranged to provide a modified release of at least one
 of the insulin sensitiser and the other antidiabetic agent.

- A modified release pharmaceutical composition, which composition comprises:
   an insulin sensitiser, such as Compound (I), and another antidiabetic agent and a pharmaceutically acceptable carrier therefor, wherein the carrier is arranged to provide a modified release of at least one of the insulin sensitiser and the other antidiabetes agent.
- 3. A composition according to claim 1 or claim 2, wherein the release of both the insulin sensitiser and the other antidiabetes agent is modified.
  - 4. A composition according to any one of claims 1 to 3, wherein the modified release is a delayed release.
- 20 5. A composition according to claim 4, wherein the composition is in the form of an enteric tablet formulation.
  - 6. A composition according to claim 5, wherein the enteric coated tablet is a single layer tablet.

25

- 7. A composition according to claim 7, wherein the enteric coated tablet is a multi-layer tablet.
- 8. A composition according to any one of claims 5 to 7, wherein the tablet is coated 30 with a gastric resistant polymer.
  - 9. A composition according to claim 8, wherein the gastric resistant polymer is selected from the list consisting of Eudragit L100-55, methacrylates, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phtahlate, in particular, Aquateric, Sureteric and HPMCP-HP-55S.
  - 10. A composition according to any one of claims 1 to 3, wherein the modified release is a sustained release.

11. A composition according to any one of claims 1 to 3, wherein the sustained release is provided by a sustained release matrix selected from disintegrating, non-disintegrating and eroding matrices.

5

13. A composition according to claim 11, wherein the non disintegrating matrix tablet formulation is provided by incorporating Eudragit RS, methacrylates, cellulose acetates, hydroxypropyl methylcellulose phthalate, Carbopol 971P or HPMCP-HP-55S into the matrix.

10

20

or a derivative thereof.

- 14. A composition according to claim 11, wherein the disintegrating matrix tablet formulation is provided by incorporating methacrylates, methylcellulose and Methocel K4M into the matrix.
- 15. A composition according to any one of claims 1 to 14, wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (pioglitazone) or (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2, 5, 7, 8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (troglitazone);
  - 16. A composition according to any one of claims 1 to 15, wherein the alpha glucosidase inhibitor is acarbose, emiglitate, miglitol or voglibose.
- 25 17. A composition according to any one of claims 1 to 15, wherein the biguanide is metformin, buformin or phenformin.
- 18. A composition according to any one of claims 1 to 15, wherein the insulin secretagogues is a sulphonylurea selected from glibenclamide, glipizide, gliclazide,
  30 glimepiride, tolazamide, tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopyamide and glycylamide, glipentide.
- 19. A composition according to any one of claims 1 to 15, wherein the insulin35 secretagogue is repaglinide or nateglinide.

## INTERNATIONAL SEARCH REPORT

I. national Application No PCT/EP 99/08704

	<del></del>			
A. CLASS IPC 7	SIFICATION OF SUBJECT MATTER A61K31/353 A61K31/4439 A61K9 A61P3/10	9/32 A61K9/52	A61K45/06	
According	to International Patent Classification (IPC) or to both national das	esification and IPC		
B. FIELDS	S SEARCHED			
IPC 7				
	ation searched other than minimum documentation to the extent to			
Electronic	data base consulted during the International search (name of dat	a base and, where practical, search t	.erms used)	
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT			
Category '	Citation of document, with indication, where appropriate, of the	e relevant passages	Relevant to claim No.	
X	EP 0 861 666 A (TAKEDA CHEMICAL LTD) 2 September 1998 (1998-09- page 10, line 3 - line 31 page 11 -page 12; examples 1,2	-02)	1-6, 8-11, 15-18	
v	page 8, line 39 - line 57 page 9, line 39 - line 55 claims 12,13,15,24,26			
X	WO 98 11884 A (KNOLL AG ;BAILEY JAMES (GB); JACKSON HELEN CHRIS 26 March 1998 (1998-03-26) page 4, line 20 -page 5, line 3 page 12, line 29 -page 13, line claims 21-25	STINE (GB)) 3	1-6, 8-11,15, 17,18	
	1	-/		
		•		
X Furth	her documents are listed in the continuation of box C.	χ Patent family members	are listed in annex.	
° Special cat	alegories of cited documents :	"T" later document published afte		
conside	ent defining the general state of the art which is not fered to be of particular relevance document but published on or after the international fate	or priority date and not in co- cited to understand the princ invention "X" document of particular releval	ordict with the application but ciple or theory underlying the ance; the claimed invention	
"L" documer which is citation	L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the			
other m	ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but nan the priority date claimed		one or more other such docu- ping obvious to a person skilled me patent family	
	actual completion of the international search	Date of mailing of the interna		
3	April 2000	07/04/2000	·	
Name and m	nailing address of the ISA  European Patent Office, P.B. 5818 Patentiaan 2  NL - 2280 HV Rijswijk	Authorized officer		
	Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Muller, S		

Form PCT/ISA/210 (second sheet) (July 1992)

# INTERNATIONAL SEARCH REPORT

I. lational Application No PCT/EP 99/08704

1-6,10, 15 1-6,10, 11 13,14 13,14 1-6,15, 17-19
1-6,10, 11 13,14 13,14
11 13,14 13,14 1-6,15,
1-6,15,

3

Form PCT/ISA/210 (continuation of second sheet) (July 1992)



Inventor One Given Name::

Family Name::

Postal Address Line One::

City:: State:: Country::

Postal or Zip Code::

Citizenship Country::

Inventor Two Given Name::

Family Name::

Postal Address Line One::

City:: State:: Country::

Postal or Zip Code::

Citizenship Country::

Inventor Three Given Name::

Family Name::

Postal Address Line One::

City:: State:: Country::

Postal or Zip Code::

Citizenship Country::

Inventor Four Given Name::

Family Name::

Postal Address Line One::

City:: State:: Country::

Postal or Zip Code::

Citizenship Country::

Chih-Ming

Chen

10680 SW 40th Manor

Davie Florida

**United States** 

33328

**United States** 

Xiu-Xiu

Cheng

3150 W. Rolling Hills Circle #506

Davie Florida

**United States** 

33328

**United States** 

Steve

Jan

512 NW 120 Drive

**Coral Springs** 

Florida

**United States** 

33071

**United States** 

Joseph

Chou

6232 Treywood Lane

Manassas Virginia

**United States** 

20112

**United States** 

## Correspondence Information

Correspondence Customer Number:: 23280

Telephone:: (212) 736-1940 Fax:: (212) 736-2427

Electronic Mail:: ddk@ddkpatent.com

**Application Information** 

Title Line One:: Methods For Treating Diabetes Via
Title Line Two:: Administration Of Controlled Release

Title Line Three:: Metformin

Total Drawings Sheets:: 8
Formal Drawings:: No
Application Type:: Utility
Docket Number:: 300.1012

Representative Information

Representative Customer Number:: 23280

**Assignee Information** 

Name:: Andrx Corporation
Postal Address Line One:: 4001 SW 47<sup>th</sup> Avenue

City:: Fort Lauderdale

State:: Florida

Country:: United States

Postal or Zip Code:: 33314

NO. 1886 P. 9

N

U. 1001) F. 3

Docket No.: 300.1012

APR 0 5 2001

DECLARATION AND POWER OF ATTORNEY

As a before patient inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original,	first and joint inventor	of the subject matter which	h is claimed and for which	h a patent is sought of	n the invention entitled:
METHODS FOR TREAT	ting diabetes via	ADMINISTRATION OF	F CONTROLLED REI	EASE METFORMI	V, the specification of
which					•

<u>x</u>	I hereby authorize and re New York 10018 to inse	3, 2000 as Application Serial No. Equest our amorney, Davidson, Dav It here in parentheses (Application date and application number of sale	ldson & Kappel, I.L.C. of 485 Seventh Avenue. 14 <sup>K</sup> F		k.
I hereby amendm	state that I have reviewed a tent referred to above.	and understand the contents of the a	bove identified specification, including the claims, as	amended by any	,
I acknow Code of	victige the duty to disclose a Faderal Regulations, §1.56	ıll information which is known to n	ne to be material to the parentability of this applicanten	as defined in T	ide 37,
inventor	's certificate listed below at	fits under Title 35, United States C ad have also identified below any fo action on which priority is claimed.	ode, §119 of any foreign and/or provisional application relign and/or provisional application for patent or inve	n(s) for patent onto or service to the contract of the contrac	or e having
PRIOR .	APPLICATION(S)			Priority	claimed
(Numbe	т)	(Country)	(Day/Month/Year Filed)	Yes	No
(Numbe	7)	(Country)	(Day/Month/Year Filed)	Yos	No
35, Unit	of the claims of this applicated States Code. §112, I ask	ion is not disclosed in the prior Un nowledge the duty to disclose mate	any United States application(s) listed below and, inso deed States application in the manner provided by the f dal information as defined in Title 37, Code of Federa national or PCT international filing date of this applica-	irst paragraph o	of Mile
(Applica	tion Serial Number)	(Filing Date)	(Status) (patented, pending, abanden	<del>cd</del> )	
(Applica	tion Serial Number)	(Filing Date)	(Smus) (patented, pending, abandon	ed)	
And The	rehvannoim Clifford M. Y	Nuddon Doolerskie N. 33 555	<b>7.1. 5.5.</b> 11. <b>5.1.</b> 1. 1. 1. 1. 1. 1. 1.		

And I hereby appoint Clifford M. Davidson. Registration No. 32,728, Leslye B. Davidson, Registration No. 38,854, Cary S. Kappel, Registration No. 36,561, William C. Gehris, Registration No. 38,156, Morey B. Wildes, Registration No. 36,968, Robert J. Paradiso, Registration No. 41,240. Erik R. Swanson, Registration No. 40,833, Scott L. Appelbaum, Registration No. 41,587, Cynthia R. Moore, Registration No. 46,086, David Knaslak, Registration No. 45,991, Salvatore J. Maiorino, Registration No. 42,830, my autorneys, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith; correspondence address: DAVIDSON, DAVIDSON & KAPPEL, LLC, 485 Seventh Avenue, 14th Floor, New York, New York 10018; Telephone: (212) 736-1940; Fax: (212) 736-2427.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may leopardize the validity of the application or any patent issued thereon.

Full name of sole or first Inventor Chih-Ming Chen	Full name of joint Inventor, if any Xiu Xiu Cheng
Inventor's signature S/14/01	Second Inventor's signature  Date 3/22/01
Residence (city) (years or country)	Residence (city) (state or country)
Citizenship (LN/TED STATES	Cirizenship UNITED STATES
Post Office Address:	Post Office Address:

02/15/01 08:	45 FAX 954 587 1054 OIP Pharm Ad	ministration	Ø 010
FEB. 14. 2001	MEN A. 31	NO. 1886 P	. 10
	ame of joint or, if any Steve Jan	Full name of John Inventor, if any Joseph Chou	
Third I	Inventor's signature 3/28/0	Pourth Inventor's signature	
Resider	nce (ciry) (state or country)	Residence (city) (state or country)	<u> </u>
Cirizen	nship UNITED STATES	Citizenship (IN/TED STATES	
Post O	Office Address:	Post Office Address:	

## **UNITED STATES PATENT & TRADEMARK OFFICE**



Application of:

Chih-Ming Chen, et al.

Serial No.:

09/705,625

Filed:

November 3, 2000

For:

Methods for Treating Diabetes Via Administration Of Controlled Release

Metformin

**BOX: MISSING PARTS** 

**Assistant Commissioner for Patents** 

Washington, D.C. 20231

April 2, 2001

### RESPONSE TO NOTICE TO FILE MISSING PARTS

Sir:

In response to the Notification of Missing Requirements dated February 2, 2001, a copy of which is enclosed, please find an executed Declaration/Power of Attorney form signed by the inventors, and a check in the amount of \$1092.00 covering the basic filing fee, additional claims fee, and surcharge.

If any additional fees are deemed to be due at this time, the Assistant Commissioner is authorized to charge payment of the same to Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

Robert J. Para


Reg. No. 41,240

Davidson, Davidson & Kappel, LLC 485 Seventh Avenue, 14th Floor New York, New York 10018 (212) 736-1940

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to "Assistant Commissioner for Patents, Washington, DC 20231" on April 2, 2001

DAVIDSON, DAVIDSON & KAPPEL, LLC

BY:



COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.usplo.gov

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/705,625

11/03/2000

Xiu Xiu Cheng

300.1012

23280 DAVIDSON, DAVIDSON & KAPPEL, LLC 485 SEVENTH AVENUE, 14TH FLOOR NEW YORK, NY 10018



Date Mailed: 02/02/2001

### NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

### FILED UNDER 37 CFR 1.53(b)

### Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
   Applicant must submit \$ 710 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$252.
  - \$252 for 14 total claims over 20.
- The oath or declaration is missing.

  A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 1092.

file://C:\APPS\PreExam\correspondence\2 B.xml

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

**FORM PTO-1083** 

ASSISTANT COMMISSIONER FOR F

Washington, DC 20231

In re application of: Chih-Ming Chen, et al.

Serial No.: 09/705,625 Filed: November 3, 2000

For: Methods For Treating Diabetes Via Administration Of Controlled Release Metformin

Sir:

[]

Transmitted herewith is a Response to Notice to File Missing Parts in the above-identified application.

Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.

Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.

IX No fee for additional claims is required.

A filing fee for additional claims calculated as shown below, is required:

	SMALL ENTITY	LARGE ENTITY
FOR: TREMAINING HIGHEST	RATE   FEE   OR	RATE   FEE
AFTER   PREVIOUSLY  PRESENT	•	
AMENDMENT PAID FOR   EXTRA		
TOTAL CLAIMS   * Minus** =   0	<u> x \$ 9 \$  </u>	x \$ 18 \$
INDEP. CLAIMS * Minus*** = 0	x \$ 40 \$	x \$ 80 \$
[ ] FIRST PRESENTATION OF MULTIPLE DEP. CLAIM]	<u> + \$135 \$                                    </u>	+ \$270 \$
	TOTAL: \$ <u>OR</u>	TOTAL: \$

[X] Also transmitted herewith are:

[ ] Petition for extension under 37 C.F.R. 1.136 (in duplicate)

[X] Other:

Copy of Notice to File Missing Parts of Nonprovisional Application

**Declaration and Power of Attorney** 

**Application Data Sheet** 

Check(s) in the amount of \$1092.00 is/are attached to cover: [X]

[X] Filing fee for additional claims under 37 C.F.R. 1.16

[ ] Petition fee for extension under 37 C.F.R. 1.136

[X] Other:

**Basic Filing Fee** 

Late Filing Fee Surcharge

- The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this [X] communication or credit any overpayment to Deposit Account No. 50-0552.
  - Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by [X] check submitted herewith.

Any patent application processing fees under 37 C.F.R. 1.17.

Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR

1.136.

Robert J. Paradiso, Reg. No. 41,240 DAVIDSON DAVIDSON & KAPPEL, LLC

485 Seventh Avenue, 14th Floor New York, New York 10018

Tel: (212) 736-1940 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to "Assistant Commissioner for Patents, Washington, D.C. 20231" on April 2, 2001.

ON, DAVIDSON & KAPPEL, LLC

AUROBINDO EX. 1006, 323

Docket No.: 300.1012 Date: April 2, 2001







### United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
www.uspto.gov

APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER

09/705,625

11/03/2000

Xiu Xiu Cheng

300.1012

23280 DAVIDSON, DAVIDSON & KAPPEL, LLC 485 SEVENTH AVENUE, 14TH FLOOR NEW YORK, NY 10018



Date Mailed: 02/02/2001

### NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

### FILED UNDER 37 CFR 1.53(b)

### Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.

  Applicant must submit \$ 710 to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).
- Total additional claim fee(s) for this application is \$252.
  - \$252 for 14 total claims over 20.
- The oath or declaration is missing.
   A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

• •	The	balance	due	by app	licant	is S	ն 1092
-----	-----	---------	-----	--------	--------	------	--------

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY

AUROBINDO EX. 1006, 324

### **UTILITY PATENT APPLICATION TRANSMITTAL** (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Subm 55

### **Box Patent Application**

Washington, D.C. 20231

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Transm inventio				filing under 35	U.S.	s.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an			
	METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE METFORMIN								
and inve	ente	d by:							
Xiu 2	Xìu Xiu CHENG, Chih-Ming CHEN, Steve JAN and Joseph CHOU								
If a CO	ITA	NUA	TION AP	PLICATION,	chec	ck appropriate box and supply the requisite information:			
□ <sub>□</sub> Co			ion 🗆	Divisional		Continuation-in-part (CIP) of prior application No.:			
Which									
☐ Co Which			ion 🗀	Divisional	Ц	Continuation-in-part (CIP) of prior application No.:			
C			ion 🗆	Divisional		Continuation-in-part (CIP) of prior application No.:			
- <b>.</b> ,,,,,			_						
	Enciosed are:								
2 m2 2 x2 1 x x2						Application Elements			
2.		Filin	g fee as	calculated and	l tran	nsmitted as described below			
2.	X	Spe	cification	having		pages and including the following:			
	a.	X	Descript	tive Title of the	: Inve	ention			
	b.		Cross R	eferences to l	Relat	ted Applications (if applicable)			
	C.		Stateme	ent Regarding	Fede	erally-sponsored Research/Development (if applicable)			
	d.		Referen	ce to Microficl	пе Ар	ppendix (if applicable)			
	e.	X	Backgro	ound of the Inv	entic	on			
	f.	X	Brief Su	mmary of the	Invei	ention			
	g.	X	Brief De	scription of the	e Dra	awings (if drawings filed)			
	h.	X	Detailed	I Description					
	i.	X	Claim(s)	) as Classified	Belo	ow			
	j.	X	Abstract	t of the Disclo	sure				

## UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission 55

	Application Elements (Continued)							
3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)	Drawing(s) (when necessary as prescribed by 35 USC 113)					
	a.	☐ Formal Number of Sheets						
	b.	✓ Informal Number of Sheets 8	,					
4.		Oath or Declaration						
	a.	☐ Newly executed (original or copy) ☐ Unexecuted						
	b.	☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application (37 CFR 1.63(d)))	tion only)					
	C.	☐ With Power of Attorney ☐ Without Power of Attorney						
	d.	☐ <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).						
see 37 C.F.R. 1.63(d)(2) and 1.33(b).  Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is so Box 4b, is considered as being part of the disclosure of the accompanying application a incorporated by reference therein.								
6.		omputer Program in Microfiche (Appendix)						
7.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)						
1,27	a.  Paper Copy  b.  Computer Readable Copy (identical to computer copy)							
1,20								
12.00	c.	☐ Statement Verifying Identical Paper and Computer Readable Copy						
	Accompanying Application Parts							
8.		Assignment Papers (cover sheet & document(s))						
9.		37 CFR 3.73(B) Statement (when there is an assignee)						
10.		English Translation Document (if applicable)						
11.		Information Disclosure Statement/PTO-1449						
12.		Preliminary Amendment						
13.	X	Acknowledgment postcard						
14.	X	Certificate of Mailing						
		☐ First Class ☑ Express Mail (Specify Label No.): EL 415 728 697 US						

## UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission 55

	Accompanying Application Parts (Continued)
15.	Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	Additional Enclosures (please identify below):
	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
	Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.
	Warning
	An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission 55

#### Fee Calculation and Transmittal

9 15 5. 10 16 7. 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1									
For	#Filed	#Allowed	#Extra		Rate	Fee			
Total Claims	34	- 20 =	14	x	\$18.00	\$252.00			
Indep. Claims	2	- 3 =	0	х	\$80.00	\$0.00			
Multiple Dependen	t Claims (check	if applicable)				\$0.00			
i suite i suite									
OTHER FEE (spec	cify purpose)					\$0.00			
100 100 100 100 100 100 100 100 100 100	\$962.00								
□ A check in the amount of to cover the filing fee is enclosed. □ The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed. □ Charge the amount of as filing fee. □ Credit any overpayment. □ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. □ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).									
Dated: November 3	3, 2000			g. No. 4	Paradise 1,240				

Page 4 of 4

23280

PATENT\_TRADEMARK OFFICE

cc:

### METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE METFORMIN

#### **Background of the Invention**

5

The present invention relates to controlled release unit dose formulations containing an antihyperglycemic drug. More specifically, the present invention relates to an oral dosage form comprising a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride or the metformin salts described in United States Patent Nos. 3,957,853 and 4,080,472 which are incorporated herein by reference.

10

In the prior art, many techniques have been used to provide controlled and extendedrelease pharmaceutical dosage forms in order to maintain therapeutic serum levels of medicaments and to minimize the effects of missed doses of drugs caused by a lack of patient compliance.

15

20

cor sur gas it c insa h

In the prior art are extended release tablets which have an osmotically active drug core surrounded by a semipermeable membrane. These tablets function by allowing a fluid such as gastric or intestinal fluid to permeate the coating membrane and dissolve the active ingredient so it can be released through a passageway in the coating membrane or if the active ingredient is insoluble in the permeating fluid, pushed through the passageway by an expanding agent such as a hydrogel. Some representative examples of these osmotic tablet systems can be found in United States Patent Nos. 3,845,770, 3,916,899, 4,034,758, 4,077,407 and 4,783,337. United States Patent No. 3,952,741 teaches an osmotic device wherein the active agent is released from a core surrounded by a semipermeable membrane only after sufficient pressure has developed

25

The basic osmotic device described in the above cited patents have been refined over time in an effort to provide greater control of the release of the active ingredient. For example United States Patent Nos. 4,777,049 and 4,851,229 describe an osmotic dosage form comprising a semipermeable wall surrounding a core. The core contains an active ingredient and a modulating agent wherein the modulating agent causes the active ingredient to be released through a passageway in the semipermeable membrane in a pulsed manner. Further refinements have

within the membrane to burst or rupture the membrane at a weak portion of the membrane.

included modifications to the semipermeable membrane surrounding the active core such as varying the proportions of the components that form the membrane; i.e., United States Patent Nos. 5,178,867, 4,587,117 and 4,522,625 or increasing the number of coatings surrounding the active core; i.e., U.S. Patent Nos. 5,650,170 and 4,892,739.

Although vast amounts of research has been performed on controlled or sustained release compositions and in particular on osmotic dosage forms, very little research has been performed in the area of controlled or sustained release compositions that employ antihyperglycemic drugs.

5

10

15

20

25

Metformin is an oral antihyperglycemic drug used in the management of non-insulin-dependent diabetes mellitus (NIDDM). It is not chemically or pharmacologically related to oral sulfonylureas. Metformin improves glucose tolerance in NIDDM patients by lowering both basal and postprandial plasma glucose. Metformin hydrochloride is currently marketed as GLUCOPHAGE® tablets by Bristol-Myers Squibb Co. Each GLUCOPHAGE® tablet contains 500, 850 or 1000 mg of metformin hydrochloride. There is no fixed dosage regimen for the management of hyperglycemia in diabetes mellitus with GLUCOPHAGE®. Dosage of GLUCOPHAGE® is individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended dose of 2550 mg per day.

Metformin has been widely prescribed for lowering blood glucose in patients with NIDDM. However, being a short acting drug, metformin requires twice-daily (b.i.d.) or three-times-a-day (t.i.d.) dosing. Adverse events associated with metformin use are often gastrointestinal in nature (e.g., anorexia, nausea, vomiting and occasionally diarrhea, etc.). These adverse events may be partially avoided by either reducing the initial and/or maintenance dose or using an extended-release dosage form. Another clear advantage of an extended release dosage form is a reduction in the frequency of administration. All of these findings suggest that an extended-release dosage form of metformin may improve the quality of therapy in patients with NIDDM and the safety profile relative to a conventional dosage form.

The limited work on controlled or sustained release formulations that employ antihyperglycemic drugs such as metformin hydrochloride includes the combination of the antihyperglycemic drug and an expanding or gelling agent to control the release of the drug from

the dosage form. This research is exemplified by the teachings of WO 96/08243 and by the GLUCOPHAGE® metformin HCl product.

It is reported in the 50<sup>th</sup> Edition of the Physicians' Desk Reference, copyright 1996, p. 753, that food decreases the extent and slightly delays the absorption of metformin delivered by the GLUCOPHAGE® dosage form. This decrease is shown by approximately a 40% lower peak concentration, a 25% lower bioavailability and a 35-minute prolongation of time to peak plasma concentration following administration of a single GLUCOPHAGE® tablet containing 850 mg of metformin HCl with food compared to the similar tablet administered under fasting conditions.

10

15

20

25

5

A controlled release metformin dosage form is also described in WO 99/47128. This reference describes a controlled release delivery system for metformin which includes an inner solid particulate phase formed of substantially uniform granules containing metformin and one or more hydrophilic polymers, one or more hydrophobic polymers and one or more hydrophobic materials, and an outer continuous phase in which the above granules are embedded and dispersed throughout. The outer continuous phase includes one or more hydrophobic polymers, one or more hydrophobic polymers and one or more hydrophobic materials.

Our own WO 99/47125 discloses controlled release metformin formulations providing a Tmax from 8 to 12 hours.

#### Objects and Summary of the Invention

It is an object of the present invention to provide a controlled or sustained release of an antihyperglycemic drug which provides effective control of blood glucose levels in humans.

It is a further object of the present invention to provide a method of treating human patients with non-insulin-dependent diabetes mellitus (NIDDM) on a once-a-day basis with an antihyperglycemic drug which provides effective control of blood glucose levels in humans.

It is a further object of the present invention to provide formulations for treating human patients with non-insulin-dependent diabetes mellitus (NIDDM) which provides advantages over

the state-of-the-art, and which may be administered on a once-a-day basis by itself or together with other antidiabetic agents, and methods thereof.

It is a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug wherein the bioavailability of the drug is not decreased by the presence of food.

It is a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug that does not employ an expanding polymer.

It is also a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug that can provide continuous and non-pulsating therapeutic levels of the drug to an animal or human in need of such treatment over a twelve hour to twenty-four hour period.

It is an additional object of other embodiments of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that obtains peak plasma levels from 5.5 to 7.5 hours after administration under various conditions. Alternatively, the time to peak plasma levels are from 6.0 to 7.0, from 5.5 to 7.0 or from 6.0 to 7.5.

It is also an object of this invention to provide a controlled or sustained release pharmaceutical formulation having a homogeneous core wherein the core component may be made using ordinary tablet compression techniques.

In accordance with the above-mentioned objects and others, the present invention provides a controlled release oral dosage form comprising an antihyperglycemic drug, preferably a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof) that is suitable for providing once-a-day administration of the drug, wherein the dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug from 5.5 to 7.5 hours after administration. The dosage form comprises the drug and a membrane. In certain preferred embodiments, the dosage form comprises a tablet.

In preferred embodiments, the controlled release oral dosage form of the present invention is a tablet comprising:

(a) a core comprising:

5

10

15

20

25

- (i) the antihyperglycemic drug;
- (ii) optionally a binding agent; and
- (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

When the drug is metformin or a pharmaceutically acceptable salt thereof and is administered on a once-a-day basis, the daily dose may vary, e.g., from about 500 mg to about 2500 mg. Such daily dose may be contained in one controlled-release dosage form of the invention, or may be contained in more than one such dosage form. For example, a controlledrelease metformin dosage form may be formulated to contain about 1000 mg of the drug, and two of said dosage form may be administered together to provide once-a-day metformin therapy. The daily dose of the drug (i.e. metformin or pharmaceutically acceptable salt thereof) may range from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient.

In certain preferred embodiments, the controlled release solid oral dosage form of the present invention provides a width at 50% of the height of a mean plasma concentration/time curve of the drug (e.g., of metformin) from about 4.5 to about 13 hours, more preferably from about 5.5 to about 10 hours, more preferably from about 6 to about 8 hours.

In certain embodiments, the controlled release oral dosage form of the present invention provides a mean maximum plasma concentration (C<sub>max</sub>) of the antihyperglycemic drug which is more than about seven times the mean plasma level of said drug at about 24 hours after administration. In preferred embodiments, the controlled release oral dosage form of the present invention provides a mean maximum plasma concentration (C<sub>max</sub>) of the drug which is from about 7 times to about 14 times the plasma level of the drug at about 24 hours after the administration, more preferably from about 8 times to about 12 times the plasma level of the drug at about 24 hours after administration.

In certain embodiments of the present invention, when the drug is metformin or a pharmaceutically acceptable salt thereof, the controlled release oral dosage form provides a mean

10

5

The state 15

M

20

maximum plasma concentration ( $C_{max}$ ) of the drug that is about 1500 ng/ml to about 3000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin, more preferably about 1700 ng/ml to about 2000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.

5

In certain embodiments of the present invention, when the drug is metformin or a pharmaceutically acceptable salt thereof, the controlled release dosage form provides a mean AUC<sub>0-24hr</sub> that is about 17200 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin; preferably about 17200 ng.hr/ml to about 26500 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin; more preferably about19800 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.

In certain embodiments of the invention, the administration of the antihyperglycemic

preferably at least 90% of the mean AUC<sub>0-24</sub> provided by administration of the reference standard

(GLUCOPHAGE) twice a day, wherein the daily dose of the reference standard is equal to the

once-a day dose of metformin administered in the controlled release oral dosage form of the

drug, e.g., at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from at least 80%,

10

15

20

The state of the s

present invention.

In certain embodiments of the present invention, the controlled release dosage form exhibits the following dissolution profiles of the antihyperglycemic drug (e.g., metformin) when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal gastric fluid (pH 7.5 phosphate buffer) at 37° C: 0-30% of the drug released after 2 hours; 10-45% of the drug released after 4 hours; 30-90% of the drug released after 8 hours; not less than 50% of the drug released after 12 hours; not less than 60% of the drug released after 16 hours; and not less than 70% of the drug released after 20 hours.

25

In certain preferred embodiments, the controlled release solid oral dosage form exhibits the following dissolution profiles when tested in USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal gastric fluid (pH 7.5 phosphate buffer) at 37° C: 0-25% of the drug (e.g., metformin or a pharmaceutically acceptable salt thereof) released after 2 hours; 20-40% of the

drug released after 4 hours; 45-90% of the drug released after 8 hours; not less than 60% of the drug released after 12 hours; not less than 70% of the drug released after 16 hours; and not less than 80% of the drug released after 20 hours.

5

10

15

20

25

ĽÑ.

With respect to embodiments of the present invention where the antihyperglycemic drug is metformin, it has been found that drugs such as metformin provide substantially linear pharmacokinetics up to a level of about 2 grams per day. Therefore, it is contemplated for purposes of the present invention that a given plasma level (e.g.,  $C_{max}$ ) of metformin per specified dose will be directly proportional to other doses of metformin. Such proportional doses and plasma levels are contemplated to be within the scope of the invention and to be within the scope of the appended claims.

The dosage form of the present invention can provide therapeutic levels of the antihyperglycemic drug for twelve to twenty-four hour periods and does not exhibit a decrease in bioavailability if taken with food. In fact, a slight increase in the bioavailability of the antihyperglycemic drug is observed when the controlled release dosage form of the present invention is administered with food. In a preferred embodiment, the dosage form can be administered once-a-day, ideally with or after a meal, preferably with or after the evening meal, and provides therapeutic levels of the drug throughout the day with peak plasma levels being obtained between 5.5 to 7.5 hours after administration.

The present invention is also directed to a method of lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis a dose of a drug comprising a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof), said drug being contained in at least one solid oral controlled release dosage form of the present invention. When the drug is metformin, the daily dose of the drug may be from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient.

The controlled release dosage form of the present invention provides a delayed  $T_{max}$ , as compared to the  $T_{max}$  provided by GLUCOPHAGE. The delayed  $T_{max}$  occurs from 5.5 to 7.5

hours after administration. If the drug (e.g., metformin) is administered at dinner time, the  $T_{max}$  would occur during the time when gluconeogenesis is usually at its highest (e.g., around 2 a.m.).

5

10

15

20

25

The present invention also includes a method of treating patients with NIDDM comprising orally administering to human patients on a once-a-day basis a dose of a drug comprising a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof), contained in at least one oral controlled release dosage form of the present invention. When the drug is metformin, the daily dose of the drug may be from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient. In certain embodiments, the method of treatment according to the present invention involves once-per-day metformin monotherapy as an adjunct to diet to lower blood glucose in patients with NIDDM whose hyperglycemia may not be satisfactorily managed on diet alone. In certain other embodiments, the once-a-day metformin therapy of the present invention may be used concomitantly with a sulfonylurea, e.g., when diet and monotherapy with a sulfonylurea alone do not result in adequate glycemic control. In certain other embodiments, the once-a-day metformin therapy of the present invention may be used concomitantly with a glitazone, e.g., when diet and monotherapy with a glitazone, e.g., when diet and monotherapy with a glitazone alone do not result in adequate glycemic control.

The present invention is further directed to a method of controlling the serum glucose concentration in human patients with NIDDM, comprising administering to patients having NIDDM on a once-a-day basis, preferably at dinner time, an effective dose of a biguanide (e.g., metformin) contained in at least one oral controlled release dosage form of the present invention.

The present invention further includes a controlled-release dosage form of a drug comprising a biguanide (e.g., metformin) suitable for once-a-day administration to human patients with NIDDM, the dosage form comprising an effective amount of the drug to control blood glucose levels for up to about 24 hours and an effective amount of a controlled-release carrier to provide controlled release of the drug with a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug from 5.5 to 7.5 hours after administration and a width at 50% of

20

25

10

the height of a mean plasma concentration/time curve of the drug from about 6 to about 13 hours. In preferred embodiments, the administration of the controlled-release dosage form occurs at fed state, more preferably at dinner time.

In certain preferred embodiments, the controlled-release dose of the drug (e.g., metformin or a pharmaceutically acceptable salt thereof) according to the present invention is provided by one or more of a controlled-release tablet comprising

- (a) a core comprising:
  - (i) the antihyperglycemic drug (e.g., metformin or a pharmaceutically acceptable salt thereof);
  - (ii) optionally a binding agent; and
  - (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

In certain preferred embodiments, the mean time to maximum plasma concentration of the drug is reached from 6.5 to 7.5 hours after administration at dinner time.

In certain embodiments of the invention when the drug is a biguanide (e.g. metformin or a pharmaceutically acceptable salt thereof), the controlled release dosage form provides upon single administration, a higher mean fluctuation index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later, preferably maintaining bioavailability from at least 80% preferably from at least 90% of the immediate release composition.

In certain embodiments of the present invention, the mean fluctuation index of the dosage form is from about 1 to about 4, preferably about 2 to about 3, more preferably about 2.5.

In certain embodiments of the invention which exhibit a higher mean fluctuation index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, the ratio of the mean fluctuation index between the dosage form and the immediate release composition is about 3:1, preferably about 2:1, more preferably 1.5:1.

5

10

25

20

When the drug is metformin or a pharmaceutically acceptable salt thereof, the doses of drug which exhibit the above disclosed mean fluctuation indexes can be any effective dose administered to a patient with NIDDM for the reduction of serum glucose levels. For example, the dose can from about 500mg to about 2500mg, from about 1000mg to about 2000 mg or from about 850mg to about 1700mg metformin or pharmaceutically acceptable salt thereof.

The drugs which may used in conjunction with the present invention include those drugs which are useful for the treatment of non-insulin-dependent diabetes mellitus (NIDDM), including but not limited to biguinides such as metformin or buformin or pharmaceutically acceptable salts thereof. When the drug used in the present invention is metformin, it is preferred that the metformin be present in a salt form, preferably as metformin hydrochloride.

The term "metformin" as it is used herein means metformin base or any pharmaceutically acceptable salt e.g., metformin hydrochloride.

The term "dosage form" as it is used herein means at least one unit dosage form of the present invention (e.g. the daily dose of the antihyperglycemic agent can be contained in 2 unit dosage forms of the present invention for single once-a-day administration).

The term "morning" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered early in the day after the patient has awakened from overnight sleep, generally between about 6 a.m. and 11 a.m. (regardless of whether breakfast is eaten at that time, unless so specified herein).

The term "dinnertime" or "at dinner" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered at a time when dinner is normally eaten (regardless of whether a meal is actually eaten at that time, unless so specified herein), generally between about 4 p.m. and 8 p.m.

The term "bedtime" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered before the patient goes to bed in the evening, generally between about 8 p.m. and 12 p.m.

The term "therapeutically effective reduction" when used herein is meant to signify that blood glucose levels are reduced by approximately the same amount as an immediate release reference standard (e.g., GLUCOPHAGE®) or more, when the controlled release dosage form is orally administered to a human patient on a once-a-day basis.

5

10

15

LF

20

25

The term "sustained release" and "controlled release" are used interchangeably in this application and are defined for purposes of the present invention as the release of the drug from the dosage form at such a rate that when a once-a-day dose of the drug is administered in the sustained release or controlled-release form, blood (e.g., plasma) concentrations (levels) of the drug are maintained within the therapeutic range but below toxic levels over a period of time from about 12 to about 24 hours. When the drug used in the present invention is metformin (preferably metformin hydrochloride) the controlled release solid oral dosage form containing such drug is also referred to as "Metformin XT."

The term " $C_{max}$ " is the highest plasma concentration of the drug attained within the dosing interval, i.e., about 24 hours.

The term  ${}^{"}C_{min}$   ${}^{"}$  is the minimum plasma concentration of the drug attained within the dosing interval, i.e. about 24 hours.

The term "Cavg" as used herein, means the plasma concentration of the drug within the dosing interval, i.e. about 24-hours, and is calculated as AUC/dosing interval.

The term " $T_{max}$ " is the time period which elapses after administration of the dosage form at which the plasma concentration of the drug attains the highest plasma concentration of drug attained within the dosing interval (i.e., about 24 hours).

The term "AUC" as used herein, means area under the plasma concentration-time curve, as calculated by the trapezoidal rule over the complete 24-hour interval.

The term "steady state" means that the blood plasma concentration curve for a given drug does not substantially fluctuate after repeated doses to dose of the formulation.

The term "single dose" means that the human patient has received a single dose of the drug formulation and the drug plasma concentration has not achieved steady state.

The term "multiple dose" means that the human patient has received at least two doses of the drug formulation in accordance with the dosing interval for that formulation (e.g., on a once-a-day basis). Patients who have received multiple doses of the controlled release formulations of the invention may or may not have attained steady state drug plasma levels, as the term multiple dose is defined herein.

The term "a patient" means that the discussion (or claim) is directed to the pharmacokinetic parameters of an individual patient and/or the mean pharmacokinetic values obtained from a population of patients, unless further specified.

The term "mean", when preceding a pharmacokinetic value (e.g. mean  $T_{max}$ ) represents the arithmetic mean value of the pharmacokinetic value taken from a population of patients unless otherwise specified (e.g. geometric mean)..

The term "Degree of Fluctuation" is expressed as (C<sub>max</sub> -C<sub>min</sub>)/C<sub>avg</sub>.

#### **Brief Description of the Drawings**

- FIG. 1 is a graph showing the relative bioavailability of the metformin XT formulation of Example 2 to GLUCOPHAGE® for Clinical Study 2.
- FIG. 2 is a graph showing the relative bioavailability of the metformin XT formulation of Example 1 (500 mg) to GLUCOPHAGE® for Clinical Study 3.
- FIG. 3 is a graph showing the difference in plasma concentration-time profiles of metformin in eight healthy volunteers between Day 1 and Day 14 dosing following oral administration of the metformin XT formulation of Example 1, 4 x 500 mg q.d. for 14 days for Clinical Study 4.
- FIG. 4 is a graph showing the mean plasma profiles and values of pharmacokinetic parameters of the metformin XT formulation of Example 3 for Clinical Study 5.
- FIG. 5 is a graph showing the mean plasma glucose concentration-time profiles after 4 weeks of treatment with the metformin XT formulation of Example 3 and GLUCOPHAGE® for Clinical Study 5.

20

5

10

i ji

15

12th

FIG. 6 is a graph showing the dissolution profile of a 500 mg controlled release metformin formulation of Example 1 of the present invention.

FIG. 7 is a graph showing the dissolution profile of a 850 mg controlled release metformin formulation of Example 2 of the present invention.

FIG. 8 is a graph showing the dissolution profile of a 1000 mg controlled release metformin formulation of Example 3 of the present invention.

#### **Detailed Description of the Invention**

The term antihyperglycemic drugs as used in this specification refers to drugs that are useful in controlling or managing noninsulin-dependent diabetes mellitus (NIDDM). Preferably, the antihyperglycemic drug is a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride.

It has surprisingly been found that when biguanides such as metformin are administered orally in a controlled release dosage form suitable for once-a-day dosing in the "fed" state, preferably at dinner, the bioavailability is improved as compared to the administration of the controlled release dosage form in the "fasted" state. This is in contrast to GLUCOPHAGE®, which exhibits opposite characteristics. In accordance with the methods and dosage forms of the present invention, it has been determined that the patients suffering from NIDDM achieve improved results (e.g., lowered blood glucose levels) than GLUCOPHAGE® administered according to accepted protocols, e.g., on a twice-a-day basis.

The methods and dosage forms of the invention provide the further advantage in that when dosed at dinnertime, the controlled release formulations of the invention provide a  $T_{max}$  (from 5.5 to 7.5 hours) after oral administration (which  $T_{max}$  is delayed relative to the reference standard, GLUCOPHAGE®), such that the level of drug is greatest at the time when human patients are manufacturing glucose at highest levels. Gluconeogenesis is well known to those skilled in the art to be greatest at night. Thus, in accordance with the invention, the  $T_{max}$  of the drug occurs for example between 11:30 p.m. and 1:30a.m., based on a dose administered at 6:00 p.m. Likewise, such administration of the dosage form provides lower drug levels during the day

25

20

5

10

15

(e.g. the afternoon) when gluconeogenesis is lower than at night. Also, the invention preferably provides the added benefit of lowering insulin levels. Insulin is considered a risk factor in NIDDM, in and of itself, for cardiovascular disease.

In comparison to a twice-daily dose of the reference standard (GLUCOPHAGE®), the plasma levels of metformin are preferably lower in the afternoon. This is an advantage particularly in patients who are under concomitant therapy with one or more additional antidiabetic agents, such as for example, a sulfonylurea. It is known in the art that to date approximately 60% of patients being treated with metformin are also being treated with at least one additional antidiabetic agent (such as a sulfonylurea). Sulfonylureas can possibly cause hypoglycemia, whereas metformin cannot, so there is a benefit to having lower metformin levels in the blood during the afternoon due to the potential for the patient to have hypoglycemia.

Accordingly, the present invention also includes a method of treating human patients with NIDDM comprising administering on a once-a-day basis a therapeutically effective dose of metformin in a controlled-release oral dosage form ("Metformin XT"), in combination with administering an effective amount of a sulfonylurea. In preferred embodiments, metformin is provided by a controlled release dosage form comprising metformin or a pharmaceutically acceptable salt thereof, the dosage form being useful for providing a once-a-day oral administration of the drug, wherein the dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin from 5.5 to 7.5 hours after administration.

In certain embodiments, the combination therapy may be provided as follows. If patients do not respond to four weeks of the maximum dose of Metformin XT (2500 mg/day) monotherapy, a sulfonylurea may be gradually added while maintaining the maximum dose of Metformin XT, even if prior primary or secondary failure to a sulfonylurea has occurred. Examples of the sulfonylurea include glyburide (glibenclamid), chloropropamide, tolbutamide, glipizide, acetohexamide and tolazamide. Although Metformin XT is preferably administered on once-a-day basis, the sulfonylurea may be administered in a different dosage form and at a different frequency.

10

5

Action and the part of the state of the stat 15

20

With concomitant Metformin XT and sulfonylurea therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug.

In certain embodiments, the foregoing objectives are met by a controlled release dosage form comprising:

- (a) a core comprising:
  - (i) an antihyperglycemic drug;
  - (ii) optionally a binding agent; and
  - (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

The binding agent may be any conventionally known pharmaceutically acceptable binder such as polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxyethyl cellulose, ethylcellulose, polymethacrylate, waxes and the like. Mixtures of the aforementioned binding agents may also be used. The preferred binding agents are water soluble such as polyvinyl pyrrolidone having a weight average molecular weight of 25,000 to 3,000,000. The binding agent comprises approximately about 0 to about 40% of the total weight of the core and preferably about 3% to about 15% of the total weight of the core.

The core may optionally comprise an absorption enhancer. The absorption enhancer can be any type of absorption enhancer commonly known in the art such as a fatty acid, a surfactant, a chelating agent, a bile salt or mixtures thereof. Examples of some preferred absorption enhancers are fatty acids such as capric acid, oleic acid and their monoglycerides, surfactants such as sodium lauryl sulfate, sodium taurocholate and polysorbate 80, chelating agents such as citric acid, phytic acid, ethylenediamine tetraacetic acid (EDTA) and ethylene glycol-big (B-aminoethyl ether -N,N,N,N-tetraacetic acid (EGTA). The core comprises approximately 0 to about 20% of the absorption enhancer based on the total weight of the core and most preferably about 2% to about 10% of the total weight of the core.

In this embodiment, the core which comprises the antihyperglycemic drug, the binder which preferably is a pharmaceutically acceptable water soluble polymer and the absorption

5

15

25

20

enhancer is preferably formed by wet granulating the core ingredients and compressing the granules with the addition of a lubricant into a tablet on a rotary press. The core may also be formed by dry granulating the core ingredients and compressing the granules with the addition of a lubricant into tablets or by direct compression.

Other commonly known excipients may also be included into the core such as lubricants, pigments or dyes.

The homogeneous core is coated with a membrane, preferably a polymeric membrane to form the controlled release tablet of the invention. The membrane can be a semipermeable membrane by being permeable to the passage of external fluid such as water and biological fluids and being impermeable to the passage of the antihyperglycemic drug in the core. Materials that are useful in forming the membrane are cellulose esters, cellulose diesters, cellulose triesters, cellulose ethers, cellulose ester-ether, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate propionate, and cellulose acetate butyrate. Other suitable polymers are described in United States Patent Nos. 3,845,770, 3,916,899, 4,008,719, 4,036,228 and 4,11210 which are incorporated herein by reference. The most preferred membrane material is cellulose acetate comprising an acetyl content of 39.3 to 40.3%, commercially available from Eastman Fine Chemicals.

In an alternative embodiment, the membrane can be formed from the above-described polymers and a flux enhancing agent. The flux enhancing agent increases the volume of fluid imbibed into the core to enable the dosage form to dispense substantially all of the antihyperglycemic drug through the passageway and/or the porous membrane. The flux enhancing agent can be a water soluble material or an enteric material. Some examples of the preferred materials that are useful as flux enhancers are sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycol (PEG), propylene glycol, hydroxypropyl cellulose, hydroxypropyl methycellulose, hydroxyprophy methycellulose phthalate, cellulose acetate phthalate, polyvinyl alcohols, methacrylic acid copolymers and mixtures thereof. The preferred flux enhancer is PEG 400.

The flux enhancer may also be a drug that is water soluble such as metformin or its pharmaceutically acceptable salts or a drug that is soluble under intestinal conditions. If the flux enhancer is a drug, the present dosage form has the added advantage of providing an immediate release of the drug which is selected as the flux enhancer.

5

The flux enhancing agent comprises approximately 0 to about 40% of the total weight of the coating, most preferably about 2% to about 20% of the total weight of the coating. The flux enhancing agent dissolves or leaches from the membrane to form paths in the membrane for the fluid to enter the core and dissolve the active ingredient.

10

15

20

25

In alternate embodiments, the membrane may also be formed with commonly known excipients such as a plasticizer. Some commonly known plasticizers include adipate, azelate, enzoate, citrate, stearate, isoebucate, sebacate, triethyl citrate, tri-n-butyl citrate, acetyl tri-n-butyl citrate, citric acid esters, and those described in the Encyclopedia of Polymer Science and Technology, Vol. 10 (1969), published by John Wiley & Sons. The preferred plasticizers are triacetin, acetylated monoglyceride, grape seed oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, glyceroltributyrate, and the like. Depending on the particular plasticizer, amounts of from 0 to about 25%, and preferably about 2% to about 15% of the plasticizer can be used based upon the total weight of the coating.

As used herein the term passageway includes an aperture, orifice, bore, hole, weakened area or an erodible element such as a gelatin plug that erodes to form an osmotic passageway for the release of the antihyperglycemic drug from the dosage form. A detailed description of the passageway can be found in United States Patent Nos. such as 3,845,770, 3,916,899, 4,034,758, 4,063,064, 4,077,407, 4,088,864, 4,783,337 and 5,071,607 (the disclosures of which are hereby incorporated by reference).

In certain embodiments, the passageway is formed by laser drilling. In other embodiments, the passageway is formed by making an indentation onto the core prior to the membrane coating to form a weakened area of the membrane at the point of the indentation. In preferred embodiments of the invention, the dosage form contains two passageways in order provide the desired pharmacokinetic parameters of the formulation.

5

10

15

20

25

Generally, the membrane coating around the core will comprise from about 1% to about 7%, preferably about 1.5% to about 3%, based on the total weight of the core and coating.

The term "membrane" means a membrane that is permeable to both aqueous solutions or bodily fluids and to the active drug or pharmaceutical ingredient (e.g. the formulations of Examples 1-3). Thus, the membrane is porous to drug and, in a preferred embodiment, drug is released through the hole or passageway and through the porous membrane in solution or in vivo. The term "membrane" also generically encompasses the term "semipermeable membrane" as heretofore defined.

In an alternative embodiment, the dosage form of the present invention may also comprise an effective amount of the antihyperglycemic drug that is available for immediate release. The effective amount of antihyperglycemic drug for immediate release may be coated onto the membrane of the dosage form or it may be incorporated into the membrane.

In certain preferred embodiments of the invention where the dosage form is prepared in accordance with the above, the dosage form will have the following composition:

INGREDIENT	<b>Preferred</b>	Most Preferred
CORE:		
Drug	50-98%	75-95%
Binder	0-40%	3-15%
Absorption Enhancer	0-20%	2-10%
COATING:		
Membrane Polymer	50-99%	75-95%
Flux Enhancer	0-40%	2-20%
Plasticizer	0-25% or 0-30%	2-15%

The dosage forms prepared according to certain embodiments of the present invention preferably exhibit the following dissolution profile when tested in a USP type 2 apparatus at 75 rpms in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37°C:

10	
	**************************************
	ı.Z
	222
	r.
	rij.

5

20

25

Time (Hours)	<u>Preferred</u>	Most Preferred
2	0.0007	
2	0-30%	0-15% or 0-25%
4	10-45%	20-40%
8	30-90%	45-90%
12	NTL 50%	NTL 60%
16	NTL 60%	NTL 70%
20	NTL 70%	NTL 80%
NTL = Not less than		

In the preparation of the tablets of the invention, various conventional well known solvents may be used to prepare the granules and apply the external coating to the tablets of the invention. In addition, various diluents, excipients, lubricants, dyes, pigments, dispersants, etc. which are disclosed in Remington's Pharmaceutical Sciences, 1995 Edition may be used to optimize the formulations of the invention.

Other controlled release technologies known to those skilled in the art can be used in order to achieve the controlled release formulations of the present invention, i.e., formulations which provide a mean  $T_{\text{max}}$  of the drug and/or other pharmacokinetic parameters described herein when orally administered to human patients. Such formulations can be manufactured as a controlled oral formulation in a suitable tablet or multiparticulate formulation known to those skilled in the art. In either case, the controlled release dosage form may optionally include a

controlled release carrier which is incorporated into a matrix along with the drug, or which is applied as a controlled release coating.

An oral dosage form according to the invention may be provided as, for example, granules, spheroids, beads, pellets (hereinafter collectively referred to as "multiparticulates") and/or particles. An amount of the multiparticulates which is effective to provide the desired dose of drug over time may be placed in a capsule or may be incorporated in any other suitable oral form.

In certain preferred embodiments, the tablet core or multiparticulates containing the drug are coated with a hydrophobic material selected from (i) an alkylcellulose and (ii) a polymeric glycol. The coating may be applied in the form of an organic or aqueous solution or dispersion. The coating may be applied to obtain a weight gain from about 2 to about 25% of the substrate in order to obtain a desired sustained release profile. The sustained release coatings of the present invention may also include an exit means comprising at least one passageway, orifice, or the like as previously disclosed.

#### **Description of Certain Preferred Embodiments**

The following examples illustrate various aspects of the present invention. They are not to be construed to limit the claims in any manner whatsoever.

20

5

10

15

#### Example 1

A controlled release tablet containing 500 mg of metformin HCl and having the following formula is prepared as follows:

#### I. Core

5

15

20

25

<u>Ingredients</u>	Amount (mg/tab)
Metformin HC1	500.0
Povidone <sup>3</sup> , USP	36.0
Sodium Lauryl Sulfate	25.8
Magnesium Stearate	2.8

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

#### (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with 15/32" round standard concave punches.

#### (c) Seal Coating (optional)

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7006), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The Opadry Clear of the coating constitutes about 11.5 mg/tablet.

#### II. Sustained Release Coating

10

5

and the first that the first that

15

20

25

<u>Ingredients</u>	Amount (mg/tablet)
Cellulose Acetate (398-10) <sup>2</sup>	21.5
Triacetin	1.3
PEG 400	2.5
<sup>2</sup> acetyl content 39.3 - 40.3%	

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

#### (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

#### Example 2

A controlled release tablet containing 850 mg of metformin HCl and having the following formula is prepared as follows:

#### I. Core

5

10

15

20

25

IngredientsAmount (mg/tab)Metformin HCl850.0Povidone³, USP61.1Sodium Lauryl Sulfate43.9Magnesium Stearate4.8

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

#### (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with 15/32" round standard concave punches.

#### (c) **Seal Coating (optional)**

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7006), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The Opadry Clear of the coating constitutes about 11.5 mg/tablet.

#### II. Sustained Release Coating

10

5

The second secon 15 In

25

Ingredients Amount (mg/tablet) Cellulose Acetate (398-10)<sup>2</sup> 24.0 Triacetin 1.4 **PEG 400** 2.8 <sup>2</sup>acetyl content 39.3 - 40.3%

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

#### (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

#### Example 3

A controlled release tablet containing 1000 mg of metformin HCl and having the following formula is prepared as follows:

#### I. Core

10

15

ma.

20

25

5	Ingredients	Amount (mg/tablet)
	Metformin HCl	1000.0
	Povidone <sup>3</sup> , USP	71.9
	Sodium Lauryl Sulfate	51.7
	Magnesium Stearate	5.6

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

#### (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with a screen equivalent to 18 mesh.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with ½" round standard concave punches.

#### (c) Seal Coating (optional)

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7003), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The core tablet is coated with the sealing solution until the tablet is coated with 23.0 mg/tablet of the Opadry material.

#### II. Sustained Release Coating

Ingredients	Amount (mg/tablet)
Cellulose Acetate (398-10) <sup>2</sup>	19.0
Triacetin	1.1
PEG 400	2.2

Cellulose Acetat

Triacetin

PEG 400

2acetyl content 39.3 - 40.3%

5

10

15

20

25

ii ļ.,

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

#### (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

#### (e) Color Coating (optional)

5

10

15

20

25

zek.

Subsequent to the sustained release coating, the laser drilled tablet is coated with a color coating using Opadry White (24 mg/tablet) and waxed with Candelilla wax powder (0.4 mg/tablet).

#### Clinical Studies

#### Study 1

In study 1, a total of twelve (12) healthy subjects (six males, six females) were randomized to receive either a single oral dose of metformin XT, 850mg, prepared in accordance with Example 2 or b.i.d. doses of GLUCOPHAGE in assigned study periods which consisted of one of the following groups: Group A - metformin XT (2 x 850 mg tablets) taken at approximately 8:00 a.m., immediately following breakfast, Group B - metformin XT (2 x 850 mg tablets) taken at approximately 6:00 p.m., immediately following dinner; and Group C - GLUCOPHAGE (1 x 850 mg tablet) taken at approximately 8:00 a.m., immediately following breakfast, and at approximately 6:00 p.m., immediately following dinner. Each drug administration was separated by a washout period of seven days. In this study, one male subject was removed from the study prior to Period II due to non-treatment-related mononucleosis. Thus, 11 (five males and six females) subjects completed the study.

For metformin XT, plasma samples were obtained from subjects at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, and 24 hour(s) after dosing. For GLUCOPHAGE, plasma samples were obtained from subjects at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, and 24 hour(s) after the first dose in the morning. Plasma concentrations of metformin were determined using a validated HPLC method. The lower quantitation limit of this method is 10 ng/ml. Mean plasma concentration-time profiles are shown in Fig. 1 and mean values of pharmacokinetic parameters of metformin obtained from this study are presented in Table 1.

 $\frac{Table\ 1}{Mean\ (\pm SD,\ n=11)\ values\ of\ pharmacokinetic\ parameters\ of\ metformin\ (Example\ 2)\ in\ 11}$  healthy subjects (metformin XT, 2 x 850 mg q.d. or GLUCOPHAGE, 1 x 850 mg b.i.d.)

						Geometric Mean Ratio*	
Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr.)	T <sub>lag</sub> (hr)	t <sub>1/2</sub> (hr)	AUC <sub>0-∞</sub>	$\mathbf{C}_{ ext{max}}$
Metformin XT after breakfast	18156 (4183)	2045 (567)	6 (2)	0.18 (0.40)	4.4 (0.7)	1.00	1.36
Metformin XT after dinner	18277 (2961)	1929 (333)	7 (2)	0.09 (0.30)	3.6 (0.8)	1.02	1.32
GLUCOPHAGE	18050 (3502)	1457 (217)	5 (3)	0 (0)	3.5 (0.9)	_	_

<sup>\*</sup>Ratio = Metformin XT/GLUCOPHAGE

As shown in Figure 1 and Table 1, when metformin XT was administered immediately after either breakfast or dinner, the relative bioavailability of metformin XT formulation to GLUCOPHAGE is approximately 100%.

The results of study 1 were used to calculate the approximate degree of fluctuation ( $C_{max}$  -  $C_{min}/C_{avg}$ ) of the formulations.

The  $C_{\text{max}}$  was directly obtained from the study (see Table 1). The  $C_{\text{avg}}$  was obtained by dividing the AUC value by the dosing interval, i.e. 24 hours. The value for  $C_{\text{min}}$  was extrapolated from Figure 1.

The results are set forth in Table 2 below:

5

10

15

T.

Ļ

Table 2

Mean ( $\pm$ SD, n = 12) values of pharmacokinetic parameters of metformin XT in 12 healthy subjects (metformin XT, 2 x 850 mg q.d. and GLUCOPHAGE, 850 mg b.i.d.)

Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	$ m C_{min} \ (ng/ml)$	C <sub>avg</sub> (ng/ml)	Degree of Fluctuation
Metformin XT after breakfast	18156 (4183)	2045 (567)	143	756	251
Metformin XT after dinner	18277 (2961)	1929 (333)	107	761	2.39
GLUCOPHAGE	18050 (3502)	1457 (217)	214 (at 24 hours)	752	1.65
			393 (between doses)	752	1.41

As shown in Figure 1 and Table 2, a single administration of the metformin XT formulation provides a higher mean fluctuation index in the plasma than a substantially equal dose of Glucophage administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

20 <u>Study 2</u>

The study design of Study 2 is the same as Study 1 except for the formulation and the dose (4 x 500 mg q.d., total dose 2000mg, for metformin XT prepared according to Example 1 and 2 x 500 mg b.i.d., total dose 2000mg, for GLUCOPHAGE in the second study). In this study, 12 healthy volunteers (five males and seven females) were randomized to receive treatments and completed the study. Mean plasma concentration-time profiles and mean values

5

10

of pharmacokinetic parameters of metformin obtained from this study are presented in Figure 2 and Table 3.

As shown in Figure 2 and Table 3, when the metformin XT formulation (500 mg) was administered immediately after dinner, the relative bioavailability of this formulation to GLUCOPHAGE is approximately 100%, while the mean  $C_{max}$  value is about the same. The relative bioavailability of metformin XT, however, is approximately 80% when administered immediately after breakfast. A prolonged profile, together with later  $T_{max}$  and similar  $C_{max}$  of metformin following administration of metformin XT immediately after dinner compared to GLUCOPHAGE indicated that metformin was released *in vivo* in a sustained fashion (Figure 2).

10

5

Model of the second of the sec

15

#### Table 3

Mean ( $\pm$ SD, n = 12) values of pharmacokinetic parameters of metformin of Example 1 in 12 healthy subjects (metformin XT, 4 x 500 mg q.d. or GLUCOPHAGE, 2 x 500 mg b.i.d.)

					Geom	etric Mean ]	Ratio*
Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr)	T <sub>lag</sub> (hr)	t <sub>1/2</sub> (hr)	AUC <sub>0-∞</sub>	$\mathbf{C}_{ ext{max}}$
Metformin XT after breakfast	17322 (4984)	2127 (545)	5 (1)	0 (0)	6.1 (1.8)	0.80	1.15
Metformin XT after dinner	20335 (4360)	2053 (447)	7 (2)	0.08 (0.29)	3.9 (0.6)	0.96	1.12
GLUCOPHAGE	21181 (4486)	1815 (302)	4 (3)	0 (0)	3.6 (0.8)		_

<sup>\*</sup>Ratio = Metformin XT/GLUCOPHAGE

The results of study 2 were used to calculate the approximate degree of fluctuation of the formulations in accordance with the calculations used in study 1 (using Figure 2 to obtain the extrapolated value for  $C_{\min}$ ).

The results are set forth in Table 4 below:

30

 $\frac{Table\ 4}{Mean\ (\pm SD,\ n=12)}\ values\ of\ pharmacokinetic\ parameters\ of\ metformin\ XT\ in\ 12\ healthy\ subjects\ (metformin\ XT,\ 4\ x\ 500\ mg\ q.d.\ and\ GLUCOPHAGE,\ 2\ x\ 500\ mg\ b.i.d.)$ 

Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	C <sub>min</sub> (ng/ml)	C <sub>avg</sub> (ng/ml)	Degree of Fluctuation
Metformin XT after breakfast	17322 (4984)	2127 (545)	143	721	2.9
Metformin XT after dinner	20335 (4360)	2053 (447)	143	847	2.25
GLUCOPHAGE	21181 (4486)	1815 (302)	214 (at 24 hours)	882	1.8
			357 (between doses)	882	1.65

As shown in Figure 2 and Table 4, a single administration of the metformin XT formulation provides a higher mean fluctuation index in the plasma than an equivalent dose of Glucophage administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

20 <u>Study 3</u>

5

10

15

25

In Study 3, a multiple-dose, open-label, one-period study was conducted to evaluate the short-term tolerability and steady-state pharmacokinetics of the 500 mg metformin XT formulation used in Study 2. In this study, eight healthy volunteers (four males and four females) were randomized to receive 2000 mg of metformin XT (4 x 500 mg tablets) at approximately 6:00 p.m., immediately following dinner, for 14 days.

Blood samples were obtained from each subject at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16 and 24 hour(s) following the first dose on Day 1 and at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 38 and 48 hour(s) following the last dose on Day 14. Blood samples were also drawn from each subject immediately prior to dosing on Days 10-13. Urine samples were collected from each subject at the following time intervals: six hours prior to the first dose; 0-6, 6-12 and 12-24 hours after the first dose; and 0-6, 6-12, 12-24 and 24-48 hours after the last dose.

Mean plasma profiles and values of pharmacokinetic parameters of metformin are presented in Table 5 below:

<u>Table 5</u> **Mean Pharmacokinetic Parameters (Example 1)** 

Day 1

5

10

25

	C <sub>max</sub>	$T_{max}$	AUC <sub>0-24hr (ng.hr/ml)</sub>
Mean	2435	6.9	22590
SD	630	1.9	3626

Day 14

	$\mathbf{C}_{max}$	T <sub>max</sub>	AUC <sub>0-24hr</sub> (ng.hr/ml)
Mean	2288	6.9	24136
SD	736	2.5	7996

Following oral administration of metformin XT, 4 x 500 mg q.d., for 14 days, there was little or no difference in plasma concentration-time profiles of metformin in eight healthy volunteers between Day 1 and Day 14 dosing (Figure 3). On average, trough plasma concentrations of metformin were nearly constant, ranging from 188.8 to 205.1 ng/ml on Days 10-14, indicating that the steady state of metformin was attained rapidly. The mean

accumulation ratio was 1.01, indicating that the once-daily dose regimen of metformin XT results in no accumulation.

Following oral administration of a single dose (4 x 500 mg) of metformin XT, approximately 31% of the dose was excreted in the urine within the first 24 hours. On average, the renal clearance of metformin was 366 ml/min. A slightly higher renal clearance (454 ml/min) was found after multiple-dose administration of 4 x 500 mg q.d. of metformin XT.

Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence and anorexia) are the most common adverse reactions to GLUCOPHAGE. In controlled trials, GLUCOPHAGE was started at low, nontherapeutic doses and gradually titrated to higher doses. In spite of this gradual titration, GLUCOPHAGE was discontinued due to gastrointestinal reactions in approximately 4% of patients. In contrast, in the multiple-dose study, metformin XT begun at a therapeutic initial dose of 2000 mg once daily with dinner was well tolerated by all healthy volunteers. Diarrhea and nausea were the most common gastrointestinal reactions probably or possibly related to metformin XT. These reactions, however, were either mild or moderate. This suggests that it may be possible to initiate metformin XT treatment with effective doses rather than using the slow titration from non-therapeutic doses required for GLUCOPHAGE.

#### Study 4

Study 4 was a study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of metformin XT compared to GLUCOPHAGE after multiple-dose treatment in patients with NIDDM. Metformin XT tablets prepared according to Example 3 were used in this study. This study had a single-center, randomized, two-way crossover design. A total of 24 NIDDM patients who were on a stable dose of GLUCOPHAGE, between 1000 and 2550 mg/day, for at least 12 weeks were selected for the study. A Pretreatment Period of at least 3 weeks preceded randomization to study treatment. At the start of the Pretreatment Period, all patients stopped taking any other hypoglycemic agents besides GLUCOPHAGE, and the GLUCOPHAGE dose was adjusted to 1000 mg b.i.d. (with breakfast and with dinner).

The series of th

5

10

15

20

10

15

25

Following the pretreatment period, patients began Treatment Period I, which lasted 4 weeks. During Period I, a total of 12 patients were randomized to receive two 1000-mg metformin XT tablets q.d. (immediately after dinner), at approximately 6:00 p.m., and 12 were randomized to receive one 1000-mg GLUCOPHAGE tablet b.i.d. (immediately after breakfast and immediately after dinner). Immediately following Period I, each patient was switched to the alternate medication for 4 weeks in Period II. There was no washout between treatment periods.

Plasma metformin concentrations were determined over a 24-hour period at the end of Treatment Periods I and II as follows: immediately prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, 22, and 24 hours after the evening dose. One subject withdrew from the study for personal reasons after two weeks of treatment in Treatment Period I, thus pharmacokinetic data were obtained from 23 patients.

Mean plasma profiles and values of pharmacokinetic parameters of metformin are presented in Figure 4 and Table 6. As shown in Figure 4 and Table 6, when metformin XT was administered immediately after dinner, the bioavailability of metformin XT relative to GLUCOPHAGE at steady state is close to 100%. Although the dose of metformin XT was twice as large as the dose of GLUCOPHAGE at dinner, the mean  $C_{\text{max}}$  value was only 32% higher.

 $\frac{Table\ 6}{Mean\ (\pm\ SD)\ values\ of\ pharmacokinetic\ parameters\ of\ metformin\ of\ Example\ 3\ in\ 23}}$  NIDDM patients (metformin\ XT, 2 x 1000 mg q.d. with dinner or GLUCOPHAGE, 1 x 1000 mg b.i.d.)

					Geo	ometric Mear	1 Ratio*
Treatment	AUC <sub>0-24hr</sub> (ng•hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr)	T <sub>lag</sub> (hr)	t <sub>1/2</sub> (hr)	AUC <sub>0-24hr</sub>	$C_{max}$
Metformin XT after dinner	26818 (7052)	2849 (797)	6 (2)	0 (0)	5.4	0.96	1.32
GLUCOPHAGE	27367 (5759)	2131 (489)	14 (6)	0 (0)	4.4		

<sup>\*</sup> Ratio = Metformin XT/GLUCOPHAGE

10

15

20

25

When the metformin XT was administered immediately after dinner, the bioavailability of metformin XT relative to GLUCOPHAGE at steady state was close to 100%. However, when metformin XT was administered immediately after breakfast, the corresponding relative bioavailability of metformin XT was approximately 80%. The safety profile of metformin XT, 2000 mg given once daily either after dinner or after breakfast was comparable to that of an equal dose of GLUCOPHAGE given b.i.d. The efficacy profile of metformin XT, 2000 mg given once daily after dinner was similar to that of an equal dose of GLUCOPHAGE given b.i.d. The efficacy of metformin XT, 2000 mg given once daily after breakfast, however, appeared to be comparable to or slightly less than that of GLUCOPHAGE given b.i.d.

While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention.

#### WHAT IS CLAIMED IS:

- 1. A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of at least one suitable antihyperglycemic agent or a pharmaceutically acceptable salt thereof and a controlled release carrier, wherein the dosage form provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from 5.5 to 7.5 hours after administration.
- 2. The controlled release dosage form of claim 1 wherein said at least one antihyperglycemic agent is a biguanide.
- 3. The controlled release dosage form of claim 2 wherein said biguanide is metformin or a pharmaceutically acceptable salt thereof.
- 4. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from 6.0 to 7.0 hours after administration.
- 5. The method of claim 3, in which the administration of the at least one metformin dosage form occurs at dinner time and provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from about 5.5 to 7.0 hours after the administration.
- 6. The method of claim 3, in which the administration of the at least one metformin dosage form occurs at breakfast and provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from about 6.0 to about 7.5 hours after the administration.

- 7. The method of claim 3, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of the drug from about 4.5 to about 13 hours.
- 8. The method of claim 3, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of the drug from about 5.5 to about 10 hours.
- 9. The method of claim 3, in which the administration of the at east one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is more than about 7 times the mean plasma level of said metformin at about 24 hours after administration.
- 10. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 7 times to about 14 times the plasma level of said metformin at about 24 hours after administration.
- 11. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 8 times to about 12 times the plasma level of said metformin at about 24 hours after administration.
- 12. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1500 ng/ml to about 3000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.

- 13. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1700 ng/ml to about 2000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 14. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from at least 80% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 15. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> that is from at least 90% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 16. The method of claim 3, in which the once-a-day dose of the metformin is administered at dinner.
- 17. The method of claim 16, in which the once-a-day dose of metformin is administered at fed state.
- 18. The method of claim 16, in which the once-a-day dose of the metformin is about 2000 mg, which is provided by two controlled release dosage forms containing about 1000 mg metformin each.

- 19. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 20. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 26500 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 21. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about19800 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 22. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 1, based on administration of a 1700 mg once-a-day dose of metformin.
- 23. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 2, based on administration of a 2000 mg once-a-day dose of metformin.
- 24. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 4, based on administration of a 2000 mg once-a-day dose of metformin at dinner.
- 25. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set

forth in FIG. 6, based on administration of a 2000 mg once-a-day dose of metformin at breakfast.

- 26. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma glucose concentration-time profile substantially as set forth in FIG. 5, based on administration of a 2000 mg once-a-day dose of metformin at dinner.
- 27. The method of claim 3, further comprising administering to said human patients at least one additional pharmaceutically active ingredient for treatment of NIDDM.
- 28. The method of claim 3, further comprising administering to said human patients an additional pharmaceutically active ingredient for treatment of NIDDM, said additional pharmaceutically active ingredient selected from the group consisting of a sulfonylurea, a glitazone or a second biguanide.
- 29. The method of claim 3, in which the dose of metformin comprises metformin hydrochloride.
- 30. The method of claim 29, in which the once-a-day dose of metformin hydrochloride is about 1000 mg to about 2500 mg.
- 31. The method of claim 29, in which the once-a-day dose of metformin hydrochloride is about 2000 mg to about 2500 mg metformin.
- 32. A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering at least one biguanide or pharmaceutically acceptable salt thereof and a controlled release carrier wherein a single administration of said dosage form provides a higher mean fluctuation

index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

- 33. The method of claim 32 wherein said dosage form maintains bioavailability from at least 80% of the immediate release composition.
- 34. The method of claim 32 wherein said dosage form maintains bioavailability from aat least 90% of the immediate release composition.

### **ABSTRACT**

A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.






FIGURE 3





withinks oral closes of methranta XT (2 × 1000 mg, q.d. with diance) or Mean steady-state plasma concentration-time profiles of metformin in NIDDM pati GLUCOPHAGE (1 x 1000 mg, b.l.d.)


### Metformin HCI Dissolution Profiles

Paddle at 75rpm, in pH7.5











- 850mg





**=** 1000 mg

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submit

# 325 S

### TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:										
METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE METFORMIN										
and invented by:										
Xiu X	Xiu Xiu CHENG, Chih-Ming CHEN, Steve JAN and Joseph CHOU									
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:										
Continuation Divisional Continuation-in-part (CIP) of prior application No.:										
Which i			ion [	٦.	Divisional		Continuation	in nort (CID)	of prior application No.:	
Which i			1011 <u> </u>		Divisional	u	Continuation-	in-part (Cir)	of prior application No	
□≟co			ion [	ב	Divisional		Continuation-i	in-part (CIP)	of prior application No.:	
**************************************										
Enclose	ed a	re:					Application	n Flements		
2007										
		Filin	g tee as	s c	alculated and	tran	smitted as desc	ribed below		
2.	X	Spe	cificatio	n h	having		42	_ pages and ir	ncluding the following:	
	a.	X	Descri	pti	ve Title of the	lnve	ention			
	b.		Cross	Re	eferences to I	Relat	ed Applications	(if applicable)		
	C.		Staten	ner	nt Regarding	Fede	erally-sponsored	Research/De	evelopment (if applicable)	
	d.		Refere	enc	ce to Microfich	пе Ар	pendix (if applic	cable)		
	e. 🗵 Background of the Invention									
	f. 🗵 Brief Summary of the Invention									
	g. 🗵 Brief Description of the Drawings (if drawings filed)									
	h. 🗷 Detailed Description									
	i. 🛛 Claim(s) as Classified Below									
	j. 🗵 Abstract of the Disclosure									

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission 55

	Application Elements (Continued)												
3.	X	Drawing(s) (when necessary as prescribed by 35 USC 113)											
	a.	☐ Formal Number of Sheets											
	b.												
4.		Oath or Declaration											
	a.	☐ Newly executed (original or copy) ☐ Unexecuted											
	b.	Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)											
	C.	☐ With Power of Attorney ☐ Without Power of Attorney											
	d. DELETION OF INVENTOR(S)  Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).												
		Incorporation By Reference (usable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.											
6		Computer Program in Microfiche (Appendix)											
7.		Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)											
	a.	☐ Paper Copy											
	b.	☐ Computer Readable Copy (identical to computer copy)											
1200	c.	☐ Statement Verifying Identical Paper and Computer Readable Copy											
		Accompanying Application Parts											
8.		Assignment Papers (cover sheet & document(s))											
9.		37 CFR 3.73(B) Statement (when there is an assignee)											
10.		English Translation Document (if applicable)											
11.		Information Disclosure Statement/PTO-1449   Copies of IDS Citations											
12.		Preliminary Amendment											
13.	×	Acknowledgment postcard											
14.	X	Certificate of Mailing											
		☐ First Class ☒ Express Mail (Specify Label No.): EL 415 728 697 US											

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission 55

		Accompanying Application Parts (Continued)
15.		Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.		Additional Enclosures (please identify below):
The state of the s	۵	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.  Warning
		An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission 55

#### Fee Calculation and Transmittal

CLAIMS AS FILED									
For	#Filed	#Allowed	#Extra		Rate	Fee			
Total Claims	34	- 20 =	14	х	\$18.00	\$252.00			
Indep. Claims	ms 2 - 3 = 0 x \$80.00								
Multiple Dependent C		\$0.00							
1 miles   2 miles	BASIC FEE								
OTHER FEE (specify	/ purpose)					\$0.00			
, 101 h									
□ A check in the amount of to cover the filing fee is enclosed. □ The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed. □ Charge the amount of as filing fee. □ Credit any overpayment. □ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. □ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).									
Dated: November 3, 2	2000			g. No. 41	***************************************				

cc:

 $\underset{\text{patent\_trademark office}}{23280}$ 

### METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE METFORMIN

#### **Background of the Invention**

5

The present invention relates to controlled release unit dose formulations containing an antihyperglycemic drug. More specifically, the present invention relates to an oral dosage form comprising a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride or the metformin salts described in United States Patent Nos. 3,957,853 and 4,080,472 which are incorporated herein by reference.

10

In the prior art, many techniques have been used to provide controlled and extendedrelease pharmaceutical dosage forms in order to maintain therapeutic serum levels of medicaments and to minimize the effects of missed doses of drugs caused by a lack of patient compliance.

15

In the prior art are extended release tablets which have an osmotically active drug core surrounded by a semipermeable membrane. These tablets function by allowing a fluid such as gastric or intestinal fluid to permeate the coating membrane and dissolve the active ingredient so it can be released through a passageway in the coating membrane or if the active ingredient is insoluble in the permeating fluid, pushed through the passageway by an expanding agent such as a hydrogel. Some representative examples of these osmotic tablet systems can be found in United States Patent Nos. 3,845,770, 3,916,899, 4,034,758, 4,077,407 and 4,783,337. United States Patent No. 3,952,741 teaches an osmotic device wherein the active agent is released from a core surrounded by a semipermeable membrane only after sufficient pressure has developed

25

20

The basic osmotic device described in the above cited patents have been refined over time in an effort to provide greater control of the release of the active ingredient. For example United States Patent Nos. 4,777,049 and 4,851,229 describe an osmotic dosage form comprising a semipermeable wall surrounding a core. The core contains an active ingredient and a modulating agent wherein the modulating agent causes the active ingredient to be released through a passageway in the semipermeable membrane in a pulsed manner. Further refinements have

within the membrane to burst or rupture the membrane at a weak portion of the membrane.

included modifications to the semipermeable membrane surrounding the active core such as varying the proportions of the components that form the membrane; i.e., United States Patent Nos. 5,178,867, 4,587,117 and 4,522,625 or increasing the number of coatings surrounding the active core; i.e., U.S. Patent Nos. 5,650,170 and 4,892,739.

5

Although vast amounts of research has been performed on controlled or sustained release compositions and in particular on osmotic dosage forms, very little research has been performed in the area of controlled or sustained release compositions that employ antihyperglycemic drugs.

10

15

20

25

Metformin is an oral antihyperglycemic drug used in the management of non-insulindependent diabetes mellitus (NIDDM). It is not chemically or pharmacologically related to oral sulfonylureas. Metformin improves glucose tolerance in NIDDM patients by lowering both basal and postprandial plasma glucose. Metformin hydrochloride is currently marketed as GLUCOPHAGE® tablets by Bristol-Myers Squibb Co. Each GLUCOPHAGE® tablet contains 500, 850 or 1000 mg of metformin hydrochloride. There is no fixed dosage regimen for the management of hyperglycemia in diabetes mellitus with GLUCOPHAGE®. Dosage of GLUCOPHAGE® is individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended dose of 2550 mg per day.

Metformin has been widely prescribed for lowering blood glucose in patients with NIDDM. However, being a short acting drug, metformin requires twice-daily (b.i.d.) or three-times-a-day (t.i.d.) dosing. Adverse events associated with metformin use are often gastrointestinal in nature (e.g., anorexia, nausea, vomiting and occasionally diarrhea, etc.). These adverse events may be partially avoided by either reducing the initial and/or maintenance dose or using an extended-release dosage form. Another clear advantage of an extended release dosage form is a reduction in the frequency of administration. All of these findings suggest that an extended-release dosage form of metformin may improve the quality of therapy in patients with NIDDM and the safety profile relative to a conventional dosage form.

The limited work on controlled or sustained release formulations that employ antihyperglycemic drugs such as metformin hydrochloride includes the combination of the antihyperglycemic drug and an expanding or gelling agent to control the release of the drug from

the dosage form. This research is exemplified by the teachings of WO 96/08243 and by the GLUCOPHAGE® metformin HCl product.

It is reported in the 50<sup>th</sup> Edition of the Physicians' Desk Reference, copyright 1996, p. 753, that food decreases the extent and slightly delays the absorption of metformin delivered by the GLUCOPHAGE® dosage form. This decrease is shown by approximately a 40% lower peak concentration, a 25% lower bioavailability and a 35-minute prolongation of time to peak plasma concentration following administration of a single GLUCOPHAGE® tablet containing 850 mg of metformin HCl with food compared to the similar tablet administered under fasting conditions.

A controlled release metformin dosage form is also described in WO 99/47128. This

10

15

20

25

5

ļu iŠ:

reference describes a controlled release delivery system for metformin which includes an inner solid particulate phase formed of substantially uniform granules containing metformin and one or more hydrophilic polymers, one or more hydrophobic polymers and one or more hydrophobic materials, and an outer continuous phase in which the above granules are embedded and dispersed throughout. The outer continuous phase includes one or more hydrophilic polymers,

one or more hydrophobic polymers and one or more hydrophobic materials. Our own WO 99/47125 discloses controlled release metformin formulations providing a Tmax from 8 to 12 hours.

#### Objects and Summary of the Invention

It is an object of the present invention to provide a controlled or sustained release of an antihyperglycemic drug which provides effective control of blood glucose levels in humans.

It is a further object of the present invention to provide a method of treating human patients with non-insulin-dependent diabetes mellitus (NIDDM) on a once-a-day basis with an antihyperglycemic drug which provides effective control of blood glucose levels in humans.

It is a further object of the present invention to provide formulations for treating human patients with non-insulin-dependent diabetes mellitus (NIDDM) which provides advantages over the state-of-the-art, and which may be administered on a once-a-day basis by itself or together with other antidiabetic agents, and methods thereof.

It is a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug wherein the bioavailability of the drug is not decreased by the presence of food.

It is a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug that does not employ an expanding polymer.

It is also a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug that can provide continuous and non-pulsating therapeutic levels of the drug to an animal or human in need of such treatment over a twelve hour to twenty-four hour period.

It is an additional object of other embodiments of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that obtains peak plasma levels from 5.5 to 7.5 hours after administration under various conditions. Alternatively, the time to peak plasma levels are from 6.0 to 7.0, from 5.5 to 7.0 or from 6.0 to 7.5.

It is also an object of this invention to provide a controlled or sustained release pharmaceutical formulation having a homogeneous core wherein the core component may be made using ordinary tablet compression techniques.

In accordance with the above-mentioned objects and others, the present invention provides a controlled release oral dosage form comprising an antihyperglycemic drug, preferably a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof) that is suitable for providing once-a-day administration of the drug, wherein the dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug from 5.5 to 7.5 hours after administration. The dosage form comprises the drug and a membrane. In certain preferred embodiments, the dosage form comprises a tablet.

In preferred embodiments, the controlled release oral dosage form of the present invention is a tablet comprising:

(a) a core comprising:

5

10

15

20

25

- (i) the antihyperglycemic drug;
- (ii) optionally a binding agent; and
- (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

When the drug is metformin or a pharmaceutically acceptable salt thereof and is administered on a once-a-day basis, the daily dose may vary, e.g., from about 500 mg to about 2500 mg. Such daily dose may be contained in one controlled-release dosage form of the invention, or may be contained in more than one such dosage form. For example, a controlled-release metformin dosage form may be formulated to contain about 1000 mg of the drug, and two of said dosage form may be administered together to provide once-a-day metformin therapy. The daily dose of the drug (i.e. metformin or pharmaceutically acceptable salt thereof) may range from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient.

In certain preferred embodiments, the controlled release solid oral dosage form of the present invention provides a width at 50% of the height of a mean plasma concentration/time curve of the drug (e.g., of metformin) from about 4.5 to about 13 hours, more preferably from about 5.5 to about 10 hours, more preferably from about 6 to about 8 hours.

In certain embodiments, the controlled release oral dosage form of the present invention provides a mean maximum plasma concentration ( $C_{max}$ ) of the antihyperglycemic drug which is more than about seven times the mean plasma level of said drug at about 24 hours after administration. In preferred embodiments, the controlled release oral dosage form of the present invention provides a mean maximum plasma concentration ( $C_{max}$ ) of the drug which is from about 7 times to about 14 times the plasma level of the drug at about 24 hours after the administration, more preferably from about 8 times to about 12 times the plasma level of the drug at about 24 hours after administration.

In certain embodiments of the present invention, when the drug is metformin or a pharmaceutically acceptable salt thereof, the controlled release oral dosage form provides a mean

10

5

15

The same state

20

maximum plasma concentration (C<sub>max</sub>) of the drug that is about 1500 ng/ml to about 3000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin, more preferably about 1700 ng/ml to about 2000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.

5

In certain embodiments of the present invention, when the drug is metformin or a pharmaceutically acceptable salt thereof, the controlled release dosage form provides a mean AUC<sub>0-24hr</sub> that is about 17200 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin; preferably about 17200 ng.hr/ml to about 26500 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin; more preferably about 19800 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.

In certain embodiments of the invention, the administration of the antihyperglycemic

preferably at least 90% of the mean AUC<sub>0-24</sub> provided by administration of the reference standard

(GLUCOPHAGE) twice a day, wherein the daily dose of the reference standard is equal to the

once-a day dose of metformin administered in the controlled release oral dosage form of the

drug, e.g., at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from at least 80%,

10

15

present invention.

20

In certain embodiments of the present invention, the controlled release dosage form exhibits the following dissolution profiles of the antihyperglycemic drug (e.g., metformin) when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal gastric fluid (pH 7.5 phosphate buffer) at 37° C: 0-30% of the drug released after 2 hours; 10-45% of the drug released after 4 hours; 30-90% of the drug released after 8 hours; not less than 50% of the drug released after 12 hours; not less than 60% of the drug released after 16 hours; and not less than 70% of the drug released after 20 hours.

25

In certain preferred embodiments, the controlled release solid oral dosage form exhibits the following dissolution profiles when tested in USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal gastric fluid (pH 7.5 phosphate buffer) at 37° C: 0-25% of the drug (e.g., metformin or a pharmaceutically acceptable salt thereof) released after 2 hours; 20-40% of the

drug released after 4 hours; 45-90% of the drug released after 8 hours; not less than 60% of the drug released after 12 hours; not less than 70% of the drug released after 16 hours; and not less than 80% of the drug released after 20 hours.

With respect to embodiments of the present invention where the antihyperglycemic drug is metformin, it has been found that drugs such as metformin provide substantially linear pharmacokinetics up to a level of about 2 grams per day. Therefore, it is contemplated for purposes of the present invention that a given plasma level (e.g.,  $C_{max}$ ) of metformin per specified dose will be directly proportional to other doses of metformin. Such proportional doses and plasma levels are contemplated to be within the scope of the invention and to be within the scope of the appended claims.

5

10

15

20

25

ĽÑ.

The dosage form of the present invention can provide therapeutic levels of the antihyperglycemic drug for twelve to twenty-four hour periods and does not exhibit a decrease in bioavailability if taken with food. In fact, a slight increase in the bioavailability of the antihyperglycemic drug is observed when the controlled release dosage form of the present invention is administered with food. In a preferred embodiment, the dosage form can be administered once-a-day, ideally with or after a meal, preferably with or after the evening meal, and provides therapeutic levels of the drug throughout the day with peak plasma levels being obtained between 5.5 to 7.5 hours after administration.

The present invention is also directed to a method of lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis a dose of a drug comprising a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof), said drug being contained in at least one solid oral controlled release dosage form of the present invention. When the drug is metformin, the daily dose of the drug may be from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient.

The controlled release dosage form of the present invention provides a delayed  $T_{max}$ , as compared to the  $T_{max}$  provided by GLUCOPHAGE. The delayed  $T_{max}$  occurs from 5.5 to 7.5

hours after administration. If the drug (e.g., metformin) is administered at dinner time, the  $T_{max}$  would occur during the time when gluconeogenesis is usually at its highest (e.g., around 2 a.m.).

5

10

15

20

25

The present invention also includes a method of treating patients with NIDDM comprising orally administering to human patients on a once-a-day basis a dose of a drug comprising a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof), contained in at least one oral controlled release dosage form of the present invention. When the drug is metformin, the daily dose of the drug may be from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient. In certain embodiments, the method of treatment according to the present invention involves once-per-day metformin monotherapy as an adjunct to diet to lower blood glucose in patients with NIDDM whose hyperglycemia may not be satisfactorily managed on diet alone. In certain other embodiments, the once-a-day metformin therapy of the present invention may be used concomitantly with a sulfonylurea, e.g., when diet and monotherapy with a sulfonylurea alone do not result in adequate glycemic control. In certain other embodiments, the once-a-day metformin therapy of the present invention may be used concomitantly with a glitazone, e.g., when diet and monotherapy with a glitazone, e.g., when diet and monotherapy with a glitazone alone do not result in adequate

The present invention is further directed to a method of controlling the serum glucose concentration in human patients with NIDDM, comprising administering to patients having NIDDM on a once-a-day basis, preferably at dinner time, an effective dose of a biguanide (e.g., metformin) contained in at least one oral controlled release dosage form of the present invention.

The present invention further includes a controlled-release dosage form of a drug comprising a biguanide (e.g., metformin) suitable for once-a-day administration to human patients with NIDDM, the dosage form comprising an effective amount of the drug to control blood glucose levels for up to about 24 hours and an effective amount of a controlled-release carrier to provide controlled release of the drug with a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug from 5.5 to 7.5 hours after administration and a width at 50% of

20

25

the height of a mean plasma concentration/time curve of the drug from about 6 to about 13 hours. In preferred embodiments, the administration of the controlled-release dosage form occurs at fed state, more preferably at dinner time.

In certain preferred embodiments, the controlled-release dose of the drug (e.g., metformin or a pharmaceutically acceptable salt thereof) according to the present invention is provided by one or more of a controlled-release tablet comprising

- (a) a core comprising:
  - (i) the antihyperglycemic drug (e.g., metformin or a pharmaceutically acceptable salt thereof);
  - (ii) optionally a binding agent; and
  - (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

In certain preferred embodiments, the mean time to maximum plasma concentration of the drug is reached from 6.5 to 7.5 hours after administration at dinner time.

In certain embodiments of the invention when the drug is a biguanide (e.g. metformin or a pharmaceutically acceptable salt thereof), the controlled release dosage form provides upon single administration, a higher mean fluctuation index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later, preferably maintaining bioavailability from at least 80% preferably from at least 90% of the immediate release composition.

In certain embodiments of the present invention, the mean fluctuation index of the dosage form is from about 1 to about 4, preferably about 2 to about 3, more preferably about 2.5.

In certain embodiments of the invention which exhibit a higher mean fluctuation index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, the ratio of the mean fluctuation index between the dosage form and the immediate release composition is about 3:1, preferably about 2:1, more preferably 1.5:1.

25

When the drug is metformin or a pharmaceutically acceptable salt thereof, the doses of drug which exhibit the above disclosed mean fluctuation indexes can be any effective dose administered to a patient with NIDDM for the reduction of serum glucose levels. For example, the dose can from about 500mg to about 2500mg, from about 1000mg to about 2000 mg or from about 850mg to about 1700mg metformin or pharmaceutically acceptable salt thereof.

The drugs which may used in conjunction with the present invention include those drugs which are useful for the treatment of non-insulin-dependent diabetes mellitus (NIDDM), including but not limited to biguinides such as metformin or buformin or pharmaceutically acceptable salts thereof. When the drug used in the present invention is metformin, it is preferred that the metformin be present in a salt form, preferably as metformin hydrochloride.

The term "metformin" as it is used herein means metformin base or any pharmaceutically acceptable salt e.g., metformin hydrochloride.

The term "dosage form" as it is used herein means at least one unit dosage form of the present invention (e.g. the daily dose of the antihyperglycemic agent can be contained in 2 unit dosage forms of the present invention for single once-a-day administration).

The term "morning" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered early in the day after the patient has awakened from overnight sleep, generally between about 6 a.m. and 11 a.m. (regardless of whether breakfast is eaten at that time, unless so specified herein).

The term "dinnertime" or "at dinner" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered at a time when dinner is normally eaten (regardless of whether a meal is actually eaten at that time, unless so specified herein), generally between about 4 p.m. and 8 p.m.

The term "bedtime" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered before the patient goes to bed in the evening, generally between about 8 p.m. and 12 p.m.

The term "therapeutically effective reduction" when used herein is meant to signify that blood glucose levels are reduced by approximately the same amount as an immediate release reference standard (e.g., GLUCOPHAGE®) or more, when the controlled release dosage form is orally administered to a human patient on a once-a-day basis.

5

LF

10

15

20

25

The term "sustained release" and "controlled release" are used interchangeably in this application and are defined for purposes of the present invention as the release of the drug from the dosage form at such a rate that when a once-a-day dose of the drug is administered in the sustained release or controlled-release form, blood (e.g., plasma) concentrations (levels) of the drug are maintained within the therapeutic range but below toxic levels over a period of time from about 12 to about 24 hours. When the drug used in the present invention is metformin (preferably metformin hydrochloride) the controlled release solid oral dosage form containing such drug is also referred to as "Metformin XT."

The term " $C_{max}$ " is the highest plasma concentration of the drug attained within the dosing interval, i.e., about 24 hours.

The term  ${}^{"}C_{min}$   ${}^{"}$  is the minimum plasma concentration of the drug attained within the dosing interval, i.e. about 24 hours.

The term "Cavg" as used herein, means the plasma concentration of the drug within the dosing interval, i.e. about 24-hours, and is calculated as AUC/dosing interval.

The term " $T_{max}$ " is the time period which elapses after administration of the dosage form at which the plasma concentration of the drug attains the highest plasma concentration of drug attained within the dosing interval (i.e., about 24 hours).

The term "AUC" as used herein, means area under the plasma concentration-time curve, as calculated by the trapezoidal rule over the complete 24-hour interval.

The term "steady state" means that the blood plasma concentration curve for a given drug does not substantially fluctuate after repeated doses to dose of the formulation.

The term "single dose" means that the human patient has received a single dose of the drug formulation and the drug plasma concentration has not achieved steady state.

The term "multiple dose" means that the human patient has received at least two doses of the drug formulation in accordance with the dosing interval for that formulation (e.g., on a once-a-day basis). Patients who have received multiple doses of the controlled release formulations of the invention may or may not have attained steady state drug plasma levels, as the term multiple dose is defined herein.

The term "a patient" means that the discussion (or claim) is directed to the pharmacokinetic parameters of an individual patient and/or the mean pharmacokinetic values obtained from a population of patients, unless further specified.

The term "mean", when preceding a pharmacokinetic value (e.g. mean  $T_{max}$ ) represents the arithmetic mean value of the pharmacokinetic value taken from a population of patients unless otherwise specified (e.g. geometric mean)..

The term "Degree of Fluctuation" is expressed as (C<sub>max</sub> -C<sub>min</sub>)/C<sub>avg</sub>.

### **Brief Description of the Drawings**

- FIG. 1 is a graph showing the relative bioavailability of the metformin XT formulation of Example 2 to GLUCOPHAGE® for Clinical Study 2.
- FIG. 2 is a graph showing the relative bioavailability of the metformin XT formulation of Example 1 (500 mg) to GLUCOPHAGE® for Clinical Study 3.
- FIG. 3 is a graph showing the difference in plasma concentration-time profiles of metformin in eight healthy volunteers between Day 1 and Day 14 dosing following oral administration of the metformin XT formulation of Example 1, 4 x 500 mg q.d. for 14 days for Clinical Study 4.
- FIG. 4 is a graph showing the mean plasma profiles and values of pharmacokinetic parameters of the metformin XT formulation of Example 3 for Clinical Study 5.
- FIG. 5 is a graph showing the mean plasma glucose concentration-time profiles after 4 weeks of treatment with the metformin XT formulation of Example 3 and GLUCOPHAGE® for Clinical Study 5.

25

20

5

10

i ji

15

12th

FIG. 6 is a graph showing the dissolution profile of a 500 mg controlled release metformin formulation of Example 1 of the present invention.

FIG. 7 is a graph showing the dissolution profile of a 850 mg controlled release metformin formulation of Example 2 of the present invention.

FIG. 8 is a graph showing the dissolution profile of a 1000 mg controlled release metformin formulation of Example 3 of the present invention.

### **Detailed Description of the Invention**

The term antihyperglycemic drugs as used in this specification refers to drugs that are useful in controlling or managing noninsulin-dependent diabetes mellitus (NIDDM). Preferably, the antihyperglycemic drug is a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride.

It has surprisingly been found that when biguanides such as metformin are administered orally in a controlled release dosage form suitable for once-a-day dosing in the "fed" state, preferably at dinner, the bioavailability is improved as compared to the administration of the controlled release dosage form in the "fasted" state. This is in contrast to GLUCOPHAGE®, which exhibits opposite characteristics. In accordance with the methods and dosage forms of the present invention, it has been determined that the patients suffering from NIDDM achieve improved results (e.g., lowered blood glucose levels) than GLUCOPHAGE® administered according to accepted protocols, e.g., on a twice-a-day basis.

The methods and dosage forms of the invention provide the further advantage in that when dosed at dinnertime, the controlled release formulations of the invention provide a  $T_{max}$  (from 5.5 to 7.5 hours) after oral administration (which  $T_{max}$  is delayed relative to the reference standard, GLUCOPHAGE®), such that the level of drug is greatest at the time when human patients are manufacturing glucose at highest levels. Gluconeogenesis is well known to those skilled in the art to be greatest at night. Thus, in accordance with the invention, the  $T_{max}$  of the drug occurs for example between 11:30 p.m. and 1:30a.m., based on a dose administered at 6:00 p.m. Likewise, such administration of the dosage form provides lower drug levels during the day

20

5

10

(e.g. the afternoon) when gluconeogenesis is lower than at night. Also, the invention preferably provides the added benefit of lowering insulin levels. Insulin is considered a risk factor in NIDDM, in and of itself, for cardiovascular disease.

In comparison to a twice-daily dose of the reference standard (GLUCOPHAGE®), the plasma levels of metformin are preferably lower in the afternoon. This is an advantage particularly in patients who are under concomitant therapy with one or more additional antidiabetic agents, such as for example, a sulfonylurea. It is known in the art that to date approximately 60% of patients being treated with metformin are also being treated with at least one additional antidiabetic agent (such as a sulfonylurea). Sulfonylureas can possibly cause hypoglycemia, whereas metformin cannot, so there is a benefit to having lower metformin levels in the blood during the afternoon due to the potential for the patient to have hypoglycemia.

Accordingly, the present invention also includes a method of treating human patients with NIDDM comprising administering on a once-a-day basis a therapeutically effective dose of metformin in a controlled-release oral dosage form ("Metformin XT"), in combination with administering an effective amount of a sulfonylurea. In preferred embodiments, metformin is provided by a controlled release dosage form comprising metformin or a pharmaceutically acceptable salt thereof, the dosage form being useful for providing a once-a-day oral administration of the drug, wherein the dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin from 5.5 to 7.5 hours after administration.

In certain embodiments, the combination therapy may be provided as follows. If patients do not respond to four weeks of the maximum dose of Metformin XT (2500 mg/ day) monotherapy, a sulfonylurea may be gradually added while maintaining the maximum dose of Metformin XT, even if prior primary or secondary failure to a sulfonylurea has occurred. Examples of the sulfonylurea include glyburide (glibenclamid), chloropropamide, tolbutamide, glipizide, acetohexamide and tolazamide. Although Metformin XT is preferably administered on once-a-day basis, the sulfonylurea may be administered in a different dosage form and at a different frequency.

10

5

15

20

With concomitant Metformin XT and sulfonylurea therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug.

In certain embodiments, the foregoing objectives are met by a controlled release dosage form comprising:

- (a) a core comprising:
  - (i) an antihyperglycemic drug;
  - (ii) optionally a binding agent; and
  - (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

The binding agent may be any conventionally known pharmaceutically acceptable binder such as polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxyethyl cellulose, ethylcellulose, polymethacrylate, waxes and the like. Mixtures of the aforementioned binding agents may also be used. The preferred binding agents are water soluble such as polyvinyl pyrrolidone having a weight average molecular weight of 25,000 to 3,000,000. The binding agent comprises approximately about 0 to about 40% of the total weight of the core and preferably about 3% to about 15% of the total weight of the core.

The core may optionally comprise an absorption enhancer. The absorption enhancer can be any type of absorption enhancer commonly known in the art such as a fatty acid, a surfactant, a chelating agent, a bile salt or mixtures thereof. Examples of some preferred absorption enhancers are fatty acids such as capric acid, oleic acid and their monoglycerides, surfactants such as sodium lauryl sulfate, sodium taurocholate and polysorbate 80, chelating agents such as citric acid, phytic acid, ethylenediamine tetraacetic acid (EDTA) and ethylene glycol-big (B-aminoethyl ether -N,N,N,N-tetraacetic acid (EGTA). The core comprises approximately 0 to about 20% of the absorption enhancer based on the total weight of the core and most preferably about 2% to about 10% of the total weight of the core.

In this embodiment, the core which comprises the antihyperglycemic drug, the binder which preferably is a pharmaceutically acceptable water soluble polymer and the absorption

5

15

20

5

15

20

25

enhancer is preferably formed by wet granulating the core ingredients and compressing the granules with the addition of a lubricant into a tablet on a rotary press. The core may also be formed by dry granulating the core ingredients and compressing the granules with the addition of a lubricant into tablets or by direct compression.

Other commonly known excipients may also be included into the core such as lubricants, pigments or dyes.

The homogeneous core is coated with a membrane, preferably a polymeric membrane to form the controlled release tablet of the invention. The membrane can be a semipermeable membrane by being permeable to the passage of external fluid such as water and biological fluids and being impermeable to the passage of the antihyperglycemic drug in the core. Materials that are useful in forming the membrane are cellulose esters, cellulose diesters, cellulose triesters, cellulose ethers, cellulose ester-ether, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate propionate, and cellulose acetate butyrate. Other suitable polymers are described in United States Patent Nos. 3,845,770, 3,916,899, 4,008,719, 4,036,228 and 4,11210 which are incorporated herein by reference. The most preferred membrane material is cellulose acetate comprising an acetyl content of 39.3 to 40.3%, commercially available from Eastman Fine Chemicals.

In an alternative embodiment, the membrane can be formed from the above-described polymers and a flux enhancing agent. The flux enhancing agent increases the volume of fluid imbibed into the core to enable the dosage form to dispense substantially all of the antihyperglycemic drug through the passageway and/or the porous membrane. The flux enhancing agent can be a water soluble material or an enteric material. Some examples of the preferred materials that are useful as flux enhancers are sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycol (PEG), propylene glycol, hydroxypropyl cellulose, hydroxypropyl methycellulose, hydroxyprophy methycellulose phthalate, cellulose acetate phthalate, polyvinyl alcohols, methacrylic acid copolymers and mixtures thereof. The preferred flux enhancer is PEG 400.

The flux enhancer may also be a drug that is water soluble such as metformin or its pharmaceutically acceptable salts or a drug that is soluble under intestinal conditions. If the flux enhancer is a drug, the present dosage form has the added advantage of providing an immediate release of the drug which is selected as the flux enhancer.

5

The flux enhancing agent comprises approximately 0 to about 40% of the total weight of the coating, most preferably about 2% to about 20% of the total weight of the coating. The flux enhancing agent dissolves or leaches from the membrane to form paths in the membrane for the fluid to enter the core and dissolve the active ingredient.

10

15

20

25

In alternate embodiments, the membrane may also be formed with commonly known excipients such as a plasticizer. Some commonly known plasticizers include adipate, azelate, enzoate, citrate, stearate, isoebucate, sebacate, triethyl citrate, tri-n-butyl citrate, acetyl tri-n-butyl citrate, citric acid esters, and those described in the Encyclopedia of Polymer Science and Technology, Vol. 10 (1969), published by John Wiley & Sons. The preferred plasticizers are triacetin, acetylated monoglyceride, grape seed oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, triethylcitrate, tributylcitrate, glyceroltributyrate, and the like. Depending on the particular plasticizer, amounts of from 0 to about 25%, and preferably about 2% to about 15% of the plasticizer can be used based upon the total weight of the coating.

As used herein the term passageway includes an aperture, orifice, bore, hole, weakened area or an erodible element such as a gelatin plug that erodes to form an osmotic passageway for the release of the antihyperglycemic drug from the dosage form. A detailed description of the passageway can be found in United States Patent Nos. such as 3,845,770, 3,916,899, 4,034,758, 4,063,064, 4,077,407, 4,088,864, 4,783,337 and 5,071,607 (the disclosures of which are hereby incorporated by reference).

In certain embodiments, the passageway is formed by laser drilling. In other embodiments, the passageway is formed by making an indentation onto the core prior to the membrane coating to form a weakened area of the membrane at the point of the indentation. In preferred embodiments of the invention, the dosage form contains two passageways in order provide the desired pharmacokinetic parameters of the formulation.

Generally, the membrane coating around the core will comprise from about 1% to about 7%, preferably about 1.5% to about 3%, based on the total weight of the core and coating.

5

10

15

20

25

The term "membrane" means a membrane that is permeable to both aqueous solutions or bodily fluids and to the active drug or pharmaceutical ingredient (e.g. the formulations of Examples 1-3). Thus, the membrane is porous to drug and, in a preferred embodiment, drug is released through the hole or passageway and through the porous membrane in solution or in vivo. The term "membrane" also generically encompasses the term "semipermeable membrane" as heretofore defined.

In an alternative embodiment, the dosage form of the present invention may also comprise an effective amount of the antihyperglycemic drug that is available for immediate release. The effective amount of antihyperglycemic drug for immediate release may be coated onto the membrane of the dosage form or it may be incorporated into the membrane.

In certain preferred embodiments of the invention where the dosage form is prepared in accordance with the above, the dosage form will have the following composition:

INGREDIENT	<b>Preferred</b>	Most Preferred
CORE:		
Drug	50-98%	75-95%
Binder	0-40%	3-15%
Absorption Enhancer	0-20%	2-10%
COATING:		
Membrane Polymer	50-99%	75-95%
Flux Enhancer	0-40%	2-20%
Plasticizer	0-25% or 0-30%	2-15%

The dosage forms prepared according to certain embodiments of the present invention preferably exhibit the following dissolution profile when tested in a USP type 2 apparatus at 75 rpms in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37°C:

10	
•	
	3 22

5

20

25

Time (Hours)	<u>Preferred</u>	Most Preferred
2	0-30%	0-15% or 0-25%
4	10-45%	20-40%
8	30-90%	45-90%
12	NTL 50%	NTL 60%
16	NTL 60%	NTL 70%
20	NTL 70%	NTL 80%
NTL = Not less than		

In the preparation of the tablets of the invention, various conventional well known solvents may be used to prepare the granules and apply the external coating to the tablets of the invention. In addition, various diluents, excipients, lubricants, dyes, pigments, dispersants, etc. which are disclosed in Remington's Pharmaceutical Sciences, 1995 Edition may be used to optimize the formulations of the invention.

Other controlled release technologies known to those skilled in the art can be used in order to achieve the controlled release formulations of the present invention, i.e., formulations which provide a mean  $T_{\text{max}}$  of the drug and/or other pharmacokinetic parameters described herein when orally administered to human patients. Such formulations can be manufactured as a controlled oral formulation in a suitable tablet or multiparticulate formulation known to those skilled in the art. In either case, the controlled release dosage form may optionally include a

controlled release carrier which is incorporated into a matrix along with the drug, or which is applied as a controlled release coating.

An oral dosage form according to the invention may be provided as, for example, granules, spheroids, beads, pellets (hereinafter collectively referred to as "multiparticulates") and/or particles. An amount of the multiparticulates which is effective to provide the desired dose of drug over time may be placed in a capsule or may be incorporated in any other suitable oral form.

In certain preferred embodiments, the tablet core or multiparticulates containing the drug are coated with a hydrophobic material selected from (i) an alkylcellulose and (ii) a polymeric glycol. The coating may be applied in the form of an organic or aqueous solution or dispersion. The coating may be applied to obtain a weight gain from about 2 to about 25% of the substrate in order to obtain a desired sustained release profile. The sustained release coatings of the present invention may also include an exit means comprising at least one passageway, orifice, or the like as previously disclosed.

## **Description of Certain Preferred Embodiments**

The following examples illustrate various aspects of the present invention. They are not to be construed to limit the claims in any manner whatsoever.

20

5

10

15

#### Example 1

A controlled release tablet containing 500 mg of metformin HCl and having the following formula is prepared as follows:

#### I. Core

5

į 15

20

25

<u>Ingredients</u>	Amount (mg/tab)
Metformin HC1	500.0
Povidone <sup>3</sup> , USP	36.0
Sodium Lauryl Sulfate	25.8
Magnesium Stearate	2.8

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

#### (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### (b) **Tableting**

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with 15/32" round standard concave punches.

#### (c) **Seal Coating (optional)**

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7006), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The Opadry Clear of the coating constitutes about 11.5 mg/tablet.

# II. Sustained Release Coating

10

5

a alla

25

<u>Ingredients</u>	Amount (mg/tablet)
Cellulose Acetate (398-10) <sup>2</sup>	21.5
Triacetin	1.3
PEG 400	2.5
<sup>2</sup> acetyl content 39.3 - 40.3%	

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

# (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

# Example 2

A controlled release tablet containing 850 mg of metformin HCl and having the following formula is prepared as follows:

## I. Core

5

10

15

20

25

IngredientsAmount (mg/tab)Metformin HCl850.0Povidone³, USP61.1Sodium Lauryl Sulfate43.9Magnesium Stearate4.8

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

#### (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with 15/32" round standard concave punches.

#### (c) **Seal Coating (optional)**

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7006), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The Opadry Clear of the coating constitutes about 11.5 mg/tablet.

# II. Sustained Release Coating

25

10

5

The second secon 15 In

Ingredients Amount (mg/tablet) Cellulose Acetate (398-10)<sup>2</sup> 24.0 Triacetin 1.4 **PEG 400** 2.8 <sup>2</sup>acetyl content 39.3 - 40.3%

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

# (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

# Example 3

A controlled release tablet containing 1000 mg of metformin HCl and having the following formula is prepared as follows:

## I. Core

10

15

ma.

20

25

5	<u>Ingredients</u>	Amount (mg/tablet)
	Metformin HCl	1000.0
	Povidone <sup>3</sup> , USP	71.9
	Sodium Lauryl Sulfate	51.7
	Magnesium Stearate	5.6

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

## (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with a screen equivalent to 18 mesh.

## (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with ½" round standard concave punches.

# (c) Seal Coating (optional)

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7003), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The core tablet is coated with the sealing solution until the tablet is coated with 23.0 mg/tablet of the Opadry material.

# II. Sustained Release Coating

Ingredients	Amount (mg/tablet)
Cellulose Acetate (398-10) <sup>2</sup>	19.0
Triacetin	1.1
PEG 400	2.2

Cellulose Acetat

Triacetin

PEG 400

2acetyl content 39.3 - 40.3%

5

10

15

20

25

ii ļ.,

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

## (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

# (e) Color Coating (optional)

5

10

15

20

25

zek.

Subsequent to the sustained release coating, the laser drilled tablet is coated with a color coating using Opadry White (24 mg/tablet) and waxed with Candelilla wax powder (0.4 mg/tablet).

# Clinical Studies

# Study 1

In study 1, a total of twelve (12) healthy subjects (six males, six females) were randomized to receive either a single oral dose of metformin XT, 850mg, prepared in accordance with Example 2 or b.i.d. doses of GLUCOPHAGE in assigned study periods which consisted of one of the following groups: Group A - metformin XT (2 x 850 mg tablets) taken at approximately 8:00 a.m., immediately following breakfast, Group B - metformin XT (2 x 850 mg tablets) taken at approximately 6:00 p.m., immediately following dinner; and Group C - GLUCOPHAGE (1 x 850 mg tablet) taken at approximately 8:00 a.m., immediately following breakfast, and at approximately 6:00 p.m., immediately following dinner. Each drug administration was separated by a washout period of seven days. In this study, one male subject was removed from the study prior to Period II due to non-treatment-related mononucleosis. Thus, 11 (five males and six females) subjects completed the study.

For metformin XT, plasma samples were obtained from subjects at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, and 24 hour(s) after dosing. For GLUCOPHAGE, plasma samples were obtained from subjects at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, and 24 hour(s) after the first dose in the morning. Plasma concentrations of metformin were determined using a validated HPLC method. The lower quantitation limit of this method is 10 ng/ml. Mean plasma concentration-time profiles are shown in Fig. 1 and mean values of pharmacokinetic parameters of metformin obtained from this study are presented in Table 1.

 $\frac{Table\ 1}{Mean\ (\pm SD,\ n=11)\ values\ of\ pharmacokinetic\ parameters\ of\ metformin\ (Example\ 2)\ in\ 11}$  healthy subjects (metformin XT, 2 x 850 mg q.d. or GLUCOPHAGE, 1 x 850 mg b.i.d.)

									netric Ratio*
Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr.)	T <sub>lag</sub> (hr)	t <sub>1/2</sub> (hr)	AUC <sub>0-∞</sub>	$\mathbf{C}_{ ext{max}}$		
Metformin XT after breakfast	18156 (4183)	2045 (567)	6 (2)	0.18 (0.40)	4.4 (0.7)	1.00	1.36		
Metformin XT after dinner	18277 (2961)	1929 (333)	7 (2)	0.09 (0.30)	3.6 (0.8)	1.02	1.32		
GLUCOPHAGE	18050 (3502)	1457 (217)	5 (3)	0 (0)	3.5 (0.9)	_			

<sup>\*</sup>Ratio = Metformin XT/GLUCOPHAGE

As shown in Figure 1 and Table 1, when metformin XT was administered immediately after either breakfast or dinner, the relative bioavailability of metformin XT formulation to GLUCOPHAGE is approximately 100%.

The results of study 1 were used to calculate the approximate degree of fluctuation ( $C_{max}$  -  $C_{min}/C_{avg}$ ) of the formulations.

The  $C_{max}$  was directly obtained from the study (see Table 1). The  $C_{avg}$  was obtained by dividing the AUC value by the dosing interval, i.e. 24 hours. The value for  $C_{min}$  was extrapolated from Figure 1.

The results are set forth in Table 2 below:

25

5

10

15

n.

Table 2

Mean ( $\pm$ SD, n = 12) values of pharmacokinetic parameters of metformin XT in 12 healthy subjects (metformin XT, 2 x 850 mg q.d. and GLUCOPHAGE, 850 mg b.i.d.)

Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	$ m C_{min} \ (ng/ml)$	C <sub>avg</sub> (ng/ml)	Degree of Fluctuation
Metformin XT after breakfast	18156 (4183)	2045 (567)	143	756	251
Metformin XT after dinner	18277 (2961)	1929 (333)	107	761	2.39
GLUCOPHAGE	18050 (3502)	1457 (217)	214 (at 24 hours)	752	1.65
			393 (between doses)	752	1.41

As shown in Figure 1 and Table 2, a single administration of the metformin XT formulation provides a higher mean fluctuation index in the plasma than a substantially equal dose of Glucophage administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

20 <u>Study 2</u>

The study design of Study 2 is the same as Study 1 except for the formulation and the dose (4 x 500 mg q.d., total dose 2000mg, for metformin XT prepared according to Example 1 and 2 x 500 mg b.i.d., total dose 2000mg, for GLUCOPHAGE in the second study). In this study, 12 healthy volunteers (five males and seven females) were randomized to receive treatments and completed the study. Mean plasma concentration-time profiles and mean values

10

5

15

25

of pharmacokinetic parameters of metformin obtained from this study are presented in Figure 2 and Table 3.

As shown in Figure 2 and Table 3, when the metformin XT formulation (500 mg) was administered immediately after dinner, the relative bioavailability of this formulation to GLUCOPHAGE is approximately 100%, while the mean C<sub>max</sub> value is about the same. The relative bioavailability of metformin XT, however, is approximately 80% when administered immediately after breakfast. A prolonged profile, together with later  $T_{max}$  and similar  $C_{max}$  of metformin following administration of metformin XT immediately after dinner compared to GLUCOPHAGE indicated that metformin was released in vivo in a sustained fashion (Figure 2).

10

15

i,#

5

Table 3

Mean ( $\pm$ SD, n = 12) values of pharmacokinetic parameters of metformin of Example 1 in 12 healthy subjects (metformin XT, 4 x 500 mg q.d. or GLUCOPHAGE, 2 x 500 mg b.i.d.)

					Geom	etric Mean ]	Ratio*
Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr)	T <sub>lag</sub> (hr)	t <sub>1/2</sub> (hr)	AUC <sub>0-∞</sub>	C <sub>max</sub>
Metformin XT after breakfast	17322 (4984)	2127 (545)	5 (1)	0 (0)	6.1 (1.8)	0.80	1.15
Metformin XT after dinner	20335 (4360)	2053 (447)	7 (2)	0.08 (0.29)	3.9 (0.6)	0.96	1.12
GLUCOPHAGE	21181 (4486)	1815 (302)	4 (3)	0 (0)	3.6 (0.8)		_

<sup>\*</sup>Ratio = Metformin XT/GLUCOPHAGE

The results of study 2 were used to calculate the approximate degree of fluctuation of the formulations in accordance with the calculations used in study 1 (using Figure 2 to obtain the extrapolated value for  $C_{\min}$ ).

The results are set forth in Table 4 below:

30

 $\frac{Table\ 4}{Mean\ (\pm SD,\ n=12)}\ values\ of\ pharmacokinetic\ parameters\ of\ metformin\ XT\ in\ 12\ healthy\ subjects\ (metformin\ XT,\ 4\ x\ 500\ mg\ q.d.\ and\ GLUCOPHAGE,\ 2\ x\ 500\ mg\ b.i.d.)$ 

Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	C <sub>min</sub> (ng/ml)	C <sub>avg</sub> (ng/ml)	Degree of Fluctuation
Metformin XT after breakfast	17322 (4984)	2127 (545)	143	721	2.9
Metformin XT after dinner	20335 (4360)	2053 (447)	143	847	2.25
GLUCOPHAGE	21181 (4486)	1815 (302)	214 (at 24 hours)	882	1.8
			357 (between doses)	882	1.65

As shown in Figure 2 and Table 4, a single administration of the metformin XT formulation provides a higher mean fluctuation index in the plasma than an equivalent dose of Glucophage administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

20 <u>Study 3</u>

5

10

15

25

In Study 3, a multiple-dose, open-label, one-period study was conducted to evaluate the short-term tolerability and steady-state pharmacokinetics of the 500 mg metformin XT formulation used in Study 2. In this study, eight healthy volunteers (four males and four females) were randomized to receive 2000 mg of metformin XT (4 x 500 mg tablets) at approximately 6:00 p.m., immediately following dinner, for 14 days.

Blood samples were obtained from each subject at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16 and 24 hour(s) following the first dose on Day 1 and at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 38 and 48 hour(s) following the last dose on Day 14. Blood samples were also drawn from each subject immediately prior to dosing on Days 10-13. Urine samples were collected from each subject at the following time intervals: six hours prior to the first dose; 0-6, 6-12 and 12-24 hours after the first dose; and 0-6, 6-12, 12-24 and 24-48 hours after the last dose.

Mean plasma profiles and values of pharmacokinetic parameters of metformin are presented in Table 5 below:

<u>Table 5</u>

Mean Pharmacokinetic Parameters (Example 1)

Day 1

5

10

25

	C <sub>max</sub>	T <sub>max</sub>	AUC <sub>0-24hr (ng.hr/ml)</sub>
Mean	2435	6.9	22590
SD	630	1.9	3626

Day 14

	C <sub>max</sub>	T <sub>max</sub>	AUC <sub>0-24hr (ng.hr/ml)</sub>		
Mean	2288	6.9	24136		
SD	736	2.5	7996		

Following oral administration of metformin XT, 4 x 500 mg q.d., for 14 days, there was little or no difference in plasma concentration-time profiles of metformin in eight healthy volunteers between Day 1 and Day 14 dosing (Figure 3). On average, trough plasma concentrations of metformin were nearly constant, ranging from 188.8 to 205.1 ng/ml on Days 10-14, indicating that the steady state of metformin was attained rapidly. The mean

accumulation ratio was 1.01, indicating that the once-daily dose regimen of metformin XT results in no accumulation.

Following oral administration of a single dose (4 x 500 mg) of metformin XT, approximately 31% of the dose was excreted in the urine within the first 24 hours. On average, the renal clearance of metformin was 366 ml/min. A slightly higher renal clearance (454 ml/min) was found after multiple-dose administration of 4 x 500 mg q.d. of metformin XT.

Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence and anorexia) are the most common adverse reactions to GLUCOPHAGE. In controlled trials, GLUCOPHAGE was started at low, nontherapeutic doses and gradually titrated to higher doses. In spite of this gradual titration, GLUCOPHAGE was discontinued due to gastrointestinal reactions in approximately 4% of patients. In contrast, in the multiple-dose study, metformin XT begun at a therapeutic initial dose of 2000 mg once daily with dinner was well tolerated by all healthy volunteers. Diarrhea and nausea were the most common gastrointestinal reactions probably or possibly related to metformin XT. These reactions, however, were either mild or moderate. This suggests that it may be possible to initiate metformin XT treatment with effective doses rather than using the slow titration from non-therapeutic doses required for GLUCOPHAGE.

## Study 4

Study 4 was a study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of metformin XT compared to GLUCOPHAGE after multiple-dose treatment in patients with NIDDM. Metformin XT tablets prepared according to Example 3 were used in this study. This study had a single-center, randomized, two-way crossover design. A total of 24 NIDDM patients who were on a stable dose of GLUCOPHAGE, between 1000 and 2550 mg/day, for at least 12 weeks were selected for the study. A Pretreatment Period of at least 3 weeks preceded randomization to study treatment. At the start of the Pretreatment Period, all patients stopped taking any other hypoglycemic agents besides GLUCOPHAGE, and the GLUCOPHAGE dose was adjusted to 1000 mg b.i.d. (with breakfast and with dinner).

15

20

5

5

10

15 

25

Following the pretreatment period, patients began Treatment Period I, which lasted 4 weeks. During Period I, a total of 12 patients were randomized to receive two 1000-mg metformin XT tablets q.d. (immediately after dinner), at approximately 6:00 p.m., and 12 were randomized to receive one 1000-mg GLUCOPHAGE tablet b.i.d. (immediately after breakfast and immediately after dinner). Immediately following Period I, each patient was switched to the alternate medication for 4 weeks in Period II. There was no washout between treatment periods.

Plasma metformin concentrations were determined over a 24-hour period at the end of Treatment Periods I and II as follows: immediately prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, 22, and 24 hours after the evening dose. One subject withdrew from the study for personal reasons after two weeks of treatment in Treatment Period I, thus pharmacokinetic data were obtained from 23 patients.

Mean plasma profiles and values of pharmacokinetic parameters of metformin are presented in Figure 4 and Table 6. As shown in Figure 4 and Table 6, when metformin XT was administered immediately after dinner, the bioavailability of metformin XT relative to GLUCOPHAGE at steady state is close to 100%. Although the dose of metformin XT was twice as large as the dose of GLUCOPHAGE at dinner, the mean  $C_{\text{max}}$  value was only 32% higher.

Table 6

Mean (± SD) values of pharmacokinetic parameters of metformin of Example 3 in 23

NIDDM patients (metformin XT, 2 x 1000 mg q.d. with dinner or GLUCOPHAGE, 1 x 1000 mg b.i.d.)

Geometric Mean Ratio*									
Treatment	AUC <sub>0-24hr</sub> (ng•hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr)	T <sub>lag</sub> (hr)	t <sub>1/2</sub> (hr)	AUC <sub>0-24hr</sub>	$C_{max}$		
Metformin XT after dinner	26818 (7052)	2849 (797)	6 (2)	0 (0)	5.4	0.96	1.32		
GLUCOPHAGE	27367 (5759)	2131 (489)	14 (6)	0 (0)	4.4				

<sup>\*</sup> Ratio = Metformin XT/GLUCOPHAGE

5

10

20

25

When the metformin XT was administered immediately after dinner, the bioavailability of metformin XT relative to GLUCOPHAGE at steady state was close to 100%. However, when metformin XT was administered immediately after breakfast, the corresponding relative bioavailability of metformin XT was approximately 80%. The safety profile of metformin XT, 2000 mg given once daily either after dinner or after breakfast was comparable to that of an equal dose of GLUCOPHAGE given b.i.d. The efficacy profile of metformin XT, 2000 mg given once daily after dinner was similar to that of an equal dose of GLUCOPHAGE given b.i.d. The efficacy of metformin XT, 2000 mg given once daily after breakfast, however, appeared to be comparable to or slightly less than that of GLUCOPHAGE given b.i.d.

While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention.

# WHAT IS CLAIMED IS:

- 1. A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of at least one suitable antihyperglycemic agent or a pharmaceutically acceptable salt thereof and a controlled release carrier, wherein the dosage form provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from 5.5 to 7.5 hours after administration.
- 2. The controlled release dosage form of claim 1 wherein said at least one antihyperglycemic agent is a biguanide.
- 3. The controlled release dosage form of claim 2 wherein said biguanide is metformin or a pharmaceutically acceptable salt thereof.
- 4. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from 6.0 to 7.0 hours after administration.
- 5. The method of claim 3, in which the administration of the at least one metformin dosage form occurs at dinner time and provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from about 5.5 to 7.0 hours after the administration.
- 6. The method of claim 3, in which the administration of the at least one metformin dosage form occurs at breakfast and provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from about 6.0 to about 7.5 hours after the administration.

- 7. The method of claim 3, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of the drug from about 4.5 to about 13 hours.
- 8. The method of claim 3, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of the drug from about 5.5 to about 10 hours.
- 9. The method of claim 3, in which the administration of the at east one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is more than about 7 times the mean plasma level of said metformin at about 24 hours after administration.
- 10. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 7 times to about 14 times the plasma level of said metformin at about 24 hours after administration.
- 11. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 8 times to about 12 times the plasma level of said metformin at about 24 hours after administration.
- 12. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1500 ng/ml to about 3000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.

- 13. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1700 ng/ml to about 2000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 14. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from at least 80% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 15. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> that is from at least 90% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 16. The method of claim 3, in which the once-a-day dose of the metformin is administered at dinner.
- 17. The method of claim 16, in which the once-a-day dose of metformin is administered at fed state.
- 18. The method of claim 16, in which the once-a-day dose of the metformin is about 2000 mg, which is provided by two controlled release dosage forms containing about 1000 mg metformin each.

- 19. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 20. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 26500 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 21. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about19800 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 22. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 1, based on administration of a 1700 mg once-a-day dose of metformin.
- 23. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 2, based on administration of a 2000 mg once-a-day dose of metformin.
- 24. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 4, based on administration of a 2000 mg once-a-day dose of metformin at dinner.
- 25. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set

forth in FIG. 6, based on administration of a 2000 mg once-a-day dose of metformin at breakfast.

- 26. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma glucose concentration-time profile substantially as set forth in FIG. 5, based on administration of a 2000 mg once-a-day dose of metformin at dinner.
- 27. The method of claim 3, further comprising administering to said human patients at least one additional pharmaceutically active ingredient for treatment of NIDDM.
- 28. The method of claim 3, further comprising administering to said human patients an additional pharmaceutically active ingredient for treatment of NIDDM, said additional pharmaceutically active ingredient selected from the group consisting of a sulfonylurea, a glitazone or a second biguanide.
- 29. The method of claim 3, in which the dose of metformin comprises metformin hydrochloride.
- 30. The method of claim 29, in which the once-a-day dose of metformin hydrochloride is about 1000 mg to about 2500 mg.
- 31. The method of claim 29, in which the once-a-day dose of metformin hydrochloride is about 2000 mg to about 2500 mg metformin.
- 32. A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering at least one biguanide or pharmaceutically acceptable salt thereof and a controlled release carrier wherein a single administration of said dosage form provides a higher mean fluctuation

index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

- 33. The method of claim 32 wherein said dosage form maintains bioavailability from at least 80% of the immediate release composition.
- 34. The method of claim 32 wherein said dosage form maintains bioavailability from aat least 90% of the immediate release composition.

# **ABSTRACT**

A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.







FIGURE 3






# Metformin HCI Dissolution Profiles


Paddle at 75rpm, in pH7.5




-**=**- 500mg

FIGURE 6









- 850mg


FIGURE 7





-**=** 1000 mg

FIGURE 8





S	EAR	CHE	)
Class	Sub.	Date	Exmr.
424 <b>5</b> 14	473 469 479 479 479 479 480 480 591 592 593	12:20-01	Ta

INTERFERENCE SEARCHED										
Sub.	Date	Exmr.								

SEARCH (INCLUDING SEA	NOTE	ES ATEGY)
Inverter Search	Date	Exmr.
BRS	/z-30-01	Tw

AUROBINDO EX. 1006, 434

#### ISSUE SLIP STAPLE AREA (for additional cross references)

INITIALS	ID NO.	DATE
-	1100/ =	1/24/11
	100	11/29
	69652	11107
2.2	69134	4-13-01
	TS	71496 = 18452 55 69134

### **INDEX OF CLAIMS**

Rejected	N Non-elected
= Allowed	IInterference
<ul> <li>(Through numeral) Canceled</li> </ul>	A Appeal
÷ Restricted	O Objected

÷										F	?est	rict	ed				0	••••	••••	•••••	• • • • • • • • • • • • • • • • • • • •	•••••	Obje	cted											
Cla	im					Dat	te						Cla	ılm					Dat	e					Cla	im				Date	a				٦
		12	<u> </u>					[	Γ	П										$\neg$			$\neg$	$\neg$				Т	Т	T	П	Т	$\exists$	T	٦
Final	Original	الم											Final	Original											Final	Original				ł		1			
ŧ	፩	d.	_		L	<u> </u>		<u>L</u>	L	Ш			ıΈ	ō		_		_				_	_	_	ίĒ	ŏ	Ш	$\perp$	_	_	_	_	_	$\bot$	╛
	1 Y	1	L		L	L			L	Ш				51									_	_		101		$\perp$	_	$\perp$	_	_	_	$\perp$	┛
	2		<u></u>											52	}										L	102			$\perp$			$\perp$			
	3	1	1					l						53			1									103						$_{\perp}$			
	4	L				L								54									$\Box$			104								$\perp$	
	5	L												55												105	Ш	$\perp$							
	6													56												106					$\Box$				$\Box$
	7													57												107			Τ			$\Box$	$\Box$		$\Box$
	8	Γ	Π											58												108									
	9	Γ	Γ						Г					59												109			I	Ι				Т	٦
П	10	T								П				60						Ī						110			П	П	$\Box$	П	П	Т	П,
П	11	T								П			Г	61						╗		П		$\neg$		111	П	Т	Т	T	П	$\neg$	П	П	$\neg$
П	12	T												62						一						112	П	T	$\neg$	П	$\neg$	T	$\neg$		
	13	1												63						$\neg$				$\neg$		113	П	T	T	П	$\neg$	$\neg$	П		┑
П	14	1	Π										П	64						$\neg$	$\neg$			$\neg$		114	П	$\top$	$\top$	$\exists$	丁	$\neg$	寸	$\exists$	ヿ
"	15	1	Г				П		Г	П				65			П	$\neg$		$\dashv$	$\neg$	$\Box$		$\neg$		115	П	1	$\top$	1	ヿ	$\neg$	$\neg$	7	ヿ
$\vdash$	16	1	Ι_				П			П		}	Г	66			•				$\neg$			$\neg$		116	П	$\dashv$	$\top$	T	ヿ	$\dashv$	$\neg$	$\exists$	П
	17	t			_	_			_				$\vdash$	67	_					$\neg$			$\dashv$	$\neg$		117	$\Box$	┪	$\top$	7	┪	┪	╗	_	ᅦ
	18	t	<u> </u>			<u> </u>								68						_		_		$\dashv$		118	П	$\dashv$	_	7		┪	$\neg$	$\neg$	ᅱ
	19	t	$\vdash$	$\vdash$		_				Н			$\vdash$	69	$\neg$			$\neg$	$\neg$	7	_	$\neg$	$\neg$	$\neg$	_	119		$\top$	7	7	7		_	7	-1
	20	t	├-	-	-	-	┝┈	-		Н			$\vdash$	70	-			$\dashv$	$\dashv$	-	-		-+	$\dashv$	<u> </u>	120	$\vdash$	+	$^+$	-	-+	_	-	+	$\dashv$
Н		╀	-			-	H	$\vdash$	┢	Н			$\vdash$		$\dashv$				-		-			$\dashv$	-		<del>                                     </del>	+	+	$\dashv$	-+	$\dashv$	$\dashv$		ᅴ
-	21	╀	-	_		<u> </u>		┝		H	_		$\vdash$	71	-	$\dashv$	$\vdash$	$\dashv$	-		$\dashv$	$\dashv$	-	$\dashv$	-	121	$\vdash$	+	+	-	$\dashv$	$\dashv$	-	$\dashv$	⊣
-	22 23	Ļ	├-	-		-			-	Н	-		$\vdash$	72 73	$\dashv$	_			-		$\dashv$			-	-	123	╌	$\dashv$	+	-	-+	-	$\dashv$	┥	ᅱ
$\vdash$	24	╀		-	ļ	<u> </u>	-	<u> </u>	-	Н		ŀ	-	74					$\dashv$	$\dashv$	$\dashv$	$\dashv$	-	$\dashv$	$\vdash$	124	$\vdash$	+	+	-	-			$\dashv$	ᅴ
		┢	⊢	<u> </u>	_		-	-	_	$\vdash$	-	ł	$\vdash$										-		-		$\vdash$	+	-	$\dashv$	-+	$\dashv$	-	-	ᅱ
<u> </u>	25	┡	┞-	<u> </u>	_	<u> </u>		<u> </u>	<u> </u>	Н			$\vdash$	75	_			_					-	_	-	125	11	-	$\dashv$	4	$\dashv$		$\dashv$		$\dashv$
_	26	L	⊢		L		Ш	<u> </u>	_	Ш				76	_	_	_	_			_	-	-	_	<u> </u>	126	<b>├</b>	$\dashv$	4	-		$\dashv$	$\dashv$	-	긕
	27	L	<u> </u>	<u> </u>	<u> </u>	_	<u> </u>	<u> </u>	_	Ш		ŀ	<u> </u>	77				$\Box$		_	_	-	_	_	$\vdash$	127	┷	-	-	4	-	Н	$\dashv$	_	-
	28	L	<u> </u>	L			Ш	<u> </u>		Ш			$\vdash$	78		_		_			_	$\dashv$	$\perp$	_	<u> </u>	128	H	4		4	4	$\square$	$\dashv$		4
	29	L	L					L_	<u> </u>	Ш	_		<u> </u>	79		_		_			_	_	_	_	$\perp$	129	$\sqcup$	4	_	_	_	$\sqcup$		_	_
Щ	30	1	L	L		L.	Щ	<u> </u>	<u> </u>			ļ	$\vdash$	80						_	_			_	<u> </u>	130	1	_	4			Ш	_	_	_
$\Box$	31 <b>53</b>	1	<u> </u>			L		L		Ш			$\vdash$	81					$\Box$	_	_		_	_	<u> </u>	131	$\sqcup$	4	4	_	_	Ш	_	_	_
	3	L				_	_	L		Ш			L_	82						_	_					132	Ш		$\perp$	_	_		_		
il	33	1	L			L								83												133				$\dashv$					
	34	J	L	L_	Ш		Ш	L	L	Ш			L	84										_	L	134	Ш	_	$\perp$				$\sqcup$		_
	35		<u></u>	L		L.							L	85					$\perp$			I				135	Ш			$\perp$		Ш	丄		
	36					L								86												136	Ш					Ш			
	37		L						L					87												137	$\Box$	$oldsymbol{\perp}$	$\Box$				$oldsymbol{\bot}$	_ [	
	38													88												138	$\square$	$oldsymbol{ol}oldsymbol{oldsymbol{ol{ol}}}}}}}}}}}}}}}} $	$oldsymbol{\mathbb{I}}$	J				$oldsymbol{\bot}$	
	39													89												139	$\Box$	$oldsymbol{\mathbb{I}}$		$oldsymbol{\mathbb{J}}$	$\Box$				
	40					Γ							П	90				$\neg$		$\neg$	$\neg$					140		Т	Т	$\neg$			П	Ī	
	41				_					Н				91	_	_							$\neg$	$\neg$		141	$\Box$	7	$\neg$	T	$\neg$		$\neg$		
	42			Н		$\vdash$	Н		<del>                                     </del>	H	_		$\vdash$	92	$\dashv$	-		$\neg$		$\dashv$	$\neg$	$\vdash$	$\dashv$	$\dashv$		142	$\vdash$	$\dashv$	$\dashv$	7	_	$\dashv$		7	⊣
	43		$\vdash$	Н	П	$\vdash$	_	$\vdash$	<del>                                     </del>	Н				93	$\dashv$	$\exists$	$\dashv$				-		_	$\dashv$		143	1 1	$\dashv$	7	$\dashv$	$\dashv$		_	┪	$\dashv$
	44	-	┢┈	$\vdash$	$\dashv$	<del> </del>	$\vdash$	$\vdash$	┢	H				94	_	$\exists$		_	$\dashv$	-	┪	$\vdash$	$\dashv$	$\dashv$	-	144	H	$\dashv$	7	7	$\dashv$	$\neg$	$\dashv$	7	ᅥ
	45	-	$\vdash$	-	Н	$\vdash$	-		<del> </del>	$\vdash \vdash$			$\vdash$	95		$\dashv$	$\dashv$	$\dashv$	-	$\dashv$	$\dashv$		$\dashv$	$\dashv$		145	$\vdash$	+	$\dashv$	+	+	$\dashv$	$\dashv$	-	$\dashv$
	46	-					$\vdash$		$\vdash$	$\vdash$	_		$\vdash$	96	$\dashv$	$\dashv$	-		-		$\dashv$	$\vdash$	$\overline{}$	$\dashv$	-	146	┼┤	+	$\dashv$	+	-+	$\dashv$	_	$\dashv$	ᅥ
	47	-	<del>                                     </del>	$\vdash$	Н	$\vdash$	$\vdash$	$\vdash$	$\vdash$	Н	-			97	-	$\dashv$	$\dashv$	$\dashv$	$\dashv$	$\dashv$	$\dashv$	$\dashv$	-+	$\dashv$	<u> </u>	147	1-1	$\dashv$	+	$\dashv$	-+	$\dashv$	$\dashv$	$\dashv$	$\dashv$
	48	-	-	$\vdash$	Н	$\vdash$	-	H	$\vdash$	$\vdash$	-		-	98	-	$\dashv$	$\dashv$		$\dashv$	$\dashv$	$\dashv$	$\dashv$	+	$\dashv$	$\vdash$	148	$\vdash$	+	┰	-	$\dashv$	$\dashv$	$\dashv$	┪	$\dashv$
	49		-	$\vdash$	$\vdash$	H	-	-	-	$\vdash\vdash$	_		$\vdash$	99		$\dashv$						$\dashv$	┪	$\dashv$	$\vdash$	149	$\vdash$	+	+	-	$\dashv$	-	-+	$\dashv$	ᅥ
	50	-	$\vdash$	-	-	H	Н	$\vdash$	-	$\vdash$	-		$\vdash$	100		$\dashv$	$\dashv$				-		$\dashv$	$\dashv$	$\vdash$	150	╁╌┤	+	+		$\dashv$	$\dashv$	-	┪	$\dashv$
	~~						_						-	į					1									1_		_1					

If more than 150 claims or 10 actions staple additional sheet here

### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submis

### TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an								
invention entitled:								
METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE METFORMIN								
and invented by:								
Xiu Xiu CHENG, Chih-Ming CHEN, Steve JAN and Joseph CHOU								
If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:								
Continuation Divisional Continuation-in-part (CIP) of prior application No.:								
Whith is a:								
Continuation Divisional Continuation-in-part (CIP) of prior application No.:								
Whiteh is a:								
Continuation Divisional Continuation-in-part (CIP) of prior application No.:								
Enclosed are:  Application Elements								
Filing fee as calculated and transmitted as described below								
2. 図 Specification having								
The Description of the Invention								
a. Descriptive Title of the Invention								
b.   Cross References to Related Applications (if applicable)								
c.   Statement Regarding Federally-sponsored Research/Development (if applicable)								
d. Reference to Microfiche Appendix (if applicable)								
e. 🗵 Background of the Invention								
f. 🗵 Brief Summary of the Invention								
i. Ed bhei dummary of the invention								
g. 🗵 Brief Description of the Drawings (if drawings filed)								
·								
g. 🗵 Brief Description of the Drawings (if drawings filed)								

## UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission

3.	X	Drav	wing(s) <i>(when nece</i> s	ssary as prescribed by 35 USC 113)									
	a.		Formal	Number of Sheets									
	b.	X	Informal	Number of Sheets 8									
4.		Oatl	h or Declaration	$\cdot$									
	a.		Newly executed (o	riginal or copy)									
	b.		Copy from a prior a	application (37 CFR 1.63(d)) (for continuation/divisional application only)									
	C.	☐ With Power of Attorney ☐ Without Power of Attorney											
1,11	d.		DELETION OF INV Signed statement a see 37 C.F.R. 1.63	attached deleting inventor(s) named in the prior application,									
		Incorporation By Reference (usable if Box 4b is checked)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.											
6		Computer Program in Microfiche (Appendix)											
<b>7.</b>													
	a.		☐ Paper Copy										
	b.	☐ Computer Readable Copy (identical to computer copy)											
	C.		Statement Verifying	g Identical Paper and Computer Readable Copy									
				Accompanying Application Parts									
8.		Ass	ignment Papers (co	ver sheet & document(s))									
9.		37 (	CFR 3.73(B) Statem	ent (when there is an assignee)									
10.		Eng	lish Translation Doc	ument (if applicable)									
11.		Info	rmation Disclosure S	Statement/PTO-1449									
12.		Pre	liminary Amendmen										
13.	X	Ack	nowledgment postc	ard									
14.	X	Cer	tificate of Mailing										
			First Class 🗵	Express Mail (Specify Label No.): EL 415 728 697 US									

**Application Elements (Continued)** 

### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission 55

	Accompanying Application Parts (Continued)
15.	Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.	Additional Enclosures (please identify below):
<b>Q</b> .	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)  Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in
The state of the s	this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.  Warning
	An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. 300.1012

Total Pages in this Submission 55

#### **Fee Calculation and Transmittal**

CLAIMS AS FILED										
#Filed	#Allowed	#Extra		Rate	Fee					
34	- 20 =	14	x	\$18.00	\$252.00					
2	- 3 =	0	x	\$80.00	\$0.00					
Multiple Dependent Claims (check if applicable)										
BASIC FEE \$710.00										
OTHER FEE (specify purpose) \$0.00										
TOTAL FILING FEE \$962.00										
□ A check in the amount of to cover the filing fee is enclosed. □ The Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed. □ Charge the amount of as filing fee. □ Credit any overpayment. □ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17. □ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).										
	311(h)		/i /	/ // . // /						
	ad 2 laims (check purpose)  punt of r is hereby aut w. A duplicate e amount of v overpayment	34 - 20 =  2 - 3 =  laims (check if applicable)  purpose)  ount of to ount of to ount of the purpose of the pur	34 -20 = 14  2 -3 = 0  laims (check if applicable)  purpose)  count of to cover the filing r is hereby authorized to charge and credit D w. A duplicate copy of this sheet is enclosed a mount of as filing fee.	34 -20 = 14 x  2 -3 = 0 x  laims (check if applicable)  purpose)  to cover the filing fee is a cover is hereby authorized to charge and credit Deposit Av. A duplicate copy of this sheet is enclosed.  to a filing fee.  to overpayment.	34 - 20 = 14 × \$18.00  2 - 3 = 0 × \$80.00  Basic FEE  purpose  TOTAL FILING FEE  ount of to cover the filing fee is enclosed. or is hereby authorized to charge and credit Deposit Account No. or. A duplicate copy of this sheet is enclosed. e amount of as filing fee. overpayment.					

cc:

Dated: November 3, 2000

23280
PATENT TRADEMARK OFFICE

Reg. No. 41,240

	AILING BY "EXPRESS I		Docket No. 300.1012
Serial No.	Filing Date	Examiner	Group Art Unit
Not Yet Known	Herewith	To Be Assigned	To Be Assigned
Invention: METHODS FO RELEASE ME		A ADMINISTRATION OF CO	NTROLLED SINCE
I hereby certify that the fo	ollowing correspondence:		
Utility Patent Applicatio	n with accompanying documen	its.	
	(Identify type	of correspondence)	
is being deposited with the	he United States Postal Servi	ce "Express Mail Post Office to	o Addressee" service under
37 CFR 1.10 in an envelo	ope addressed to: The Assista	nt Commissioner for Patents, '	Washington, D.C. 20231 on
November 3,	2000		
•	•	Randolph K. M	<b>IcQueen</b>
	A	(Typed or Printed Name of Person I	Mailing Correspondence)  MCQUULV  G Correspondence)
		EL 415 728 6	697 US
		("Express Mail" Mailing	Label Number)
	Note: Each paper must ha	ve its own certificate of mailing.	
			•
		•	

THE PROPERTY







FIGURE 3








### Metformin HCI Dissolution Profiles

Paddle at 75rpm, in pH7.5




-**=**- 500mg

FIGURE 6

### Metformin HCI Dissolution Profiles

Paddle at 75rpm, in pH7.5



-**=**- 850mg

FIGURE 7

# Metformin HCI Dissolution Profiles Paddle at 75rpm in pH7.5




FIGURE 8

### METHODS FOR TREATING DIABETES VIA ADMINISTRATION OF CONTROLLED RELEASE METFORMIN

### **Background of the Invention**

5

The present invention relates to controlled release unit dose formulations containing an antihyperglycemic drug. More specifically, the present invention relates to an oral dosage form comprising a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride or the metformin salts described in United States Patent Nos. 3,957,853 and 4,080,472 which are incorporated herein by reference.

10

In the prior art, many techniques have been used to provide controlled and extendedrelease pharmaceutical dosage forms in order to maintain therapeutic serum levels of medicaments and to minimize the effects of missed doses of drugs caused by a lack of patient compliance.

15

n

ļ,Ļ

In the prior art are extended release tablets which have an osmotically active drug core surrounded by a semipermeable membrane. These tablets function by allowing a fluid such as gastric or intestinal fluid to permeate the coating membrane and dissolve the active ingredient so it can be released through a passageway in the coating membrane or if the active ingredient is insoluble in the permeating fluid, pushed through the passageway by an expanding agent such as a hydrogel. Some representative examples of these osmotic tablet systems can be found in United States Patent Nos. 3,845,770, 3,916,899, 4,034,758, 4,077,407 and 4,783,337. United States Patent No. 3,952,741 teaches an osmotic device wherein the active agent is released from a core surrounded by a semipermeable membrane only after sufficient pressure has developed within the membrane to burst or rupture the membrane at a weak portion of the membrane.

25

20

The basic osmotic device described in the above cited patents have been refined over time in an effort to provide greater control of the release of the active ingredient. For example United States Patent Nos. 4,777,049 and 4,851,229 describe an osmotic dosage form comprising a semipermeable wall surrounding a core. The core contains an active ingredient and a modulating agent wherein the modulating agent causes the active ingredient to be released through a passageway in the semipermeable membrane in a pulsed manner. Further refinements have

included modifications to the semipermeable membrane surrounding the active core such as varying the proportions of the components that form the membrane; i.e., United States Patent Nos. 5,178,867, 4,587,117 and 4,522,625 or increasing the number of coatings surrounding the active core; i.e., U.S. Patent Nos. 5,650,170 and 4,892,739.

5

Although vast amounts of research has been performed on controlled or sustained release compositions and in particular on osmotic dosage forms, very little research has been performed in the area of controlled or sustained release compositions that employ antihyperglycemic drugs.

10

U

15

20

25

Metformin is an oral antihyperglycemic drug used in the management of non-insulin-dependent diabetes mellitus (NIDDM). It is not chemically or pharmacologically related to oral sulfonylureas. Metformin improves glucose tolerance in NIDDM patients by lowering both basal and postprandial plasma glucose. Metformin hydrochloride is currently marketed as GLUCOPHAGE® tablets by Bristol-Myers Squibb Co. Each GLUCOPHAGE® tablet contains 500, 850 or 1000 mg of metformin hydrochloride. There is no fixed dosage regimen for the management of hyperglycemia in diabetes mellitus with GLUCOPHAGE®. Dosage of GLUCOPHAGE® is individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended dose of 2550 mg per day.

Metformin has been widely prescribed for lowering blood glucose in patients with NIDDM. However, being a short acting drug, metformin requires twice-daily (b.i.d.) or three-times-a-day (t.i.d.) dosing. Adverse events associated with metformin use are often gastrointestinal in nature (e.g., anorexia, nausea, vomiting and occasionally diarrhea, etc.). These adverse events may be partially avoided by either reducing the initial and/or maintenance dose or using an extended-release dosage form. Another clear advantage of an extended release dosage form is a reduction in the frequency of administration. All of these findings suggest that an extended-release dosage form of metformin may improve the quality of therapy in patients with NIDDM and the safety profile relative to a conventional dosage form.

The limited work on controlled or sustained release formulations that employ antihyperglycemic drugs such as metformin hydrochloride includes the combination of the antihyperglycemic drug and an expanding or gelling agent to control the release of the drug from

the dosage form. This research is exemplified by the teachings of WO 96/08243 and by the GLUCOPHAGE® metformin HCl product.

It is reported in the 50th Edition of the Physicians' Desk Reference, copyright 1996, p. 753, that food decreases the extent and slightly delays the absorption of metformin delivered by the GLUCOPHAGE® dosage form. This decrease is shown by approximately a 40% lower peak concentration, a 25% lower bioavailability and a 35-minute prolongation of time to peak plasma concentration following administration of a single GLUCOPHAGE® tablet containing 850 mg of metformin HCl with food compared to the similar tablet administered under fasting conditions.

A controlled release metformin dosage form is also described in WO 99/47128. This

10

15

5

---

Tmax from 8 to 12 hours.

reference describes a controlled release delivery system for metformin which includes an inner solid particulate phase formed of substantially uniform granules containing metformin and one or more hydrophilic polymers, one or more hydrophobic polymers and one or more hydrophobic materials, and an outer continuous phase in which the above granules are embedded and dispersed throughout. The outer continuous phase includes one or more hydrophilic polymers, one or more hydrophobic polymers and one or more hydrophobic materials. Our own WO 99/47125 discloses controlled release metformin formulations providing a

20

25

### Objects and Summary of the Invention

It is an object of the present invention to provide a controlled or sustained release of an antihyperglycemic drug which provides effective control of blood glucose levels in humans.

It is a further object of the present invention to provide a method of treating human patients with non-insulin-dependent diabetes mellitus (NIDDM) on a once-a-day basis with an antihyperglycemic drug which provides effective control of blood glucose levels in humans.

It is a further object of the present invention to provide formulations for treating human patients with non-insulin-dependent diabetes mellitus (NIDDM) which provides advantages over the state-of-the-art, and which may be administered on a once-a-day basis by itself or together with other antidiabetic agents, and methods thereof.

It is a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug wherein the bioavailability of the drug is not decreased by the presence of food.

It is a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug that does not employ an expanding polymer.

It is also a further object of the present invention to provide a controlled or sustained release formulation of an antihyperglycemic drug that can provide continuous and non-pulsating therapeutic levels of the drug to an animal or human in need of such treatment over a twelve hour to twenty-four hour period.

It is an additional object of other embodiments of the present invention to provide a controlled or sustained release formulation for an antihyperglycemic drug that obtains peak plasma levels from 5.5 to 7.5 hours after administration under various conditions. Alternatively, the time to peak plasma levels are from 6.0 to 7.0, from 5.5 to 7.0 or from 6.0 to 7.5.

It is also an object of this invention to provide a controlled or sustained release pharmaceutical formulation having a homogeneous core wherein the core component may be made using ordinary tablet compression techniques.

In accordance with the above-mentioned objects and others, the present invention provides a controlled release oral dosage form comprising an antihyperglycemic drug, preferably a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof) that is suitable for providing once-a-day administration of the drug, wherein the dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug from 5.5 to 7.5 hours after administration. The dosage form comprises the drug and a membrane. In certain preferred embodiments, the dosage form comprises a tablet.

In preferred embodiments, the controlled release oral dosage form of the present invention is a tablet comprising:

(a) a core comprising:

5

10

15

20

25

- (i) the antihyperglycemic drug;
- (ii) optionally a binding agent; and
- (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

When the drug is metformin or a pharmaceutically acceptable salt thereof and is administered on a once-a-day basis, the daily dose may vary, e.g., from about 500 mg to about 2500 mg. Such daily dose may be contained in one controlled-release dosage form of the invention, or may be contained in more than one such dosage form. For example, a controlled-release metformin dosage form may be formulated to contain about 1000 mg of the drug, and two of said dosage form may be administered together to provide once-a-day metformin therapy. The daily dose of the drug (i.e. metformin or pharmaceutically acceptable salt thereof) may range from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient.

In certain preferred embodiments, the controlled release solid oral dosage form of the present invention provides a width at 50% of the height of a mean plasma concentration/time curve of the drug (e.g., of metformin) from about 4.5 to about 13 hours, more preferably from about 5.5 to about 10 hours, more preferably from about 6 to about 8 hours.

In certain embodiments, the controlled release oral dosage form of the present invention provides a mean maximum plasma concentration ( $C_{max}$ ) of the antihyperglycemic drug which is more than about seven times the mean plasma level of said drug at about 24 hours after administration. In preferred embodiments, the controlled release oral dosage form of the present invention provides a mean maximum plasma concentration ( $C_{max}$ ) of the drug which is from about 7 times to about 14 times the plasma level of the drug at about 24 hours after the administration, more preferably from about 8 times to about 12 times the plasma level of the drug at about 24 hours after administration.

In certain embodiments of the present invention, when the drug is metformin or a pharmaceutically acceptable salt thereof, the controlled release oral dosage form provides a mean

5

J

20

15

maximum plasma concentration ( $C_{max}$ ) of the drug that is about 1500 ng/ml to about 3000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin, more preferably about 1700 ng/ml to about 2000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.

5

In certain embodiments of the present invention, when the drug is metformin or a pharmaceutically acceptable salt thereof, the controlled release dosage form provides a mean AUC<sub>0-24hr</sub> that is about 17200 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin; preferably about 17200 ng.hr/ml to about 26500 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin; more preferably about 19800 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.

10

M

15 Ų 20

25

In certain embodiments of the invention, the administration of the antihyperglycemic drug, e.g., at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from at least 80%, preferably at least 90% of the mean AUC<sub>0-24</sub> provided by administration of the reference standard (GLUCOPHAGE) twice a day, wherein the daily dose of the reference standard is equal to the once-a day dose of metformin administered in the controlled release oral dosage form of the present invention. In certain embodiments of the present invention, the controlled release dosage form

exhibits the following dissolution profiles of the antihyperglycemic drug (e.g., metformin) when tested in a USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal gastric fluid (pH 7.5 phosphate buffer) at 37° C: 0-30% of the drug released after 2 hours; 10-45% of the drug released after 4 hours; 30-90% of the drug released after 8 hours; not less than 50% of the drug released after 12 hours; not less than 60% of the drug released after 16 hours; and not less than 70% of the drug released after 20 hours.

In certain preferred embodiments, the controlled release solid oral dosage form exhibits the following dissolution profiles when tested in USP type 2 apparatus at 75 rpm in 900 ml of simulated intestinal gastric fluid (pH 7.5 phosphate buffer) at 37° C: 0-25% of the drug (e.g., metformin or a pharmaceutically acceptable salt thereof) released after 2 hours; 20-40% of the

drug released after 4 hours; 45-90% of the drug released after 8 hours; not less than 60% of the drug released after 12 hours; not less than 70% of the drug released after 16 hours; and not less than 80% of the drug released after 20 hours.

5

10

15

20

25

With respect to embodiments of the present invention where the antihyperglycemic drug is metformin, it has been found that drugs such as metformin provide substantially linear pharmacokinetics up to a level of about 2 grams per day. Therefore, it is contemplated for purposes of the present invention that a given plasma level (e.g.,  $C_{max}$ ) of metformin per specified dose will be directly proportional to other doses of metformin. Such proportional doses and plasma levels are contemplated to be within the scope of the invention and to be within the scope of the appended claims.

The dosage form of the present invention can provide therapeutic levels of the antihyperglycemic drug for twelve to twenty-four hour periods and does not exhibit a decrease in bioavailability if taken with food. In fact, a slight increase in the bioavailability of the antihyperglycemic drug is observed when the controlled release dosage form of the present invention is administered with food. In a preferred embodiment, the dosage form can be administered once-a-day, ideally with or after a meal, preferably with or after the evening meal, and provides therapeutic levels of the drug throughout the day with peak plasma levels being obtained between 5.5 to 7.5 hours after administration.

obtained between 5.5 to 7.5 hours after administration.

The present invention is also directed to a method of lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis a dose of a drug comprising a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof), said drug being contained in at least one solid oral controlled release dosage form of the present invention. When the drug is metformin, the daily dose of the drug may be from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient.

The controlled release dosage form of the present invention provides a delayed  $T_{max}$ , as compared to the  $T_{max}$  provided by GLUCOPHAGE. The delayed  $T_{max}$  occurs from 5.5 to 7.5

hours after administration. If the drug (e.g., metformin) is administered at dinner time, the T<sub>max</sub> would occur during the time when gluconeogenesis is usually at its highest (e.g., around 2 a.m.).

5

10

15

20

25

The present invention also includes a method of treating patients with NIDDM comprising orally administering to human patients on a once-a-day basis a dose of a drug comprising a biguanide (e.g., metformin or a pharmaceutically acceptable salt thereof), contained in at least one oral controlled release dosage form of the present invention. When the drug is metformin, the daily dose of the drug may be from about 500 mg to about 2500 mg, from about 1000 mg to about 2500 mg, or from about 2000 mg to about 2500 mg, depending on the clinical needs of the patient. In certain embodiments, the method of treatment according to the present invention involves once-per-day metformin monotherapy as an adjunct to diet to lower blood glucose in patients with NIDDM whose hyperglycemia may not be satisfactorily managed on diet alone. In certain other embodiments, the once-a-day metformin therapy of the present invention may be used concomitantly with a sulfonylurea, e.g., when diet and monotherapy with a sulfonylurea alone do not result in adequate glycemic control. In certain other embodiments, the once-a-day metformin therapy of the present invention may be used concomitantly with a glitazone, e.g., when diet and monotherapy with a glitazone alone do not result in adequate glycemic control.

The present invention is further directed to a method of controlling the serum glucose concentration in human patients with NIDDM, comprising administering to patients having NIDDM on a once-a-day basis, preferably at dinner time, an effective dose of a biguanide (e.g., metformin) contained in at least one oral controlled release dosage form of the present invention.

The present invention further includes a controlled-release dosage form of a drug comprising a biguanide (e.g., metformin) suitable for once-a-day administration to human patients with NIDDM, the dosage form comprising an effective amount of the drug to control blood glucose levels for up to about 24 hours and an effective amount of a controlled-release carrier to provide controlled release of the drug with a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug from 5.5 to 7.5 hours after administration and a width at 50% of In certain preferred embodiments, the controlled-release dose of the drug (e.g., metformin or a pharmaceutically acceptable salt thereof) according to the present invention is provided by one or more of a controlled-release tablet comprising

- (a) a core comprising:
  - (i) the antihyperglycemic drug (e.g., metformin or a pharmaceutically acceptable salt thereof);
  - (ii) optionally a binding agent; and
  - (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

In certain preferred embodiments, the mean time to maximum plasma concentration of the drug is reached from 6.5 to 7.5 hours after administration at dinner time.

In certain embodiments of the invention when the drug is a biguanide (e.g. metformin or a pharmaceutically acceptable salt thereof), the controlled release dosage form provides upon single administration, a higher mean fluctuation index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later, preferably maintaining bioavailability from at least 80% preferably from at least 90% of the immediate release composition.

In certain embodiments of the present invention, the mean fluctuation index of the dosage form is from about 1 to about 4, preferably about 2 to about 3, more preferably about 2.5.

In certain embodiments of the invention which exhibit a higher mean fluctuation index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, the ratio of the mean fluctuation index between the dosage form and the immediate release composition is about 3:1, preferably about 2:1, more preferably 1.5:1.

5

15

20

When the drug is metformin or a pharmaceutically acceptable salt thereof, the doses of drug which exhibit the above disclosed mean fluctuation indexes can be any effective dose administered to a patient with NIDDM for the reduction of serum glucose levels. For example, the dose can from about 500mg to about 2500mg, from about 1000mg to about 2000 mg or from about 850mg to about 1700mg metformin or pharmaceutically acceptable salt thereof.

The drugs which may used in conjunction with the present invention include those drugs which are useful for the treatment of non-insulin-dependent diabetes mellitus (NIDDM), including but not limited to biguinides such as metformin or buformin or pharmaceutically acceptable salts thereof. When the drug used in the present invention is metformin, it is preferred that the metformin be present in a salt form, preferably as metformin hydrochloride.

The term "metformin" as it is used herein means metformin base or any pharmaceutically acceptable salt e.g., metformin hydrochloride.

The term "dosage form" as it is used herein means at least one unit dosage form of the present invention (e.g. the daily dose of the antihyperglycemic agent can be contained in 2 unit dosage forms of the present invention for single once-a-day administration).

The term "morning" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered early in the day after the patient has awakened from overnight sleep, generally between about 6 a.m. and 11 a.m. (regardless of whether breakfast is eaten at that time, unless so specified herein).

The term "dinnertime" or "at dinner" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered at a time when dinner is normally eaten (regardless of whether a meal is actually eaten at that time, unless so specified herein), generally between about 4 p.m. and 8 p.m.

The term "bedtime" as it is used herein with respect to the dosing of the controlled release formulations of the invention means that the controlled release formulation is orally administered before the patient goes to bed in the evening, generally between about 8 p.m. and 12 p.m.

5

10

25

The term "therapeutically effective reduction" when used herein is meant to signify that blood glucose levels are reduced by approximately the same amount as an immediate release reference standard (e.g., GLUCOPHAGE®) or more, when the controlled release dosage form is orally administered to a human patient on a once-a-day basis.

The term "sustained release" and "controlled release" are used interchangeably in this

5

application and are defined for purposes of the present invention as the release of the drug from the dosage form at such a rate that when a once-a-day dose of the drug is administered in the sustained release or controlled-release form, blood (e.g., plasma) concentrations (levels) of the drug are maintained within the therapeutic range but below toxic levels over a period of time from about 12 to about 24 hours. When the drug used in the present invention is metformin (preferably metformin hydrochloride) the controlled release solid oral dosage form containing such drug is also referred to as "Metformin XT."

10

The term "C<sub>max</sub>" is the highest plasma concentration of the drug attained within the dosing interval, i.e., about 24 hours.

15

20

The term "C<sub>min</sub>" is the minimum plasma concentration of the drug attained within the dosing interval, i.e. about 24 hours.

13

i,ñ

ĻN

j.A The term "C<sub>ave</sub>" as used herein, means the plasma concentration of the drug within the dosing interval, i.e. about 24-hours, and is calculated as AUC/dosing interval.

The term "T<sub>max</sub>" is the time period which elapses after administration of the dosage form at which the plasma concentration of the drug attains the highest plasma concentration of drug attained within the dosing interval (i.e., about 24 hours).

The term "AUC" as used herein, means area under the plasma concentration-time curve, as calculated by the trapezoidal rule over the complete 24-hour interval.

25

The term "steady state" means that the blood plasma concentration curve for a given drug does not substantially fluctuate after repeated doses to dose of the formulation.

The term "single dose" means that the human patient has received a single dose of the drug formulation and the drug plasma concentration has not achieved steady state.

The term "multiple dose" means that the human patient has received at least two doses of the drug formulation in accordance with the dosing interval for that formulation (e.g., on a once-a-day basis). Patients who have received multiple doses of the controlled release formulations of the invention may or may not have attained steady state drug plasma levels, as the term multiple dose is defined herein.

The term "a patient" means that the discussion (or claim) is directed to the pharmacokinetic parameters of an individual patient and/or the mean pharmacokinetic values obtained from a population of patients, unless further specified.

The term "mean", when preceding a pharmacokinetic value (e.g. mean  $T_{max}$ ) represents the arithmetic mean value of the pharmacokinetic value taken from a population of patients unless otherwise specified (e.g. geometric mean)..

The term "Degree of Fluctuation" is expressed as  $(C_{max} - C_{min})/C_{avg}$ .

### **Brief Description of the Drawings**

- FIG. 1 is a graph showing the relative bioavailability of the metformin XT formulation of Example 2 to GLUCOPHAGE® for Clinical Study 2.
- FIG. 2 is a graph showing the relative bioavailability of the metformin XT formulation of Example 1 (500 mg) to GLUCOPHAGE® for Clinical Study 3.
- FIG. 3 is a graph showing the difference in plasma concentration-time profiles of metformin in eight healthy volunteers between Day 1 and Day 14 dosing following oral administration of the metformin XT formulation of Example 1, 4 x 500 mg q.d. for 14 days for Clinical Study 4.
- FIG. 4 is a graph showing the mean plasma profiles and values of pharmacokinetic parameters of the metformin XT formulation of Example 3 for Clinical Study 5.
- FIG. 5 is a graph showing the mean plasma glucose concentration-time profiles after 4 weeks of treatment with the metformin XT formulation of Example 3 and GLUCOPHAGE® for Clinical Study 5.

20

5

10

15 II

ıú

FIG. 6 is a graph showing the dissolution profile of a 500 mg controlled release metformin formulation of Example 1 of the present invention.

FIG. 7 is a graph showing the dissolution profile of a 850 mg controlled release metformin formulation of Example 2 of the present invention.

FIG. 8 is a graph showing the dissolution profile of a 1000 mg controlled release metformin formulation of Example 3 of the present invention.

5

10

ijħ

ľ

15

20

25

### **Detailed Description of the Invention**

The term antihyperglycemic drugs as used in this specification refers to drugs that are useful in controlling or managing noninsulin-dependent diabetes mellitus (NIDDM). Preferably, the antihyperglycemic drug is a biguanide such as metformin or buformin or a pharmaceutically acceptable salt thereof such as metformin hydrochloride.

It has surprisingly been found that when biguanides such as metformin are administered orally in a controlled release dosage form suitable for once-a-day dosing in the "fed" state, preferably at dinner, the bioavailability is improved as compared to the administration of the controlled release dosage form in the "fasted" state. This is in contrast to GLUCOPHAGE®, which exhibits opposite characteristics. In accordance with the methods and dosage forms of the present invention, it has been determined that the patients suffering from NIDDM achieve improved results (e.g., lowered blood glucose levels) than GLUCOPHAGE® administered according to accepted protocols, e.g., on a twice-a-day basis.

The methods and dosage forms of the invention provide the further advantage in that when dosed at dinnertime, the controlled release formulations of the invention provide a  $T_{max}$  (from 5.5 to 7.5 hours) after oral administration (which  $T_{max}$  is delayed relative to the reference standard, GLUCOPHAGE®), such that the level of drug is greatest at the time when human patients are manufacturing glucose at highest levels. Gluconeogenesis is well known to those skilled in the art to be greatest at night. Thus, in accordance with the invention, the  $T_{max}$  of the drug occurs for example between 11:30 p.m. and 1:30a.m., based on a dose administered at 6:00 p.m. Likewise, such administration of the dosage form provides lower drug levels during the day

(e.g. the afternoon) when gluconeogenesis is lower than at night. Also, the invention preferably provides the added benefit of lowering insulin levels. Insulin is considered a risk factor in NIDDM, in and of itself, for cardiovascular disease.

In comparison to a twice-daily dose of the reference standard (GLUCOPHAGE®), the plasma levels of metformin are preferably lower in the afternoon. This is an advantage particularly in patients who are under concomitant therapy with one or more additional antidiabetic agents, such as for example, a sulfonylurea. It is known in the art that to date approximately 60% of patients being treated with metformin are also being treated with at least one additional antidiabetic agent (such as a sulfonylurea). Sulfonylureas can possibly cause hypoglycemia, whereas metformin cannot, so there is a benefit to having lower metformin levels in the blood during the afternoon due to the potential for the patient to have hypoglycemia.

Accordingly, the present invention also includes a method of treating human patients with NIDDM comprising administering on a once-a-day basis a therapeutically effective dose of metformin in a controlled-release oral dosage form ("Metformin XT"), in combination with administering an effective amount of a sulfonylurea. In preferred embodiments, metformin is provided by a controlled release dosage form comprising metformin or a pharmaceutically acceptable salt thereof, the dosage form being useful for providing a once-a-day oral administration of the drug, wherein the dosage form provides a mean time to maximum plasma concentration  $(T_{max})$  of metformin from 5.5 to 7.5 hours after administration.

In certain embodiments, the combination therapy may be provided as follows. If patients do not respond to four weeks of the maximum dose of Metformin XT (2500 mg/day) monotherapy, a sulfonylurea may be gradually added while maintaining the maximum dose of Metformin XT, even if prior primary or secondary failure to a sulfonylurea has occurred. Examples of the sulfonylurea include glyburide (glibenclamid), chloropropamide, tolbutamide, glipizide, acetohexamide and tolazamide. Although Metformin XT is preferably administered on once-a-day basis, the sulfonylurea may be administered in a different dosage form and at a different frequency.

10

5

m 15 ļ.ā. ļ.

20

With concomitant Metformin XT and sulfonylurea therapy, the desired control of blood glucose may be obtained by adjusting the dose of each drug.

In certain embodiments, the foregoing objectives are met by a controlled release dosage form comprising:

- (a) a core comprising:
  - (i) an antihyperglycemic drug;
  - (ii) optionally a binding agent; and
  - (iii) optionally an absorption enhancer;
- (b) a membrane coating surrounding the core; and
- (c) at least one passageway in the membrane.

The binding agent may be any conventionally known pharmaceutically acceptable binder such as polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxyethyl cellulose, ethylcellulose, polymethacrylate, waxes and the like. Mixtures of the aforementioned binding agents may also be used. The preferred binding agents are water soluble such as polyvinyl pyrrolidone having a weight average molecular weight of 25,000 to 3,000,000. The binding agent comprises approximately about 0 to about 40% of the total weight of the core and preferably about 3% to about 15% of the total weight of the core.

The core may optionally comprise an absorption enhancer. The absorption enhancer can be any type of absorption enhancer commonly known in the art such as a fatty acid, a surfactant, a chelating agent, a bile salt or mixtures thereof. Examples of some preferred absorption enhancers are fatty acids such as capric acid, oleic acid and their monoglycerides, surfactants such as sodium lauryl sulfate, sodium taurocholate and polysorbate 80, chelating agents such as citric acid, phytic acid, ethylenediamine tetraacetic acid (EDTA) and ethylene glycol-big (B-aminoethyl ether -N,N,N,N-tetraacetic acid (EGTA). The core comprises approximately 0 to about 20% of the absorption enhancer based on the total weight of the core and most preferably about 2% to about 10% of the total weight of the core.

In this embodiment, the core which comprises the antihyperglycemic drug, the binder which preferably is a pharmaceutically acceptable water soluble polymer and the absorption

5

Ü

20

enhancer is preferably formed by wet granulating the core ingredients and compressing the granules with the addition of a lubricant into a tablet on a rotary press. The core may also be formed by dry granulating the core ingredients and compressing the granules with the addition of a lubricant into tablets or by direct compression.

Other commonly known excipients may also be included into the core such as lubricants, pigments or dyes.

The homogeneous core is coated with a membrane, preferably a polymeric membrane to form the controlled release tablet of the invention. The membrane can be a semipermeable membrane by being permeable to the passage of external fluid such as water and biological fluids and being impermeable to the passage of the antihyperglycemic drug in the core. Materials that are useful in forming the membrane are cellulose esters, cellulose diesters, cellulose triesters, cellulose ethers, cellulose ester-ether, cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate, cellulose acetate propionate, and cellulose acetate butyrate. Other suitable polymers are described in United States Patent Nos. 3,845,770, 3,916,899, 4,008,719, 4,036,228 and 4,11210 which are incorporated herein by reference. The most preferred membrane material is cellulose acetate comprising an acetyl content of 39.3 to 40.3%, commercially available from Eastman Fine Chemicals.

In an alternative embodiment, the membrane can be formed from the above-described polymers and a flux enhancing agent. The flux enhancing agent increases the volume of fluid imbibed into the core to enable the dosage form to dispense substantially all of the antihyperglycemic drug through the passageway and/or the porous membrane. The flux enhancing agent can be a water soluble material or an enteric material. Some examples of the preferred materials that are useful as flux enhancers are sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycol (PEG), propylene glycol, hydroxypropyl cellulose, hydroxypropyl methycellulose, hydroxyprophy methycellulose phthalate, cellulose acetate phthalate, polyvinyl alcohols, methacrylic acid copolymers and mixtures thereof. The preferred flux enhancer is PEG 400.

5

10

n 15 l,L

20

The flux enhancer may also be a drug that is water soluble such as metformin or its pharmaceutically acceptable salts or a drug that is soluble under intestinal conditions. If the flux enhancer is a drug, the present dosage form has the added advantage of providing an immediate release of the drug which is selected as the flux enhancer.

5

The flux enhancing agent comprises approximately 0 to about 40% of the total weight of the coating, most preferably about 2% to about 20% of the total weight of the coating. The flux enhancing agent dissolves or leaches from the membrane to form paths in the membrane for the fluid to enter the core and dissolve the active ingredient.

In alternate embodiments, the membrane may also be formed with commonly known

10

excipients such as a plasticizer. Some commonly known plasticizers include adipate, azelate, enzoate, citrate, stearate, isoebucate, sebacate, triethyl citrate, tri-n-butyl citrate, acetyl tri-n-butyl

citrate, citric acid esters, and those described in the Encyclopedia of Polymer Science and Technology, Vol. 10 (1969), published by John Wiley & Sons. The preferred plasticizers are

triacetin, acetylated monoglyceride, grape seed oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate,

dibutylsuccinate, diethylmalonate, dioctylphthalate, dibutylsebacate, triethylcitrate,

tributylcitrate, glyceroltributyrate, and the like. Depending on the particular plasticizer, amounts of from 0 to about 25%, and preferably about 2% to about 15% of the plasticizer can be used

based upon the total weight of the coating.

20

As used herein the term passageway includes an aperture, orifice, bore, hole, weakened area or an erodible element such as a gelatin plug that erodes to form an osmotic passageway for the release of the antihyperglycemic drug from the dosage form. A detailed description of the passageway can be found in United States Patent Nos. such as 3,845,770, 3,916,899, 4,034,758, 4,063,064, 4,077,407, 4,088,864, 4,783,337 and 5,071,607 (the disclosures of which are hereby incorporated by reference).

25

In certain embodiments, the passageway is formed by laser drilling. In other embodiments, the passageway is formed by making an indentation onto the core prior to the membrane coating to form a weakened area of the membrane at the point of the indentation. In

preferred embodiments of the invention, the dosage form contains two passageways in order provide the desired pharmacokinetic parameters of the formulation.

Generally, the membrane coating around the core will comprise from about 1% to about 7%, preferably about 1.5% to about 3%, based on the total weight of the core and coating.

5

10

15

The term "membrane" means a membrane that is permeable to both aqueous solutions or bodily fluids and to the active drug or pharmaceutical ingredient (e.g. the formulations of Examples 1-3). Thus, the membrane is porous to drug and, in a preferred embodiment, drug is released through the hole or passageway and through the porous membrane in solution or in vivo. The term "membrane" also generically encompasses the term "semipermeable membrane" as heretofore defined.

In an alternative embodiment, the dosage form of the present invention may also comprise an effective amount of the antihyperglycemic drug that is available for immediate release. The effective amount of antihyperglycemic drug for immediate release may be coated onto the membrane of the dosage form or it may be incorporated into the membrane.

In certain preferred embodiments of the invention where the dosage form is prepared in accordance with the above, the dosage form will have the following composition:

	IJ	INGREDIENT	<u>Preferred</u>	Most Preferred
	lu Lu	CORE:		
20	•	Drug	50-98%	75-95%
		Binder	0-40%	3-15%
		Absorption Enhancer	0-20%	2-10%
25		COATING:		
		Membrane Polymer	50-99%	75-95%
		Flux Enhancer	0-40%	2-20%
		Plasticizer	0-25% or 0-30%	2-15%

The dosage forms prepared according to certain embodiments of the present invention preferably exhibit the following dissolution profile when tested in a USP type 2 apparatus at 75 rpms in 900 ml of simulated intestinal fluid (pH 7.5 phosphate buffer) and at 37°C:

5

	Time (Hours)	<u>Preferred</u>	Most Preferred
	2	0-30%	0-15% or 0-25%
	4	10-45%	20-40%
10	8	30-90%	45-90%
G.	12	NTL 50%	NTL 60%
	16	NTL 60%	NTL 70%
	20	NTL 70%	NTL 80%
74	NTL = Not less than		

15

In the preparation of the tablets of the invention, various conventional well known solvents may be used to prepare the granules and apply the external coating to the tablets of the invention. In addition, various diluents, excipients, lubricants, dyes, pigments, dispersants, etc. which are disclosed in Remington's Pharmaceutical Sciences, 1995 Edition may be used to optimize the formulations of the invention.

20

Other controlled release technologies known to those skilled in the art can be used in order to achieve the controlled release formulations of the present invention, i.e., formulations which provide a mean  $T_{max}$  of the drug and/or other pharmacokinetic parameters described herein when orally administered to human patients. Such formulations can be manufactured as a controlled oral formulation in a suitable tablet or multiparticulate formulation known to those skilled in the art. In either case, the controlled release dosage form may optionally include a

controlled release carrier which is incorporated into a matrix along with the drug, or which is applied as a controlled release coating.

An oral dosage form according to the invention may be provided as, for example, granules, spheroids, beads, pellets (hereinafter collectively referred to as "multiparticulates") and/or particles. An amount of the multiparticulates which is effective to provide the desired dose of drug over time may be placed in a capsule or may be incorporated in any other suitable oral form.

In certain preferred embodiments, the tablet core or multiparticulates containing the drug are coated with a hydrophobic material selected from (i) an alkylcellulose and (ii) a polymeric glycol. The coating may be applied in the form of an organic or aqueous solution or dispersion. The coating may be applied to obtain a weight gain from about 2 to about 25% of the substrate in order to obtain a desired sustained release profile. The sustained release coatings of the present invention may also include an exit means comprising at least one passageway, orifice, or the like as previously disclosed.

### **Description of Certain Preferred Embodiments**

The following examples illustrate various aspects of the present invention. They are not to be construed to limit the claims in any manner whatsoever.

20

5

10

15

Į,T

#### Example 1

A controlled release tablet containing 500 mg of metformin HCl and having the following formula is prepared as follows:

#### 5 I. Core

10

15 "

20

25

n N

LΠ

<u>Ingredients</u>	Amount (mg/tab)
Metformin HCl	500.0
Povidone <sup>3</sup> , USP	36.0
Sodium Lauryl Sulfate	25.8
Magnesium Stearate	2.8

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

#### (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with 15/32" round standard concave punches.

21.5

1.3

2.5

#### (c) **Seal Coating (optional)**

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7006), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The Opadry Clear of the coating constitutes about 11.5 mg/tablet.

# II. Sustained Release Coating

<sup>2</sup>acetyl content 39.3 - 40.3%

15

25

10

5

UM 20

Amount (mg/tablet) Ingredients Cellulose Acetate (398-10)<sup>2</sup> Triacetin **PEG 400** 

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

## (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

## Example 2

A controlled release tablet containing 850 mg of metformin HCl and having the following formula is prepared as follows:

#### I. Core

10

44

١,.

I,N

Ų

I,M

15 :

20

25

5	<u>Ingredients</u>	Amount (mg/tab)
	Metformin HCl	850.0
	Povidone <sup>3</sup> , USP	61.1
	Sodium Lauryl Sulfate	43.9
	Magnesium Stearate	4.8

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

#### (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a top-spray fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with the equivalent of an 18 mesh screen.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with 15/32" round standard concave punches.

#### (c) Seal Coating (optional)

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7006), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The Opadry Clear of the coating constitutes about 11.5 mg/tablet.

# II. Sustained Release Coating

10

5

I,T

20

25

Amount (mg/tablet) Ingredients Cellulose Acetate (398-10)<sup>2</sup> 24.0 Triacetin 1.4 2.8 **PEG 400** <sup>2</sup>acetyl content 39.3 - 40.3%

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

#### (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

# Example 3

A controlled release tablet containing 1000 mg of metformin HCl and having the following formula is prepared as follows:

#### I. Core

5

10

ū

15 III

...A

20

25

IngredientsAmount (mg/tablet)Metformin HCl1000.0Povidone³, USP71.9Sodium Lauryl Sulfate51.7Magnesium Stearate5.6

<sup>3</sup>approximate molecular weight = 1,000,000; dynamic viscosity (10%w/v solution at 20°C) = 300-700 m Pa s.

# (a) Granulation

The metformin HCl and sodium lauryl sulfate are delumped by passing them through a 40 mesh screen and collecting them in a clean, polyethylene-lined container. The povidone, K-90-F is dissolved in purified water. The delumped metformin HCl and sodium lauryl sulfate are then added to a fluidized bed granulator and granulated by spraying with the binding solution of povidone under the following conditions: inlet air temperature of 50-70°C; atomization air pressure of 1-3 bars; and spray rate of 10-100 ml/min.

Once the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2%. The dried granules are passed through a Comil equipped with a screen equivalent to 18 mesh.

#### (b) Tableting

The magnesium stearate is passed through a 40 mesh stainless steel screen and blended with the metformin HCl granules for approximately five (5) minutes. After blending, the granules are compressed on a rotary press fitted with ½" round standard concave punches.

## (c) Seal Coating (optional)

The core tablet is seal coated with an Opadry material or other suitable water-soluble material by first dissolving the Opadry material, preferably Opadry Clear (YS-1-7003), in purified water. The Opadry solution is then sprayed onto the core tablet using a pan coater under the following conditions: exhaust air temperature of 38-42°C; atomization pressure of 28-40 psi; and spray rate of 10-15 m1/min. The core tablet is coated with the sealing solution until the tablet is coated with 23.0 mg/tablet of the Opadry material.

#### II. Sustained Release Coating

Ingredients	Amount (mg/tablet)
Cellulose Acetate (398-10) <sup>2</sup>	19.0
Triacetin	1.1
PEG 400	2.2

<sup>2</sup>acetyl content 39.3 - 40.3%

5

10

15

20

25

> l-d l-A

The cellulose acetate is dissolved in acetone while stirring with a homogenizer. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The tablet is coated by spraying the clear coating solution onto the seal coated tablets in a fluidized bed coater employing the following conditions: product temperature of 16-22°C; atomization pressure of approximately three bars; and spray rate of 120-150 ml/min.

#### (d) Laser Drilling

The coated tablets were laser drilled two holes (one hole on each side of the tablet).

## (e) Color Coating (optional)

5

10

ijħ

n.

20

25

15

Subsequent to the sustained release coating, the laser drilled tablet is coated with a color coating using Opadry White (24 mg/tablet) and waxed with Candelilla wax powder (0.4 mg/tablet).

#### Clinical Studies

#### Study 1

In study 1, a total of twelve (12) healthy subjects (six males, six females) were randomized to receive either a single oral dose of metformin XT, 850mg, prepared in accordance with Example 2 or b.i.d. doses of GLUCOPHAGE in assigned study periods which consisted of one of the following groups: Group A - metformin XT (2 x 850 mg tablets) taken at approximately 8:00 a.m., immediately following breakfast, Group B - metformin XT (2 x 850 mg tablets) taken at approximately 6:00 p.m., immediately following dinner; and Group C - GLUCOPHAGE (1 x 850 mg tablet) taken at approximately 8:00 a.m., immediately following breakfast, and at approximately 6:00 p.m., immediately following dinner. Each drug administration was separated by a washout period of seven days. In this study, one male subject was removed from the study prior to Period II due to non-treatment-related mononucleosis. Thus, 11 (five males and six females) subjects completed the study.

For metformin XT, plasma samples were obtained from subjects at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, and 24 hour(s) after dosing. For GLUCOPHAGE, plasma samples were obtained from subjects at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 14, 15, 16, 18, 20, 22, and 24 hour(s) after the first dose in the morning. Plasma concentrations of metformin were determined using a validated HPLC method. The lower quantitation limit of this method is 10 ng/ml. Mean plasma concentration-time profiles are shown in Fig. 1 and mean values of pharmacokinetic parameters of metformin obtained from this study are presented in Table 1.

 $\frac{Table\ 1}{Mean\ (\pm SD,\ n=11)}\ values\ of\ pharmacokinetic\ parameters\ of\ metformin\ (Example\ 2)\ in\ 11$  healthy subjects (metformin XT, 2 x 850 mg q.d. or GLUCOPHAGE, 1 x 850 mg b.i.d.)

						Geon Mean	netric Ratio*
Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr.)	T <sub>lag</sub> (hr)	t <sub>1/2</sub> (hr)	AUC <sub>0-∞</sub>	$\mathbf{C}_{max}$
Metformin XT after breakfast	18156 (4183)	2045 (567)	6 (2)	0.18 (0.40)	4.4 (0.7)	1.00	1.36
Metformin XT after dinner	18277 (2961)	1929 (333)	7 (2)	0.09 (0.30)	3.6 (0.8)	1.02	1.32
GLUCOPHAGE	18050 (3502)	1457 (217)	5 (3)	0 (0)	3.5 (0.9)	_	_

<sup>\*</sup>Ratio = Metformin XT/GLUCOPHAGE

As shown in Figure 1 and Table 1, when metformin XT was administered immediately after either breakfast or dinner, the relative bioavailability of metformin XT formulation to GLUCOPHAGE is approximately 100%.

The results of study 1 were used to calculate the approximate degree of fluctuation ( $C_{max}$  -  $C_{min}/C_{ave}$ ) of the formulations.

The  $C_{max}$  was directly obtained from the study (see Table 1). The  $C_{avg}$  was obtained by dividing the AUC value by the dosing interval, i.e. 24 hours. The value for  $C_{min}$  was extrapolated from Figure 1.

The results are set forth in Table 2 below:

5

10

15

IJ

-£

.4

 $\frac{Table\ 2}{Mean\ (\pm SD,\ n=12)\ values\ of\ pharmacokinetic\ parameters\ of\ metformin\ XT\ in\ 12\ healthy\ subjects\ (metformin\ XT,\ 2\ x\ 850\ mg\ q.d.\ and\ GLUCOPHAGE,\ 850\ mg\ b.i.d.)}$ 

Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	C <sub>min</sub> (ng/ml)	C <sub>avg</sub> (ng/ml)	Degree of Fluctuation
Metformin XT after breakfast	18156 (4183)	2045 (567)	143	756	251
Metformin XT after dinner	18277 (2961)	1929 (333)	107	761	2.39
GLUCOPHAGE	DPHAGE 18050 1457 (3502) (217)		214 (at 24 hours)	752	1.65
			393 (between doses)	752	1.41

As shown in Figure 1 and Table 2, a single administration of the metformin XT formulation provides a higher mean fluctuation index in the plasma than a substantially equal dose of Glucophage administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

20 <u>Study 2</u>

5

10

THE STATE

15

25

The study design of Study 2 is the same as Study 1 except for the formulation and the dose (4 x 500 mg q.d., total dose 2000mg, for metformin XT prepared according to Example 1 and 2 x 500 mg b.i.d., total dose 2000mg, for GLUCOPHAGE in the second study). In this study, 12 healthy volunteers (five males and seven females) were randomized to receive treatments and completed the study. Mean plasma concentration-time profiles and mean values

of pharmacokinetic parameters of metformin obtained from this study are presented in Figure 2 and Table 3.

As shown in Figure 2 and Table 3, when the metformin XT formulation (500 mg) was administered immediately after dinner, the relative bioavailability of this formulation to GLUCOPHAGE is approximately 100%, while the mean  $C_{max}$  value is about the same. The relative bioavailability of metformin XT, however, is approximately 80% when administered immediately after breakfast. A prolonged profile, together with later  $T_{max}$  and similar  $C_{max}$  of metformin following administration of metformin XT immediately after dinner compared to GLUCOPHAGE indicated that metformin was released *in vivo* in a sustained fashion (Figure 2).

10

20

25

15 III

5

<u>Table 3</u>

Mean ( $\pm$ SD, n = 12) values of pharmacokinetic parameters of metformin of Example 1 in 12 healthy subjects (metformin XT, 4 x 500 mg q.d. or GLUCOPHAGE, 2 x 500 mg b.i.d.)

Geometric Mean Ratio										
Treatment	AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr)	T <sub>lag</sub> (hr)	t <sub>1/2</sub> (hr)	AUC <sub>0-∞</sub>	C <sub>max</sub>			
Metformin XT after breakfast	17322 (4984)	2127 (545)	5 (1)	0 (0)	6.1 (1.8)	0.80	1.15			
Metformin XT after dinner	20335 (4360)	2053 (447)	7 (2)	0.08 (0.29)	3.9 (0.6)	0.96	1.12			
GLUCOPHAGE	21181 (4486)	1815 (302)	4 (3)	0 (0)	3.6 (0.8)		_			

<sup>\*</sup>Ratio = Metformin XT/GLUCOPHAGE

The results of study 2 were used to calculate the approximate degree of fluctuation of the formulations in accordance with the calculations used in study 1 (using Figure 2 to obtain the extrapolated value for  $C_{min}$ ).

The results are set forth in Table 4 below:

30

 $\frac{Table\ 4}{Mean\ (\pm SD,\ n=12)\ values\ of\ pharmacokinetic\ parameters\ of\ metformin\ XT\ in\ 12\ healthy\ subjects\ (metformin\ XT,\ 4\ x\ 500\ mg\ q.d.\ and\ GLUCOPHAGE,\ 2\ x\ 500\ mg\ b.i.d.)}$ 

AUC <sub>0-∞</sub> (ng-hr/ml)	C <sub>max</sub> (ng/ml)	C <sub>min</sub> (ng/ml)	C <sub>avg</sub> (ng/ml)	Degree of Fluctuation
17322 (4984)	2127 (545)	143	721	2.9
20335 (4360)	2053 (447)	143	847	2.25
21181 (4486)	1815 (302)	214 (at 24 hours)	882	1.8
		357 (between doses)	882	1.65
	(ng-hr/ml)  17322 (4984)  20335 (4360)  21181	(ng-hr/ml)     (ng/ml)       17322     2127       (4984)     (545)       20335     2053       (4360)     (447)       21181     1815	(ng-hr/ml)         (ng/ml)         (ng/ml)           17322 (4984)         2127 (545)         143           20335 (4360)         2053 (447)         143           21181 (4486)         1815 (302)         214 (at 24 hours)           357 (between	(ng-hr/ml)         (ng/ml)         (ng/ml)         (ng/ml)           17322 (4984)         2127 (545)         143 20335 (4360)         721 2053 (447)           21181 (4486)         1815 (302)         214 (at 24 hours)         882 882           357 (between         882

As shown in Figure 2 and Table 4, a single administration of the metformin XT formulation provides a higher mean fluctuation index in the plasma than an equivalent dose of Glucophage administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

20 Study 3

5

10

refi

15

25

In Study 3, a multiple-dose, open-label, one-period study was conducted to evaluate the short-term tolerability and steady-state pharmacokinetics of the 500 mg metformin XT formulation used in Study 2. In this study, eight healthy volunteers (four males and four females) were randomized to receive 2000 mg of metformin XT (4 x 500 mg tablets) at approximately 6:00 p.m., immediately following dinner, for 14 days.

Blood samples were obtained from each subject at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16 and 24 hour(s) following the first dose on Day 1 and at 0 (predose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 24, 38 and 48 hour(s) following the last dose on Day 14. Blood samples were also drawn from each subject immediately prior to dosing on Days 10-13. Urine samples were collected from each subject at the following time intervals: six hours prior to the first dose; 0-6, 6-12 and 12-24 hours after the first dose; and 0-6, 6-12, 12-24 and 24-48 hours after the last dose.

Mean plasma profiles and values of pharmacokinetic parameters of metformin are presented in Table 5 below:

10

15

5

<u>Table 5</u>

Mean Pharmacokinetic Parameters (Example 1)

Day 1

Day 1

	C <sub>max</sub>	$\mathbf{T}_{max}$	AUC <sub>0-24hr (ng.hr/ml)</sub>
Mean	2435	6.9	22590
SD	630	1.9	3626

Day 14

20

25

	C <sub>max</sub>	T <sub>max</sub>	AUC <sub>0-24hr (ng.hr/ml)</sub>			
Mean	2288	6.9	24136			
SD	736	2.5	7996			

Following oral administration of metformin XT, 4 x 500 mg q.d., for 14 days, there was little or no difference in plasma concentration-time profiles of metformin in eight healthy volunteers between Day 1 and Day 14 dosing (Figure 3). On average, trough plasma concentrations of metformin were nearly constant, ranging from 188.8 to 205.1 ng/ml on Days 10-14, indicating that the steady state of metformin was attained rapidly. The mean

accumulation ratio was 1.01, indicating that the once-daily dose regimen of metformin XT results in no accumulation.

Following oral administration of a single dose (4 x 500 mg) of metformin XT, approximately 31% of the dose was excreted in the urine within the first 24 hours. On average, the renal clearance of metformin was 366 ml/min. A slightly higher renal clearance (454 ml/min) was found after multiple-dose administration of 4 x 500 mg q.d. of metformin XT.

Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence and anorexia) are the most common adverse reactions to GLUCOPHAGE. In controlled trials, GLUCOPHAGE was started at low, nontherapeutic doses and gradually titrated to higher doses. In spite of this gradual titration, GLUCOPHAGE was discontinued due to gastrointestinal reactions in approximately 4% of patients. In contrast, in the multiple-dose study, metformin XT begun at a therapeutic initial dose of 2000 mg once daily with dinner was well tolerated by all healthy volunteers. Diarrhea and nausea were the most common gastrointestinal reactions probably or possibly related to metformin XT. These reactions, however, were either mild or moderate. This suggests that it may be possible to initiate metformin XT treatment with effective doses rather than using the slow titration from non-therapeutic doses required for GLUCOPHAGE.

#### Study 4

20

25

5

10

15

Study 4 was a study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of metformin XT compared to GLUCOPHAGE after multiple-dose treatment in patients with NIDDM. Metformin XT tablets prepared according to Example 3 were used in this study. This study had a single-center, randomized, two-way crossover design. A total of 24 NIDDM patients who were on a stable dose of GLUCOPHAGE, between 1000 and 2550 mg/day, for at least 12 weeks were selected for the study. A Pretreatment Period of at least 3 weeks preceded randomization to study treatment. At the start of the Pretreatment Period, all patients stopped taking any other hypoglycemic agents besides GLUCOPHAGE, and the GLUCOPHAGE dose was adjusted to 1000 mg b.i.d. (with breakfast and with dinner).

5

10

 Following the pretreatment period, patients began Treatment Period I, which lasted 4 weeks. During Period I, a total of 12 patients were randomized to receive two 1000-mg metformin XT tablets q.d. (immediately after dinner), at approximately 6:00 p.m., and 12 were randomized to receive one 1000-mg GLUCOPHAGE tablet b.i.d. (immediately after breakfast and immediately after dinner). Immediately following Period I, each patient was switched to the alternate medication for 4 weeks in Period II. There was no washout between treatment periods.

Plasma metformin concentrations were determined over a 24-hour period at the end of Treatment Periods I and II as follows: immediately prior to dosing and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 15, 16, 17, 18, 19, 20, 22, and 24 hours after the evening dose. One subject withdrew from the study for personal reasons after two weeks of treatment in Treatment Period I, thus pharmacokinetic data were obtained from 23 patients.

Mean plasma profiles and values of pharmacokinetic parameters of metformin are presented in Figure 4 and Table 6. As shown in Figure 4 and Table 6, when metformin XT was administered immediately after dinner, the bioavailability of metformin XT relative to GLUCOPHAGE at steady state is close to 100%. Although the dose of metformin XT was twice as large as the dose of GLUCOPHAGE at dinner, the mean  $C_{max}$  value was only 32% higher.

25

20

Table 6

Mean (± SD) values of pharmacokinetic parameters of metformin of Example 3 in 23

NIDDM patients (metformin XT, 2 x 1000 mg q.d. with dinner or GLUCOPHAGE, 1 x 1000 mg b.i.d.)

Geometric Mean Ratio										
Treatment	AUC <sub>0-24hr</sub> (ng•hr/ml)	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (hr)	T <sub>lag</sub> (hr)	t <sub>½</sub> (hr)	AUC <sub>0-24hr</sub>	$C_{max}$			
Metformin XT after dinner	26818 (7052)	2849 (797)	6 (2)	0 (0)	5.4	0.96	1.32			
GLUCOPHAGE	27367 (5759)	2131 (489)	14 (6)	0 (0)	4.4		-			

<sup>\*</sup> Ratio = Metformin XT/GLUCOPHAGE

5

10

15

20

25

When the metformin XT was administered immediately after dinner, the bioavailability of metformin XT relative to GLUCOPHAGE at steady state was close to 100%. However, when metformin XT was administered immediately after breakfast, the corresponding relative bioavailability of metformin XT was approximately 80%. The safety profile of metformin XT, 2000 mg given once daily either after dinner or after breakfast was comparable to that of an equal dose of GLUCOPHAGE given b.i.d. The efficacy profile of metformin XT, 2000 mg given once daily after dinner was similar to that of an equal dose of GLUCOPHAGE given b.i.d. The efficacy of metformin XT, 2000 mg given once daily after breakfast, however, appeared to be comparable to or slightly less than that of GLUCOPHAGE given b.i.d.

While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention.

#### **WHAT IS CLAIMED IS:**

hours after administration.

1. A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering to human patients on a once-a-day basis at least one oral controlled release dosage form comprising an effective dose of at least one suitable antihyperglycemic agent or a pharmaceutically acceptable salt thereof and a controlled release carrier, wherein the dosage form provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from 5.5 to 7.5

ncentration (T<sub>max</sub>) of metformin at from 5.5 to 7.5

Not: femally implified india, have devay

- 2. The controlled release dosage form of claim 1 wherein said at least one antihyperglycemic agent is a biguanide.
- 3. The controlled release dosage form of claim 2 wherein said biguanide is metformin or a pharmaceutically acceptable salt thereof.
  - The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of metformin at from 6.0 to 7.0 hours after administration.
  - The method of claim 3, in which the administration of the at least one metformin dosage form occurs at dinner time and provides a mean time to maximum plasma concentration  $(T_{max})$  of metformin at from about 5.5 to 7.0 hours after the administration.
- 6. The method of claim 3, in which the administration of the at least one metformin dosage form occurs at breakfast and provides a mean time to maximum plasma concentration (T<sub>max</sub>) of metformin at from about 6.0 to about 7.5 hours after the administration.

- 7. The method of claim 3, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of the drug from about 4.5 to about 13 hours.
- 8. The method of claim 3, in which the administration of the at least one metformin dosage form provides a width at 50% of the height of a mean plasma concentration/time curve of the drug from about 5.5 to about 10 hours.

The method of claim 3, in which the administration of the at east one metformin dosage form provides a mean maximum plasma concentration ( $C_{max}$ ) of metformin which is more than about 7 times the mean plasma level of said metformin at about 24 hours after administration.

- 10. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 7 times to about 14 times the plasma level of said metformin at about 24 hours after administration.
- 11. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin which is from about 8 times to about 12 times the plasma level of said metformin at about 24 hours after administration.
- 12. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1500 ng/ml to about 3000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.

13. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean maximum plasma concentration (C<sub>max</sub>) of metformin from about 1700 ng/ml to about 2000 ng/ml, based on administration of a 2000 mg once-a-day dose of metformin.

Sul 14.

The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24h</sub> from at least 80% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.

- 15. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24</sub> that is from at least 90% of the mean AUC<sub>0-24</sub> provided by administration of an immediate release reference standard twice a day, wherein the daily dose of the reference standard is substantially equal to the once-a-day dose of metformin administered in the controlled release oral dosage form.
- 16. The method of claim, in which the once-a-day dose of the metformin is administered at dinner.
- 17. The method of claim 16, in which the once-a-day dose of metformin is administered at fed state.
- 18. The method of claim 16, in which the once-a-day dose of the metformin is about 2000 mg, which is provided by two controlled release dosage forms containing about 1000 mg metformin each.



The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.

- 20. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 17200 ng.hr/ml to about 26500 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 21. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean AUC<sub>0-24hr</sub> from about 19800 ng.hr/ml to about 33900 ng.hr/ml, based on administration of a 2000 mg once-a-day dose of metformin.
- 22. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 1, based on administration of a 1700 mg once-a-day dose of metformin.
  - The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 2, based on administration of a 2000 mg once-a-day dose of metformin.
- 24. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set forth in FIG. 4, based on administration of a 2000 mg once a-day dose of metformin at dinner.
- 25. The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma concentration-time profile of metformin substantially as set

Sub Az Cont. forth in FIG. 6, based on administration of a 2000 mg once-a-day dose of metformin at breakfast.

- The method of claim 3, in which the administration of the at least one metformin dosage form provides a mean plasma glucose concentration-time profile substantially as set forth in FIG. 5, based on administration of a 2000 mg once-a-day dose of metformin at dinner.
  - The method of claim 3, further comprising administering to said human patients at least one additional pharmaceutically active ingredient for treatment of NIDDM.
- 28. The method of claim 3, further comprising administering to said human patients an additional pharmaceutically active ingredient for treatment of NIDDM, said additional pharmaceutically active ingredient selected from the group consisting of a sulfonylurea, a glitazone or a second biguanide.
- The method of claim 3, in which the dose of metformin comprises metformin hydrochloride.
- 30. The method of claim 29, in which the once-a-day dose of metformin hydrochloride is about 1000 mg to about 2500 mg.
- 31. The method of claim 29, in which the once-a-day dose of metformin hydrochloride is about 2000 mg to about 2500 mg metformin.
- 32. A method for lowering blood glucose levels in human patients needing treatment for non-insulin-dependent diabetes mellitus (NIDDM), comprising orally administering at least one biguanide or pharmaceutically acceptable salt thereof and a controlled release carrier wherein á single administration of said dosage form provides a higher mean fluctuation

index in the plasma than an equivalent dose of an immediate release composition administered as two equal divided doses, one divided dose at the start of the dosing interval and the other divided dose administered 12 hours later.

- 33. The method of claim 32 wherein said dosage form maintains bioavailability from at least 80% of the immediate release composition.
- 34. The method of claim 32 wherein said dosage form maintains bioavailability from aat least 90% of the immediate release composition.

#### **ABSTRACT**

A method for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration ( $T_{max}$ ) of the drug which occurs at a 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.

**Application or Docket Number** 

,.:= ``

# PATENT APPLICATION FEE DETERMINATION RECORD

Effective October 1, 2000

CLAIMS AS FILED - PART (Column 1) TOTAL CLAIMS						mn 2)		SMALL EN	ITITY	OR	OTHER SMALL	
TC	OTAL CLAIMS		1 34				į	RATE	FEE		RATE	FEE
FO	)R		NUMBER	FILED	NUMB	ER EXTRA		BASIC FEE	355.00	OR	BASIC FEE	710.00
то	TAL CHARGEA	BLE CLAIMS	34 mir	us 20=	*			X\$ 9=		OR	X\$18=	252
	DEPENDENT CL	<del> </del>		nus 3 =	*			X40=		OR	X80=	
MU	ILTIPLE DEPEN	IDENT CLAIM P	RESENT					+135=		OR	+270=	
* If	the difference	in column 1 is	less than ze	ero, ente	r "0" in c	olumn 2		TOTAL		OR	TOTAL	962
	C	LAIMS AS A	MENDED	- PAR	T II			•		-	OTHER	THAN
		(Column 1)		(Colui		(Column 3)	_	SMALL E	ENTITY	OR.	SMALL	ENTITY
AMENDMENT A		CLAIMS REMAINING AFTER AMENDMENT		HIGH NUM PREVIO PAID	BER OUSLY	PRESENT EXTRA		RATE	ADDI- TIONAL FEE		RATE	ADDI- TIONAL FEE
NDN	Total	*	Minus	**		=		X\$ 9=		OR	X\$18=	
AME	Independent	*	Minus	***	T CL AIRA	=		X40=		OR	X80=	
	FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM							+135=		OR	+270=	
								TOTAL		OR	TOTAL	
		(Column 4)		(Cale	mn 3/	(Column 3)		ADDIT. FEE			ADDIT. FEE	
		(Column 1) CLAIMS		(Colu	IEST	(Column 3)			ADDI-			ADDI-
ENT B		REMAINING AFTER AMENDMENT		NUM PREVI PAID		PRESENT EXTRA		RATE	TIONAL FEE		RATE	TIONAL FEE
<b>AMENDMENT</b>	Total	* .	Minus	**		=		X\$ 9=		OR	X\$18=	
AME	Independent	*	Minus	***	F (0) 4 14 4	=		X40=		OR	X80=	
	FIRST PRESE	NTATION OF M	OLTIPLE DEF	'ENDEN	CLAIM	L		+135=		OR	+270=	
								TOTAL		OD	TOTAL	
								ADDIT. FEE		OR	ADDIT. FEE	
		(Column 1) CLAIMS		(Colu		(Column 3)	ı .			<b>,</b>		
ENT C		REMAINING AFTER AMENDMENT		NUM PREVI	BER	PRESENT EXTRA		RATE	ADDI- TIONAL FEE		RATE	ADDI- TIONAL FEE
<b>AMENDMENT</b>	Total	*	Minus	**	•	=		X\$ 9=		OR	X\$18=	
AME	Independent	*	Minus	***		=		X40=		OR	X80=	
_	FIRST PRESE	NTATION OF M	ULTIPLE DEI	PENDEN.	CLAIM		l					
• 1	If the entry in colu	mn 1 is less than t	he entry in colu	ımn 2. write	e "0" in co	olumn 3.		+135=		OR	+270=	
•••	If the entry in column 1 is less than the entry in column 2, write "0" in column 3.  If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20."  TOTAL ADDIT. FEE  OR ADDIT. FEE  TOTAL ADDIT. FEE  TOTAL ADDIT. FEE  TOTAL ADDIT. FEE  TOTAL ADDIT. FEE  OR TOTAL ADDIT. FEE  TOTAL ADDIT. FEE  TOTAL ADDIT. FEE  OR TOTAL ADDIT. FEE  OR TOTAL ADDIT. FEE  TOTAL ADDIT. FEE  OR TOTA											